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Abstract 
 
Bioartificial Liver Devices (BAL) could provide hepatic function in patients with liver 
failure awaiting transplantation or liver regeneration. Certain BALs use human 
hepatoblastoma-derived HepG2 cells that can perform many hepatocyte specific 
functions, however they cannot adequately detoxify xenobiotics via Cytochrome P450 
(CYP) mediated pathways. 
The aim of this thesis was to identify and develop a cell source able to provide CYP 
function in a BAL, and focused on CYP1A2, since its inducible function has been well 
established in HepG2 cells and CYP3A due its large contribution to hepatic CYP 
expression and function. 
Firstly, gold standard comparators of freshly isolated primary human hepatocytes 
(PHH) were established. The influence of BAL culture conditions on CYP function 
were evaluated, including chemical induction, culture media composition, alginate 
encapsulation and microgravity 3D culture: HepG2 cells were able to provide sufficient 
CYP1A2 but limited CYP3A function. 
Intestinal cell lines LS147T and Caco2 and the hepatocyte derived cell line HC-04 were 
investigated as potential sources to provide CYP3A BAL function. All three were 
shown to proliferate in BAL specific medium within a 3D culture system. Under these 
conditions, increased CYP3A function was demonstrated for each cell line, but their 
usefulness within our BAL was limited. 
The effects of increasing HepG2 expression of two nuclear receptors (Constitutive 
Androstane Receptor and Retinoid X Receptor α) were examined. Within a transient 
system, increased nuclear receptor expression, in conjunction with chemical induction, 
resulted in improved function of multiple CYP isoforms; CYP3A function was 
increased to levels approaching those measured in PHH. Inducible CYP3A function of a 
stable CAR transfectant was then demonstrated in 3D culture.  
Lastly HepG2 cell CYP function was also shown to be source-dependent. Overall it was 
concluded that through adaptation of culture conditions and genetic manipulation, these 
cells have the potential to provide CYP function within a BAL.    
  4 
Table of Contents 
DECLARATION........................................................................................................................................2 
ABSTRACT................................................................................................................................................3 
TABLE OF CONTENTS...........................................................................................................................4 
TABLE OF FIGURES.............................................................................................................................10 
LIST OF TABLES...................................................................................................................................15 
LIST OF ABBREVIATIONS..................................................................................................................16 
ACKNOWLEDGEMENTS.....................................................................................................................19 
CHAPTER 1  INTRODUCTION.......................................................................................................20 
1.1  INTRODUCTION TO THE LIVER .................................................................................................20 
1.1.1  Structure of the Liver..........................................................................................................20 
1.1.1.1  Parenchymal Cells.................................................................................................................. 21 
1.1.1.2  Non-Parenchymal Cells.......................................................................................................... 22 
1.1.1.3  Oval Cells............................................................................................................................... 23 
1.1.2  Physiological Functions of the Liver..................................................................................23 
1.1.2.1  Synthetic Function.................................................................................................................. 23 
1.1.2.2  Metabolic Function................................................................................................................. 23 
1.1.2.3  Biotransformation and Excretion............................................................................................ 24 
1.2  CYTOCHROME P450 ENZYMES ................................................................................................26 
1.2.1  Cytochrome P450 Nomenclature .......................................................................................28 
1.2.2  Human Cytochrome P450 in Xenobiotic Metabolism........................................................28 
1.2.3  Species Specificity of CYP Expression...............................................................................29 
1.2.4  Specific Characteristics of CYP Isoforms ..........................................................................30 
1.2.4.1  Cytochrome P450 1A2 Structure Activity Relationship......................................................... 30 
1.2.4.2  The CYP3A Subfamily........................................................................................................... 31 
1.2.5  Factors Influencing CYP Function.....................................................................................32 
1.2.5.1  Cytochrome P450 Inhibition................................................................................................... 33 
1.2.5.2  Cytochrome P450 Induction................................................................................................... 34 
1.2.6  CYP Induction by Nuclear Receptors.................................................................................34 
1.2.6.1  Aryl Hydrocarbon Receptor and CYP1A Induction............................................................... 35 
1.2.6.2  Nuclear Receptor Mediated CYP3A induction....................................................................... 36 
1.2.6.3  Nuclear Receptor Cross-Talk.................................................................................................. 39 
1.3  LIVER DISEASE AND TREATMENT............................................................................................40 
1.3.1  Acute Liver Failure............................................................................................................40 
1.4  EXTRACORPOREAL LIVER SUPPORT AS A TREATMENT OF ALF................................................41 
1.4.1  Artificial Liver Devices ......................................................................................................41 
1.4.2  Bioartificial Liver Devices.................................................................................................42 
1.5  SOURCES OF CELLS THAT MAY BE CONSIDERED FOR A BAL IN ORDER TO ESTABLISH A 
FUNCTIONING CYTOCHROME P450 SYSTEM..........................................................................................44    
  5 
1.5.1  Primary Human Hepatocytes.............................................................................................44 
1.5.2  Porcine Hepatocytes ..........................................................................................................45 
1.5.3  Human Hepatocyte Cell Lines............................................................................................46 
1.5.3.1  Hep G2 Cells: The Cell Line of Choice for the Liver Group BAL......................................... 46 
1.5.3.2  Alternative Hepatocyte Cell Lines for BAL Use.................................................................... 49 
1.5.4  Human Foetal Hepatocytes for BAL Use...........................................................................50 
1.5.4.1  Ontogeny of Human Hepatic CYP3A..................................................................................... 50 
1.5.4.2  Role of CYP3A7 in FHH........................................................................................................ 51 
1.5.4.3  FHH Mediated CYP Metabolism within a BAL..................................................................... 51 
1.5.5  Stem Cells for BAL Use......................................................................................................52 
1.5.5.1  Human Embryonic Stem Cells (hESC)................................................................................... 52 
1.5.5.2  NeoHep Cells.......................................................................................................................... 53 
1.5.5.3  Human Hepatoblasts from Foetal Hepatocytes....................................................................... 54 
1.5.5.4  Human Adult Liver Resident Stem Cells (HLSC).................................................................. 54 
1.5.5.5  Stem Cell Conclusions............................................................................................................ 55 
1.5.6  Alternative Cell Lines for a Co-Culture Approach ............................................................55 
i)  Co-culture to enhance existing CYP function................................................................................... 55 
ii)  Non-liver cell lines to provide a detoxificatory component .............................................................. 56 
1.6  THE LIVER GROUP BAL..........................................................................................................57 
1.6.1  Considerations Relevant to the Use of Cell Lines in a Bioartifical Liver Device ..............58 
1.6.1.1  Regulations Relevant to the Development of a BAL for Clinical Use.................................... 58 
1.6.1.2  Cryopreservation and Storage................................................................................................. 59 
1.6.1.3  Culture Conditions and Media Supplements........................................................................... 60 
1.6.1.4  Using Human Fresh Frozen Plasma to Supplement Culture Medium..................................... 60 
1.6.1.5  The Effect of Liver Failure Plasma Exposure on CYP Function............................................ 60 
1.7  EXPERIMENTAL APPROACHES SELECTED FOR THIS PROJECT...................................................62 
1.7.1  Chemical Induction of CYP Function ................................................................................62 
1.7.1.1  BAL Relevant Considerations With Respect to Inducers....................................................... 63 
1.7.1.2  Duration of Induction ............................................................................................................. 63 
1.7.2  Methods of Quantification..................................................................................................64 
1.7.2.1  Broad Spectrum CYP Activity ............................................................................................... 64 
1.7.2.2  Identifying Activity Within a Specific CYP Family............................................................... 65 
1.8  AIMS AND HYPOTHESIS ...........................................................................................................67 
CHAPTER 2  GENERAL METHODS..............................................................................................69 
2.1  MAMMALIAN CELL CULTURE..................................................................................................69 
2.1.1  Preparation of Collagen Type I from Rat Tail Tendons.....................................................69 
2.1.2  Collagen Coating of Cell Culture Plates............................................................................70 
2.1.3  Preparation of Culture Media............................................................................................70 
2.1.3.1  Primary Adult Human Hepatocyte Media (AHM).................................................................. 70 
2.1.3.2  Human Foetal Hepatocyte Medium (HFM)............................................................................ 71 
2.1.3.3  Hep G2 Culture Medium (Complete Culture Medium).......................................................... 71 
2.1.3.4  HC-04 Culture Medium.......................................................................................................... 71 
2.1.3.5  Caco 2 and LS147T Culture Medium..................................................................................... 72 
2.1.3.6  Preparation of FFP.................................................................................................................. 72    
  6 
2.1.4  Culture of Human Cell Lines .............................................................................................72 
2.1.4.1  Determination of Cell Number and Viability.......................................................................... 74 
2.1.4.2  Cryopreservation and Reconstitution of Cell Lines................................................................ 74 
2.2  ALGINATE ENCAPSULATION AND 3D CULTURE.......................................................................75 
2.2.1  Inotech Cell Encapsulation................................................................................................75 
2.2.2  JetCutter Cell Encapsulation.............................................................................................78 
2.2.3  Removing Cells from Alginate............................................................................................80 
2.3  ANALYSIS OF CELL VIABILITY AND PROTEIN CONTENT..........................................................81 
2.3.1  FDA/PI Staining.................................................................................................................81 
2.3.2  Tetrazolium Salt Viability Assays.......................................................................................82 
2.3.3  Bicinchoninic Acid Protein Assay......................................................................................83 
2.4  MOLECULAR BIOLOGY METHODS ...........................................................................................84 
2.4.1  DEPC Treatment of Solutions............................................................................................84 
2.4.2  DNA Precipitation by Ethanol/Sodium Acetate .................................................................84 
2.4.3  RNA Extraction and DNase Treatment..............................................................................84 
2.4.4  cDNA Synthesis..................................................................................................................86 
2.4.5  Reverse Transcriptase –Polymerase Chain Reaction (RT-PCR) .......................................87 
2.4.5.1  Preparation of Olignucleotides............................................................................................... 87 
2.4.5.2  RT-PCR Set-up and Cycling Conditions................................................................................ 87 
2.4.5.3  Agarose Gel Electrophoresis .................................................................................................. 89 
2.4.5.4  Reverse Transcriptase Quantitative PCR (RT-qPCR) ............................................................ 90 
2.5  ANALYSIS OF CYTOCHROME P450 FUNCTION AND INDUCTION...............................................93 
2.5.1  Cytochrome P450 Inducers................................................................................................93 
2.5.2  Functional Assays ..............................................................................................................93 
2.5.2.1  Ethoxycoumarin Assay to Determine Broad Spectrum CYP Activity.................................... 94 
2.5.2.2  Promega P450 Glo Assays to Determine Isoform Specific CYP Activity.............................. 95 
2.5.2.3  Invitrogen Vivid® BOMFC Assay......................................................................................... 95 
2.5.2.4  HPLC Analysis of CYP Mediated Testosterone Depletion and Metabolite Formation.......... 97 
2.6  STATISTICAL ANALYSIS...........................................................................................................98 
CHAPTER 3  CHARACTERISING CYTOCHROME P450 ACTIVITY IN HUMAN LIVER TO 
ESTABLISH A GOLD STANDARD COMPARATOR.......................................................................99 
3.1  CYTOCHROME P450 ACTIVITY IN ADULT HUMAN LIVER........................................................99 
3.1.1  Primary Human Hepatocytes...........................................................................................100 
3.1.1.1  Methods................................................................................................................................ 100 
3.1.1.2  Results.................................................................................................................................. 102 
3.1.1.3  Discussion ............................................................................................................................ 112 
3.1.2  Human Liver Microsomes................................................................................................114 
3.1.2.1  Human Liver Microsome Isolation....................................................................................... 114 
3.1.2.2  Analysis of Cytochrome P450 Function in HLM................................................................. 115 
3.1.2.3  Results.................................................................................................................................. 116 
3.1.2.4  Discussion ............................................................................................................................ 119 
3.2  CYTOCHROME P450 ACTIVITY IN HUMAN FOETAL LIVER.....................................................120 
3.2.1  Methods............................................................................................................................120    
  7 
3.2.1.1  Isolation of Human Foetal Hepatocytes................................................................................ 120 
3.2.1.2  Culture of Human Foetal Hepatocytes.................................................................................. 120 
3.2.2  Results..............................................................................................................................121 
3.2.3  Discussion........................................................................................................................123 
3.3  CONCLUSIONS........................................................................................................................123 
CHAPTER 4  WORKING WITH WHAT’S AVAILABLE: ADAPTING HEPG2 CULTURE 
CONDITIONS TO IMPROVE CYTOCHROME P450 FUNCTION WITHIN A BAL.................125 
4.1  CHEMICAL INDUCTION OF CYTOCHROME P450 IN MONOLAYER HEPG2 CELLS.....................126 
4.1.1  Methods............................................................................................................................126 
4.1.2  Results..............................................................................................................................126 
4.1.2.1  Effect of Inducers on ECOD Activity................................................................................... 126 
4.1.2.2  Effect of Inducers on CYP1A2 (Luciferin ME) Activity...................................................... 127 
4.1.2.3  Effect of Inducers on CYP3A (Luciferin BE) Activity......................................................... 128 
4.1.2.4  Effect of Inducers on WST-1 Activity.................................................................................. 131 
4.1.2.5  Effect of DBA on Cell Proliferation..................................................................................... 131 
4.1.3  Discussion........................................................................................................................132 
4.2  CYTOCHROME P450 FUNCTION IN ENCAPSULATED HEP G2 CELLS.......................................134 
4.2.1  Methods............................................................................................................................137 
4.2.1.1  CYP Function in Encapsulated HepG2 Cells Maintained in Static Culture.......................... 137 
4.2.1.2  CYP Function in HepG2 Cells Maintained in Microgravity Culture.................................... 137 
4.2.1.3  CYP Function in HLM Isolated From HepG2 Cells Following Bioreactor Culture............. 137 
4.2.2  Results..............................................................................................................................138 
4.2.2.1  3D Culture of HepG2 Cells Maintained in Static Culture..................................................... 138 
4.2.2.2  3D Culture of Encapsulated HepG2 Cells Maintained in Microgravity Culture................... 144 
4.2.3  Discussion........................................................................................................................148 
4.3  EFFECTS OF HUMAN PLASMA EXPOSURE ON HEPG2 CELLS ..................................................150 
4.3.1  Methods............................................................................................................................150 
4.3.1.1  Monolayer Induction ............................................................................................................ 150 
4.3.1.2  3D-Culture and P450 Induction of FFP Exposed Cells........................................................ 150 
4.3.1.3  Nile Red Staining of HepG2 Cells........................................................................................ 150 
4.3.2  Results..............................................................................................................................151 
4.3.2.1  Effect of FFP on ECOD Activity in Monolayer HepG2 Cultures......................................... 151 
4.3.2.2  Effect of FFP on CYP1A2 (Luciferin ME) Activity in Monolayer HepG2 Cultures............ 153 
4.3.2.3  Effect of FFP on CYP3A (Luciferin BE) Activity in Monolayer HepG2 Cultures .............. 154 
4.3.2.4  Effect of 3D Culture on CYP Function Following FFP Exposure........................................ 156 
4.3.2.5  Effect of FFP on Nile Red Staining...................................................................................... 157 
4.3.3  Discussion........................................................................................................................158 
4.4  CONCLUSION .........................................................................................................................161 
 
 
 
    
  8 
CHAPTER 5  ALTERNATIVE CELL LINES TO PROVIDE CYTOCHROME P450 
FUNCTION WITHIN A BAL...............................................................................................................163 
5.1  CYTOCHROME P450 ACTIVITY IN INTESTINAL CELL LINES...................................................164 
5.1.1  Methods............................................................................................................................166 
5.1.1.1  Gene Expression................................................................................................................... 166 
5.1.1.2  Monolayer Induction of CYP Function ................................................................................ 166 
5.1.1.3  Treatment of Caco2 Monolayers with VD3.......................................................................... 166 
5.1.1.4  Encapsulation of Intestinal Cell Lines.................................................................................. 166 
5.1.1.5  CYP Induction in 3D Culture............................................................................................... 167 
5.1.2  Results..............................................................................................................................167 
5.1.2.1  CYP Gene Expression in Caco2 and LS147T Cells ............................................................. 167 
5.1.2.2  Nuclear Receptor Gene Expression in Caco2 and LS147T Cells ......................................... 168 
5.1.2.3  ECOD Activity in Caco2 and LS147T Cells........................................................................ 169 
5.1.2.4  CYP1A2 Induction in Monolayer Caco2 and LS147T Cells................................................ 170 
5.1.2.5  CYP3A Induction in Monolayer Caco2 and LS147T Cells.................................................. 171 
5.1.2.6  Effect of Prolonged Exposure to VD3 in Caco2 Cells.......................................................... 173 
5.1.2.7  Alginate Encapsulation of Caco2 Cells ................................................................................ 174 
5.1.2.8  Alginate Encapsulation of LS147T Cells.............................................................................. 175 
5.1.2.9  CYP3A Function in 3D Cultures of Caco2 and LS147T Cells............................................. 176 
5.1.2.10  A Comparison of PHH, HepG2 and Intestinal Cell Lines .................................................... 180 
5.1.3  Discussion........................................................................................................................181 
5.2  CYTOCHROME P450 ACTIVITY IN THE HC-04 LIVER CELL LINE...........................................185 
5.2.1  Methods............................................................................................................................186 
5.2.1.1  CYP Induction in Monolayer Culture................................................................................... 186 
5.2.1.2  Metabolism of Testosterone ................................................................................................. 187 
5.2.1.3  Encapsulation of HC-04 Cells.............................................................................................. 187 
5.2.1.4  CYP Induction in 3D Culture............................................................................................... 187 
5.2.1.5  Gene Expression in HC-04 Cells.......................................................................................... 187 
5.2.2  Results..............................................................................................................................188 
5.2.2.1  ECOD Activity in HC-04 Cells............................................................................................ 188 
5.2.2.2  CYP1A2 induction in Monolayer Culture............................................................................ 189 
5.2.2.3  CYP3A Function in Monolayer Culture............................................................................... 190 
5.2.2.4  Metabolism of Testosterone ................................................................................................. 191 
5.2.2.5  3D Culture of HC-04 Cells................................................................................................... 191 
5.2.2.6  CYP3A Function in HC-04 Cells is Improved in 3D-Culture.............................................. 192 
5.2.2.7  Influences on mRNA Expression in HC-04 Cells................................................................. 193 
5.2.2.8  A Comparison of PHH, HepG2 and HC-04 Cells................................................................. 196 
5.2.3  Discussion........................................................................................................................197 
5.3  CONCLUSIONS........................................................................................................................199 
CHAPTER 6  MODIFYING CYP3A FUNCTION IN HEPG2 CELLS.......................................201 
6.1  IMPROVING INDUCIBLE CYP3A FUNCTION IN HEPG2 CELLS................................................202 
6.1.1  Creation of Constructs.....................................................................................................204 
6.1.1.1  Methods................................................................................................................................ 204 
6.1.1.2  Results.................................................................................................................................. 210    
  9 
6.1.2  Transient Transfection of Nuclear Receptors and CYP Induction...................................211 
6.1.2.1  Methods................................................................................................................................ 211 
6.1.2.2  Results.................................................................................................................................. 212 
6.1.2.3  Discussion ............................................................................................................................ 221 
6.1.3  Creation of a Stable Cell Line for Encapsulation............................................................227 
6.1.3.1  Methods................................................................................................................................ 228 
6.1.3.2  Results.................................................................................................................................. 230 
6.1.3.3  Discussion ............................................................................................................................ 236 
6.2  CYTOCHROME P450 FUNCTION IN HEPG2 CELLS FROM AN ALTERNATIVE SOURCE .............237 
6.2.1  Methods............................................................................................................................237 
6.2.1.1  Adaptation to Culture Media................................................................................................ 237 
6.2.1.2  Cytochrome P450 Induction in BALG2 Cells...................................................................... 238 
6.2.1.3  Gene Expression in BALG2 Cells........................................................................................ 238 
6.2.2  Results..............................................................................................................................238 
6.2.2.1  A Comparison of CYP1A2 (Luciferin ME) Activity in HepG2 and BALG2 Cells.............. 239 
6.2.2.2  A Comparison of CYP3A (Luciferin BE) Activity in HepG2 and BALG2 Cells................. 241 
6.2.2.3  A Comparison of CYP mRNA Expression in BALG2 and HepG2 Cells............................. 242 
6.2.2.4  A Comparison of Nuclear Receptor mRNA Expression in BALG2 and HepG2 Cells......... 243 
6.2.2.5  Testosterone Metabolism in BALG2 Cells........................................................................... 245 
6.2.2.6  A Comparison of PHH and BALG2 in Monolayer Culture.................................................. 245 
6.2.3  Discussion........................................................................................................................246 
6.3  CONCLUSIONS........................................................................................................................248 
CHAPTER 7  GENERAL DISCUSSION........................................................................................249 
7.1  CHARACTERISING AND IMPROVING CYP FUNCTION IN THE LG BAL....................................249 
7.1.1  How Much Function is Sufficient for a BAL? ..................................................................249 
7.1.2  What Were the Limitations of HepG2 Cells?...................................................................250 
7.1.3  Why Are Intestinal Cells Unsuitable?..............................................................................251 
7.1.4  Do HC-04 Cells Have LG BAL Potential?.......................................................................251 
7.1.5  Can CYP Function be Improved in HepG2 Cells?...........................................................252 
7.2  FURTHER CONSIDERATIONS...................................................................................................254 
7.2.1  Indirubin Improves Cytochrome P450 Function by Multiple Mechanisms......................254 
7.2.2  What is Preventing CYP Expression/Protein Translation and is this Recovered Following 
Improved Differentiation?..............................................................................................................255 
7.2.3  Maintaining CYP Expression Following Induction (Post Translational Stabilisation)...256 
7.2.4  Considering Flavin-Containing Monooxygenases...........................................................256 
7.3  WHAT THE CURRENT SYSTEM CAN ACHIEVE........................................................................257 
APPENDIX A: ADAPTING HC-04 CELLS TO LG CULTURE CONDITIONS...........................259 
APPENDIX B: DURATION OF INDUCTION IN HEPG2 CELLS.................................................264 
REFERENCES…………………………………………………………………………………………266    
  10 
Table of Figures 
FIGURE 1-1. ZONATION IN THE LIVER ACINUS.............................................................................................22 
FIGURE 1-2. CYTOCHROME P450 ENZYMES CONTAIN HEME IRON BOUND WITHIN A PORPHYRIN RING........26 
FIGURE 1-3. CYTOCHROME P450 CATALYSIS..............................................................................................27 
FIGURE 1-4. CONTRIBUTION OF KEY CYTOCHROME P450 ISOFORMS TO XENOBIOTIC METABOLISM IN 
HUMANS............................................................................................................................................29 
FIGURE 1-5. MECHANISM OF CYP INDUCTION............................................................................................35 
FIGURE 1-6. FOLLOWING ALGINATE ENCAPSULATION OF A SINGLE CELL SUSPENSION, MULTICELLULAR 
COLONIES OR SPHEROIDS FORM WITHIN ALGINATE BEADS.................................................................57 
FIGURE 1-7. LUMINOGENIC P450-GLO SUBSTRATES...................................................................................66 
FIGURE 2-1. INOTECH IER-20 CELL ENCAPSULATOR SYSTEM....................................................................75 
FIGURE 2-2. JETCUTTER ENCAPSULATION SYSTEM. ....................................................................................78 
FIGURE 2-3. DNA LADDERS........................................................................................................................90 
FIGURE 2-4. AN EXAMPLE OF MELT CURVE ANALYSIS ................................................................................91 
FIGURE 2-5. STANDARD CURVES TO DEMONSTRATE SEPARATION OF TESTOSTERONE AT 15 MINUTES AND 
6Β-HYDROXYTESTOSTERONE AT 9 MINUTES......................................................................................97 
FIGURE 3-1. CYTOCHROME P450 FUNCTION IN FRESHLY ISOLATED PHH.................................................103 
FIGURE 3-2. % SUBSTRATE DEPLETION AND 6Β-OHTST PRODUCTION MEASURED BY HPLC ANALYSIS OF 
SUPERNATANT OBTAINED FROM FRESHLY ISOLATED PHH INCUBATED FOR 1 HOUR WITH TST.......104 
FIGURE 3-3. HPLC ANALYSIS OF CULTURE MEDIUM SPIKED WITH 200µM TST AND CULTURE MEDIUM 
SPIKED WITH 200µM TST AND INCUBATED FOR 1 HOUR WITH FRESHLY ISOLATED PHH. ...............105 
FIGURE 3-4. EXAMPLES OF HEPATOCYTE CULTURES WHICH COULD BE USED FOR EXPERIMENTS REQUIRING 
PROLONGED CULTURE, AND HEPATOCYTE CULTURES WHICH WERE EXCLUDED FROM MONOLAYER 
EXPERIMENTS..................................................................................................................................106 
FIGURE 3-5. CYTOCHROME P450 (ECOD) ACTIVITY DECLINES IN PHH DURING PROLONGED CULTURE..107 
FIGURE 3-6. CYP FUNCTION WAS COMPARED IN PHH CULTURED FOR 48 HOURS +/- GROWTH FACTORS..108 
FIGURE 3-7. ECOD ACTIVITY WAS COMPARED IN PHH THAT WERE PLATED AND THEN CULTURED IN 10% 
FCS OR 10% FFP............................................................................................................................109 
FIGURE 3-8. ECOD ACTIVITY WAS MEASURED IN PHH FOLLOWING 48 HOUR INDUCTION WITH CYP 
INDUCERS IN WEM CONTAINING 10% FCS, 10% FCS AND HEPARIN OR 10% FFP........................111 
FIGURE 3-9. BOMFC METABOLISM MEASURED +/- 100µM CLARITHROMYCIN IN PHH............................112 
FIGURE 3-10. CYP ACTIVITIES WERE COMPARED FOR HLM FROM A SINGLE DONOR (PHH28) PREPARED 
FROM TISSUE OR FRESHLY ISOLATED HEPATOCYTES .......................................................................116 
FIGURE 3-11. INTERINDIVIDUAL VARIATION IN CYP ACTIVITY WAS WHEN ACTIVITIES WERE COMPARED 
BETWEEN HLM AND FRESHLY ISOLATED PHH ISOLATED FROM THE SAME DONOR.........................117 
FIGURE 3-12. INTERINDIVIDUAL VARIATION IN CYP ACTIVITY WAS MAINTAINED WHEN DONOR ACTIVITIES 
WERE COMPARED BETWEEN  HLM AND PHH FOLLOWING 72 HOURS CULTURE..............................118 
FIGURE 3-13. CYP3A (LUCIFERIN BE) ACTIVITY WAS MEASURED IN FHH ISOLATED FROM 3 SEPARATE 
DONORS AND EXPANDED IN CULTURE UNTIL CONFLUENT................................................................121    
  11 
FIGURE 3-14. CYP ACTIVITY IN FHH (ISOLATED FROM A SINGLE DONOR-FHH3) EXPANDED IN CULTURE 
FOR 10 DAYS POST ISOLATION AND TREATED FOR 96 HOURS WITH  INDUCERS MEASURED BY  
LUCIFERIN BE ASSAY AND TESTOSTERONE METABOLISM/ 6Β-OHTST PRODUCTION......................122 
FIGURE 4-1. HEPG2 CELLS WERE TREATED FOR 48 HOURS WITH DECREASING CONCENTRATIONS OF CYP 
INDUCERS AND CYP FUNCTION THEN MEASURED BY ECOD ASSAY.. .............................................127 
FIGURE 4-2. CYP1A2 (LUCIFERIN ME) ACTIVITY MEASURED IN THE PRESENCE OF 10µM SULFAPHENAZOLE 
IN HEPG2 CELLS FOLLOWING 48 HOUR TREATMENT WITH  CYP1A AND  CYP3A INDUCERS..........128 
FIGURE 4-3. CYP3A (LUCIFERIN BE) ACTIVITY MEASURED IN HEPG2 CELLS FOLLOWING 48 HOUR 
TREATMENT WITH CYP3A AND CYP1A INDUCERS.  ......................................................................129 
FIGURE 4-4. CYP3A INDUCTION IN HEPG2 CELLS MEASURED USING LUCIFERIN BE OR LUCIFERIN PFBE 
SUBSTRATE FOLLOWING 48 HOUR EXPOSURE TO A RANGE OF INDUCERS.........................................130 
FIGURE 4-5 WST-1 ACTIVITY MEASURED IN MONOLAYER HEPG2 CELLS FOLLOWING 48 HOUR EXPOSURE 
TO INDUCERS...................................................................................................................................131 
FIGURE 4-6. TOTAL CELL PROTEIN (MEASURED BY BCA ASSAY) COMPARED UP TO 72 HOURS POST 
INDUCTION FOR HEPG2 CELLS TREATED FOR 48 HOURS WITH DBA OR 0.1% DMSO VEHICLE.......132 
FIGURE 4-7. SETUP OF THE RCCS.............................................................................................................135 
FIGURE 4-8. SETUP OF THE FBB CULTURE SYSTEM...................................................................................136 
FIGURE 4-9. CELL VIABILITY STAINING OF ENCAPSULATED HEPG2 CELLS MAINTAINED FOR UP TO 8 DAYS IN 
STATIC CULTURE. ............................................................................................................................139 
FIGURE 4-10. COMPARISON OF ECOD ACTIVITY IN HEPG2 CELLS CULTURED IN 3D FORMAT FOR 8 DAYS OR 
IN MONOLAYER AND TREATED FOR 48 HOURS WITH 0.1% DMSO VEHICLE OR DBA......................140 
FIGURE 4-11. CYP3A FUNCTION MEASURED IN HEPG2 CELLS CULTURED IN 3D FORMAT FOR 8 DAYS OR IN 
MONOLAYER AND TREATED FOR 48 HOURS WITH 0.1% DMSO VEHICLE OR RIFAMPICIN  ...............141 
FIGURE 4-12. METABOLISM OF TESTOSTERONE IN  ENCAPSULATED HEPG2 CELLS TREATED WITH 50µM 
RIFAMPICIN OR  FRESHLY ISOLATED PHH INCUBATED FOR 1 HOUR WITH TST…………………...  142 
FIGURE 4-13. METABOLISM OF TESTOSTERONE IN HEPG2 CELLS TREATED WITH 50µM RIFAMPICIN IN 
MONOLAYER OR 3D CULTURE AND THEN INCUBATED WITH TST FOR 8 HOURS, OR FRESHLY ISOLATED 
PHH INCUBATED WITH 200µM TST FOR 1 HOUR............................................................................143 
FIGURE 4-14. CELL VIABILITY STAINING OF ENCAPSULATED HEPG2 CELLS FOLLOWING 8 DAYS OF RCCS 
MICROGRAVITY CULTURE................................................................................................................144 
FIGURE 4-15. ECOD ACTIVITY WAS MEASURED IN HEPG2 CELLS CULTURED IN 3D FORMAT MAINTAINED 
FOR 8 DAYS IN EITHER STATIC OR MICROGRAVITY CULTURE AND TREATED FOR 48 HOURS WITH 
EITHER 0.1% DMSO VEHICLE OR 10µM DBA. ...............................................................................145 
FIGURE 4-16. CYP3A (LUCIFERIN BE) ACTIVITY WAS MEASURED IN HEPG2 CELLS CULTURED IN 3D 
FORMAT MAINTAINED FOR 8 DAYS IN EITHER STATIC OR MICROGRAVITY CULTURE........................146 
FIGURE 4-17. CYTOCHROME P450 FUNCTION MEASURED BY ECOD ASSAY AND LUCIFERIN BE ASSAY IN 
HLM ISOLATED FROM FRESHLY ISOLATED PHH AND 3D BIOREACTOR CULTURES OF HEPG2 CELLS 
........................................................................................................................................................147 
FIGURE 4-18. EFFECT OF CYP INDUCTION (48 HOURS) ON ECOD ACTIVITY MEASURED IN HEPG2 CELLS 
FOLLOWING MONOLAYER CULTURE IN COMPLETE CULTURE MEDIUM SUPPLEMENTED WITH 10% FCS 
+/- HEPARIN OR 10% FFP................................................................................................................152    
  12 
FIGURE 4-19. EFFECT OF CYP INDUCTION (48 HOURS) ON CYP1A2 ACTIVITY (LUCIFERIN ME 
METABOLISM DETECTED IN THE PRESENCE OF 10µM SULFAPHENAZOLE) MEASURED IN HEPG2 CELLS 
FOLLOWING MONOLAYER CULTURE IN COMPLETE CULTURE MEDIUM SUPPLEMENTED WITH 10% FCS 
+/- HEPARIN OR 10% FFP................................................................................................................153 
FIGURE 4-20. EFFECT OF CYP INDUCTION (48 HOURS) ON CYP3A ACTIVITY (LUCIFERIN BE METABOLISM) 
MEASURED IN HEPG2 CELLS FOLLOWING MONOLAYER CULTURE IN COMPLETE CULTURE MEDIUM 
SUPPLEMENTED WITH 10% FCS +/- HEPARIN OR 10% FFP.. ...........................................................155 
FIGURE 4-21. ECOD ACTIVITY FOLLOWING TREATMENT WITH CYP INDUCERS COMPARED IN MONOLAYER 
AND 3D CULTURES OF HEPG2 CELLS CULTURED IN 10 % FCS WITH HEPARIN OR 10% FFP............157 
FIGURE 4-22. NILE RED STAINING OF HEPG2 CELLS FOLLOWING CULTURE IN 10% FCS OR 10%FFP......158 
FIGURE 5-1. MONOLAYER APPEARANCE  OF CACO 2 CELLS AND  LS147T CELLS.....................................165 
FIGURE 5-2. CYP EXPRESSION MEASURED IN MRNA ISOLATED FROM CACO2 AND LS147T CELLS 
FOLLOWING MONOLAYER CULTURE. ...............................................................................................168 
FIGURE 5-3. NUCLEAR RECEPTOR EXPRESSION MEASURED IN MRNA ISOLATED FROM CACO2 AND LS147T 
CELLS FOLLOWING MONOLAYER CULTURE......................................................................................168 
FIGURE 5-4. ECOD ACTIVITY MEASURED IN MONOLAYER CACO2 AND LS147T CELLS FOLLOWING 48 
HOURS TREATMENT WITH CYP1A AND CYP3A INDUCERS.............................................................169 
FIGURE 5-5. LUCIFERIN ME METABOLISM MEASURED IN THE PRESENCE OF 10µM SULFAPHENAZOLE IN 
MONOLAYER CACO2 AND LS147T CELLS FOLLOWING 48 HOURS INDUCTION WITH CYP1A INDUCERS
........................................................................................................................................................170 
FIGURE 5-6. LUCIFERIN BE METABOLISM IN CACO2 AND LS147T CELLS FOLLOWING 48 HOUR TREATMENT 
WITH CYP3A INDUCERS..................................................................................................................171 
FIGURE 5-7. CYP3A ACTIVITY IN CACO2 AND LS147T CELLS FOLLOWING 48 HOUR TREATMENT WITH 
CYP1A INDUCERS...........................................................................................................................172 
FIGURE 5-8. CYP3A ACTIVITY MEASURED IN CACO2 MONOLAYERS CULTURED IN A RANGE OF VD3 
CONCENTRATIONS FOR 7 DAYS........................................................................................................173 
FIGURE 5-9. CELL VIABILITY STAINING OF CACO2 CELLS MAINTAINED IN 3D STATIC CULTURE FOR UP TO 12 
DAYS...............................................................................................................................................174 
FIGURE 5-10. CELL VIABILITY STAINING  OF LS147T CELLS MAINTAINED IN 3D STATIC CULTURE FOR UP TO 
8 DAYS. ...........................................................................................................................................175 
FIGURE 5-11. CYP3A ACTIVITY WAS COMPARED IN MONOLAYER AND 3D CULTURES FOLLOWING 
INDUCTION IN CACO2 AND LS147T CELLS......................................................................................177 
FIGURE 5-12. METABOLISM OF TESTOSTERONE IN ENCAPSULATED CACO2 CELLS INDUCED WITH 0.1% 
DMSO VEHICLE, 50µM RIFAMPICIN OR 1µM VD3 AND THEN INCUBATED WITH TESTOSTERONE FOR 8 
HOURS, OR FRESHLY ISOLATED PHH INCUBATED WITH TESTOSTERONE FOR 1 HOUR......................178 
FIGURE 5-13. METABOLISM OF TESTOSTERONE IN ENCAPSULATED LS147T CELLS INDUCED WITH  0.1% 
DMSO VEHICLE, 50µM RIFAMPICIN OR 1µM VD3 AND THEN INCUBATED WITH TESTOSTERONE FOR 8 
HOURS, OR FRESHLY ISOLATED PHH INCUBATED WITH TESTOSTERONE FOR 1 HOUR......................179 
FIGURE 5-14. MONOLAYER APPEARANCE OF HC-04 CELLS COMPARED TO HEPG2 CELLS........................185 
FIGURE 5-15. ECOD ACTIVITY MEASURED IN MONOLAYER HC-04 CELLS FOLLOWING 48 HOURS INDUCTION 
WITH CYP1A INDUCERS..................................................................................................................188    
  13 
FIGURE 5-16. LUCIFERIN ME METABOLISM MEASURED IN THE PRESENCE OF 10µM SULFAPHENAZOLE IN 
MONOLAYER HC-04 CELLS FOLLOWING 48 HOURS INDUCTION CYP1A INDUCERS.........................189 
FIGURE 5-17. CYP3A (LUCIFERIN BE) ACTIVITY MEASURED IN MONOLAYER HC-04 CELLS FOLLOWING 48 
HOUR TREATMENT WITH CYP3A INDUCERS....................................................................................190 
FIGURE 5-18. MEASUREMENT OF TESTOSTERONE METABOLISM IN RIFAMPICIN TREATED HC-04 CELLS 
INCUBATED FOR 8 HOURS WITH 200µM TESTOSTERONE AND FRESHLY ISOLATED PHH INCUBATED 
FOR 1 HOUR WITH µM TESTOSTERONE.............................................................................................191 
FIGURE 5-19. CELL VIABILITY STAINING OF ENCAPSULATED HC-04 CELLS MAINTAINED IN 3D STATIC 
CULTURE FOR UP TO 15 DAYS..........................................................................................................192 
FIGURE 5-20. CYP3A FUNCTION WAS MEASURED IN HC-04 CELLS CULTURED IN 3D FORMAT FOR 8 OR 15 
DAYS AND TREATED FOR 48 HOURS WITH EITHER 0.1% DMSO VEHICLE OR 50µM RIFAMPICIN......193 
FIGURE 5-21 CYP MRNA EXPRESSION WAS MEASURED IN HC-04 CELLS CULTURED IN MONOLAYER OR 3D 
FORMAT AND TREATED FOR 48 HOURS WITH 50µM RIFAMPICIN......................................................194 
FIGURE 5-22. NR MRNA EXPRESSION WAS MEASURED IN HC-04 CELLS CULTURED IN MONOLAYER OR 3D 
FORMAT AND TREATED FOR 48 HOURS WITH 50µM RIFAMPICIN......................................................196 
FIGURE 6-1. CONFIGURATION OF PTRACER EF/BSD A.............................................................................206 
FIGURE 6-2. CLONING OF CAR FROM HUMAN LIVER DNA.......................................................................210 
FIGURE 6-3. CLONING OF RXRΑ FROM HUMAN LIVER DNA.....................................................................211 
FIGURE 6-4. TRANSFECTION EFFICIENCY MONITORED BY GFP EXPRESSION.............................................212 
FIGURE 6-5. HEPG2 CELL CAR AND RXRΑ EXPRESSION DETERMINED BY RT-QPCR IN MRNA ISOLATED 
72 HOURS POST TRANSFECTION FROM CONTROL TRANSFECTED HEPG2 CELLS AND CELLS 
TRANSFECTED WITH CAR, RXRΑ AND CAR/RXRΑ.OR FROM PHH...............................................213 
FIGURE 6-6. CYP3A INDUCTION IN HEPG2 CELLS FOLLOWING 48 HOUR TREATMENT WITH CYP3A 
INDUCERS IN HEPG2 CELLS FOLLOWING TRANSFECTION WITH EITHER MOCK CONTROL, CAR, RXRΑ 
OR CAR/RXRΑ...............................................................................................................................214 
FIGURE 6-7. CYP3A ACTIVITY IN HEPG2 CELLS FOLLOWING TRANSFECTION WITH CAR, RXRΑ, 
CAR/RXRΑ OR MOCK CONTROL AND 48 HOUR TREATMENT WITH CYP3A INDUCERS. ..................215 
FIGURE 6-8. EFFECT OF AHR AGONISTS ON CYP3A ACTIVITY IN HEPG2 CELLS TRANSFECTED WITH MOCK 
CONTROL, CAR, RXRΑ OR CAR/RXRΑ AND TREATED FOR 48 HOURS WITH INDUCERS.................216 
FIGURE 6-9. EFFECT OF CYP1A2 INDUCERS ON HEPG2 CYP1A2 FUNCTION FOLLOWING TRANSFECTION 
WITH MOCK CONTROL, CAR, RXRΑ OR CAR/RXRΑ......................................................................218 
FIGURE 6-10. CYP1A2 IN HEPG2 CELLS FOLLOWING TRANSFECTION WITH MOCK CONTROL, CAR, RXRΑ, 
OR CAR/RXRΑ AND 48 HOUR TREATMENT WITH CYP3A INDUCERS..............................................219 
FIGURE 6-11. WST-1 ASSAY DEMONSTRATES THAT CELL VIABILITY WAS UNAFFECTED BY BOTH INDUCER 
TREATMENT AND TRANSFECTION OF CAR, RXRΑ, CAR/RXRΑ OR MOCK CONTROL......................220 
FIGURE 6-12. WNT/Β -CATENIN INTRACELLULAR SIGNALLING PATHWAY................................................225 
FIGURE 6-13. PROPOSED EFFECTS OF  INDIRUBIN AND RXRΑ ON Β-CATENIN SIGNALLING.. .....................226 
FIGURE 6-14. GFP EXPRESSION IN HEPG2 CELLS WHICH HAVE BEEN TRANSFECTED WITH PTRACER 
CONSTRUCT AND UNDERGONE BLASTICIDIN SELECTION..................................................................230 
FIGURE 6-15. GENE EXPRESSION WAS COMPARED IN CONTROL (UNTRANSFECTED) HEPG2 CELLS AND BSD 
SELECTED CAR TRANSFECTANT TREATED IN MONOLAYER CULTURE FOR 48 HOURS WITH 50µM 
RIFAMPICIN......................................................................................................................................231    
  14 
FIGURE 6-16. CYP3A (LUCIFERIN BE) ACTIVITY WAS MEASURED IN MONOLAYER CAR TRANSFECTANTS 
THAT HAD UNDERGONE BLASTICIDIN SELECTION PRIOR TO ENCAPSULATION AND WAS INHIBITED 
WHEN MEASURED IN THE PRESENCE OF CLARITHROMYCIN..............................................................232 
FIGURE 6-17. CELL VIABILITY STAINING OF ENCAPSULATED HEPG2 CELL CAR TRANSFECTANT FOLLOWING 
8 DAYS OF STATIC CULTURE............................................................................................................233 
FIGURE 6-18. CYP3A INDUCTION IN CONTROL (UNTRANSFECTED) HEPG2 CELLS AND BSD SELECTED CAR 
TRANSFECTANT MAINTAINED FOR 8 DAYS 3D FORMAT AND TREATED FOR  48 HOURS (ON DAY 6) 
WITH 50µM RIFAMPICIN OR 0.1% DMSO VEHICLE. CYP3A ACTIVITY MEASURED USING LUCIFERIN 
BE OR LUCIFERIN PFBE SUBSTRATES.............................................................................................234 
FIGURE 6-19. METABOLISM OF TESTOSTERONE IN CAR TRANSFECTANTS TREATED FOR 48 HOURS WITH 
50µM RIFAMPICIN IN 3D CULTURE COMPARED TO PHH..................................................................235 
FIGURE 6-20. CYP1A2 (LUCIFERIN ME) ACTIVITY IN HEPG2 CELLS OR BALG2 CELLS..........................240 
FIGURE 6-21. CYP3A (LUCIFERIN BE) ACTIVITY IN HEPG2 CELLS OR BALG2 CELLS.............................242 
FIGURE 6-22. CYP EXPRESSION IN HEPG2 AND BALG2 ..........................................................................243 
FIGURE 6-23. NR EXPRESSION IN HEPG2 AND BALG2 ............................................................................244 
FIGURE 6-24. TESTOSTERONE METABOLISM IN HEPG2 AND BALG2 CELLS.............................................245 
FIGURE 7-1. PATHWAYS OF CYP INDUCTION............................................................................................253 
FIGURE A-1. CYP3A ACTIVITY WAS COMPARED IN HC-04 CELLS CULTURED IN HCM CULTURE MEDIUM ON 
COLLAGEN MATRIX OR ADAPTED TO ΑMEM AND CULTURED ON TISSUE CULTURE PLASTIC............260 
FIGURE A-2. CYP3A ACTIVITY MEASURED OVER 4 WEEKS IN HC-04 CELLS CULTURED IN HCM OR ΑMEM 
+/- COLLAGEN MATRIX....................................................................................................................261 
FIGURE A-3. ALGINATE ENCAPSULATED HC-04 CELLS FOLLOWING 8 DAYS OF CULTURE.........................261 
FIGURE A-4. MYCOPLASMA PCR OF CONTAMINATED HC-04 CELLS........................................................262 
FIGURE A-5. MYCOPLASMA PCR FOLLOWING BM-CYCLIN TREATMENT ................................................263 
FIGURE B-1. INDUCTION OF ECOD ACTIVITY FOLLOWING 24 HOUR DBA EXPOSURE................................264 
FIGURE B-2.  INDUCTION OF ECOD ACTIVITY FOLLOWING 48 HOURS DBA EXPOSURE............................265 
FIGURE B-3. INCREASED ECOD ACTIVITY FOLLOWING EXPOSURE TO 10µM DBA WAS MAINTAINED IN 
HEPG2 CELLS FOLLOWING REMOVAL OF INDUCER..........................................................................265    
  15 
List of Tables 
TABLE 1-1. CYTOCHROME P450 NOMENCLATURE .....................................................................................28 
TABLE 1-2. RECENTLY DEVELOPED HEPATOCYTE CELL LINES WITH CYP FUNCTIONALITY........................49 
TABLE 1-3. CHEMICAL INDUCERS SELECTED FOR USE IN THIS THESIS.........................................................62 
TABLE 2-1. PRIMERS USED FOR THE ANALYSIS OF GENE EXPRESSION BY RT-PCR.....................................87 
TABLE 2-2. ANNEALING TEMPERATURE, NUMBER OF CYCLES AND EXPECTED FRAGMENT SIZE FOR EACH 
PRIMER SET USED IN THIS THESIS.......................................................................................................89 
TABLE 3-1. AVAILABLE DONOR INFORMATION AND % VIABILITY OF ISOLATED HEPATOCYTES FOR EACH 
LIVER SAMPLE USED IN THIS THESIS.................................................................................................101 
TABLE 3-2. MEAN, MEDIAN AND RANGE VALUES (PMOLES PRODUCT/MIN/MG PROTEIN) FOR CYTOCHROME 
P450 FUNCTION IN FRESHLY ISOLATED PHH FROM 9 SEPARATE DONORS. ......................................103 
TABLE 4-1. CALCULATED LOG P VALUES FOR INDUCERS USED IN THIS STUDY.........................................160 
TABLE 5-1. A COMPARISON OF INTESTINAL CELL LINES CACO 2 AND LS147T.........................................165 
TABLE 5-2. INDEPENDENT AND SYNERGISTIC EFFECTS OF INDUCTION AND 3D CULTURE ON CYP3A 
FUNCTION IN CACO2 AND LS147T CELLS........................................................................................176 
TABLE 5-3. CYP3A (LUCIFERIN-BE) ACTIVITY WAS HIGHER IN FRESHLY ISOLATED PRIMARY HUMAN 
HEPATOCYTES THAN IN CACO2 CELLS BUT NOT LS147T CELLS FOLLOWING 3D CULTURE)............180 
TABLE 5-4. INDEPENDENT AND SYNERGISTIC EFFECTS OF RIFAMPICIN MEDIATED INDUCTION AND 3D 
CULTURE ON CYP EXPRESSION IN HC-04 CELLS.............................................................................194 
TABLE 5-5. EFFECTS OF 50µM RIFAMPICIN EXPOSURE AND 3D CULTURE ON NUCLEAR RECEPTOR 
EXPRESSION IN HC-04 CELLS ..........................................................................................................195 
TABLE 5-6. CYP3A (LUCIFERIN-BE) ACTIVITY WAS HIGHER IN FRESHLY ISOLATED PRIMARY HUMAN 
HEPATOCYTES THAN HC-04 CELLS BUT THE DIFFERENCE WAS ABROGATED BY 3D CULTURE.........197 
TABLE 6-1. NESTED PCR PRIMERS FOR AMPLIFICATION OF RXRΑ AND CAR..........................................204 
TABLE 6-2. CYP3A (LUCIFERIN-BE) ACTIVITY WAS HIGHER IN FRESHLY ISOLATED PRIMARY HUMAN 
HEPATOCYTES THAN HEPG2 CELLS BUT THE DIFFERENCE WAS DIMINISHED IN TRANSFECTED HEPG2 
CELLS TREATED WITH RIFAMPICIN...................................................................................................221 
TABLE 6-3. CYP3A (LUCIFERIN-BE) ACTIVITY WAS HIGHER IN FRESHLY ISOLATED PRIMARY HUMAN 
HEPATOCYTES THAN HEPG2 CELLS BUT NOT BALG2 CELLS.. ........................................................246    
  16 
List of Abbreviations 
[ ] : Concentration 
a-MEM: Alpha Minimal Essential Medium 
3D: 3-dimensional 
6β-OHTST: 6β-Hydroxytestosterone 
AhR: Aryl Hydrocarbon Receptor 
ACN: Acetonitrile 
ADR: Adverse Drug Reaction 
ALF: Acute Liver Failure 
AMC-BAL: Amsterdam Medical Centre Bioartificial Liver Device 
ARNT: Aryl Hydrocarbon Receptor Nuclear Translocator  
ATRA: all-trans retinoic acid 
BAL: Bioartificial Liver Device 
bp: base pairs 
BCA: Bicinchoninic Acid 
BOMFC: Benzyloxymethylfluorescein 
BSA: Bovine Serum Albumin 
Bsd: Blasticidin S-HCL 
CAR: Constitutive Androstane Receptor 
C/EBP: CCAAT/enhancer binding protein 
CYP: Cytochrome P450 
DBA: Dibenz [a,h] anthracene 
DBD: DNA Binding Domain 
DEPC: Diethylpyrocarbonate 
DEX: Dexamethasone 
DMEM: Dulbecco’s Modified Eagle Medium 
DMSO: Dimethyl Sulfoxide 
DR: Direct Repeat 
7-EC: 7-Ethoxycoumarin 
ECACC: European Collection of Cell Cultures 
ECM: Extracellular Matrix 
ECOD: Ethoxycoumarin-O-Deethylation 
EDTA: Ethylene Diamine Tetraacetic Acid 
EGF: Epidermal Growth Factor 
ELAD: Extracorporeal Liver Assist Device    
  17 
ER-6: Everted Repeat separated by 6 base pairs 
EtOH: Ethanol 
FBB: Fluidised Bed Bioreactor 
FCS: Foetal Calf Serum  
FFP: (Human) Fresh Frozen Plasma 
FHH: Foetal Human Hepatocytes 
GFP: Green Fluorescent Protein 
GI: Gastrointestinal 
GST: Glutathione-S-transferase 
GR: Glucocorticoid Receptor 
HBSS: Hanks Balanced Salt Solution 
7-HC: 7-Hydroxycoumarin 
HGF: Hepatocyte Growth Factor 
HLM: Human Liver Microsome 
HNF: Hepatocyte Nuclear Factor 
HPACC: Health Protection Agency Culture Collections 
Hsp90: Heat shock protein 90 
IU: International Units 
kDa: kilodaltons 
LBD: Ligand Binding Domain 
LFP: Liver Failure Plasma 
3MC: 3-Methylcholanthrene 
MDR1: Multiple Drug Resistance 1 
MeOH: Methanol 
mPMS: 1-Methoxy-5-methyl-phenazinium 
NADPH: β-Nicotinamide Adenine Dinucleotide Phosphate 
NR: Nuclear Receptor 
PB: Phenobarbital 
PBREM: Phenobarbital-Responsive Enhancer Module 
PBS: Phosphate Buffered Saline 
PHH: Primary Human Hepatocytes 
PXR: Pregnane X Receptor 
RAR: Retinoic acid receptor 
RCCS: Rotary Cell Culture System 
RE: Response Element    
  18 
RIF: Rifampicin 
RPM: Revolutions per Minute 
RT-PCR: Reverse Transcriptase Polymerase Chain Reaction 
qRT-PCR: Quantitative Reverse Transcriptase Polymerase Chain Reaction 
SOC: Super Optimal Broth for Catabolite Repression 
SULT: Sulfotransferase 
TAE: Tris-acetate-EDTA 
TRH: Thyroid Releasing Hormone 
TST: Testosterone 
UGT: Uridyl Diphosphate Glucuronosyltransferase 
UV: Ultra Violet 
VDR: Vitamin D Receptor 
VD3: 1α, 25-dihydroxyvitamin D3 (alternatively termed 1,25-(OH)2-D3) 
WST-1: 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium 
monosodium salt 
XRE: Xenobiotic Response Element 
XREM: Xenobiotic-Responsive Enhancer Module    
  19 
Acknowledgements 
 
I would like to thank Dr Clare Selden and Professor Humphrey Hodgson for their 
supervision and guidance throughout this project. I would also like to thank the Liver 
Group Charity for funding my studentship and this research. 
 
The HPLC and LC-MS analysis would not have been possible without the advice of Dr 
Graham Taylor and Dr Nigel Rendell and I am extremely grateful to them for all the 
help that they gave me. 
 
To all those lab members and other colleagues, past and present, who have provided 
scientific advice, moral support and a small amount of sanity, thank you. 
 
And finally, the greatest thanks of all go to my family et Ol who have been an unfailing 
source of patience, wisdom, encouragement and support. 
  
  20 
CHAPTER 1  Introduction 
 
Acute liver failure carries a high mortality rate, which could be reduced by the use of a 
bioartificial liver device (BAL). Within a BAL, a functioning method of xenobiotic 
metabolism seems essential. The following study investigates Cytochrome P450 (CYP) 
activity and induction in the human hepatoma-derived cell line HepG2, and the 
suitability of alternative hepatic and intestinal cell lines for BAL use. CYP activity in 
human liver was also investigated as a comparator.  
 
In this chapter an overview will be given of: 
i)  the structure and functions of the liver;  
ii)  Cytochrome P450 enzymes and their role in drug metabolism;  
iii)  development of liver support devices; and 
iv)  in vitro methods to measure Cytochrome P450 enzyme function. 
 
1.1  Introduction to the Liver 
The liver is the largest internal organ, weighing approximately 1.5kg in an adult human 
and performs many vital metabolic, synthetic and excretory functions, without which 
life cannot be sustained 
1, 2. 
1.1.1  Structure of the Liver 
The liver is located in the right upper quadrant of the abdomen. Where it crosses the 
midline of the trunk it is intersected by the falciform ligament which separates the 
functionally independent left and right lobes. Each lobe has a dual blood supply and 
receives oxygenated blood from the aorta via the hepatic artery and a venous supply via 
the hepatic portal system which drains the spleen, pancreas and gastrointestinal tract. 
Within the liver, blood vessels drain into sinusoids, which run in channels alongside the 
acinus (the smallest functional unit within the liver), and this allows liver cells to be 
perfused with blood. The venous blood is rich in nutrients but also high in toxins from 
digestive processes and is processed by the liver before being returned to the heart via 
the hepatic vein. Most waste is removed from the liver by the hepatic bile duct which 
joins with the cystic duct coming from the gall bladder to form the common bile duct 
which empties into the duodenum. Other waste is transported in the blood to the kidneys 
where it is excreted in urine 
3.   
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In order to perform a complex range of functions, the liver is comprised of different 
classes of cells which are parenchymal and non-parenchymal. 
1.1.1.1  Parenchymal Cells 
Hepatocytes account for only two thirds of the liver cell population, but fulfil the 
majority of synthetic, detoxificatory and intermediary metabolic functions. They are 
large cuboidal cells with central nuclei which may occasionally be tetraploid and 
binucleate cells also arise. Hepatocytes are highly metabolically active and contain 
many intracellular organelles including  smooth endoplasmic reticulum 
(lipid/cholesterol synthesis), rough endoplasmic reticulum (protein synthesis), 
mitochondria (metabolic reactions, Krebs cycle, urea cycle, chemical energy 
generation), lysosomes, peroxisomes, endocytic vesicles (digestive functions) and 
storage vacuoles, glycogen granules and fat droplets. Hepatocytes have a unique 
proliferative capacity which allows the liver to regenerate after injury 
4. 
 
Liver parenchyma is homogenous throughout. In liver acini, hepatocytes are 
functionally polarised with sinusoidal and canilicular poles and form cell plates of about 
20 hepatocytes each, which in humans are one cell thick and separated by sinusoids 
which allow perfusion of blood.  Inlet (periportal) and outlet (perivenous) sides of each 
acinus are exposed to gradients of oxygen, hormones, toxins and metabolites, which 
form as a consequence of uptake along the sinusoids 
5, 6. This results in a zonated gene 
expression pattern and metabolic capacity varies along the acinus (Figure 1-1).  
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Figure 1-1. Zonation in the liver acinus. Nutrient rich blood from the portal vein mixes with oxygen 
rich blood from the hepatic artery in the periportal area and then drains along the sinusoids to the 
central veins in the perivenous area. Bile flows in the opposite direction into the bile ducts. 
Hepatocyte function varies along the acinus depending on periportal or perivenous proximity. CYP 
expression is highest in the perivenous zone where drug metabolism is more extensive. 
 
1.1.1.2  Non-Parenchymal Cells 
The main types of non-parenchymal cells in the liver are Kupffer cells, stellate cells and 
sinusoidal endothelial cells. Kupffer cells are monocyte derived and are resident liver 
macrophages, responsible for cytokine production and phagocytosis. Kupffer cells are 
the main source of TNFα production which is involved in stellate cell activation 
7. 
Quiescent stellate cells are found in normal liver amongst endothelial cells in the 
perisinusoidal Space of Disse and store droplets of fat and retinoic acid (from Vitamin 
A) as well as growth factors including hepatocyte growth factor. Following liver 
damage, stellate cells turn to an activated state which is characterised by a 
myofibroblast-like phenotype as well as decreased retinoic acid storage. Activated cells 
provide growth factors and extracellular matrix to promote liver regeneration and are 
involved in fibrosis 
8, 9. Sinusoidal endothelial cells contain a high amount of endocytic 
vesicles, are involved in uptake of proteins from the blood and have been implicated in 
the immune response. These cells are fenestrated to control the passage of particles from 
the blood through the Space of Disse into the underlying parenchyma 
10.  
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Like hepatocytes, non-parenchymal cells are subject to zonation and are generally more 
numerous in the periportal region. Increased endothelial fenestrae in the perivenous 
region allow greater molecular filtering 
6.  
1.1.1.3  Oval Cells 
Oval cells are an inducible progenitor cell population, which are recruited when 
hepatocytes are unable to regenerate following liver injury; potentially they are 
activated by stellate cells following ECM production. Oval cells are bipotential and 
differentiate into hepatocytes or biliary epithelial cells and therefore have the potential 
to be a major contributing factor to liver regeneration following certain types of injury 
11, 12. 
1.1.2  Physiological Functions of the Liver 
As alluded to above, hepatocytes are responsible for the majority of synthetic, metabolic 
and detoxificatory functions in the liver. These are reviewed below. 
1.1.2.1  Synthetic Function 
The liver synthesises many proteins including some for its own processes such as haem 
and plasma proteins for export including clotting factors, acute phase proteins and most 
abundantly, albumin which binds toxic molecules, transports hydrophobic molecules 
through the blood and maintains oncotic pressure 
4. 
 
The liver manufactures bile salts used for the emulsification and digestion of lipids and 
fat soluble vitamins. Bile salts are secreted in bile along canaliculi into the bile duct and 
stored in the gall bladder and are then released into the small intestine following 
accumulation of fatty substances. Bile acids can also be used in hepatocytes to excrete 
fat soluble toxins 
4. 
1.1.2.2  Metabolic Function 
Normal blood glucose levels are maintained by the liver. Excess glucose is converted to 
glycogen (gluconeogenesis), which is stored in the liver and can be converted to glucose 
by glycogenolysis. When blood glucose is high, insulin acts to suppress hepatic glucose 
production, whereas glucagon acts to stimulate glucose release into the bloodstream. 
When glycogen stores are depleted, fatty acids are released from adipose tissue and 
converted to ketones to be used as an energy source and eventually muscle is broken 
down into amino acids to produce glucose 
4.   
  24 
 
The liver breaks down lipids into their component parts and subsequently secretes 
cholesterol and triacyglycerol as lipoproteins which can then be distributed around the 
body in the bloodstream. Cholesterol for example is essential for cell membrane 
permeability and is a precursor of bile salts and steroid hormones. The liver additionally 
synthesises cholesterol, although this process is regulated when cholesterol levels are 
high 
4. 
 
Essential amino acids are produced by transamination and modification of dietary 
amino acids and then reabsorbed into the bloodstream for protein synthesis elsewhere in 
the body. Excess amino acids cannot be stored and are therefore metabolised by the 
removal of amino groups (which are then used in gluconeogenesis), resulting in the 
production of highly toxic ammonia. In the liver, ammonia is converted to urea via the 
urea cycle which can be excreted by the kidneys. Inadequate detoxification of ammonia 
occurs in liver failure and results in hyperammonemia; this is thought to be an 
underlying cause of hepatic encephalopathy 
13. 
 
The liver is also responsible for modification of hormones, for example conversion of 
thyroxin (T4) to the more active tri-iodothyronine (T3) which regulates metabolic 
functions. Inadequate conversion of T4 to T3 can result in hypothyroidism 
14. 
1.1.2.3  Biotransformation and Excretion 
Biotransformation of xenobiotics in the liver is a multistep process which is carried out 
by hepatocytes. 
 
Phase I metabolism reactions include oxidation, reduction and hydrolysis of the 
substrate to add (or unmask) a functional group. For drug molecules, Phase I reactions 
are mainly represented by oxidations by Cytochrome P450 monooxygenases which will 
be described in further detail in section 1.2. 
 
Flavin-containing monooxygenases (FMOs) are another group of microsomal 
monooygenase enzymes that contribute to hepatic Phase I metabolism. These enzymes 
are polymorphically expressed in humans but unlike CYPs are less readily inhibited or 
inducible. The number of characterised FMOs is relatively small compared to CYPs: 
there are currently 5 identified functional human FMO enzymes, FMO3 is the most  
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predominant in human hepatic metabolism. Compared to CYP enzymes, the role of 
FMOs in xenobiotic metabolism is less well documented (although FMOs exhibit a 
higher degree of thermal instability in vitro, which may cause a metabolic shift to CYP 
activity). With respect to drug metabolism, there is a degree of substrate overlap 
between CYPs and FMOs, but it is generally accepted that CYP enzymes have the more 
significant role in xenobiotic metabolism 
15, 16.  
 
Other enzymes involved in oxidative metabolism include molybdenum oxygenases, 
prostaglandin H synthase, lipoxygenases, amine oxidases, and alcohol and amine 
dehydrogenases 
17. 
 
Phase II conjugations modify the functional group added in Phase I (although 
conjugations can occur without Phase I metabolism for some substrates) to improve 
polarity therefore increasing excretion into the bile or urine. The most common Phase II 
reactions are glucuronidation, involving coupling with glucuronic acid via UDP-
glucuronosyltransferases (UGT), and sulphation, involving coupling with sulphate via 
sulphotransferases (SULTs). Other important Phase II enzymes include glutathione-S-
transferase (GST), arylamine N-acetyltransferase (NAT) and epoxide hydroylase 
(EPHX) 
18, 19. 
 
Phase III elimination prevents intracellular accumulation of Phase II conjugation 
products. This involves removal of metabolites to the extracellular medium by active 
transport using membrane transporters including P-glycoprotein (P-gp), multidrug 
resistance-associated protein (MRP) and organic anion transporting polypeptide 2 
(OATP2). 
 
The biotransformation processes described above facilitate the detoxification and 
excretion of many xenobiotics, but in some instances can promote mutagen formation. 
For example benzo [a] pyrene, which is found in cigarette smoke and chargrilled meat, 
is converted to a carcinogenic metabolite by CYP1A and EPHX 
18, 20.  
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1.2  Cytochrome P450 Enzymes 
Cytochrome P450 (CYP) enzymes are the most prominent group of drug metabolising 
enzymes in humans, responsible for as much as 90% of xenobiotic metabolism. Their 
name derives from their structure (they contain a cytochrome b-type haemprotein) and 
the discovery that they absorb light at 450nm when the reduced form of the protein is 
bound to carbon monoxide (Figure 1-2). CYP enzymes are haemproteins and are 
comprised of a heme group (Protoporphyrin IX) and an apoprotein of 44-60 kDa. The 
porphyrin is common to all CYP enzymes (and other hemeproteins), however the 
apoprotein varies between different CYP isoforms and this accounts for the differences 
in their properties, including molecular weight, substrate and product specificities 
21. 
 
Figure 1-2. Cytochrome P450 enzymes contain haem iron bound within a porphyrin ring 
(Protoporphyrin IX).  Four ligands to the haem iron are provided by the nitrogens on the heme 
ring. Above and below the plane of the haem iron there is room for two additional (non-porphyrin) 
ligands. In Cytochrome P450 proteins the 5
th ligand (Prot-Cys-S) is a thiolate anion which comes 
from a cysteine at the haem binding region of the active site. The 6
th postion (Y) is available to bind 
small molecules such as carbon monoxide which have a high affininty for the ferrous haem. Image 
obtained from 
21. 
 
CYP enzymes are expressed in many tissues throughout the body, including the gut 
wall, kidney, lung, placenta, skin (not 3A4, 1A2 
22), brain and blood cells 
23, 24, but they 
are located at highest concentrations within the liver. The xenobiotic metabolising 
forms of CYP enzymes are membrane bound within the smooth endoplasmic reticulum 
(ER). CYP enzymes are anchored to the membrane bilayer of the ER by their N 
terminal segments and the remainder of the protein is exposed to the cytosolic 
compartment allowing access to the active site of the enzyme. The cofactor NADPH  
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cytochrome P450 reductase, which donates electrons for CYP catalysis via electron 
transfer chain, is similarly located and thus is associated with CYP enzymes in the ER.  
 
The mechanism of CYP catalysis has been extensively characterised and described 
21, 25-
27. CYP mediated catalysis consists of a two stage reaction, using electrons provided 
from NADPH via associated NADPH CYP reductase for the reduction of molecular 
oxygen and subsequent single oxygen insertion into substrate molecules reversibly 
bound to the active domain of the CYP enzyme. A simplified summary of this is shown 
in Figure 1-3. 
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Figure 1-3. Cytochrome P450 catalysis.  Upon binding of the substrate (X) to the CYP enzyme (1), 
the spin state of the heme bound iron changes from resting to active allowing it to accept electrons 
from NADPH via NADPH cytochrome P450 reductase (2). This changes the iron oxidation state 
from Fe
3+ to Fe
2+ resulting in binding of molecular oxygen (3), which is then reduced and cleaved 
(4). CYP enzymes are monooxygenases, and so incorporate one atom of an oxygen molecule the 
substrate, whilst the other is reduced to water (5). 
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1.2.1  Cytochrome P450 Nomenclature 
A universally recognised nomenclature system for CYP enzymes was devised in 1987 
and there are now more than 9000 named Cytochrome P450 sequences. All new CYP 
genes that are discovered are submitted to the Committee on Standardized Cytochrome 
P450 Nomenclature for naming 
28. Cytochrome P450 proteins are categorised into 
families and subfamilies by their sequence similarities (Table 1-1). Each isoform is 
prefixed by CYP. Sequences that are greater than 40% identical at the amino acid level 
belong to the same family denoted by a number. Sequences demonstrating greater than 
55% similarity belong to the same subfamily as denoted by a letter, with a final number 
representing each individual enzyme.  
 
Table 1-1. Cytochrome P450 Nomenclature. 
 
Category 
 
Addition to CYP  Example 
Family 
> 40% amino acid identity 
Number  CYP1 
Subfamily 
>55% amino acid identity 
Number 
+ Letter 
CYP1A 
Single Gene/Protein 
Number 
+ Letter 
+ Number 
CYP1A2 
 
1.2.2  Human Cytochrome P450 in Xenobiotic Metabolism 
To date, there are 18 known families of human Cytochrome P450, of which 3 play a 
major role in xenobiotic metabolism: CYP1, CYP2 and CYP3A (Figure 1-4).  
Other CYP families play important roles, including the metabolism of endogenous 
compounds and cholesterol, steroid and lipid biosynthesis, however, this thesis will 
focus upon CYP1A and CYP3A since the former is readily inducible in BAL relevant 
cell lines, and the latter is deemed necessary for a BAL since it demonstrates the least 
substrate specificity, is the most abundantly expressed CYP subfamily in adult human 
liver and plays the greatest role in drug metabolism.   
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Figure 1-4. Contribution of key Cytochrome P450 isoforms to xenobiotic metabolism in humans. 
The pie chart indicates % hepatic expression and values are shown for CYP1A2 and CYP3A. The 
blue values below correspond to the % of drugs metabolised by each CYP. Data was adapted 
from
27, 29-31. 
1.2.3  Species Specificity of CYP Expression 
Hepatic expression of CYP1A, CYP2B, CYP2C, CYP2D, CYP2E and CYP3A 
subfamilies arises in other mammalian  species including rat, mouse, dog, rabbit, pig 
and primates, although expression of individual CYP isoforms is species specific. The 
predominant isoform within the same CYP family is usually different among animal 
species 
32, 33. An exception to this is CYP1A which is present across species, with 
CYP1A2 as the predominant hepatic isoform. With regard to CYP3A, in adult humans 
CYP3A4 is generally predominant, but this varies for other species including rat 
(CYP3A1/23), dog (CYP3A1/2), monkey (CYP3A8), rabbit (CYP3A6) and pig 
(CYP3A1/2) 
30, 34. These species are all reported to metabolise common CYP3A 
substrates including nifedipine, midazolam and testosterone 
35, 36, although there are 
some species differences in metabolite profiles. For example the main metabolite of 
testosterone is 6β-hydroxytestosterone (6β-OHTST) in human hepatocytes, but not rat 
(17-OHTST), rabbit (16α-OHTST) or dog cells (17-OHTST); pig hepatocytes have a 
more similar testosterone metabolite profile to humans 
29.  
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In contrast to substrate metabolism, there are marked differences in species responses to 
inducers of both CYP1A and CYP3A. Omeprazole is a potent inducer of CYP1A in 
human, dog and pig hepatocytes but not in rat or mouse. TCDD (2,3,7,8-
tetrachlorodibenzo-p-dioxin) is reported to preferentially induce CYP1A1 in rat 
hepatocytes and CYP1A2 in human hepatocytes 
37. With regard to CYP3A, rifampicin 
is a potent inducer of CYP3A in humans, rabbits, pigs and dogs but is ineffective in rats. 
Dexamethasone is a less potent inducer of CYP3A than rifampicin in humans, and is 
ineffective in pigs and dogs, but strongly induces this subfamily in rats 
35, 38. One 
proposed reason for species-specific mechanisms of CYP induction is structural 
differences in the ligand binding domain of nuclear receptors which mediate CYP 
induction 
37, 39. The molecular mechanisms of CYP induction will be addressed further 
in section.1.2.6.  
1.2.4  Specific Characteristics of CYP Isoforms  
The mechanism of CYP dependent catalysis is thought to be consistent across isoforms 
and it is therefore the relationship between active site and substrate which governs the 
isoform responsible for metabolism 
40, 41. For each isoform, enzyme-substrate 
interaction may be governed by factors including (i) topography of the active site, (ii) 
the extent of steric hindrance of the CYP iron-oxygen complex to possible sites of 
metabolism and (iii) binding affinity of the substrate and subsequent hydrogen/electron 
extraction. 
 
CYP enzymes show an affinity for a diverse range of substrates and individual isoforms 
exhibit distinct but overlapping substrate specificities; only a few xenobiotics are 
metabolised exclusively by one enzyme. For human CYP enzymes, some general 
relationships have been identified between the physicochemical properties of ligands 
and their interactions with the major CYP isoforms including CYP1A2 and CYP3A4. 
 
1.2.4.1   Cytochrome P450 1A2 Structure Activity Relationship 
The active site of CYP1A2 is modelled as a rectangular cavity whose size and shape is 
restricted by aromatic side chains. Substrates undertake π – π interactions with the 
aromatic portions of the active site, and hydrogen bonding further from the active site. 
CYP1A2 substrates have been characterised as neutral, basic or lipophilic planar 
polyaromatic or heterocyclic amines and amides with a large area/depth ratio and at 
least one putative H-bond donating site. Examples of CYP1A2 substrates include  
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acetanilide, aromatic amines, caffeine, lidocaine, paracetamol, phenacetin and R-
warfarin. CYP1A2 metabolism is associated with the metabolic activation of 
procarcinogens partly due to the formation of reactive intermediates 
21, 42. 
1.2.4.2  The CYP3A Subfamily 
In terms of hepatic expression and amount of drugs metabolised, the CYP3A subfamily 
is predominant in adult human liver. Currently there are four identified CYP3A genes in 
humans: CYP3A4, CYP3A5, CYP3A7 and CYP3A43. CYP3A4 is the major isoform 
expressed in adult human liver but expression in adults is varies up to 100-fold 
43-45. 
CYP3A7 is the major CYP3A in foetal liver and expression decreases after birth, 
although has been detected at low levels in many human adults (it contributes around 
2% of total CYP3A although this value may increase up to 36% in some individuals 
46). 
CYP3A43 contributes the least to adult hepatic CYP3A (0.1% of CYP3A4 expression) 
and its reported role in CYP3A mediated metabolism is negligible 
47. CYP3A5 is 
polymorphically expressed, although where present (about a third of adult livers) can 
comprise up to 50% of hepatic CYP3A 
48. 
 
The majority of CYP3A substrates can be metabolised by all CYP3A isoforms, with 
CYP3A4 having the highest metabolic capacity, although there are exceptions. 
Cisapride is not well metabolised by CYP3A7 
48-50. CYP3A is the major subfamily 
involved in testosterone metabolism, but CYP3A7 does not substantially contribute to 
testosterone 6β-hydroxylation 
51, 52. CYP3A7 has a greater catalytic activity towards 16-
α hydroxylation of dehydroepiandrosterone (involved in estriol biosynthesis 
53) than 
CYP3A4. 
 
CYP3A induction is also differentially upregulated in humans. CYP3A4 expression 
exclusively is upregulated by St Johns Wort. Rifampicin exposure leads to induction of 
CYP3A4 and to a lesser extent CYP3A7 but has minimal effect on CYP3A5 
54-56. 
Dexamethasone, although less potent than rifampicin, induces the expression of (in 
order of potency) CYP3A4, CYP3A7 and CYP3A5 
57.  
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1.2.4.2.1  Cytochrome P450 3A4 Structure Activity Relationship 
CYP3A4 is the most widely expressed CYP in adult human liver and demonstrates the 
broadest substrate specificity. It is an allosteric protein and exhibits atypical kinetics for 
which several models have been proposed; these centre around either multiple substrate 
binding at a single active site or multiple substrate binding at distinct active sites within 
the enzyme 
58-60. As a result of this, conflicting events can occur during substrate 
metabolism such as enzyme activation and inhibition. 
 
Some common features related to CYP3A4 binding are hydrogen bonding and π – π 
stacking, but substrates are structurally diverse. Examples of CYP3A4 substrates 
include caffeine, cyclosporin, HIV protease inhibitors, androstenedione, lidocaine, 
midazolam, omeprazole and testosterone 
21.  
 
1.2.5  Factors Influencing CYP Function 
Poor pharmacokinetics is a major contributing factor to adverse drug reactions (ADR) 
as well as to the attrition of compounds during the drug discovery and development 
process, therefore variations in Cytochrome P450 function can have considerable 
impact in a clinical setting.  
 
In humans, there is considerable variation in CYP expression and this may be attributed 
to several factors.   
 
Genetic polymorphisms in CYP expression can result in low metabolic capacity and 
have been characterised for a number of isoforms. For certain populations, 
polymorphisms have a particular impact on CYP2C19 and CYP2D6 activity. Up to 20% 
of the Asian population are carriers of null CYP2C19 alleles resulting in poor CYP2C19 
metabolism and 5-10% of Caucasians and 0-1% of Africans and Asians are poor 
CYP2D6 metabolisers 
31.   
 
As mentioned above (section 1.2.4.2), polymorphisms related to CYP3A5 and CYP3A7 
expression in adult liver have also been identified 
43, 46. Although genotypic variations  
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in CYP1A2 and CYP3A4 genes have been described, functional variations in these 
isoforms are rarely attributed to genetics 
30, 31. 
 
CYP variation may arise due to environmental factors, such as exposure to alcohol and 
tobacco, pollution and diet. For example, smokers present with higher expression of 
CYP1A and exposure to environmental pollutants such as polycyclic aromatic 
hyrdrocarbons (PAH) has a similar effect 
24, 61. Acetaminophen toxicity is enhanced by 
alcohol consumption due to the inductory effect of ethanol on CYP2E1, 
62 and dietary 
components including chargrilled meat, cruciferous vegetables and green tea all cause 
induction of CYP1A 
63. Certain disease pathologies, notably hepatic cirrhosis and 
steatosis are associated with decreased CYP function, and down-regulation of CYP 
enzymes arises in humans during inflammatory response in the liver 
64-68. 
 
Most human CYP enzymes do not show marked sexual differentiation in expression and 
there is a large variation in CYP activity in both males and females. CYP1A2 activity 
has been shown to be higher in human liver microsomes isolated from males although 
not all clinical studies support these findings. Liver microsomal CYP3A4 activity was 
also shown to be higher in females in the same study, and some, but not all, clinical 
studies support this finding 
68. There are many factors that may contribute to apparent 
sex differences in drug metabolism including the use of oral contraceptive steroids in 
females, therefore meaningful differences in the human population are difficult to 
ascertain. Similarly, age-related differences in CYP function in humans are difficult to 
interpret. 
 
Most commonly, ADR arise as a result of polypharmacy causing drug-drug interactions, 
resulting in pharmacological potentiation (apparent overdosing) or decreased clinical 
response (underdosing). Both of these effects are caused by CYP enzymes. 
1.2.5.1  Cytochrome P450 Inhibition 
Pharmacological potentiation arises as a result of Cytochrome P450 inhibition. This 
response occurs almost immediately post exposure and can occur through competitive 
inhibition (substrate and inhibitor binding the same active site), mechanism based 
inhibition (inactivation of CYP by a drug metabolite), or may be non-specific (caused 
by inhibitor binding directly to the heme portion of CYP) 
29.   
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1.2.5.2  Cytochrome P450 Induction 
Clinically, induction of CYP isoforms can lead to a decrease in the therapeutic efficacy 
of medications (a well documented example is induction in the metabolism of the 
CYP3A4 substrate cyclosporin by rifampicin resulting in organ graft rejection), or 
create an imbalance between detoxification and activation by the increased production 
of reactive metabolites, particularly in the case of CYP2E1 
69.  
 
In contrast to CYP inhibition, induction is a slow regulatory process which commonly 
occurs by increased gene transcription and protein synthesis. However alternative 
mechanisms of CYP induction involve post translational stabilisation of the CYP 
enzyme or inhibition of the enzyme degradation pathway. For instance ethanol mediated 
CYP2E1 induction 
70, 71 and CYP3A induction in rats following administration of 
troleandomycin arise through protein stabilisation 
37. 
 
Compounds causing de novo synthesis of CYP enzymes act through receptor mediated 
mechanisms involving nuclear receptors. 
1.2.6  CYP Induction by Nuclear Receptors 
Nuclear receptors (NR) comprise a family of ligand activated transcription factors and 
are responsible for the xenobiotic mediated induction of a number of genes involved in 
Phase I (CYP enzymes), Phase II (GSTs, SULTs) and Phase III metabolism (drug 
transporters) 
72-74. Sequencing of the human genome resulted in the identification of 48 
NRs, of which half are classified as orphan receptors since they have no known natural 
ligands. Within this category are true orphans (no known ligand) or adopted orphans 
(candidate ligands recently identified) 
75.  
 
A unified nomenclature system for the NR super-family was adopted in 1999 (Nuclear 
Receptor Nomenclature Committee 1999). This phylogeny based system divides NR 
into subfamilies, groups and genes based upon their sequence alignment: generally 
members of the same group share at least 80-90% identity in the DNA binding domain 
and at least 40-60% in the ligand binding domain 
75, 76. The system was based on the 
CYP nomenclature system and provides a logical numbering system and receptor code 
to support the trivial names given to many NR. For example RXRα is alternatively 
termed NR2B1 
75. 
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CYP inducers bind to, or activate, the aryl hydrocarbon receptor (AhR) or nuclear 
receptors (NR) including pregnane X receptor (PXR) and constitutive androstane 
receptor (CAR). AhR and CAR are located predominantly in the cytoplasm and 
translocate to the nucleus following activation. PXR has been detected in the cytoplasm 
but is widely thought to be concentrated in the nucleus 
37.  
 
Once activated, NR form heterodimers with a co-receptor which then binds to response 
elements located in the promoter region of the CYP gene, leading to increased 
transcription (Figure 1-5). 
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Figure 1-5. Mechanism of CYP induction: Nuclear Receptors (NR) form heterodimers with a co-
receptor (CoR) in the presence of CYP inducers. Heterodimer binding to Response Elements (NR-
RE), located in both proximal and distal CYP gene promoters, leads to increased transcription of 
CYP mRNA and increased xenobiotic metabolism. Adapted from
77.  
 
1.2.6.1  Aryl Hydrocarbon Receptor and CYP1A Induction 
The main chemical class responsible for CYP1A induction is aromatic hydrocarbons 
78, 
and it is activation of the aryl hydrocarbon receptor (AhR) which results in increased 
expression of CYP1A mRNA. Unliganded AhR is retained in the cytoplasm as a  
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stabilised protein complex also comprising two molecules of hsp90, XAP2 and p23. 
Following agonist binding, AhR undergoes a transformational change and is 
translocated to the nucleus where it loses its chaperone partners and forms a 
heterodimer with aryl hydrocarbon nuclear translocator (Arnt). AhR and Arnt both 
belong to the basic helix-loop-helix (bHLH)/Per-Arnt-Sim (PAS) protein family and it 
is these domains which drive heterodimer formation and DNA binding. AhR-Arnt 
heterodimers bind xenobiotic response element (XRE) in the proximal and distal 
promoter regions of the CYP1A gene resulting in transcription
79.  
 
The greatest exogenous source of AhR ligands are dietary components, including 
vegetables and teas, and environmental pollutants. In addition to CYP1A1, CYP1A2 
and CYP1B1, AhR mediated induction also regulates the expression of Phase II 
enzymes (UGT1A1, SULT 1A1, GST-A2) and multi-drug transporters (MDR1) 
30, 79, 80.  
 
1.2.6.2  Nuclear Receptor Mediated CYP3A induction 
As is the case with its substrates, CYP3A inducers may also be broad ranging. Ligands 
that bind the pregnane X receptor (PXR) and constitutive androstane receptor (CAR) 
both cause induction of CYP3A following heterodimerisation with RXRα. 
 
PXR (NR1I2) and CAR (NR1I3) are members of the same NR subfamily and have 
closely related sequences: in humans they share 66% sequence identity in the DNA 
binding domain and 45% in the ligand binding domain 
81. PXR and CAR also share the 
same co-receptor (RXRα) and can signal through the same response elements.  
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1.2.6.2.1  Pregnane X Receptor 
Although its primary target gene is CYP3A4, PXR also mediates the induction of 
CYP3A7, CYP2B6, CYP2C9 and CYP2C8, as well as UGTs, GST, and MDR1 and 
OATP2. PXR is activated by a wide variety of structurally diverse chemicals including 
drugs such as rifampicin, steroid hormones including progesterone, and dietary 
components such as St. John’s wort 
77, 82.  
 
PXR/RXRα heterodimers bind specific response elements in the CYP3A gene. These 
elements contain two nuclear receptor half-sites of the consensus sequence 
AG(G/T)TCA arranged as different configurations such as DR3 (direct repeat with 3 
nucleotide spacing) or ER-6 (everted repeat separated by 6 base pairs). 
In the proximal promoter of CYP3A4, the response element is an ER6 motif. 
The distal xenobiotic responsive enhancer module (XREM) contains three elements 
dNR1 (DR-3), dNR2 (ER-6) and dNR3 (DR3). Transfection experiments have shown 
that binding at both elements is required for maximum PXR transactivation. Further 
upstream from the distal element is a far enhancer containing an ER-6 element and 
binding here, along with the other response elements, further synergistically increases 
CYP3A4 transactivation 
83.  
 
The XREM is conserved in CYP3A7 and the motifs within can mediate PXR and CAR 
dependent induction. Like CYP3A4, the CYP3A7 promoter contains an ER6 motif 
which is responsive to rifampicin, however it contains two mutations which decrease 
affinity for PXR and CAR 
56, 84. High CYP3A7 expression in adult liver is associated 
with an allele that contains the CYP3A4 ER-6 motif 
46, 84. Other mutations in the 
CYP3A7 ER-6 promoter may increase CAR but not PXR mediated transcription 
84. 
 
Splice variants of PXR have been identified in human liver; PXR2 and PXR3 represent 
~7% and 0.3% of total PXR transcripts and lack a portion of the LBD 
85, 86. It is 
proposed that PXR1 and PXR2 have comparable transcriptional activity for CYP3A4 
but the splice variant has a restricted range of activators 
87.  
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1.2.6.2.2  Constitutive Androstane Receptor 
CAR was first identified as a mediator of CYP2B6 induction which heterodimerises 
with RXRα and then binds DR4 motifs in the phenobarbital-responsive enhancer 
module (PBREM) of the CYP2B6 promoter. CAR is now recognised as a mediator of 
CYP3A induction as well as CYP2C, CYP2A, SULT1A1, OATP2 and MRP3 
30, 80. 
 
CAR is transcriptionally active in the absence of ligand, and its activity is repressed 
upon binding of steroid ligands (androstanol and androstenol), which act as inverse 
agonists and prevent transactivation. Upon exposure to inducer, CAR translocates to the 
nucleus and activates its target genes. CAR localisation is regulated by 
dephosphorylation and translocation can be inhibited by phosphatase inhibitors 
37, 82. 
 
CAR is also activated by structurally diverse compounds, however it has a more 
restricted ligand profile than PXR. This can partly be explained by modelling studies 
which have demonstrated that the LBD of PXR is more accommodating to a wider 
range of compounds 
81. PXR and CAR share many ligands, however there are 
transcriptional differences. For example, androstenol and clotrimazole are both 
activators of PXR that inhibit CAR 
82. In the case of CAR, ligand binding alone may be 
insufficient to induce CAR translocation into the nucleus 
74. Phenobarbital is an indirect 
inducer of CAR which does not bind the receptor yet causes translocation. 
 
As described, PXR and CAR share response elements, hence both can activate multiple 
CYP genes (cross-talk). In the CYP2B6 gene, binding of CAR/RXRα predominates at 
the PBREM promoter, although this can also be bound by PXR/RXRα  
 
Like PXR, CAR binds the ER-6 motif in the CYP3A4 proximal promoter and the dNR1 
portion of the XREM; co-operation is required between the two response elements for 
CYP3A4 activation. Within the XREM, CAR has a weaker affinity than PXR to the 
dNR2 and dNR3 regions 
88. 
 
The CAR gene also undergoes alternative splicing. Effects of these splice variations in 
human liver are reported to include increased and decreased ligand dependent activity, 
and decreased formation of RXRα heterodimers 
89-92.  
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1.2.6.3  Nuclear Receptor Cross-Talk 
The signalling pathways of CAR and PXR converge at common response elements, for 
example in the CYP3A4 gene, and therefore they regulate overlapping sets of target 
genes. Moreover RXRα is a promiscuous nuclear partner forming heterodimers with 
multiple NRs and overlapping induction pathways are not limited to CAR and PXR. For 
example, upon activation, the vitamin D receptor (VDR), forms an RXRα heterodimer 
and induces the expression of CYP3A4, 2B6 and 2C9 (through ER6, DR3 and DR4), 
therefore competing for CYP regulation 
93, 94. 
 
For CAR, PXR (and VDR) mediated induction, RXRα is an obligate dimerisation 
partner in CYP induction, therefore decreased RXRα leads to diminished NR mediated 
responses and vice versa. 
 
CAR, PXR and RXRα expression have all been demonstrated to be under control of the 
glucocorticoid receptor (GR) and glucocorticoids (including dexamethasone and 
hydrocortisone) increase expression of these receptor proteins. Pascussi et al 
95-97 
propose a two step model whereby physiological concentrations of glucocorticoids act 
at GR to increase CAR, PXR and RXRα levels, and high concentrations of 
glucocorticoids directly activate PXR and CAR. GR activation may also have a direct 
role in CYP expression since glucocorticoid response elements have been identified in 
the CYP3A5 and CYP2C9 gene promoters. 
 
An alternative mechanism for NR cross-talk is biotransformation. For example the AhR 
antagonist omeprazole sulphide is metabolised by CYP3A4 to the AhR agonist 
omeprazole which in turn results in increased CYP 1A expression. This process is 
therefore increased in the presence of CYP3A4 induction 
73.  
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1.3  Liver Disease and Treatment 
Severe liver injury can result from toxic insult such as acetaminophen overdose or 
mushroom poisoning. Damage can also occur after exposure to other injurious agents, 
for example viruses and alcohol, which can cause massive and acute hepatic damage, or 
over a longer period of time, they may cause chronic liver injury leading to eventual 
fibrosis and then cirrhosis culminating in liver failure 
98. Metabolic diseases causing 
liver failure include Wilson’s disease in which an accumulation of copper causes liver 
damage 
99. Liver failure may also arise as an idiosyncratic drug reaction, as a 
complication of pregnancy or may (rarely) be idiopathic. 
 
1.3.1  Acute Liver Failure 
Acute liver failure (ALF) has a 60-90% mortality rate depending on the underlying 
cause 
100. Early symptoms include altered mental status, jaundice and abnormal blood 
clotting factors progressing to hepatic encephalopathy and multi-organ failure 
98. In 
addition to general therapies to treat these symptoms (such as administration of Vitamin 
K to treat coagulopathy), there are also some specific treatments available for certain 
etiologies (N-acetylcysteine (NAC) is an effective antidote for acetaminophen 
hepatotoxicity, Penicillin G and silibinin (silymarin or milkthistle) are antidotes for 
mushroom poisoning) 
215. A consideration relevant to the treatment of ALF is, that if 
metabolised by the liver (in particular by Cytochrome P450 enzymes), drugs will have a 
longer half-life due to delayed clearance. In these instances, drug exposure can be 
limited by administering smaller doses. All non-essential medications can also be 
withdrawn. 
 
Although individual symptoms of ALF can be mitigated by medical management, no 
agent or therapy that is beneficial to all patients has been identified. Whilst there are 
some patients who are able to achieve regeneration of sufficient liver mass to sustain 
survival, the only effective treatment for acute liver failure, currently recognised, is 
orthotopic liver transplantation. However, there is a shortage of donor organs, 
progression of disease is often too quick for a suitable donor organ to be found and 
contraindications to transplant may exist. Though a liver assist device could provide 
liver function in order to correct the manifestations of ALF, decades of research have 
thus far failed to identify a reliable liver support system with clear therapeutic benefit.  
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1.4  Extracorporeal Liver Support as a Treatment of ALF 
Extracorporeal liver support devices could provide short term support to liver function 
in patients with ALF and would serve as a bridge to liver transplantation or to liver 
regeneration. Providing time for liver regeneration would reduce demand for donor 
organs and also eliminate the necessity for the lifelong immunosuppressant regimen that 
arises as a consequence of transplantation.  
 
Existing devices can be divided into two categories: artificial (detoxificatory) or 
bioartificial liver devices. 
 
1.4.1  Artificial Liver Devices  
Artificial liver devices were designed to remove toxins from patient plasma that cause 
hepatic encephalopathy and multi-organ failure and work using one or more of the 
following methods: 
i)  membrane filtration to remove large molecules; 
ii)  dialysis of smaller molecules by diffusion exchange; and/or 
iii)  molecular adsorption by charcoal, resins or albumin. 
 
Devices that have undergone clinical evaluation include single pass albumin dialysis 
(SPAD), Molecular Adsorbents Recirculating System (MARS) and the Prometheus 
(fractionated plasma separation and adsorption) system. 
 
SPAD is based on albumin dialysis whereby an albumin dialysate acts as an acceptor 
for toxins. MARS is similar to SPAD, but includes an additional step to partially 
cleanse the albumin for recirculation by charcoal adsorption and anion exchange. In the 
Prometheus system, filtered plasma is passed through two adsorption columns (a natural 
resin and an anion exchange resin) to remove albumin bound toxins and this is 
combined with hemodialysis to remove water soluble toxins 
98, 101-105.  
 
These devices have had mixed success clinically. They have significant impact on 
removal of plasma toxins, but do not improve survival in ALF patients. The limitations 
of these devices probably reflect their non-specificity when removing compounds and 
their inability to replace the synthetic capacity that is lost when liver function is  
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compromised. Attempts to address these shortfalls have been made through the design 
of bioartificial liver devices.  
1.4.2  Bioartificial Liver Devices 
Bioartificial liver devices (BAL) contain a biological (cellular) component which 
performs liver specific functions such as protein synthesis, ammonia detoxification and 
drug metabolism. A number of BALs have undergone clinical evaluation, however, 
proof of success in a controlled human trial is lacking 
98. 
 
In order to successfully develop a BAL which, in addition to performing liver specific 
functions, is widely and readily available, certain biological and technical aspects 
should be addressed. 
 
i)  Cell type and source 
Choice of cell type is dependent on both function and availability. Hepatocytes are 
responsible for the majority of liver functions (see section 1.1.1), and so form the key 
component of a BAL. Although human hepatocytes may appear the strongest candidate, 
their use is restricted by a number of factors. Other cell types that have been considered 
in BAL systems include xenogeneic hepatocytes, cell lines of human liver origin, foetal 
hepatocytes and, most recently, stem cells. Advantages and limitations of potential cell 
types will be discussed in section 1.5. 
 
ii)  Cell number required to replace liver function 
The hepatocyte number in an adult human liver is in the order of 2x10
11 (assuming a 
1.5kg liver). Within a BAL, the provided cell function will be additive to the residual 
function of the patient’s damaged liver and restoring as little as 10% of liver function 
could make a critical impact. A biomass equating to this amount of normal liver cell 
mass (150g of cells) has been proposed by others as minimum required for a BAL to 
provide liver function 
106. This assumes, however, that function of supporting cells 
equals hepatocytes in vivo. Taking a more cautious approach, the Liver Group (LG) 
BAL provides for a cell number of 7x10
10 cells or 30% of hepatocyte cell mass.  
 
iii)  Culture format 
Classical monolayer cultures are not appropriate for BAL, not least because an 
extremely large surface area would be needed to achieve a sufficient cell number. Dead  
  43 
space and culture volume can be minimised in bioreactor culture and this is achieved by 
cell aggregation into a 3D culture format either by encapsulation or mechanical 
promotion of spheroid formation, or by allowing cells to proliferate and populate a 
defined space (hollow fibre). Maintaining hepatocytes in 3D culture also has beneficial 
effects on differentiation. 
 
In monolayer culture, hepatocytes flatten and spread following attachment. This results 
in loss of polarity and cuboidal shape, which disrupts their natural cell architecture.   
Improved differentiated function can be achieved in vitro by culture on extracellular 
matrix (ECM) such as collagen, but use of ECM is difficult in a bioreactor culture that 
allows direct contact with patient plasma - collagen promotes clotting factors and 
soluble ECM components could be released into the patient’s circulation. Additionally 
the majority of ECM preparations are animal derived, with therefore some biological 
hazard. 
 
In hepatocytes, perturbation of microtubule network has a deleterious effect on cell 
functions including NR signalling 
107, 108, hence CYP expression. The use of 3D culture 
systems promotes cell organisation to resemble that found in vivo, the cytoskeletal 
network and polarity of hepatocytes is maintained and this results in improved 
differentiated function including xenobiotic metabolism 
109-112.  
 
iv)  Bioreactor design 
In terms of bioreactor architecture, cells may be anchored to a matrix in 3D 
configuration with interwoven fibres providing gas exchange or plasma perfusion 
(hollow fibre devices). Alternatively encapsulated hepatocyte systems may be used, in 
which cell performance can be improved by a microgravity environment that provides 
decreased sheer stress and increased mass transfer. Cells in the device may be perfused 
by either whole blood or plasma which may come into direct cell contact or be 
separated by a mass transfer membrane 
98, 103, 105, 113. Environmental factors including 
supply of gases, flow rate and pH as well as nutrient replenishment can be tightly 
controlled, so that a physiological environment can be maintained during mass cell 
culture. Cryopreservation and transport of bioreactor cultures are also important 
considerations. 
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As described above, there are numerous constraining factors in BAL development. 
Early devices were designed using cells with limited function; these have allowed 
improvements in bioreactor design and culture conditions in order to generate and 
maintain larger biomasses. As the next step, identification of a more suitable cell source 
seems imperative. This involves the identification of cells that are obtainable on a large 
scale which are able to perform a full range of liver functions over a prolonged period of 
time.  
 
1.5  Sources of Cells That May be Considered for a BAL in Order to Establish a 
Functioning Cytochrome P450 System 
As the major drug metabolising enzyme in humans, achieving a functioning 
Cytochrome P450 system in bioartificial liver is critical. Potential cell sources which 
could provide this function will be discussed below. 
1.5.1  Primary Human Hepatocytes 
Primary human hepatocytes (PHH) have been extensively studied as in vitro models of 
liver function and are able to fulfil, to some extent, each of the metabolic demands 
required of BAL. However the use of PHH is impractical for a number of reasons. 
Availability is limited: liver cell mass obtained from partial hepatectomy is insufficient, 
explanted organs are preferentially used for transplantation and in discarded donor 
organs hepatocyte quality is generally compromised by steatosis and/or cirrhosis or 
traumatic insult. Bioreactor cultures comprised of PHH obtained from individual donor 
organs require extensive characterisation 
113. This is of particular relevance to 
xenobiotic metabolism due to the large range of interindividual variability in CYP 
expression levels that arises between donors (as discussed in section 1.2.5 above). 
 
When regards to cell volume, primary cells cannot be expanded in culture to provide a 
reliable biomass that is readily available. As an approximation, it has been suggested 
that the PHH yield required from hepatocyte elutriation is threefold greater than the 
number required for experimental purposes due to cells lost during processing (although 
this figure includes cryopreservation in the processing stages 
114. Pooling allogeneic 
hepatocytes (frequently done in functional studies) is possible, but is logistically more 
complicated and would theoretically introduce an increased immunological risk to the 
patient. Freezing procedures for PHH are inefficient, cell viability is often lost upon 
thawing, and this also restricts the utility of PHH.  
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There are also functional limitations to the use of PHH within a BAL. Loss of 
transcription of liver-specific genes occurs during isolation and subsequent culture: 
Cytochrome P450 function declines by up to 50% per day in culture and stabilises at 
around 10% of initial activity 
115. Loss of cell-cell contacts results in greater decreases 
in CYP expression 
116. CYP expression in PHH can be maintained through culture on 
ECM (such as collagen) or in 3D format using adapted media 
110, 111, 117-120, however, as 
discussed in section 1.4.2, use of certain culture matrices and media supplements are 
restricted by BAL compatibility.  
 
With regard to CYP expression, primary human hepatocytes can be considered as a 
‘gold standard comparator’ but are unsuitable for use in the LG BAL due to availability 
constraints and their inability to sustain function. 
 
1.5.2  Porcine Hepatocytes 
Porcine hepatocytes are readily available in large quantities and have been trialled with 
some success within the Amsterdam Medical Centre Bioartificial Liver (AMC-BAL) 
121. Although bioreactor systems loaded with porcine hepatocytes were demonstrated to 
be less stable than those loaded with human ones 
122, this has been addressed by 
immortalisation in the HepLui Porcine hepatocyte cell line, albeit (like in human cells) 
with some compromise in CYP function 
123, 124.  
 
Species specific differences are associated with metabolic incompatibility, particularly 
with regard to xenobiotic clearance. In spite of an inter-species discrepancy in CYP3A 
induction (CYP3A expression in pigs is induced by rifampicin but not by 
dexamethasone), porcine hepatocytes are considered to be a relatively good 
experimental model for human CYP3A function (including testosterone, nifedipine and 
midazolam metabolism) 
35, 36, 38, 125-127. Also, CYP expression in porcine hepatocytes 
could be considered less susceptible to variation caused by genetic and environmental 
influences that manifest in hepatocytes of human origin.  
 
In spite of the (limited) positive results obtained with porcine BAL systems, their use is 
largely considered unsuitable since xenotransplantation regulations in many European 
countries restrict the use of porcine hepatocytes in clinically applied BAL systems 
105;  
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xenogeneic cell lines are associated with protein incompatibilities and impart a risk of 
zoonoses, including porcine endoretroviruses (PERVs) and Hepatitis E 
128-130. Therefore 
cell lines of human origin are the long term viable option in BAL development.   
1.5.3  Human Hepatocyte Cell Lines 
Human hepatocyte cell lines could be used to obtain sufficient cell quantities for BAL 
use, although identifying a cell line that retains both proliferative capacity and hepatic 
function remains challenging. Hepatoma derived cell lines offer proliferative capacity 
but do not conserve normal hepatocellular properties due to gene silencing/ 
dedifferentiation. Additionally, hepatoma derived cell lines present a risk of 
tumorigenesis in the patient. Immortalisation of human hepatocytes results in better 
conservation of function, but this is at the cost of proliferation; increased proliferation 
leads to concomitant loss in function and carries a risk of oncogenic transformation; 
hence achievable biomass size is limited. 
 
1.5.3.1  Hep G2 Cells: The Cell Line of Choice for the Liver Group BAL 
The human hepatocellular carcinoma cell line Hep G2, isolated from a liver biopsy 
sample from a 15 year old Caucasian male, has been extensively characterised and is the 
hepatocyte cell line of choice for The Liver Group (LG) BAL. A subclone of HepG2 
cells, C3A, has been used in a BAL to treat patients in a pilot-controlled trial 
131 and, 
although no improvement in survival was observed in the hollow fibre based 
Extracorporeal Liver Asist Device (ELAD), this sets a regulatory precedence for use of 
HepG2 cells in a device to treat humans. A modified ELAD system using C3A cells 
(VitaGen ELAD®) is currently undergoing further clinical trials. 
 
HepG2 is a well characterised cell line that retains many hepatocyte characteristics 
compared to other hepatoma-derived cells 
132. It has been demonstrated that 3D culture 
of HepG2 cells results in the formation of cohesive spheroids leading to increases in 
hepatocyte specific functions, such as synthesis of albumin and clotting factors 
109, 133, 
134. Moreover HepG2 cells remain viable and retain their metabolic and synthetic 
capacity during liver failure plasma perfusion 
135. 
 
Drawbacks of HepG2 cells include a lack of ammonia metabolism and other limited 
levels of detoxificatory functions, including Cytochrome P450 activity, observed in 
monolayer culture.  
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1.5.3.1.1  Xenobiotic Metabolism in HepG2 Cells 
Reports of CYP expression in HepG2 cells are often conflicting. Some authors report no 
CYP3A4 expression in HepG2 cells; others have demonstrated inducible CYP3A 
function in these cells 
20, 136. It has been proposed that CYP activity in HepG2 cells is 
source dependent 
51 and that CYP function (or lack of) in HepG2 cells is influenced by 
a number of factors including culture media and passage number 
137-139. 
As a general consensus, transcripts of those CYP isoforms involved in drug metabolism 
are present at HepG2 cells but at levels lower than measured in PHH. As a result, under 
basal conditions in monolayer culture, Cytochrome P450 function in HepG2 cells is 
virtually undetectable 
20, 45, 136. 
Reasonable levels of CYP1A function can be achieved in HepG2 cells by chemical 
induction 
139; CYP1A activity alone is probably insufficient for a BAL since in humans 
it accounts for less than 10% of xenobiotic metabolism and in many instances may 
result in procarcinogen production 
42. Transcript levels of CYP3A4 in HepG2 cells are 
far lower (100-1000 fold) than in adult PHH 
136, 139. CYP3A7 expression in HepG2 cells 
has been measured at levels approaching adult primary human hepatocytes 
20 but, as 
described in section 1.2.4.2, the contribution of CYP3A7 to CYP3A expression and 
function in adult PHH is minimal. This implies that the level of HepG2 CYP3A7 
expression is insufficient to provide CYP3A function within a BAL.  
 
Expression of enzymes involved in Phase II metabolism are more in accordance with 
those found in PHH. Levels of SULT1A1, 1A2, 1E1, mGST-1, GST  1, NAT1 and 
EPHX1 in HepG2 cells are similar to or exceed those measured in PHH and GST 
enzyme activity in HepG2 cells was approaching levels in PHH. As an exception, UGT 
expression and activity is compromised in HepG2 cells 
18.  
 
Overall, there is an imbalance between Phase I and Phase II metabolism in HepG2 cells. 
This could be addressed by improving CYP expression in HepG2 cells, which could be 
achieved in a number of ways.  
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i)  Adaption of Culture Conditions to Improve HepG2 CYP Function 
In HepG2 cells, modified culture conditions can alter hepatocyte specific functions.  
In the case of C3A cells, parental HepG2 cells were adapted to different culture 
medium, which had the apparent effect of increasing urea production
131. WGA cells 
were derived from HepG2 cells by metabolic selection involving culture in medium 
containing fructose in place of glucose. These cells have a higher level of CAR and 
CYP2B6 which is inducible by phenobarbital 
140. Induction of CYP3A4 function in 
HepG2 cells has also been achieved by co-culture with bovine endothelial cells 
141. 
ii)  Genetic Manipulation of Hep G2 Cells: Cytochrome P450 Isoforms 
The construction of a stable HepG2 derived CYP containing cell line would lend itself 
to a designer cell line approach for the bioartificial liver device. Transient transfection 
of single CYP isoforms results in high levels of CYP function in HepG2 cells
142. Other 
laboratories have previously produced HepG2 cell lines which stably express single 
isoforms of CYPs 
143-146, however these cell lines had a low metabolic activity relative 
to PHH; sustained function of multiple CYP isoforms at a level high enough for use in a 
BAL is difficult to attain.  
iii)  Genetic Manipulation of HepG2 Cells: Transcription Factors and Nuclear 
Receptors 
Creation of stable CYP transfectants does not address deficiencies in mediators of CYP 
expression in HepG2 cells: nuclear receptors (NR) and liver-specific transcription 
factors are expressed at lower levels in HepG2 cells. Increased HepG2 expression of 
transcription factors, including HNF-4 and C/EBPα or nuclear receptors including PXR, 
CAR and GR, results in upregulated CYP function 
44, 147-152. NR reporter gene assays 
are frequently used by the pharmaceutical industry as part of the drug discovery process 
153; potentially this could provide a means to introduce HepG2 CYP3A function within 
a BAL.   
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1.5.3.2  Alternative Hepatocyte Cell Lines for BAL Use 
Recently, a number of immortalised human hepatocyte cell lines have been developed 
with reported CYP3A activity. Selected cell lines are compared in Table 1-2. 
 
Table 1-2. Recently developed hepatocyte cell lines with CYP functionality demonstrated by 
Western blot and/or mRNA analysis with functional assay. 
Cell Type  Origin  Culture 
Format/ 
Recommended 
Media 
CYP 
Function/ 
Nuclear 
Receptors 
References 
Fa2N-4  12 year old 
female 
Immortalisation 
following SV-
40 
transformation 
of PHH culture 
Collagen 
substratum 
Multicelltech 
proprietary 
medium 
(MFE™) 
CYP1A2, 
2C9, 3A4 
AhR, PXR 
 
154-156 
 
HepaRG  Adult female 
Hepatocellular 
carcinoma 
derived 
2% DMSO  
Williams’ E 
Medium + 
50 M 
hydrocortisone 
CYP1A2, 
2C9, 2D6, 
2E1, 3A4 
AhR, PXR, 
CAR, PPARα 
 
157-159 
HC-04  Spontaneously 
immortalised 
from normal 
liver obtained 
following 
hepatoma 
resection 
Fibronectin and 
collagen matrix 
Cambrex 
Hepatocyte 
Culture Medium 
(HCM) Bulletkit  
CYP1A2, 2C9 
2E1, 3A4 
PXR, AhR 
 
160, 161 
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Although these cell lines demonstrate CYP functionality, they may not necessarily be 
suited to large scale BAL culture. In addition to being able to perform drug metabolism 
functions in standard monolayer conditions, these cells must be able to function in BAL 
specific medium, and survive bioreactor culture. 
 
HepaRG cells only differentiate into hepatocyte-like morphology following treatment 
with 2% DMSO 
162 and HC-04 and Fa2N-4 cell lines are both cultured on collagen 
matrices which are unsuitable for use in extracorporeal circuits. Furthermore CYP 
function of these cell lines may be insufficient (based upon reported literature values). 
CYP3A4 protein expression can be increased in HC-04 cells by the PXR agonist 
rifampicin and these cells are able to metabolise the CYP3A substrate midazolam, 
however their drug metabolising capacity is equivalent only to PHH from donors with 
low levels of CYP3A4 function 
160.  
 
Fa2N-4 cells demonstrate both CYP1A2 (EROD) and CYP3A4 (testosterone, 
midazolam) activity, but their levels of function are less than 75% of PHH. Expression 
levels of mediators of CYP1A2 (AhR) and CYP2C/3A (PXR) induction in Fa2N-4 cells 
match those found in PHH but their reduced drug metabolism capacity could partially 
be explained by a deficiency in the CYP2B/CYP3A mediator CAR and by decreased 
expression of hepatic uptake transporters 
154, 155.  
 
1.5.4  Human Foetal Hepatocytes for BAL Use 
Human foetal hepatocytes (FHH) are expandable and express relevant drug 
metabolising enzymes that are upregulated by 3D culture 
163, so may be a considered as 
a source of CYP3A function within a BAL. FHH differ from adult PHH in their 
preferential expression of CYP3A7 to CYP3A4 and in this respect are often compared 
to HepG2 cells which are widely reported to share this characteristic 
20, 138, 164. As in 
adult liver, there is a high level of interindividual variability in both CYP and NR 
expression in FHH 
165. 
1.5.4.1  Ontogeny of Human Hepatic CYP3A 
In FHH, variation in CYP expression can in part be attributed to ontogeny. Whilst some 
report a ‘developmental switch’ at birth between the two isoforms 
166, others more  
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recently have reported a ‘developmental transition’ 
53, 167. The latter author described a 
study that examined CYP expression in human liver samples obtained from 8 weeks 
gestation to 18 years of age. CYP3A7 expression was found to be high in foetal liver 
and decreased after birth (although continued to be the predominant CYP3A isoform in 
the neonate until several years after birth), whereas CYP3A4 expression was low in the 
foetal liver and remained so at birth and during the neonatal period; increases in human 
liver CYP3A4 expression are not achieved until several years after birth. 
 
1.5.4.2  Role of CYP3A7 in FHH 
The dominant expression of CYP3A7 in the foetus could be attributed to its role in 
foetal development 
168. CYP3A7 is central to the role of placental estriol biosynthesis 
(important to foetal growth and parturition) and CYP3A7 specific catalysis also has a 
protective role, preventing foetal exposure to steroids and retinoic acid which may 
influence proliferation and differentiation. CYP3A7 has also been implicated in 
promutagen activation 
169, although the determinants of CYP3A7 expression in HepG2 
cells are less clearly defined. 
 
1.5.4.3  FHH Mediated CYP Metabolism within a BAL 
As described above, whilst expression of CYP3A4 in FHH is lower than in adult cells, 
CYP3A7 expression is increased. Potentially this could provide a means to CYP3A 
mediated metabolism within a BAL. In order to address the issue of limited supply, 
immortalised foetal liver cell lines could also be considered 
170, 171.  
 
When evaluated within the AMC-Bioreactor, CYP function  (lidocaine metabolism) of 
the immortalised foetal hepatocyte cell line cBAL111 was lower (>99%) than levels 
measured in adult PHH 
171. In contrast, FHH loaded into a laboratory scale (10x 
downscale; 55ml) bioreactor consisting of a perfused 3D culture system were able to 
metabolise lidocaine, indicating CYP3A (and CYP1A2) function; moreover extent of 
elimination was 3.5 fold greater than in mature porcine hepatocytes and 6.6 fold greater 
than adult primary human hepatocytes 
122, though this may be due to the phenotypic 
instability of the primary adult cells. The use of FHH within a BAL will be discussed 
further in Chapter 3.  
  52 
1.5.5  Stem Cells for BAL Use 
Stem cells regenerate themselves through mitotic cell division and generate specialised 
cells through differentiation and so have the potential to offer an unlimited hepatocyte 
cell supply for a BAL. A number of stem cell-like cells that can differentiate into 
hepatocyte-like cells have been identified which could act as potential surrogates to 
provide liver functions within a BAL. The benefits and limitations, including their CYP 
activity, of four cell lines of differing stem cell origin will be discussed below. 
1.5.5.1  Human Embryonic Stem Cells (hESC) 
Cytochrome P450 function was measured in hepatocyte-like cell lines (SA cells) 
differentiated from hESC by 18-30 day treatment with basic fibroblast growth factor 
(bFGF) 
172. Gene expression (mRNA) was compared between PHH, HepG2 and SA cell 
lines. Both CYP1A2 and CYP3A4/7 expression were lower in SA cells than PHH; the 
discrepancy in CYP3A expression between PHH and SA cells was greater for CYP3A4 
than CYP3A7 and there was greater expression of CYP3A7 than CYP3A4 in the latter 
cell type. CYP1A2 expression was higher in SA cells than in HepG2 cells, CYP3A4/7 
expression was generally comparable between HepG2 cells and SA cell lines. Both 
CAR and PXR mRNA expression were present in SA cells. 
 
Western blot analysis was used to quantify CYP1A2, 3A4 and 3A7 protein expression 
in SA cells and PHH. Presence of all 3 proteins was detected in SA cells and their 
expression was increased by chemical induction, but expression levels were low 
compared to PHH and CYP3A/1A function could not be detected in SA cell lines. 
 
In the example described above, hepatocyte-like cells derived from hESC demonstrated 
expression of relevant CYPs at mRNA and protein level but were unable to provide 
CYP function. They did however express high levels of a number of hepatic 
transcription factors including HNF4α, C/EPBα and β, and the increased presence of 
CYP3A7 relative to CYP3A4 could be indicative of an immature phenotype. Potentially 
hepatic function could be improved by further differentiation.  
 
The cells characterised in the above study illustrated a practical consideration of stem 
cell development for BAL use. Proliferation of hESC is generally superior when 
performed on a feeder cell layer (probably due to cell-cell interaction between the two 
cell types). SA cells were grown on a layer of mouse embryonic fibroblasts (MEFs) and  
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contained a low amount (around 12%) of MEF contamination. Contamination of 
progenitor cells with a feeder cell line, which has also been described by others 
173, 
could have an impact on cell function and (particularly in the case of cross-species 
contamination) would render cells unsuitable for BAL use. Use of feeder cell lines can 
be avoided by the use of ECM such as Matrigel but these are of animal origin and also 
carry a risk of cell line contamination 
100, 173. 
1.5.5.2  NeoHep Cells 
NeoHep cells are generated by transdifferentiation of human peripheral blood 
monocytes (PBMC) obtained from healthy human donors. They were developed by 
culturing PBMC in dedifferentiation medium to generate “programmable cells of 
monocytic origin” which were then induced to hepatic differentiation by 14 day 
treatment with fibroblast growth factor-4 (FGF-4) 
174, 175. They resemble PHH with 
respect to their phenotype (although are 2-4 times larger), express hepatocyte markers 
and a range of hepatocyte specific functions including albumin secretion, urea 
production, lactate production and phase I and phase II metabolism.  
 
CYP1A2 and CYP3A4 mRNA expression was quantified in NeoHep and both isoforms 
were shown to increase during differentiation, however CYP1A2 and CYP3A4 mRNA 
expression was lower (62 and 83%) than in PHH. CYP3A4 mRNA expression in 
NeoHep cells was also decreased relative to HepG2 cells. Both CYP1A2 and CYP3A4 
proteins were present in NeoHep and were inducible with 3-MC or rifampicin 
respectively; however level of expression was lower than measured in PHH. 
 
Function of CYP1A and CYP3A4 was also quantified in NeoHep cells under basal 
conditions and, in accordance with their mRNA and protein expression, was decreased 
relative to PHH 
175, 176: CYP1A1/1A2 function was ~9 fold lower in NeoHep cells 
although the fold induction values measured between PHH and NeoHep cells were 
comparable, hence function remained lower in the latter cell type. CYP3A4/CYP1A2 
function was ~ 5-fold lower in NeoHep compared to PHH but the fold induction 
between PHH and NeoHeps were comparable 
177, 178. 
 
Testosterone metabolism was also measured in NeoHep cells to determine CYP3A4 
function. Following rifampicin induction their production of 6β-hydroxytestosterone  
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was ~ 1000 times less than induced human PHH and ~10-times less than vehicle treated 
PHH maintained in culture 
175. 
 
Interestingly, CYP expression varied in NeoHep cell lines which were developed from 
PBMC from different donors. This demonstrates that interindividual variation in CYP 
expression described in section 1.2.5 is conserved at the stem cell level. Practically this 
phenomenon could be addressed by using PBMCs pooled from multiple donors and 
selection of high-activity cell lines for expansion. Function of NeoHep cells is 
insufficient for BAL; potentially this could (like hepatocyte cell lines) be increased by 
bioreactor culture. Considerations relevant to this would include the stability of these 
cells during mass expansion and prolonged culture. Use of growth factors during this 
process would be a prohibitive factor for large-scale bioreactor culture. 
1.5.5.3  Human Hepatoblasts from Foetal Hepatocytes 
Hepatoblasts are hepatic stem cells in foetal liver which develop to mature hepatocytes 
during foetal liver development and have been considered for BAL use 
179. Sodium 
butyrate (SB) was used to induce hepatoblast formation from foetal hepatocytes. These 
cells were then cultured on hydroxyapatite microcarriers (derived from a biocompatible 
mineral species which lends itself to artificial organ use) in order to produce high 
density cultures for bioreactor use. Under high density culture conditions, following SB 
differentiation, hepatoblast cells had improved CYP function which was induced by 
rifampicin and measured by benzyloxyresorufin-O-dealkylation activity. However in 
preliminary experiments, proliferation on a clinically applicable scale was not achieved, 
and CYP3A4 function was not characterised any further. 
1.5.5.4  Human Adult Liver Resident Stem Cells (HLSC) 
Human liver stem cells have been identified in adult liver that have self regenerating 
capacity and are multipotent 
180. In adhesion, these cells differentiate into mature 
hepatocytes only after the addition of growth factors (HGF, FGF4). By using a hollow 
fibre rotary BAL, differentiation can occur without the addition of growth factors and, 
when cultured in this manner, Cytochrome P450 activity is increased (approximately 
three-fold) relative to adhesion cultures 
181 which supports a hypothesis that 
Cytcohrome P450 function is favoured by a 3D culture environment. Achieving stem 
cell differentiation in this manner could abrogate the use of exogenous growth factors 
which would provide a more economic means of achieving BAL scale biomasses of 
stem cells.   
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1.5.5.5  Stem Cell Conclusions 
With respect to the use of stem cells within a BAL, challenges include achieving 
sufficient function relative to adult PHH, achieving unlimited proliferation and 
controlling differentiation to achieve relevant levels of hepatic function without the use 
of culture matrices or exogenous growth factors. Expression of various isoforms of CYP 
enzymes occur at different stages of differentiation 
182: CYP 1B1 and 2E1 proteins and 
mRNA have been detected in cells at early stages of differentiation, but CYPs 3A4, 3A7 
were 2C9 were absent. Additionally, phenotypic and genotypic stability in vitro must be 
maintained in bioreactor culture in order to generate large biomasses 
98. Beneficial 
effects of bioreactor culture on CYP expression and function have been shown for 
human stem cells however these need to be demonstrated for longer term cultures on a 
clinically applicable scale.  
 
1.5.6  Alternative Cell Lines for a Co-Culture Approach 
Within a BAL, it may be feasible to enhance or supplement hepatocyte function through 
the use of a dual cell approach and there are two possible options for this. 
i)  Co-culture to enhance existing CYP function 
Heterotypic cell interactions are absent from pure hepatocyte cultures and, when 
included as part of a 3D culture environment, may aid in the maintenance of CYP 
function by improving hepatocyte viability and maintaining differentiation. This has 
been demonstrated in primary hepatocytes of both rat and human origin using both 
allogeneic (human cells from multiple donors) and xenogeneic (rat and mouse) cells of 
hepatic and non-hepatic origin. Examples of cell types which result in improved 
hepatocyte CYP function in co-cultures include, but are not limited to, stellate cells, 
endothelial cells, biliary epithelial cells and fibroblasts 
110, 141, 183-185.  
 
Co-cultures of the above nature improve ECM deposition and cell-cell contact, which in 
turn improves hepatocyte specific functions in PHH such as CYP activity. However, 
influence of these co-cultures on HepG2 function may be less beneficial since HepG2 
cells themselves are able to produce many ECM proteins and form cell-cell contacts in 
3D culture. In addition, issues associated with cell line contamination would need to be 
addressed.  
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ii)  Non-liver cell lines to provide a detoxificatory component 
As described in section 1.2, Cytochrome P450 drug metabolising functions are not 
restricted to the liver and the expression and function of these enzymes has been 
considered in many non-hepatic cell lines. Potentially a non-liver cell line could be 
cultured alongside HepG2 cells to provide CYP3A function within the LG BAL. 
(Arguably) cell lines derived from the gastrointestinal (GI) tract are the most promising 
option since CYP3A4 and associated transcription factors are expressed in the GI 
mucosa and contribute heavily to first-pass metabolism at this site 
186, 187.  
 
A study was carried out by Schmiedlin-Ren et al. 
188 to compare CYP expression in 
monolayer cultures of primary human hepatocytes with cell lines derived from tissues 
known in man to express CYP3A enzymes. 1α, 25-dihydroxyvitamin D3 (VD3) 
mediated CYP3A4 induction was observed in Caco-2 (colon), LS180 (colon), and 
HPAC (pancreas) cell lines. In the monolayer culture conditions used by the authors 
(laminin ECM with optimised differentiation medium), CYP3A4 enzyme expression 
and substrate metabolism were considerably lower in the cell lines than in the primary 
cultures. This may be a significant limitation to the use of these cells within a BAL, 
although the effects of 3D culture on CYP3A function in these cell lines has not been 
widely explored. This will be addressed further in Chapter 5.  
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1.6  The Liver Group BAL 
The biomass of the current LG BAL comprises HepG2 cells encapsulated in alginate 
(Figure 1-6). Alginate forms a hydrogel which is permeable, provides anchor support 
and allows cell proliferation in 3D format. Patient plasma is perfused through the beads 
and this allows direct contact with the spheroids, and therefore exchange of large 
proteins between plasma and spheroids, which is not restricted by mass transfer 
membranes used in some devices. 
 
A B C A B C
 
Figure 1-6. Following alginate encapsulation of a single cell suspension (A), multicellular colonies or 
spheroids (B) form within alginate beads (C). Typically, following 8 days of static culture, a 450 M 
bead contains 20-25 spheroids and each spheroid contains 8-20 HepG2 cells 
189. 
 
The BAL process would begin by expanding HepG2 cells in monolayer culture prior to 
encapsulation in alginate at a seeding density of 1.5x10
6 cell/ml beads. The beads would 
be cultured in a fluidised bed bioreactor (FBB) using a medium optimised for maximum 
growth and differentiation. FBB culture provides a microgravity environment allowing 
high mass transfer between beads and medium without shear stress and improved cell 
proliferation within the beads thereby increasing bead performance. Parameters 
including flow rate, oxygenation, temperature and pH can also be also tightly regulated 
within the bioreactor circuit to provide optimal conditions. Cells would be cultured for 
8-10 days to generate at least a third of the total cell numbers found in a 70kg male 
human liver (7 x 10
10 hepatocytes).  
 
The LG BAL would be a dual circuit device. In the first circuit, plasma is isolated from 
the patient by plasmapheresis and then passed to the secondary circuit, comprising  
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HepG2 cells held within the FBB, where it is purified by recirculation through the 
biomass. Plasma is then returned to the primary circuit via a quality management 
system which is included for the removal of cell debris and DNA. 
 
So that the device can be used as a bedside treatment in an emergency situation, the 
cartridge holding the cultured beads would ideally be cryopreserved for long-term 
storage.   
 
1.6.1  Considerations Relevant to the Use of Cell Lines in a Bioartifical Liver 
Device  
As described in previous sections, there are several existing cell sources available that 
exhibit CYP3A function, however in order to be fit for purpose, these cells must be able 
to fulfil regulatory requirements and be easily adaptable to BAL relevant culture 
conditions whilst maintaining a high level of function.  
1.6.1.1  Regulations Relevant to the Development of a BAL for Clinical Use 
A device intended for use in treating humans must comply with healthcare regulations 
stipulated by governing bodies such as the MHRA (Medicines and Healthcare products 
Regulatory Agency, UK), the FDA (Food and Drugs Administration, USA), the EMEA 
(European Medicines Agency) and the JPAL (Japanese Compliance and Medical 
Approval Agency). The requirements of these agencies are by no means unified 
190, 
however to attain multi-market approval, the following components should be 
considered. 
 
Cell Source: immortalised cell lines should not contain active retroviral elements. 
Tumor derived cell lines should not carry risk of tumorigenesis. Any cell line should 
have traceable origins and also be homogenous and free from contamination (potentially 
caused by components such as feeder cells, murine viral elements from Matrigel 
matrices or adventitious microbial elements). 
 
Culture Matrix: alginate is the selected culture matrix for the LG BAL. It was originally 
purified from seaweed, is bio-compatible, easy to manipulate and can be cryopreserved. 
Importantly, is already widely used within the food industry and in the development of 
pharmaceuticals and wound dressings. Alginate purity, although outside the scope of  
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this thesis, has been considered by others during LG BAL development. To be used 
within the LG BAL any cell line should be compatible with this culture matrix: 
proliferation, function and viability of selected cell types should not be adversely 
affected by alginate encapsulation.  
 
DNA/Cell Debris Transfer: biological contaminants from the biomass should be 
controlled, purified and eliminated. As described, DNA and cell debris transfer will be 
controlled and monitored by a Quality Management System. Cell viability will have 
considerable impact on biomass integrity and so should be maintained at a high level 
within bioreactor culture.  
1.6.1.2  Cryopreservation and Storage 
To allow a BAL to be used routinely in clinical applications, a long-term storage 
method must be developed. This will most likely involve cryopreservation. 
 
The effect of cryopreservation on Cytochrome P450 function has been studied in both 
animal and human hepatocytes 
191-194 and has been shown to be minimal; hepatocytes 
appear to maintain their CYP function subsequent to cryopreservation (albeit with a 
slight decrease in basal activity), and various techniques employed during freezing 
(such as use of cryoprotectants and progressive freezing) may aid in this endeavour 
191, 
195. 
 
It should, however, be noted that impact of cryopreservation on CYP function has 
mainly been considered following freezing of low volume simple cell suspensions. 
Cryopreservation of encapsulated liver spheroids, particularly on a large scale, bears 
greater resemblance to the cryopreservation of tissue. The impact of this process 
(including the influence of components of the solutions used) on Cytochrome P450 
function will need to be accounted for. 
 
Short-term storage should also be addressed. When measured in vivo, a period of 
prolonged (5-10 days) 4°C exposure resulted in increased rat hepatic CYP content 
particularly for CYP1A1/2 
196, 197. Studies using the AMC-BAL 
198 found that 
detoxificatory function was maintained in porcine hepatocytes  following a period of 
mild hypothermic preservation (15°C for up to 24 hours ).   
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1.6.1.3  Culture Conditions and Media Supplements 
Choice of culture media is important when considering CYP function within BAL 
relevant cell lines and there are both practical and functional constraints. Large volumes 
of media are required for BAL culture, and so it should not therefore be prohibitively 
costly. Addition of growth factors can promote hepatocyte differentiation, but these are 
also expensive for mass culture use and may decrease CYP function; presence of human 
hepatocyte growth factor had an inhibitory effect on both CYP function and expression 
for multiple isoforms of CYP1, CYP2 and CYP3 
199, 200.  
 
In primary cultures, different culture media have a demonstrable effect on CYP function 
(although this effect is species specific) 
117, 201, 202. If culture medium does not support 
hepatocyte differentiation, there will be a rapid drop in drug-metabolising capacity and 
there is also compelling evidence that CYP function in HepG2 cells is influenced by 
culture media 
51, 137.  
 
Media supplements, used in hepatocyte studies to improve differentiation, include 
glucocorticoid agonists (such as dexamethasone, prednisolone, or hydrocortisone) and 
insulin. These also regulate expression of Cytochrome P450 and nuclear receptors 
including PXR, CAR and RXRα 
55, 95, 96, 203-205.  
1.6.1.4  Using Human Fresh Frozen Plasma to Supplement Culture Medium 
In order to eliminate the use of animal derived reagents within the LG BAL, human 
fresh frozen plasma (FFP) has been used in culture medium in place of place of foetal 
calf serum (FCS). Plasma is pooled from multiple donors in order to minimise donor 
dependent effects and the use of FFP as a media supplement has been shown to 
significantly improve LG BAL proliferation (data not yet published). Improved 
hepatocyte differentiation following culture in human FFP should improve CYP 
function, however, plasma components including cytokines and free fatty acids could 
also regulate Cytochrome P450 expression. The possible effects of FFP exposure on 
CYP induction will be explored in Chapters 3 and 4. 
 
1.6.1.5  The Effect of Liver Failure Plasma Exposure on CYP Function 
Since it will be in direct contact with patient plasma, prolonged perfusion of the BAL 
biomass in liver failure plasma (LFP) could affect its Cytochrome P450 function.  
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Following perfusion (3-15 hours) of human hepatocyte cell lines in normal human 
plasma, improved function (relative to culture medium) of some but not all Cytochrome 
P450 isoforms has been demonstrated 
133, 171, however plasma from patients with acute 
liver failure is potentially cytotoxic and could have further implications for BAL 
function. 
 
In addition to its pro-apoptopic properties 
206, plasma from liver failure patients may 
potentially contain endogenous and xenobiotic components which could inhibit CYP 
enzyme function; within a BAL, LFP will be from a single patient and the effects of 
interpatient variation, arising from the range of clinical and biochemical manifestations 
that present during acute liver failure, cannot be discounted. This has been demonstrated 
using monolayer cultures of the immortalised human hepatocyte cell line HHY41 
exposed to normal plasma, LFP or culture medium for 16 hours 
133. Dibenzanthracene 
(DBA) mediated induction of CYP1A was significantly reduced in three out of four 
LFP samples (determined by a decrease in MROD and EROD activity when compared 
to control plasma). Two out of four LFP samples significantly decreased the 
biotransformation of caffeine to its primary metabolites. Steroid (androst-4-ene-3, 17 –
dione) metabolism was altered in two out of four LFP samples. EROD and MROD 
activities were improved following incubation with normal plasma (4 independent 
samples) relative to culture medium whereas caffeine biotransformation and steroid 
metabolism were unaffected.  
 
More recently the effect of LFP on CYP function has been examined in an alginate 
encapsulated HepG2 system. Coward et al 
135 demonstrated that DBA induced CYP 
function was maintained in HepG2 cells following a 3 hour exposure to LFP which 
diminished by around 30% after 6 hours of exposure. In contrast, CYP function was 
maintained following 6 hour exposure to plasma from healthy donor plasma.   
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1.7  Experimental Approaches Selected for this Project 
As described, existing CYP expression may be upregulated by chemical induction. This 
may be exploited within BAL relevant cell lines to achieve improved CYP function. 
Cells will be treated with compounds that are known CYP inducers and their function 
then measured using a range of bioassays. 
1.7.1  Chemical Induction of CYP Function 
Inducers that have been shown to increase CYP1A and CYP3A expression were 
selected and these are shown in Table 1-3. 
Table 1-3. Chemical inducers selected for use in this thesis. 
Inducer 
Chemical 
Class 
CYP  NR 
Dimerisation 
Partner 
References 
Dibenzanthracene 
Aryl 
hydrocarbon 
CYP1A  AhR  ARNT 
61 
Indirubin 
Kinase 
Inhibitor 
Endogenous 
Ligand 
CYP1A  AhR  ARNT 
207, 208 
Dexamethasone  Glucocorticoid  CYP3A 
GR/  
PXR/CAR 
RXRα 
95, 96, 204 
Rifampicin 
Rifamycin 
antibiotic 
CYP3A 
CYP2C  
CYP2B 
PXR  RXRα 
209 
Phenobarbital  Barbituate 
CYP2B 
CYP2C 
CYP3A 
CAR  RXRα 
209 
1α,25-
Dihydroxyvitamin 
D3 
Hormone 
(Biologically 
active form of 
Vitamin D3) 
CYP3A  VDR  RXRα 
188 
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1.7.1.1  BAL Relevant Considerations With Respect to Inducers 
Both vehicle and inducer must be suitable for use in a device intended for human use. In 
this thesis, dimethyl sulfoxide (DMSO) 0.1% v/v was selected as a vehicle due to its 
ability to solubilise all of the selected inducers. Although the concentration of DMSO 
selected was one that has been previously demonstrated not to have an effect on CYP 
induction 
210-212, DMSO will not be used as a solvent vehicle within the LG BAL. If 
necessary, an appropriate vehicle would have to be sought depending upon selected 
inducer, which with the exception of dibenzanthracene (DBA) are therapeutic agents 
and/or endogenous ligands and so would meet regulatory guidelines in the context of 
human exposure. DBA is carcinogenic and human exposure should be avoided, 
therefore would probably be inappropriate for BAL use, but was included in this study 
as a classical CYP1A inducer with a different chemical class to indirubin which is an 
endogenous AhR ligand found in human urine, and has been identified as the active 
component of several Chinese herbal medicines utilised in the treatment of cancer. 
1.7.1.2  Duration of Induction 
Chemical induction is a slow regulatory process which may take between 24 and 96 
hours to come about. Although this is partly due to the system in which induction is 
measured (in vivo, liver slices, cell culture systems), this time frame is also CYP 
dependent; it is widely thought that CYP1A induction occurs between 24 and 48 hours 
post exposure whereas CYP3A induction peaks 48-96 hours post exposure 
61, 213. These 
time differences are likely due to the different receptors involved in isoform specific 
induction as described in Table 1-3.  
 
Since inducer will not be present within a BAL while it detoxifies patient plasma, an 
equally pertinent point to consider is how long the upregulated effect would last in the 
absence of inducer. Although there is little in vitro data available, a consensus based on 
in vivo data derived from humans is that it takes time for enzyme function to return to 
basal levels following induction. Upregulated CYP1A function was measured up to 5 
days following aryl hydrocarbon exposure and CYP3A mediated verapamil metabolism 
was increased above baseline for up to 2 weeks in patients following 1 week of 
rifampicin treatment 
37, 63.  
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1.7.2  Methods of Quantification 
Chemical induction of Cytochrome P450 function requires existing expression in 
relevant cell lines. The aim of induction experiments will be to increase and 
subsequently quantify CYP function, as demonstrated by the following schematic:  
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1.7.2.1  Broad Spectrum CYP Activity 
7-Ethoxycoumarin (7-EC) is metabolised by Cytochrome P450 to produce 7-
Hydroycoumarin (7-HC), which can then be extracted and quantified by fluorescence; 
any increases in CYP activity directly correlate to an increase in fluorescent product 
formation. 
 
7-EC is often described as a “general” CYP substrate since it has been demonstrated 
that multiple enzymes in the CYP1, CYP2 and CYP3 families are active catalysts of 7- 
ethoxycoumarin O-deethylation (ECOD). It can thus be used as a method of detection 
when an index of broad spectrum CYP activity is required 
214. 
7-Ethoxycoumarin  7-Hydroxycoumarin  CYP1/2/3 
O-deethylation  
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1.7.2.2  Identifying Activity Within a Specific CYP Family 
1.7.2.2.1  Testosterone Metabolism 
Metabolism of testosterone (TST) by Cytochrome P450 can be measured by HPLC 
coupled with UV detection. Different CYP isoforms are involved in regioselective TST 
oxidations and in humans, the relative contribution of each CYP to testosterone 
metabolism has been measured using individual isoforms expressed in baculovirus 
infected insect cells 
52. CYP3A isoforms are the most important in forming the major 
metabolites of testosterone and are responsible for 94% of all metabolite production. 
Further to this, 6β-hydroxytestosterone (OHTST) accounts for 86% of all metabolite 
production and the majority (84%) is produced by CYP3A4 > CYP3A5 > CYP3A7. 
However with respect to other metabolites, 2α-OHTST is produced as a minor 
metabolite of testosterone by CYP3A7 to a greater extent than by CYP3A4 (16 fold). It 
is also important to note that although testosterone may be metabolised by CYP1A 
(CYP1A1>CYP1A2) to produce the 6β-OHTST metabolite, it has 60 fold and 1.3 fold 
lower activities than the CYP3A4 and CYP3A7 isoforms respectively. Measurement of 
testosterone depletion and production of 6β-OHTST will therefore primarily provide a 
measurement of CYP3A4 function, however depletion of testosterone may also be 
indicative of other CYP function. 
 
1.7.2.2.2  Promega P450-Glo™ Assays 
Luminesence based assays are a relatively fast and sensitive method of measuring CYP 
activity. Promega P450 Glo™ assays use luminogenic substrates which are inactive 
until metabolised by CYP enzymes to luciferin, which then reacts with an additional 
luciferase reagent to produce an amount of light proportional to CYP enzyme activity.  
All substrates have the same core structure but each has a derivitisation which confers 
its selectivity for individual CYP isoforms.  
 
Luciferin ME and Luciferin BE were originally chosen to measure CYP1A2 and 
CYP3A activities in this thesis. Luciferin PFBE was used in some later studies to 
confirm CYP3A function. The structures and selectivity of these substrates are shown in 
Figure 1-7 and are summarised below: 
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Luciferin ME was developed as a CYP1A2 substrate but was later found to cross react 
with other CYP isoforms, most notably CYP2C8/9 (involved in xenobiotic metabolism) 
and CYP4A11 which is involved in arachidonic acid conversion in control of 
hypertension and fatty acid metabolism. Others have demonstrated that CYP2C 
metabolism by this substrate can be inhibited by 1µM sulfaphenazole 
136. 
 
Luciferin BE was the original luminogenic CYP3A substrate developed by Promega. It 
is metabolised by CYP3A4/5/7 and also cross reacts with CYP4F12 which is expressed 
in human liver. The exact function of this isoform is undefined but it is active towards 
arachidonic acid and prostaglandin H2 and is implicated in antihistamine metabolism. 
 
Luciferin PFBE was developed for use in cell based assays. It is also metabolised by 
CYP3A4/5/7 but has lower background signal and does not react with CYP4F12.  
 
 
Figure 1-7. Luminogenic P450-Glo substrates are converted to luciferin by CYP isoform spcific 
mediated catalysis. (top) Isoform specificity of substrates is determined by a derivitization upon the 
core structure (→) that arises from beetle luciferin. (bottom) Substrate specificity for individual 
CYP isoforms was measured using recombinant CYP enzymes heterologously expressed in insect 
cell microsomes. Images were all obtained from 
216.  
1.7.2.2.3  Invitrogen Vivid ® CYP450 Substrates 
Invitrogen Vivid ® CYP450 screening kits were developed to assess metabolism of 
human CYP enzymes involved in drug metabolism. The substrates are metabolised by 
specific CYP isoforms to a fluorescent metabolite which can be excited in the visible 
light spectrum. Vivid ® BOMFC (benzyloxymethylfluorescein) is metabolised by 
CYP3A and CYP2B6. Substrate metabolism can therefore be measured in the presence 
or absence of inhibitors to indicate CYP3A or CYP2B6 function; in this thesis 
clarithromycin will be used to inhibit CYP3A but not CYP2B6 function 
54, 217.  
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1.8   Aims and Hypothesis 
The aim of the following work was to identify and characterise a suitable cell source to 
provide Cytochrome P450 function within a BAL. 
 
As described, CYP3A is the most abundantly expressed subfamily in adult human liver 
and responsible for the metabolism of the largest range of xenobiotics and is therefore 
deemed essential for a BAL. Hep G2 cells, used within the LG BAL, are generally not 
believed to express this subfamily at a functional level; however CYP1A function has 
been proven in these cells.  
 
Hypothesis: When measured in vitro, Cytochrome P450 activity in human cell lines 
is dependent on culture conditions. Existing CYP expression can be improved by 
chemical induction and 3D culture which will result in improved function. It can 
also be increased by genetic manipulation. 
 
Overall, the aims of this thesis were to: 
 
1.) Determine an appropriate gold standard comparator from preparations of 
human liver 
 
CYP function will be measured in adult PHH isolated from a number of donors in order 
to assess the range of function in human liver. In order to obtain a broad representation 
of CYP activity in an adult human liver which differentiates between effect of culture 
conditions and interindividual variation, CYP activity will also be examined in human 
liver microsomes (HLM) isolated where possible from tissue and hepatocytes from the 
same donor. This will provide independent confirmation of variation in CYP activity 
discounting effects of hepatocyte isolation and culture. 
 
In foetal cells the predominant CYP3A isoform is CYP3A7 and in this respect they are 
often compared to HepG2 cells. Basal and inducible CYP activity will therefore also be 
considered in these cells. 
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2.) Characterise existing CYP activity in Hep G2 cells considering the effect of 
adaptation to BAL culture conditions 
 
When cultured in simple culture media HepG2 cells do not achieve CYP mediated drug 
metabolising functions at an appropriate level; however CYP function in HepG2 cells 
may depend both on source and culture conditions. Through chemical induction, 3D 
culture and adaptation of medium components it will be determined how our current 
BAL culture conditions, which were developed to improve hepatocyte differentiation, 
impact on CYP activity in HepG2 cells.  
 
3.) Investigate suitable cell lines that could be adapted to act as the 
detoxificatory component of a BAL to provide CYP3A function 
 
Intestinal cell lines which express CYP3A could be treated with inducers to provide 
CYP function within a BAL. Two different cell lines, Caco2 and LS147T, were 
selected. Alternatively immortalised hepatocyte cell lines from normal liver may exhibit 
superior CYP function to HepG2 cells. The human hepatocyte cell line HC-04 was 
selected due to its expression of CYP proteins and its ability to metabolise the CYP3A 
substrate midazolam.  
 
The adaptability of these three cell lines to large scale 3D culture will be investigated to 
determine their ability to both proliferate and to provide CYP functions under these 
conditions. 
 
4.) Create, by genetic manipulation, an inducible HepG2 cell line suitable for 
use in a device to treat humans  
 
It has previously been reported that decreased mRNA expression of CYPs is responsible 
for low functional activities of these enzymes in hepatoma cells; therefore improving 
HepG2 cell expression of CYP mRNA could improve enzyme function. 
 
CYP induction is regulated by nuclear receptors. The expression of nuclear receptors 
will be improved in HepG2 cells by genetic manipulation and this, in conjunction with 
chemical induction could improve CYP function in HepG2 cells to provide function 
comparable to that measured in primary human hepatocytes.  
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CHAPTER 2  General Methods 
 
Cell culture reagents were obtained from Invitrogen. All other reagents were obtained 
from Sigma Aldrich unless otherwise stated. 
2.1  Mammalian Cell Culture 
2.1.1  Preparation of Collagen Type I from Rat Tail Tendons 
 
Collagen type I was prepared from rat tails and applied to tissue culture plates to promote 
hepatocyte monolayer culture. 
 
Materials 
Rat Tails (5 will yield ~ 2g of collagen) 
0.01M Acetic Acid 
50ml polypropylene centrifuge tubes 
Sterile universal tubes 
Magnetic Stirrer 
Centrifuge 
 
Method 
Rat tails were ethanol sterilised and transferred to a class II microbiological safety hood. 
The vertebrae of the tail from tip to base were sequentially broken using artery clamps, 
and the central tendon removed after each break. The tendons were weighed and then 
300mls of acetic acid per gram of tendon added. The mixture was stirred for 2-3 days at 
4°C until the tendon was dissolved and then transferred to 50ml polypropylene 
centrifuge tubes and centrifuged for 2 hours at 800g. Supernatant was dispensed into 
sterile universal tubes and stored at 4°C until required.  
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2.1.2  Collagen Coating of Cell Culture Plates 
 
Materials 
12-well tissue culture plates 
Sterile HBSS without calcium and magnesium 
Sterile saline 
Collagen type I (prepared from rat tail) 
UV Lamp 
 
Method 
To a 12 well plate, 1 ml of collagen per well was added and left for 5 minutes at room 
temperature. Following this time, excess collagen solution was vigorously flicked from 
the wells which were then rinsed twice with 1ml of HBSS. 1ml of sterile saline solution 
was added to each well and the plate irradiated without the lid under short wave UV 
light for 15 minutes. Each plate was used on the same day as preparation. 
 
2.1.3  Preparation of Culture Media 
During media preparation, all supplements were pooled into a 50ml centrifuge tube and 
filter sterilised prior to addition to culture media. 
2.1.3.1  Primary Adult Human Hepatocyte Media (AHM) 
Phenol Red-Free Williams’ Medium E (Sigma W4128) 
2mM L-Glutamine 
100U/ml Penicillin/0.1mg/ml Streptomycin 
1.25mg/ml Fungizone 
10mM Nicotinamide 
10nM Dexamethasone 
5.8ng/ml Insulin (Actrapid Novonordisk) 
1mM Ascorbic Acid-2 Phosphate 
50mM (±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox)  
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2.1.3.2  Human Foetal Hepatocyte Medium (HFM) 
Phenol Red-Free Williams’ Medium E  
20mM HEPES 
2mM L-Glutamine 
100U/ml Penicillin/0.1mg/ml Streptomycin 
1.25mg/ml Fungizone 
10mM Nicotinamide 
200mM Ascorbic Acid-2 Phosphate 
100nM Dexamethasone 
6.25mg/ml Insulin 
6.25mg/ml Transferrin 
6.25ng/ml Sodium Selenite 
5.35mg/ml Linoleic Acid BSA 
550mg/ml Pyruvate 
 
2.1.3.3  Hep G2 Culture Medium (Complete Culture Medium) 
α-MEM with ribonucleosides and deoxyribonucleosides (Invitrogen 32571) 
10% Foetal Calf Serum (FCS) 
2mM L-Glutamine 
100U/ml Penicillin/0.1mg/ml Streptomycin 
1.25mg/ml Fungizone 
50mg/ml Linoleic Acid BSA 
0.04mg/ml Hydrocortisone 
0.04mg/ml Thyroid Releasing Hormone (TRH) 
9.5mg/ml Insulin 
0.002mg/ml Sodium Selenite 
 
To prepare high glucose (HG) medium used for 3D culture, 4.44ml of a 45% D-glucose 
solution was added to a-MEM Complete Culture Medium to give a final glucose 
concentration of 25mM. 
 
2.1.3.4  HC-04 Culture Medium 
HCM Bullet Kit (Lonza CC-3198); Includes Hepatocyte Basal Medium (HBM) and 
Singlequots). 
10% FCS  
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2.1.3.5  Caco 2 and LS147T Culture Medium 
Phenol Red-Free DMEM (Invitrogen 21063) 
10% FCS 
100U/ml Penicillin/0.1mg/ml Streptomycin 
1.25mg/ml Fungizone 
1x Non-essential amino acids 
1mM Sodium pyruvate 
 
2.1.3.6  Preparation of FFP 
For some studies, human fresh frozen plasma (FFP) was added to culture medium in 
place of FCS. During collection of FFP, the anticoagulant used was sodium citrate 
which cannot be used within the LG BAL since it sequesters calcium from alginate 
destroying polymerisation. In order to prevent this, calcium chloride was added to 
neutralise the original anticoagulant, and heparin added in its place to prevent clotting.  
 
FFP was obtained from the Royal Free Haematology Department, thawed and pooled 
from multiple donors according to blood group. 4µl/ml of a 1M CaCl2 solution was 
added to the thawed FFP along with 40 IU/ml Heparin (Multiparin, CP 
Pharmaceuticals). 50ml aliquots were stored at -20°C until required.  
Prior to media preparation, FFP was thawed overnight at +4°C, centrifuged at this 
temperature at 1000g for 20 minutes and supernatant then carefully decanted. Culture 
media containing FFP was passed through a 0.45µM filter prior to use to remove 
platelets. 
 
2.1.4  Culture of Human Cell Lines 
 
HepG2 cells were originally obtained from the HPACC (ECACC), adapted to long term 
culture in complete culture medium as described in section 2.1.3.3 and used by the 
Liver Group (LG) for a number of years. These cells were passaged 1:6 twice a week. 
 
BALG2 cells are early passage HepG2 cells which were obtained from the HPACC in 
March 2009 and were naïve to any media adaptations. The BALG2 nomination is used 
throughout this thesis to differentiate from LG HepG2 cells.   
  73 
 
HC-04 cells were obtained under licence from Siam Life Science Ltd. (Thailand). These 
cells were passaged 1:3 every 3-5 days. 
 
Caco 2 cells were from the department of Gastroenterology at the Royal Free Hospital 
and were passaged 1:6 twice a week. 
 
LS147T cells were kindly provided by Dr Hassan Shahbakhti and Dr Surinder Sharma 
from the UCL Cancer Institute. Cells were passaged 1:6 twice a week. 
 
Materials 
HBSS (without calcium and magnesium) 
0.25g/L Trypsin 0.1g/L EDTA (Invitrogen # 15400-054), 1g/L glucose in citrate saline 
(4.4g/L trisodium citrate.2H2O, 10g/L KCl) 
2% Trypan blue in PBS 
Tissue culture flasks 
Haemocytometer 
FCS containing 10% DMSO 
2ml Cryovials 
Polystyrene container lined with cotton wool 
37°C water bath 
 
Method 
Cell culture work was performed in a class II microbiological safety cabinet using 
disposable sterile plastic ware. All cell lines are adherent and were cultured in a 37°C 
incubator with a humidified atmosphere of 95% air, 5% CO2. Medium was changed 
every 2 days and cells were passaged by trypsinisation when 70-80% confluent. 
 
To passage cells, medium was poured from the flasks, cells washed twice with HBSS 
and then incubated for 1-2 minutes at 37
oC with 1.5ml trypsin-EDTA/25cm
2 of growth 
area.  After this time, cells were detached from the surface of the flask by tapping it 
firmly. An equal volume of warmed medium containing FCS was added to stop the 
action of the trypsin and cells were centrifuged at 300g (1200rpm) at room temperature 
for 4 minutes. Supernatant was discarded and the cells resuspended in 5mls growth  
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medium. The cells were then syringed with a 21G needle 4-5 times to disaggregate cell 
clumps and flasks seeded at the ratios indicated above. 
 
2.1.4.1  Determination of Cell Number and Viability 
Cell number and viability was determined by trypan blue exclusion of non viable cells.  
This was done by mixing 160ml of HBSS, 20ml of trypan blue and 20ml of homogenous 
cell suspension.  After 2 minutes 10ml of the solution was loaded onto a 
haemocytometer chamber and viable and non viable cells were counted.   
 
2.1.4.2  Cryopreservation and Reconstitution of Cell Lines 
Cell lines were maintained in culture for a maximum of 10 continuous passages, it was 
therefore necessary to prepare cell bank stocks of each cell line.  
 
Cryopreservation 
Following trypsinisation, cells were resuspended in culture medium at a density of 
1x10
7cells/ml. An equal volume of freezing mix (FCS + 10% DMSO) was then added 
and 1ml aliquots transferred to cryovials. Vials were placed in a polystyrene container 
lined with cotton wool which was placed at -80°C which allowed freezing to occur at a 
rate of approximately 1°C/minute. Once frozen, cells were transferred to liquid nitrogen 
for long term storage. 
 
Cell Revival 
To revive cells, cryovials were removed from liquid nitrogen and quickly thawed by 
swirling in a 37°C water bath. The thawed cell mix was immediately transferred to a 
50ml centrifuge tube and 10mls of medium added over a time period of 5 minutes to 
gradually dilute the freezing mix. Following centrifugation at 300g for 4 minutes at 
room temperature, supernatant was discarded, cells resuspended in 15mls of medium 
and then transferred to a T80 flask. Following attachment, medium was replenished and 
cells maintained in monolayer culture as described above. 
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2.2  Alginate Encapsulation and 3D Culture 
2.2.1  Inotech Cell Encapsulation 
Inotech encapsulation was used when small volumes of beads were required for static 
culture of cells. The Inotech IER-20 Cell Encapsulator system (Inotech, Dottikon, 
Switzerland) is based on the principle that a laminar liquid jet is broken into equally 
sized droplets by a superimposed vibration. Additionally, an electrostatic dispersion unit 
is used to charge the surface of the liquid which transforms the one-dimensional droplet 
chain into a funnel-like multilane stream. This prevents beads from hitting each other in 
flight, and from hitting each other as they enter the polymerisation solution (Figure 2-1). 
When the alginate drops contact the calcium of the polymerisation buffer beads are 
formed by cross linkage of alginate chains with divalent cations. 
 
 
Figure 2-1. Inotech IER-20 Cell Encapsulator System.  
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Materials
100ml 2% Alginate – pH 7.4 
0.15M Sodium chloride 
1M Sodium hydroxide 
15mM HEPES buffer 
2% w/v Alginic acid sodium salt from 
Macrocystispyrifera kelp             
(Sigma A2033) 
 
Polymerisation Buffer – pH 7.4 
0.15M Sodium chloride 
1M Sodium hydroxide 
15mM HEPES buffer 
0.204M Calcium chloride 
 
Consumables 
Volumetric flasks 
Schott bottle 
Magnetic flea 
Syringe filter 
Baked Pyrex beakers (3 hours at 180°C) 
Stainless steel forceps 
Inotech syringe pump system (Inotech, 
Dottiken, Switzerland) 
Bottomless beaker 
Elastic band 
Nylon mesh 
DMEM supplemented with 10% FCS, 
P/S and Fungizone 
High glucose (HG) medium 
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Preparation of 2% Alginate Solution  
100ml of HEPES buffered saline solution was prepared; pH was adjusted to 7.4 using 
1M NaOH. This solution was placed in a foil covered 250ml Schott bottle containing a 
magnetic stirrer. Alginic acid was added gradually and the solution stirred overnight at a 
slow speed. The following day it was autoclaved at 121°C for 10 minutes and then left 
to cool to room temperature before use.  
 
Preparation of Polymerisation Buffer 
A 0.204M CaCl2 solution was prepared in HEPES buffered saline. This was pH 
adjusted to 7.4 using 1M NaOH, autoclaved at 121°C for 25 minutes and then left to 
cool to room temperature. Pluronic acid was filter sterilised and added immediately 
before use. 
 
Preparation of Alginate Cell Suspension 
Cells were trypsinised, the pellet resuspended in 5ml of HG medium and cell number 
and viability determined by trypan blue exclusion. Cells were then diluted to the 
required density (typically 1x10
6/ml for HepG2 cells) in a mixture of one part 2% 
alginate to one part culture medium. This solution was drawn up through a 50 M filter 
into a 50ml syringe and attached to the syringe pump of the Inotech.  
 
Cell Encapsulation and Bead Collection 
The cell suspension was passed through the encapsulator at a flow rate of 5ml/min using 
a 200 M nozzle vibrating at 1295 Hz (vibration amplitude 3), which yielded spherical 
beads approximately 400 M in diameter. Electrostatic charge was set to 0.5 volts. The 
flow of beads fell into gently stirred polymerisation buffer where they were maintained 
for 15 minutes. After this time beads were removed from polymerisation buffer by 
pouring them into a beaker with a 200 M mesh bottom where they remained whilst 
being washed twice with DMEM. They were then transferred to 50ml centrifuge tubes 
and resuspended with HG media. Once beads had settled, the volume collected was 
estimated from the graduations marked on the side of the tube. Beads were subsequently 
diluted and cultured as required. 
 
Static Culture of Beads 
Beads were resuspended in a 175cm
2 tissue culture flask with HG media at a ratio of 
0.25ml beads to 8ml culture medium. 8mls of this suspension was transferred into each  
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well of a six well plate. Each well contained a 100 M cell strainer on which the beads 
rested. This allowed beads to be easily removed from wells during media changes or for 
assays. Media was replenished every other day. 
 
2.2.2  JetCutter Cell Encapsulation 
JetCutter encapsulation was used when large volumes of beads were required. This 
machinery was operated by more experienced colleagues. 
The JetCutter system (geniaLab®) utilises a cutting tool with asymmetrically arranged 
wires, which is inclined relative to a vertical solid stream of liquid, resulting in a 
horizontal cut as the tool passes through the liquid stream.  This produces cylindrical 
segments which form beads due to surface tension on their way to a collecting bath 
which will polymerise the material (Figure 2-2).  
 
Figure 2-2. Jetcutter encapsulation system.  
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Materials 
2% alginate solution 
Polymerisation buffer  
HG Culture Media 
DMEM medium supplemented with 10% FCS, P/S and Fungizone 
Baked Pyrex beakers  
Autoclaved JetCutter components (pressure vessel, inline filter, nozzle holder and 
nozzle assembled and autoclaved, cutting tool, cutting disc, collection cover) 
Autoclaved 5L stainless steel basin  
Baked funnel for filling pressure vessel  
Plastic beaker for collecting waste from JetCutter 
25ml measuring cylinder for calibration of flow rate 
Plastic bottomless beaker and elastic band  
200mm nylon mesh  
Magnetic Stirrers 
Stainless steel spatula  
Sterile consumables including, 15ml Nunc tubes, 50ml Nunc tubes, 50ml syringes, 25ml 
serological pipettes, Gilson tips and T175 culture flasks 
 
JetCutter Set Up 
Cells were prepared in a mixture of one part 2% alginate to one part HG culture medium 
as described for section 2.2.1. This mixture was added, through a funnel, to the pressure 
vessel which was immediately capped and the stirring motor set to 50rpm. Air pressure 
was applied and the pressure vessel outlet tap opened to begin encapsulator flow 
through. Flow rate was calibrated to 0.33ml/sec by adjusting air pressure. Run 
parameters on the control panel were set as follows: flow rate 0.33ml/sec, 350 M 
nozzle size, 60 wires (wire diameter 100), motor speed 3600rpm. JetCutter software was 
used to calculate optimal angle of inclination of the cutting tool which was then 
attached along with the cutting disk and collection cover. A 5L basin containing 3L of 
polymerisation buffer was placed on a magnetic stirrer under the nozzle and set at a low 
speed. 
 
 
  
  80 
Cell Encapsulation and Bead Collection 
Once setup was completed, the outlet tap on the pressure vessel was opened to 
commence liquid flow and the Jetcutter motor started. Initial flow through was collected 
in a beaker and discarded. Once a clean flow through was established, beads were 
collected in polymerisation buffer. Timing the duration of collection allowed the 
volume of liquid encapsulated to be calculated. Beads were then poured from their 
collection basin into a 1L beaker and polymerisation buffer removed by transferring 
them to a beaker with a 200 M mesh bottom. Beads were retained on the mesh bottom 
whilst being washed with DMEM and then transferred into 50ml centrifuge tubes where 
they were resuspended in HG medium. Once beads had settled, the volume collected 
was estimated from the graduations marked on the side of the tube. Beads were then 
diluted and cultured as required. 
2.2.3  Removing Cells from Alginate 
Cell spheroids were removed from alginate by the addition of EDTA which chelates the 
calcium from the alginate allowing it to dissolve and release the spheroids. Solutions 
used in this procedure were treated first with DEPC (described in section 2.4.1) to 
inactivate any RNase enzymes that may be present which could potentially degrade any 
RNA prepared from spheroids.  
 
Materials 
1x sterile PBS 
16mM EDTA in 0.15M NaCl treated with 0.1% DEPC, pH7.4  
0.15M NaCl treated with 0.1% DEPC, pH7.4 
6-well plates 
Small spatula 
2ml microfuge tubes 
2ml syringe 
21G needles 
 
Method for Beads Maintained in 6 Well Plates 
To harvest cells from beads, they were removed from the wells in their cell strainers and 
washed twice by immersion into 5ml of cold 1xPBS that had been added to a 6 well 
plate. The plate was kept on ice throughout the procedure. Using a small spatula the 
beads were scraped out of the strainers into 2ml microfuge tubes containing 1.8ml  
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16mM EDTA in 0.15M NaCl. Beads were incubated at room temperature with this 
solution for 15 minutes and then syringed 4-5 times using a 21g needle to disaggregate 
the cell spheroids. The samples were then centrifuged at 5000g for 5 minutes at 4°C, the 
supernatant removed and the pellet washed with 1.5ml of 0.15M NaCl and centrifuged 
again. Remaining supernatant was removed leaving the cell pellet to be used for 
subsequent experiments. 
 
Method for Large Volumes of Beads Maintained in Bioreactor Culture 
Beads were distributed evenly into 50ml centrifuge tubes (approximately 10ml 
volumes) and 35mls of 16mM EDTA in 0.15M NaCl added. The solution was incubated 
at room temperature for 15 minutes with regular mixing by inversion and then 
centrifuged at 1500g for 15 minutes. The pellet was washed with 10ml of 0.15M NaCl 
and centrifuged again. Remaining supernatant was then removed leaving the remaining 
cell pellet. 
2.3  Analysis of Cell Viability and Protein Content 
2.3.1  FDA/PI Staining 
Fluorescein diacetate (FDA) is cell-permeable and is hydrolysed by esterases that are 
only present in metabolically active cells to form a fluorescent compound. Propidium 
iodide (PI) is a membrane impermeant dye which emits a red fluorescence when bound 
to DNA. This occurs only when cell membranes are compromised and represents non-
viable cells 
218.  
 
Materials 
1mg/ml FDA in DMSO 
1mg/ml PI in water 
1x PBS containing calcium and magnesium 
1ml pipette with the end cut down by ~ 2mm 
Microscope slides 
Coverslips 
Nikon Eclipse microscope 
DX1200 camera 
FDA filter block (excitation filter of 465-495nm, emission filter of 515-555nm) 
PI filter block (excitation filter of 510-560nm, emission filter of 590nm) 
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Method 
A sample of alginate beads was transferred in culture medium to a 1.5ml microfuge 
tube, allowed to settle and the medium aspirated. Beads were washed twice with PBS 
and resuspended in 500ml of PBS.  20ml of PI and 10ml of FDA were added, the solution 
gently mixed with the beads and allowed to stand for 90 seconds. The beads were then 
washed once more with PBS and finally resuspended in 500 l of PBS. A portion of the 
stained beads were transferred to a microscope slide using a cut down pipette tip to 
allow the beads to pass through without damage.  Excess liquid was removed with a 
tissue and a coverslip placed over the beads.  The beads were then visualised with a 
fluorescence microscope. Phase contrast, live and dead images were captured using 
Lucia Imaging Software with a DX1200 camera. Live and dead images were normally 
taken at x10 magnification at exposures of 32ms and 250ms respectively. 
 
2.3.2  Tetrazolium Salt Viability Assays 
 
Tetrazolium salts are reduced to a formazan product by mitochondrial reductase 
enzymes in active cells. This conversion can therefore be directly related to 
metabolically active cells which can be quantified by determining increase in 
absorbance readings, relating to increases in product formation. WST-1 was selected for 
use in this project since, following exposure, cells remain intact and so can be used for 
further studies. 
 
Materials  
2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium 
salt (WST-1-NBS Bioligicals W201) 
1-Methoxy-5-methyl-phenazinium (mPMS) 
Serum free culture media 
HBSS 
96 well clear flat bottomed culture plate 
Spectrophotometer at 450nm 
 
Method 
A solution of prewarmed culture media containing 500mM WST-1 and 100mM mPMS 
was freshly prepared immediately prior to each assay. Cells were washed twice with  
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HBSS and an appropriate volume of reaction mix added to each well of cells (1ml for a 
12 well plate or 100ml for a 96 well plate) which were incubated in a humidified 37°C 
5% CO2 incubator for 1 hour. After this time 100ml of culture supernatant was 
transferred to a 96 well plate and absorbance read at 450nm. 
 
2.3.3  Bicinchoninic Acid Protein Assay 
 
The Bicinchoninic Acid (BCA) assay was used to determine protein content of samples. 
Presence of protein resulted in a colour change from green to purple which was 
quantified by determining increases in absorbance readings which relate directly to 
increases in protein concentration 
219. 
 
Materials 
BCA Reagent: 1% BCA, 2%Na2CO3, 0.16% NaK tartrate, 0.4% NaOH, 0.95% 
NaHCO3 - pH  corrected to 11.25 using NaOH 
4% Copper Sulphate 
10mg/ml Bovine Serum Albumin (BSA) 
Plate sealer 
Plate shaker 
96 well clear flat bottomed culture plate 
Spectrophotometer at 570nm 
 
Method 
A standard curve was prepared using BSA in PBS (1-0.03 mg/ml). Immediately prior to 
the assay, BCA reagent and copper sulphate were mixed at a ratio of 50:1. 100ml of this 
reagent was added to each well of a 96 well plate, along with 100ml of standard or 
sample. The plate was sealed, mixed on a plate shaker for 30 seconds and then 
incubated at 37°C for 30 minutes. Absorbance was read using a spectrophotometer at 
570nm. 
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2.4  Molecular Biology Methods 
2.4.1  DEPC Treatment of Solutions 
Diethylpyrocarbonate (DEPC) was used to treat laboratory prepared solutions to remove 
RNase enzymes (although it is not compatible with Tris buffers or HEPES). 
Solutions were treated overnight with 0.1% v/v DEPC (Sigma D5758) and then 
autoclaved for 25 minutes at 121°C to inactivate the DEPC yielding CO2, H2O and 
ethanol. 
 
2.4.2  DNA Precipitation by Ethanol/Sodium Acetate 
Ethanol precipitation was used to purify and concentrate DNA. Glycogen acts as an 
inert carrier to allow visualisation of low concentrations of DNA. This procedure was 
carried out on ice. All centrifugation steps were at 4°C. 
 
Materials 
100% Ethanol 
3M Sodium Acetate (pH 5.2) 
20mg/ml Glycogen from mussels (Roche) 
70% Ethanol in DEPC treated sterile H2O 
 
Method 
DNA to be precipitated was measured into a sterile microfuge tube along with 1 l of 
glycogen. A 1/10
th volume of sodium acetate was added and the solution mixed by 
vortexing. A 2.5 x volume of chilled ethanol was then added, mixed by vortexing and 
incubated on ice for 1 hour. After this time, tubes were centrifuged at 13 000g for 15 
minutes and the supernatant discarded. The remaining pellet was washed with 200 l of 
chilled 70% ethanol and centrifuged for a further 10 minutes. The pellet was air dried, 
redissolved in 6µl of sterile water and quantified using a NanoDrop at 230nm. 
 
2.4.3  RNA Extraction and DNase Treatment 
RNA extraction and precipitation was performed according to the manufacturer’s 
instructions. With the exception of 75% ethanol, all reagents were supplied with the 
RNA isolation kit. All procedures were carried out on ice, all centrifugation steps were 
performed at +4°C and all consumables were certified DNase and RNase free.   
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Following isolation, RNA was treated with DNase to remove any trace amounts of 
contaminating genomic DNA which may interfere with subsequent reactions. 
 
Materials 
RNAgents Total RNA Isolation System (Promega Z5110) 
75% Ethanol in DEPC treated sterile H2O chilled to -20°C 
RQ1 RNase-Free DNase (Promega M6101) 
Sterile 2ml microfuge tubes 
Sterile 0.2ml PCR tubes 
ND1000 Spectrophotometer (NanoDrop Technologies) 
GeneAmp® 2700 thermocycler (Applied Biosystems) 
 
RNA Isolation 
To prepare RNA from freshly isolated primary human hepatocytes and HepG2 
spheroids, 1x10
6 cells were transferred to a sterile microfuge tube and pelleted by 
centrifugation at 1000g. Supernatant was aspirated and cells resuspended in 120µl 
denaturing solution.  For monolayer cultures, media was aspirated and 120µl (12 well 
plates) or 60µl (96 well plates) of denaturing solution added. The mixture was pipetted 
several times to disrupt the cells and transferred to a sterile microfuge tube. 
 
To the disrupted cell suspension, a 1/10
th  volume of 2M Sodium Acetate was added and 
mixed by inversion, followed by an equal volume of Phenol:Chloroform:Isoamyl 
Alcohol. The tube was capped and the contents mixed by inversion, shaken vigorously 
for 10 seconds and then chilled on ice for 15 minutes. After this time the tubes were 
centrifuged at 10,000g for 20 minutes. The top aqueous phase was transferred to a fresh 
microfuge tube, taking care not to disturb the interphase material and an equal volume 
of isopropanol added. RNA was precipitated at -20°C for 30 minutes and then pelleted 
by centrifugation for 10 minutes at 10,000g. The supernatant was decanted and 1ml of 
chilled 75% ethanol added to wash the RNA which was then pelleted once more by 
centrifugation. The supernatant was removed and the RNA was air dried for 5-15 
minutes and resuspended in 15µl of nuclease-free water.  
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RNA was quantified by spectrophotometry at 230nm using the NanoDrop and purity 
assessed from the associated A260/A280 and A260/A230 absorbance ratios. 1µg of RNA 
was retained for DNase treatment and the remainder was stored at -80°C. 
 
DNAse Treatment 
To treat RNA with DNase, the following reaction was prepared in a 0.2ml PCR tube: 
 
1µg RNA 
1µl 10x RQ1 buffer 
1unit (1µl) RQ1 DNase 
Nuclease free H2O to a final volume of 10µl 
 
The reaction tubes were incubated at 37°C for 30 minutes. After this time 1µl of RQ1 
DNase stop solution was added to the tubes which were heated to 65°C for 10 minutes 
to inactivate the DNase and then cooled to 4°C. 
 
2.4.4  cDNA Synthesis 
DNase treated RNA 
RevertAid
TM First Strand cDNA Synthesis Kit (Fermentas K1622) 
0.2ml PCR tubes 
GeneAmp® 2700 thermocycler (Applied Biosystems) 
 
cDNA synthesis was carried out according to manufacturer’s directions. The tubes 
containing the DNase treated RNA (section 2.4.2) were centrifuged for 5 seconds at 
5000g to collect the contents and 1µl of random hexamer primers added. This was 
mixed gently, incubated at 70°C for 5minutes, chilled on ice and centrifuged for 5 
seconds. The tubes were then returned to ice and to each tube the following was added 
in order: 4 l 5x reaction buffer, 1 l RiboLockTM Ribonuclease Inhibitor and 2 l 
10mM dNTP mix. The tubes were incubated at 25°C for 5 minutes and then 1 l 
RevertAid™ M-MuLV Reverse Transcriptase added. The tubes were incubated at 25°C 
for 10 minutes, 42°C for 60 minutes and finally 70°C for 10 minutes (to stop the 
reaction) before being chilled on ice. cDNA was stored at -20°C until required. 
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2.4.5  Reverse Transcriptase –Polymerase Chain Reaction (RT-PCR) 
2.4.5.1  Preparation of Olignucleotides 
Oligonucleotide primers were selected that had been validated by others in quantitative 
RT-PCR assays. Sequences are given in Table 2-1. Lyophilised primers, which were 
custom synthesised by SigmaGenosys, were solubilised to 100µM in sterile H2O. These 
stocks were diluted 1:10 to provide a 10µM working stock solution. All primer 
solutions were stored at -20°C. 
Table 2-1. Primers used for the analysis of gene expression by RT-PCR listed in 5’-3’ orientation 
Gene  Primer Sequence  Reference 
CYP1A2  Forward  TGTTCAAGCACAGCAAGAAGG 
   Reverse  TGCTCCAAAGACGTCATTGAC 
220 
CYP3A4  Forward  GATTGACTCTCAGAATTCAAAAGAAACTGA 
   Reverse  GGTGAGTGGCCAGTTCATACATAATG 
220 
CYP3A7  Forward  CCTTACCCCAATTCTTGAAGCA 
   Reverse  TCCAGATCAGACAGAGCTTTGTG 
220 
CAR  Forward  GCAAGGGTTTCTTCAGGAGAAC  
   Reverse  CTTCACAGCTTCCAGCAAAGG 
221 
GR  Forward  GAGGAGGAGCTACTGTGAAGGTTT 
   Reverse  GCTGCTTGGAGTCTGATTGAGA 
221 
PXR  Forward  GGCCACTGGCTATCACTTCAA 
   Reverse  TTTCATGGCCCTCCTGAAAA 
221 
RXRα  Forward  GAGACCTACGTGGAGGCAAA 
   Reverse  GATGGAGCGGTGGGAGA 
67 
VDR  Forward  TAGAGCTGTCCCAGCTCTCCAT 
   Reverse  TGACCTTTTGGATGCTGTAACTGA 
221 
18s  Forward  CTTAGAGGGACAAGTGGCG 
   Reverse  GGACATCTAAGGGCATCACA 
13 
 
2.4.5.2  RT-PCR Set-up and Cycling Conditions 
Materials  
HotStarTaq Polymerase Master Mix (HST, Qiagen 1039620) 
Custom Synthesised Oligonucleotides (SigmaGenosys) diluted to 10µM (final reaction 
concentration = 500nM) 
Sterile (RNase DNase free) H2O (Qiagen 130181929) 
GeneAmp® 2700 thermocycler (Applied Biosystems) 
0.2ml PCR Tubes  
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Method 
 
Each PCR reaction contained the following: 
 
 
 
 
 
 
 
 
For each set of primers, a mastermix was prepared and 19µl of this was aliquoted into 
0.2ml PCR tubes. 1µl of cDNA or H2O for no template control (ntc) was added and 
PCR performed in a GeneAmp® 2700 thermocycler.  
HotStarTaq was activated by heating at 95°C for 15 minutes. Cycling conditions were 
then 15s at 94°C for denaturation, 30s at primer specific annealing temperature and 40s 
for extension at 72°C. For each primer, cycle number and annealing temperatures are 
shown in Table 2-2. 
Reagent  µl/20µl Reaction 
2x HST  10 
Forward Primer   1 
Reverse Primer  1 
H20  7 
cDNA  1  
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Table 2-2. Annealing temperature, number of cycles and expected fragment size for each primer set 
used in this thesis 
Gene Annealing Temp (°C) Cycles Fragment Size (base pair)
18s
GR
PXR
RXRα
VDR
CYP1A2
CYP3A4
CYP3A7
CAR 55
55
55
55
60
62
61
61
61
62
59
69
70
61
60
55
35
72
75
70
199
91
148
197
55
45
55
 
2.4.5.3  Agarose Gel Electrophoresis 
The density of the agarose gel used depended upon the size of fragments that were 
separated. To separate 500 bp-3 kb fragments a 1% agarose gel was used. To separate 
fragments < 500 bp a 2% agarose gel was used.  
 
Materials 
Agarose (Bioline BIO-41025) 
50xTAE stock (For 1L in ddH2O: 242g Tris base, 57.1ml glacial acetic acid, 100ml 
0.5M EDTA in ddH20, pH 8.0) 
Ethidium Bromide 10mg/ml stock (stored at 4°C in the dark) 
Hyperladder I and IV (Bioline) 
5x Loading Buffer (Bioline BIO-37045) 
Gel electrophoresis tank (BioRad) 
Microwave 
 
 
  
  90 
Method 
0.5g (1% gel) or 1g (2%) of agarose was dissolved in 50ml 1xTAE using a microwave. 
When the agarose had cooled to ~60°C, 1µl ethidium bromide was added and the gel 
poured into the casting tray and left to solidify. The gel was immersed into a gel 
electrophoresis tank filled with 1xTAE and the wells of the gel flushed gently with 
TAE. 5µl DNA Hyperladder I or IV was used for reference (Figure 2-3). PCR samples 
were mixed with 5x loading dye (1x final) and loaded into the wells. The gel was run 
for 45 minutes at 90V 140 Amps at constant voltage. 
400bp
300bp
200bp
100bp
500bp
1000bp
200bp
400bp
10000bp
2000bp
1500bp
1000bp
I IV
400bp 400bp
300bp 300bp
200bp 200bp
100bp 100bp
500bp 500bp
1000bp 1000bp
200bp 200bp
400bp 400bp
10000bp 10000bp
2000bp 2000bp
1500bp 1500bp
1000bp 1000bp
I IV
 
Figure 2-3. DNA ladders were obtained from Bioline. (left) Hyperladder I was used for 1% agarose 
gels and (right) Hyperladder IV was used for 2% agarose gels or DNA fragments up to 1000 bp. 
2.4.5.4  Reverse Transcriptase Quantitative PCR (RT-qPCR) 
In traditional PCR, results are obtained as an end-point, during the plateau phase, when 
the reaction has run to completion. Quantitative PCR allows the reaction to be 
monitored as it progresses through the exponential phase, and is achieved by 
incorporation of a fluorescent reporter. At the end of the PCR run a threshold is defined 
which is a function of the background fluorescence. For each reaction in the run, it is 
possible to determine the cycle number at which this threshold is crossed, termed the 
Cycle threshold (Ct) which is proportional to the amount of starting template. Copy 
number of the gene of interest can be calculated by generating a standard curve and 
normalisation to a reference gene or to ribosomal RNA allows the relative quantity of 
gene expression to be calculated. This thesis uses Sybr Green I which binds the minor 
groove of double stranded DNA molecules and emits a fluorescent signal when bound  
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but exhibits a low amount of fluorescent signal when in solution. A disadvantage of 
Sybr Green is that non-specific PCR products and primer dimer complexes will also 
contribute to the fluorescent signal affecting product specificity. This can be avoided by 
PCR optimisation and melt curve analysis in which the products of the PCR are 
separated by gradually increasing the thermocycler from the annealing to the denaturing 
temperature following the end of the PCR (Figure 2-4). This is equivalent to running the 
PCR products on a gel, where the only visible band should correspond to the amplified 
product. 
 
Figure 2-4. An example of melt curve analysis which is achieved by gradually increasing the 
temperature of the thermocycler. SYBR green dye is released into the reaction mix as the amplicon 
denatures and this occurs at a specific temperature for each product formed. Overlapping peaks 
shown in red represent primer specific products, the lone grey peak is an example of non-specific 
product formation. 
Materials 
HotStarTaq Polymerase Master Mix (HST, Qiagen 1039620) 
Custom Synthesised Oligonucleotides (SigmaGenosys) diluted to 10µM (final reaction 
concentration = 500nM) 
Sterile (RNase DNase free) H2O (Qiagen 130181929) 
Hyperladder I and IV (Bioline) 
5x Loading Buffer (Bioline BIO-37045) 
Montage DNA extraction columns (Millipore LSKGEL050) 
NanoDrop Spectrophotometer 
Sybr Green I (Invitrogen S7567) 1:10 000 dilution of original stock in 0.01% DMSO 
(1:200 000 dilution in final reaction) 
0.2ml PCR tubes 
Rotorgene RG-3000 Cycler (Corbett Life Science)  
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Preparation of Standards 
In order to produce standard curves to quantify gene expression, standards of known 
copy number were generated. PCR was carried out, in triplicate, on human liver cDNA 
using each set of primers as described above. Product was run on a 2% agarose gel, 
bands visualised using a UV light box and then quickly excised, transferred into a sterile 
microfuge tube and frozen at -20°C for 1 hour. The gel was thawed on ice and 
transferred to a Montage DNA Gel Extraction Column (Millipore) and DNA extracted 
by centrifugation at 5000g for 10 minutes. DNA was concentrated by ethanol 
precipitation (section 2.4.2), resuspended in 10µl sterile H2O and quantified using the 
NanoDrop. Using the concentration of DNA and the fragment length created by the 
primers, the (estimated) number of molecules per µl of cDNA was then calculated as 
follows: 
 
Average weight of a base pair (660) x amplicon length = Molecular weight (MW) of 
amplicon 
MWg (number of atoms in one mole) = Avogadros number 6.022x10
23 
Amplicon molecules/ng =6.022x10
14/amplicon MW 
Amplicon molecules (copy number)/µl= concentration (ng/µl) x amplicon molecules/ng 
 
Standard  concentration  was  adjusted  to  10
10  copies/µl  using  sterile  H20  and  then 
standards  decreasing  in  10-fold  increments  (10
10-10
1  copies/µl)  were  prepared  and 
stored at -20°C as 5µl single-use aliquots.  
 
RT-qPCR 
Each PCR reaction contained the following: 
 
 
 
 
 
 
 
 
 
Reagent  µl/20µl Reaction 
2x HST  10 
Forward Primer   1 
Reverse Primer  1 
Sybr Green I  1 
H20  6 
cDNA  1  
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For each set of primers, a mastermix was prepared and 19µl of this was aliquoted into 
0.2ml PCR tubes. 1µl of cDNA, standard or H2O no template control (ntc) was then 
added and PCR performed in a Rotorgene RG-3000 thermocycler using the conditions 
described in section 2.4.5.2. Copy number was calculated using a standard curve and for 
each gene, expression levels were normalised to ribosomal 18s RNA. 
 
2.5  Analysis of Cytochrome P450 Function and Induction 
2.5.1  Cytochrome P450 Inducers 
Dexamethasone (Sigma D4902) 
Dibenz [a,h] anthracene (Sigma D8543) 
Indirubin (Biomol CC206-0005) 
Phenobarbital (Sigma P5178) 
Rifampicin (Sigma R3501) 
1α, 25-dihydroxyvitamin D3 (VD3 – Sigma D1530) 
DMSO (Sigma spectrophotometric grade 154938) 
 
1000x stock solutions of inducers were prepared in DMSO (inducer concentrations will 
be indicated in subsequent chapters). These solutions were prepared and stored in light 
protective 2ml ampoules. Solutions were kept at room temperature and fresh stocks 
prepared every 12 weeks. Inducers were added to culture media by sequential dilution 
(1:10 then 1:100) to give a final DMSO concentration of 0.1% (v/v). A 0.1% DMSO 
vehicle control was included in each experiment. 
 
2.5.2  Functional Assays 
Assays for cells in monolayer culture were performed in microplate format. Assays 
using freshly isolated primary human hepatocytes in suspension, or encapsulated cells, 
were performed in 1.5ml microfuge tubes.  
 
For each assay, a standard curve (in duplicate) was included along with controls of cells 
without substrate and substrate without cells. Data was background corrected and then 
adjusted for protein content during analysis.  
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2.5.2.1   Ethoxycoumarin Assay to Determine Broad Spectrum CYP Activity 
7-Ethoxycoumarin (7-EC) was used as a substrate to determine general P450 activity 
since 7-Ethoycoumarin O-deethylation (ECOD) resulting in 7-Hydroxycoumarin (7-
HC) product formation may be catalyzed by CYP enzymes from CYP1, CYP2 and 
CYP3 families 
214.  
 
Materials 
7-Ethoxycoumarin (7-EC, Sigma E1379, 40mM in MeOH) 
Serum free culture media 
HBSS 
7-Hydroxycoumarin (7-HC, Sigma H2400, 160mM in 1M NaOH) 
Chloroform 
0.01M NaOH/1M NaCl in deionised H2O 
1.5ml Microfuge tubes 
Microfuge 
Vortex 
96 Well clear flat bottomed plate 
Cytofluor 4000 fluorescence reader (PerSeptive Biosystems)  
 
Method 
7-EC was diluted in pre-warmed culture media to give a final concentration of 200mM. 
Cells were washed twice with HBSS and an appropriate volume of 200mM 7-EC added 
to the culture (500ml or 100µl for 12 well or 96 well plates respectively). Plates were 
incubated at 37°C for one hour and then the supernatant was transferred to a 1.5ml 
microfuge tube. A standard curve of 7-HC (50nm -1.5nm + no standard blank control) 
was prepared in culture medium containing 200mM EC. Product was extracted by 
adding 900ml of chloroform, mixing well and then vortexing. Tubes were centrifuged at 
3000g for 1 minute and the product back extracted by transferring 500ml of the lower 
organic phase to a 1.5ml microfuge tube containing 500ml of 0.01M NaOH/1M NaCl. 
This mixture was vortexed and then centrifuged at 3000g for 1 minute. 200ml of the 
upper aqueous phase was then transferred to a 96 well plate and read using a Cytofluor 
(Excitation 364/40, Emission 460/40). Cells were harvested for protein by washing 
twice with PBS and adding PBS 0.5% Triton X. Plates were then frozen until analysis 
using the BCA assay. Data was normalised for total protein content during analysis. 
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For encapsulated cells, 0.25ml of beads were incubated with 3ml of substrate. 
 
2.5.2.2  Promega P450 Glo Assays to Determine Isoform Specific CYP Activity 
 
Materials 
Phenol red-free culture media without serum 
Promega P450-Glo CYP1A Assay (Luciferin ME V8772) 
Promega P450 Glo CYP3A Assay (Luciferin BE V8802) 
Sulfaphenazole (Sigma S0758, 10mM MeOH) 
d-Luciferin (from beetles, Promega E160, 2mM in H2O) 
White flat bottomed 96 well plates 
Tropix TR717 Microplate Luminometer (Applied Biosciences) 
 
Method 
In whole cells, assays were performed according to the manufacturer’s directions. 
Briefly 50µM Luciferin-ME +/- 10 M sulfaphenazole or Luciferin-BE was added to 
prewarmed culture media. Cells were washed twice with unsupplemented media and an 
appropriate volume of substrate added to cells, either 500µl for a 12 well plate, 200µl 
for a 48 well plate or 25µl for a 96 well plate. Plates were incubated at 37°C for 1 hour. 
Supernatant was removed from cells and cells harvested for protein as above. 25µl of 
supernatant was then transferred to white opaque 96 well plates and an equal volume of 
manufacturer’s luciferin detection reagent added. Plates were incubated in the dark for 
20 minutes and then read using a luminometer. A d-luciferin standard curve was 
included on each plate (2.5 – 0.04 nm). Data was normalised for total protein content 
during analysis. 
 
For encapsulated cells, 25µl of beads were incubated with 100µl of substrate. 
 
2.5.2.3  Invitrogen Vivid® BOMFC Assay 
Vivid ® BOMFC (benzyloxymethylfluorescein) is metabolised by CYP3A and 
CYP2B6. Substrate metabolism was therefore measured in the presence or absence of 
the CYP3A inhibitor clarithromycin in order to differentiate between CYP3A and 
CYP2B6 function.   
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Materials 
Phenol red free culture media without serum 
Vivid ® BOMFC Substrate (Invitrogen P2976, 2mM in Acetonitrile) 
Vivid ® Cyan Fluorescent Standard (7-hydroxy-4-trifluoromethylcoumarin, Invitrogen 
P2877, 100µM in DMSO) 
Clarithromycin (Sigma C9742, 100mM MeOH) 
96 Well clear flat bottomed plate 
Cytofluor 4000 fluorescence reader (PerSeptive Biosystems)  
Method 
BOMFC substrate was diluted in prewarmed culture medium to 2.5µM +/- 100µM 
clarithromycin. Cells were washed twice with unsupplemented media and an 
appropriate volume of substrate added to cells, either 500µl for a 12 well plate, 200µl 
for a 48 well plate or 25µl for a 96 well plate. Plates were incubated at 37°C for 1 hour. 
Supernatant was removed from cells and cells harvested for protein as above; 25µl of 
supernatant was then transferred to a clear bottomed 96 well plate which was read using 
a Cytofluor (Excitation 450/50, Emission 530/25). A Cyan standard curve was included 
on each plate (250µM-150nm). Data was normalised for total protein content during 
analysis. 
 
For encapsulated cells, 25µl of beads was incubated with 100µl of substrate.  
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2.5.2.4  HPLC Analysis of CYP Mediated Testosterone Depletion and Metabolite 
Formation 
Separation of testosterone and its metabolites was performed by HPLC. Subsequent 
quantification of testosterone depletion was used as a measure of general CYP3A 
activity whereas quantification of the formation of one of its metabolites,                    
6β-hydroxytestosterone, was used as a specific measure of CYP3A4 activity. 
 
8.8min
50µm
100µm
25µm
12.5µm
15 min
12.5 µm
25 µm
50 µm
100 µm
8.8min
50µm
100µm
25µm
12.5µm
15 min
12.5 µm
25 µm
50 µm
100 µm
 
Figure 2-5. Standard curves to demonstrate separation of testosterone at 15 minutes and 6β-
hydroxytestosterone at 9minutes. Concentrations may be related to peak area using JASCO HPLC 
software. 
 
Materials 
Phenol red free culture media without serum 
Testosterone (Sigma T1500, 40mM MeOH) 
6β-Hydroxytestosterone (Sigma H2898) 
Nova-Pak C18 Column, 3.9 x 150mm, 4µM, Waters 
Mobile Phase A: 15% Acetonitrile (Far UV grade Sigma 34888) in deionised H20 
Mobile Phase B: 90% Acetonitrile in deionised H20 
JASCO HPLC machine and accompanying software 
 
Method 
Testosterone was diluted in prewarmed culture media to give a final concentration of 
200µM. Cells were washed twice with unsupplemented media and an appropriate 
volume of substrate added to cells (1ml for a 12 well plate, 500µl for a 48 well plate or 
100µl for a 96 well plate). Plates were incubated at 37°C for 1 hour and supernatant  
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then removed and immediately frozen and stored at -80°C for subsequent HPLC 
analysis. Cells were harvested for protein analysis using the BCA method. 
 
For encapsulated cells, 0.25ml of beads was incubated with 3ml of substrate. 
 
All solvents used for HPLC were degassed by sonication for 15 minutes prior to use. 
Standard samples consisting of assay media containing 200µM-6µM of both 
testosterone and 6β-OHTST were included in each run. Following centrifugation at 
12000g for 5 minutes to remove any residual protein fragments, 100µl of sample was 
injected onto the column. The mobile phase was run at 1ml/min from initial starting 
conditions of 70% A:30% B to 30% A:70%B over 20 minutes. It was maintained at this 
level for a further 5 minutes before returning to initial conditions over 10 minutes. UV 
detection of testosterone and metabolite were monitored at 247nm at around 15 minutes 
and 9 minutes respectively. In order to quantify testosterone depletion and 6β-OHTST 
formation, standard curves of each were constructed by using JASCO software to relate 
peak area to concentration. Data was then normalised for total protein content during 
analysis. 
 
2.6  Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 5. 
Comparisons between two values were made using Student’s t test (two-tailed).  
One-way ANOVA was chosen when comparing more than two values.  
Two-way ANOVA was also used to analyse samples differing in two independent 
conditions, such as cell type and inducer. 
 
For ANOVA, significance is quoted as F=(degrees of freedom, sum of squares) X, P<Y 
 
A Bonferroni post test was applied to ANOVA analysis to account for multiple 
comparisons when determining P values. 
 
Unless stated otherwise, values in text, tables and figures were expressed as the mean ± 
standard deviation (SD) and n numbers are given in the accompanying text. 
Generally, P<0.05 was considered to be significant. In Tables and Figures,  
P values are expressed as * (P<0.05), ** (P<0.01) and *** (P<0.001).  
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CHAPTER 3  Characterising Cytochrome P450 Activity in Human 
Liver to Establish a Gold Standard Comparator 
 
The aim of this thesis was to develop a human cell line with Cytochrome P450 function 
equivalent to that measured in adult human liver. In order to achieve this it was 
therefore necessary to determine appropriate comparators. A number of approaches 
were used. 
 
i.) Primary human hepatocytes (PHH): CYP activity was measured immediately    
(<1 hour) post isolation in human hepatocytes obtained from a range of donors. PHH 
were also maintained in monolayer culture in order to determine culture conditions that 
may affect CYP activity. Confluency of hepatocyte cultures was considered, as well as 
duration of culture and presence of growth factors, and serum or plasma, in culture 
medium.  
 
ii.) Human liver microsomes (HLM): CYP activity was measured in HLM isolated 
from a number of donors to investigate the hypothesis that interindividual variation has 
a bigger influence on CYP activity than hepatocyte isolation and culture conditions. 
 
iii.) Human foetal hepatocytes (FHH): basal and inducible CYP activity was 
examined in human foetal hepatocytes using a panel of different CYP inducers.  
 
The work described in this Chapter also provided the context for developing and 
validating the methods selected for use in this thesis. 
 
3.1  Cytochrome P450 Activity in Adult Human Liver 
Liver samples were obtained from the Surgical Department at the North Hampshire 
Hospital, Basingstoke, UK, from patients undergoing surgery for metastases of colon 
cancer. Patients gave informed consent for the use of resected tissue for research, 
approved by the Research and Ethics Committee of the hospital. Throughout this thesis 
each sample has been assigned the prefix PHH followed by a number.  
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3.1.1  Primary Human Hepatocytes 
CYP activity was measured in PHH immediately post isolation. This was done for a 
number of donors to give an index of interindividual variation. CYP activity was also 
measured following time in culture. Effects of culture medium components were 
considered comparing CYP activity in culture medium containing FCS, FFP or no 
serum; in addition effects of growth factors in culture medium were measured. Finally 
inducible CYP activity was measured in adult PHH. 
3.1.1.1  Methods 
3.1.1.1.1  Isolation of Hepatocytes from Adult Human Liver 
Chelating Buffer (20mM HEPES, 0.5mM EGTA in PBS) 
Perfusion Buffer (20mM HEPES in PBS) 
Digestion Buffer (20mM HEPES, 1.5g BSA (0.5% w/v), 50 g/ml ascorbic acid and 
4 g/ml insulin in 300ml HBSS with calcium and magnesium. Immediately prior to 
digestion of the liver 150mg Collagenase Type IV (0.05% w/v) and 30mg DNase I 
(0.01%w/v) were added) 
Dispersal Buffer (50ml (10%v/v) FCS and 50mg DNase I (0.01% w/v) in 500ml 
Williams’ Medium E (WEM)) 
 
Primary human hepatocytes were isolated from a freshly resected piece of liver by two 
step collagenase perfusion and differential centrifugation 
206. This procedure was carried 
out by other colleagues. 
 
Donors were both male and female and ranged in age from 39-85 years old. Cell 
viability was determined by trypan blue exclusion and was between 45-80% (Table 
3-1). Due to the limited supply of hepatocytes available from each donor liver, it was 
not possible to use the same hepatocytes for all experiments. The experimental use of 
each hepatocyte preparation is therefore indicated in Table 3-1. 
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Table 3-1. Available donor information and % viability of isolated hepatocytes for each liver 
sample used in this thesis for (a) measurement of CYP function in freshly isolated hepatocytes,   
(b) HLM preparation, (c) RNA isolation, (d) monolayer culture.   
* Tissue used for RNA isolation only, therefore no hepatocyte viability information was obtained 
from this donor. 
PHH # Sex Age % Viability
Experimental 
Use
1 F 63 75 a, c, d
2 M 68 45 a, 
3 M 58 57 b, d
4 M 42 73 b, d
5 M 74 65 b, c
6 M 55 77 c
8 M 81 68 b, c, d
9 F 73 80 a, b, c
10 F 53 61 a, b, c, d
11 F 60 50 a
12 M 61 49 a
13 M 60 58 a, c
14 M 78 47 a
15 M 69 68 a
16 F 45 52 a, c
17 M 47 72 a
18 F 76 64 a, d
19 M 85 65 d
22 F 39 n/a* c
25 F 64 71 b
28 F 58 67 b
29 M 71 74 d
30 F 57 58 c, d
31 F 73 63 a, b, d
32 F 66 61 d, c
33 F 79 47 c  
3.1.1.1.2  Determination of CYP Activity in Freshly Isolated Adult Primary Human 
Hepatocytes 
Hepatocytes were resuspended in Adult Hepatocyte Medium (AHM Chapter 2) at a 
density of 1x10
6cells/ml and CYP activity measured within an hour of isolation by 
ECOD activity (1ml assay volume), testosterone metabolism (1ml assay volume) or 
luciferase assays (100µl assay volume). Luciferin ME metabolism was measured alone 
and in the presence of 10µM sulfaphenazole to inhibit CYP2C function. During  
  102 
analysis, data was normalised for protein content which was determined by the BCA 
assay and then adjusted to account for viable cells only.   
 
3.1.1.1.3  Culture of Adult Primary Human Hepatocytes 
Primary cells were maintained in an incubator at 37°C in a humidified atmosphere of 
95% air and 5% CO2.  Post isolation, hepatocytes were resuspended at a density of 1x10
6 
cells/ml in AHM, supplemented with either 10% FCS or 10% (human) FFP. 1ml/well 
was added to collagen coated 12 well plates and cells incubated overnight to allow 
attachment. 
The following morning, cells were washed twice with prewarmed unsupplemented 
WEM to remove unattached debris and medium replaced with AHM with or without 
either FCS ± HGF (20ng/ml) and EGF (10ng/ml) or FFP. Medium was replenished 
daily and CYP activity measured either by ECOD activity, testosterone metabolism or 
luciferase assays. Protein content was determined by the BCA assay. 
 
3.1.1.1.4  Induction of CYP Activity in Adult Primary Human Hepatocytes 
Inducers were added to PHH either 24 or 48 hours post isolation. Cells were treated for 
up to one week with inducers, which were replenished daily. CYP activity was then 
quantified by ECOD activity, BOMFC metabolism or luciferase assay. 
 
3.1.1.2  Results 
3.1.1.2.1  Interindividual Variation in CYP Activity in Freshly Isolated Primary Human 
Hepatocytes 
CYP function varied considerably when measured in freshly isolated PHH isolated from 
different donors (Figure 3-1).  
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Figure 3-1. Cytochrome P450 function in freshly isolated PHH. For each assay, activity was 
measured in quadruplicate in each PHH preparation. The average and range of activity measured 
in PHH isolated from 8-10 separate donors was then calculated and is expressed here for each 
assay.  Note that the y axis is plotted on a logarithmic scale. (Su) = measured in the presence of 
10µM sulfaphenazole. 
 
The mean activity level and range of function for each assay performed in freshly 
isolated PHH are summarised in Table 3-2. 
 
Table 3-2. Mean, median and range values (pmoles product/min/mg protein) for Cytochrome P450 
function in freshly isolated PHH from 8-10 separate donors. CYP activity was measured in 
quadruplicate for each PHH preparation. % CV (coefficient of variation) is included here as an 
indicator of assay variability and was calculated using the mean and standard deviation values 
obtained from the individual donors. 
  Luciferin BE 
(CYP3A) 
Luciferin ME 
(CYP1A2/2C8) 
Luciferin ME Su 
(CYP1A2) 
ECOD 
(CYP1/2/3) 
Donors  9  9  8  10 
Mean  0.071  1.550  0.816  0.0733 
Median  0.051  1.354  0.753  0.047 
Range  0.022 – 0.167  0.197-3.044  0.133-1.652  0.018-0.227 
% CV  21.2  15.5  13.1  15.2  
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3.1.1.2.2  Testosterone Metabolism in Freshly Isolated PHH 
Testosterone (TST) metabolism was measured in freshly isolated PHH prepared from 3 
separate donors and compared by one-way ANOVA. Following 1 hour incubation with 
substrate, significant donor dependent variations in substrate metabolism (P<0.001) and 
metabolite production (P<0.05) were observed (Figure 3-2).   
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Figure 3-2. (top) % substrate depletion and (bottom) 6β-OHTST production were measured by 
HPLC analysis of supernatant obtained from freshly isolated PHH from 3 separate donors 
incubated for 1 hour with 200µM TST.  
Between donors, the extent of substrate depletion did not always correspond with extent 
of 6β-OHTST metabolite production – PHH9 demonstrated the greatest level of TST 
depletion but a lower level of 6β-OHTST production than PHH1. One likely 
explanation for this was alternative metabolite production by additional CYP isoforms 
(other than CYP3A4). An example UV trace, obtained following HPLC analysis of  
  105 
supernatant from PHH incubated with TST, is shown in Figure 3-3. Testosterone and 
6β-OHTST are shown at ~ 16 and 9 minutes respectively. An additional peak is also 
highlighted which appeared only when PHH were incubated with TST and 
demonstrated a similar UV spectrum to TST and 6β-OHTST (detected at 247nm).   
 
Figure 3-3. HPLC analysis of (top) culture medium spiked with 200µM TST and (bottom) culture 
medium spiked with 200µM TST and incubated for 1 hour with freshly isolated PHH. Presence of 
TST (→), and 6β-OHTST (→) were confirmed by analysis of standards in the same run. An 
additional peak (→) was also observed only when PHH were incubated with TST.  
 
LC-MS was used to analyse this peak. In order to remove any residual salt 
contamination not eluted within the first minutes of LC analysis, a sample (500µl) of the 
assay supernatant from PHH was extracted with chloroform and concentrated by 
resuspending in 100µl of 15% ACN. This sample was then subjected to LC-MS analysis 
using the same solvent gradient defined for HPLC analysis (Chapter 2) but with a 
0.3µM column and a flow rate of 0.3ml/min. Consistent results were obtained when 
supernatant from 2 separate donors was analysed. The later peak was confirmed as 
having a molecular weight of 323. TST has an MW of 288, therefore it is not a product 
of TST breakdown, nor was it an adduct of TST and ACN. Primary β metabolites of 
testosterone have a MW of 304. Potentially this peak is a product of metabolite 
conjugation. Since it only appears when cells are incubated in the presence of TST it is 
likely a product of TST metabolism, however, since LC-MS analysis was inconclusive, 
fraction collection and GC-MS analysis would be required to confirm this. 
 
3.1.1.2.3  Culture Conditions for Adult Primary Human Hepatocytes 
In cultured hepatocytes, a large donor dependent variation in hepatocyte attachment and 
CYP function was observed. For individual donors this was also influenced by culture 
conditions.  
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3.1.1.2.3.1  Attachment and Confluency of Cultures 
Following overnight (16h) attachment, confluency of hepatocyte cultures was assessed 
by phase contrast microscopy and examples are shown in Figure 3-4. A large variation 
in attachment was observed between donors and exclusion criteria were developed 
whereby for monolayer function studies, only hepatocyte cultures with greater than 50% 
attachment, which formed good cell-cell connections (minimum doublets) were 
included. 
 
Figure 3-4. Examples of hepatocyte cultures (a1) PHH 10 and (b1) PHH 29 with good overnight 
attachment and cell-cell connections which (a2) / (b2) could be used for experiments requiring 
prolonged culture, and hepatocyte cultures (c) PHH 34 and (d) PHH 2 with poor overnight 
attachment and minimal cell-cell connections which were excluded from monolayer experiments. 
Time, where indicated, is hours post isolation.  Images are x20 magnification. 
 
a1.) 16h  a2.) 72h 
b1.)16h  b2.) 72h 
c.) 16h  d.) 16h  
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3.1.1.2.3.2  CYP Activity Declines in Adult Human Hepatocytes During Time in 
Culture 
ECOD activity was measured over up to 8 days post isolation in PHH isolated from 5 
separate donors (PHH 32, 30, 31, 10, 3) plated out in AHM with 10% FCS. In each 
instance CYP activity declined during prolonged culture (Figure 3-5). The greatest drop 
in activity (47+/-6%) was seen between days 1 and 2 post isolation. Between days 5 - 8 
function settled around 10-20% of initial measured activity.  
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Figure 3-5. Cytochrome P450 (ECOD) activity declines in PHH during prolonged culture. ECOD 
activity was measured daily over 7 (PHH 31, PHH 30, PHH 10, PHH 3) or 8 (PHH 32) days and 
final results were calculated as a % of d1 function. Data is presented as an average of donors +/-sd. 
 
3.1.1.2.3.3  Effect of Growth Factors on Cytochrome P450 Activity 
PHH were cultured for 48 hours in basal WEM or in WEM + HGF (20ng/ml) and EGF 
(10ng/ml). CYP activity was measured in PHH from multiple donors by either Luciferin 
ME, Luciferin BE or ECOD assay and then for each assay type data was analysed by 
ANOVA. 
Luciferin ME metabolism was measured in PHH isolated from 3 separate donors 
cultured +/- growth factors and data is shown in Figure 3-6 (a). A significant donor 
dependent variation in CYP1A2 activity (P < 0.001, F (2, 4242) =936) was observed in 
each instance (basal range: 1.36-36.78 pmoles d-luc/min/mg protein), however for each 
PHH preparation, a significantly lower (P<0.01, F (1, 23.63) = 10.5) level of CYP1A2 
activity was measured in PHH cultured in the presence of growth factors. The extent to 
which growth factors decreased activity was also found to be donor dependent (P<0.05,  
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F (2, 30.96) = 6.83). Following exposure to growth factors, CYP1A2 activity was 
decreased by 43% in PHH33 and to a lesser extent in PHH32 (16%) and PHH5 (20%). 
 
Luciferin BE metabolism was measured in PHH isolated from 2 separate donors 
cultured +/- growth factors (Figure 3-6 (b)). In this assay, a large donor dependent 
variation in activity was observed (basal activities: 0.39/0.08 pmoles d-luc/min/mg 
protein). Growth factors were without significant effect on CYP3A activity although 
their effects varied markedly for each donor measured. Following culture with growth 
factors, CYP3A activity was decreased by 57% in PHH5 and increased by 15% in 
PHH33.  
 
ECOD activity was measured in PHH isolated from 2 separate donors cultured +/- 
growth factors (Figure 3-6 (c)). In this assay, a large donor dependent variation in 
activity was observed (basal activities: 0.004/0.39 pmoles d-luc/min/mg protein, 
however growth factors had no significant effect on ECOD activity. Following exposure 
to growth factors, ECOD activity was decreased by 16% in PHH8 and 7% in PHH30 
(compared to basal activity).  
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Figure 3-6. CYP function was compared in PHH cultured for 48 hours +/- growth factors. At day 3 
post isolation, CYP activity in PHH cultured under basal conditions and in the presence of growth 
factors (HGF & EGF) was measured in quadruplicate for each donor. The % difference between 
the two conditions was then calculated and is expressed as mean +/- range of 2 
(CYP3A:PHH5/PHH 33 and ECOD: PHH8/PHH30) or 3 (CYP1A2: PHH5/PHH32/PHH33) 
different donors. Following two-way ANOVA ** P < 0.01 when P450 activity in presence and 
absence of growth factors was compared.  
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3.1.1.2.3.4  Effect of Serum or Plasma on Cytochrome P450 Activity 
ECOD activity was measured up to 2 days post isolation in PHH isolated from 3 
separate donors which had been plated out and cultured in WEM containing either 10% 
FCS or 10% (human) FFP. Although ECOD activities were significantly different 
between donors (P < 0.001, F (2, 0.58) = 99.1), the differences in ECOD activity 
between PHH cultured in FCS and FFP were negligible for each donor (Figure 3-7 top). 
However there was a slight difference observed between FCS and FFP when levels of 
activity measured at d1 and d2 post isolation were compared (Figure 3-7 bottom). 
Although the effect was donor dependent and was not significant for any of the PHH 
preparations measured, ECOD activity decreased less between d1 and d2 when PHH 
were plated and cultured in FFP (35-71% decrease) than in FCS (57%-110% decrease). 
 
 
Figure 3-7. ECOD activity was compared in PHH that were plated and then cultured in 10% FCS 
or 10% FFP. ECOD activity was compared d1 post isolation for the two serum types in PHH 
isolated from 3 separate donors (top, n=4+/-sd). For the same 3 donors, decline in ECOD activity 
between day 1 and day 2 was then calculated for PHH cultured in each medium type and is 
presented as mean of 3 donors +/- range (bottom).   
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3.1.1.2.4  Cytochrome P450 Activity is Maintained in PHH by Chemical Induction 
Effect of inducers on CYP function was considered in the presence of FCS, FCS + 
heparin control or FFP and measured by ECOD activity. The effect of Phenobarbital on 
CYP2B6 and CYP3A4 function in PHH was then measured by BOMFC metabolism. 
3.1.1.2.4.1  Influence of Serum or Plasma on CYP Induction 
The effect of serum on CYP induction was considered in PHH isolated from two 
separate donors (PHH1, PHH19). Cells were incubated with CYP inducers in WEM 
containing 10% FCS, 10% FCS with heparin or 10% FFP (O-ve pooled from multiple 
donors). Following 48 hour induction, CYP function was determined by ECOD activity 
and fold induction above vehicle determined. For both donors, there were significant 
differences in P450 induction (P < 0.05, F (2, 0.181) = 4.40) measured in the presence 
of FCS +/- Heparin and FFP.  
Overall, effects of inducers on ECOD activity were serum and donor dependent (Figure 
3-8). There was an effect of heparin on DBA mediated induction for both donors; in the 
presence of FCS, 10µM DBA resulted in a 1.3 fold increase in ECOD activity (above 
vehicle) which was inhibited by the addition of heparin or by (heparinised) FFP. Effects 
of indirubin (20µM) mediated induction were donor dependent; this inducer was 
without effect on PHH1 cultures. There was slight induction (1.3 fold) measured in 
PHH19 in the presence of FCS which was diminished in the presence of FCS and 
heparin or FFP. For both donors there was an effect of FFP on dexamethasone mediated 
induction; ECOD activity was diminished slightly by 50µM dexamethasone in the 
presence of FCS +/- heparin (0.83/0.83 fold compared to vehicle activity), but was 
increased (1.22 fold) in the presence of FFP. For both donors, ECOD activity was not 
improved by rifampicin (50µM) in the presence of FCS +/- heparin. This was 
unchanged by FFP for PHH19, however for PHH1 rifampicin induction in the presence 
of FFP resulted in a 1.46 fold increase in ECOD activity above vehicle treated cells.    
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Figure 3-8. ECOD activity was measured in PHH1 and PHH19 following 48 hour induction with 
CYP inducers in WEM containing 10% FCS, 10% FCS and Heparin or 10% FFP. For each 
inducer fold induction in CYP activity above vehicle was calculated and is expressed as the average 
of the two donors +/- range. 
3.1.1.2.4.2  Vivid BOMFC Metabolism and Phenobarbital Induction 
Vivid® BOMFC metabolism can be used to assess the function of CYP3A4 and 
CYP2B6 and was measured in monolayer cultures of PHH18 at either d1 post isolation 
or d3 post isolation following 48 hour incubation with phenobarbital. Substrate 
metabolism was measured in the presence or absence of 100µM clarithromycin which 
should inhibit CYP3A4 function at this concentration.  
 
Substrate metabolism was significantly affected by phenobarbital induction (P <0.05, F 
(2, 3.76) = 5.61) and the presence of inhibitor (P < 0.001, F (1, 8.50) =25.33).There was 
also a significant interaction between the two variables (P < 0.01 F (2, 5.06) = 7.51); 
phenobarbital induction was diminished in the presence of inhibitor although activity in 
uninduced controls was comparable between groups.  
 
Bonferroni post tests were used to compare BOMFC metabolism at d1 post isolation 
and d3 post isolation following induction (Figure 3-9).  
 
When measured in the absence of inhibitor, there was a significant decrease in BOMFC 
(CYP3A4/CYP2B6) metabolism between d1 and d3 post isolation (1.6 fold P <0.01). 
This difference was abrogated following phenobarbital induction which resulted in a  
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significant increase (1.7 fold P<0.01) in PHH function above 0.1% DMSO vehicle 
treated cells.  
 
In the presence of clarithromycin, BOMFC metabolism (CYP2B6) following 48 hour 
induction with phenobarbital was slight compared to vehicle treated (uninduced) cells, 
however, phenobarbital incubation did result in a significant improvement in function 
(1.9 fold P<0.05) relative to d1 PHH which was greater than the effect of vehicle alone. 
 
 
Figure 3-9. BOMFC metabolism was measured +/- 100µM clarithromycin in PHH13 either d1 post 
isolation or d3 post isolation following 48 hour incubation with 500µM Phenobarbital or 0.1% 
DMSO vehicle.   
Following two-way ANOVA and Bonferroni post test, ** P < 0.01, * P < 0.05 (n=4+/-sd).   
 
3.1.1.3  Discussion 
In summary, experiments performed on hepatocytes derived from a number of livers 
demonstrated a large variation in CYP activity between donors.  
 
CYP function was measured in freshly isolated PHH isolated from up to 10 donors by 
Luciferin BE (CYP3A), Luciferin ME (CYP1A2/2C), and ECOD assays. The ranges of 
these values were summarised in Table 3-2 and these will be referred to throughout this 
thesis. A metabolism profile of testosterone (TST) by freshly isolated PHH was also 
determined and levels of TST depletion and 6β-OHTST production measured for a 
number of donors.   
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In freshly isolated PHH, Luciferin ME derived luciferase activity, assessed both with 
and without the CYP2C inhibitor sulfaphenazole, was higher than Luciferin BE derived 
luciferase activity, implying that potentially CYP1A2 function was dominant in all 
these samples. Although cells used in this study were obtained from normal tissue, thus 
are not carcinoma derived, they were not obtained from a healthy population and 
potentially their CYP function could be affected by disease status. A limitation of the 
hepatocytes used in this thesis is the lack of clinical data on the donors that was made 
available. In particular, drug therapy (including chemotherapy regimen) and smoking 
could both contribute to variability in CYP function. 
 
As an additional consideration, as described in Chapter 1, Luciferin ME is not an 
entirely specific substrate, and is also metabolised by several other CYP isoforms 
(particularly CYP4A11 and CYP2C8/9) which are involved in endogenous and 
exogenous metabolism. This will be considered in future chapters when comparing data 
from these assays.  
 
It is well established that a number of factors including genetics, diet and environmental 
influences will alter an individual’s CYP expression, however, it is also reported that 
various artefacts associated with isolating hepatocytes and maintaining them in culture 
can have an effect 
63, 65, 222. Attachment of PHH and therefore confluency varied for 
each donor which may have affected CYP function. The effect of time in culture and 
presence of growth factors, serum and inducers on CYP activity in human hepatocytes 
was demonstrated here. Potentially culture media components such as serum in addition 
to CYP inducers could be varied within a BAL to achieve both enhanced cell growth 
and improved hepatic function. In PHH, however, effects of media components and 
CYP inducers were both found to be donor dependent. 
 
CYP activity was therefore examined in human liver tissue or freshly isolated PHH to 
assess variation in CYP function independent of hepatocyte preparation and culture. 
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3.1.2  Human Liver Microsomes 
Human liver microsomes (HLM) were isolated from a number of donor samples and 
their CYP function measured to compare interindividual variation in function with that 
measured in primary human hepatocytes (PHH).  
3.1.2.1  Human Liver Microsome Isolation 
Where possible, microsomes were isolated from fresh tissue or hepatocytes. In all other 
cases samples were immediately snap frozen in liquid nitrogen and stored at -80°C until 
required. These samples were thawed in an appropriate volume of homogenisation 
buffer at 4°C immediately prior to microsome preparation.  
 
Homogenisation Buffer (pH 7.5) 
0.25 M Sucrose 
50mM HEPES 
100mM NaCl 
Complete mini EDTA-free Protease Inhibitor Cocktail Tablets (Roche 04 693 159 00, 1 
tablet/10ml buffer) 
 
Resuspension Buffer (pH 8.5) 
0.5 M Triethyl ammonium biocarbonate 
0.1% SDS (sodium dodecyl sulphate).   
 
(The original intended use for some of these HLM preparations was proteomic analysis 
which is the reason this resuspension buffer was chosen. For consistency therefore all 
the HLM preparations were resuspended in this buffer but at a sufficient protein 
concentration that it was diluted substantially when HLM were added to CYP functional 
assays). 
 
Potassium Phosphate Buffer (KPO4) pH 7.4 
50mM K2HPO4 
50mM KH2PO4 
 
Beckman ultra-clear centrifuge tubes (14 x 89mm # 344059) 
CAT X-120 electronic homogeniser (Finemech) 
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Liver was finely minced and this or hepatocytes were homogenised on ice in 
homogenisation buffer (1ml of buffer per 0.1g of tissue or 1.5x10
7 cells) and 
microsomes were then isolated by differential centrifugation at 4°C 
223. Initially, 
homogenate was centrifuged at 1000g for 10 minutes to sediment cell debris, nuclei and 
unbroken cells. The supernatant from this spin was transferred to fresh microfuge tubes 
and centrifuged at 12,000g to pellet the mitochondrial fraction. The supernatant was 
transferred to centrifuge tubes and centrifuged for a third time in an ultracentrifuge at 
180,000g for one hour. The resultant pelleted microsomal fraction was resuspended in 
an appropriate volume of resuspension buffer (determined by estimated yield) and 
protein content determined by the BCA method. Diluted microsomes were distributed 
into 50ml aliquots (~250mg protein) which were stored at -80°C until required. 
 
3.1.2.2  Analysis of Cytochrome P450 Function in HLM 
CYP activity was assessed in HLM by ECOD or luciferase assays.  
3.1.2.2.1  ECOD Activity 
20µg of microsomal protein was combined with 7-EC (at a final concentration of 
500µM, 2%MeOH) in 100mM KPO4/ 0.1mM EDTA in polypropylene microfuge tubes 
in a total volume of 180µl. Tubes were prewarmed to 37ºC for 10 minutes and then  
20ml of 10mM NADPH added to initiate the enzymatic reaction. Tubes were gently 
mixed and incubated in a water bath for 30 minutes. After this time period, tubes were 
placed on ice and 25ml of chilled 2M HCl was added to terminate the reaction. 
 
Product was then extracted to remove background fluorescence caused by NADPH at 
similar wavelengths. This was done by adding 900ml of chloroform, mixing well and 
vortexing .Tubes were centrifuged at 3000g for 1 minute and the product back extracted 
by transferring 500ml of the lower organic phase to a 1.5ml microfuge tube containing 
500ml of 0.01M NaOH/1M NaCl. This mixture was vortexed and centrifuged at 3000g 
for 1 minute. 200ml of the upper aqueous phase was transferred to a 96 well plate and 
analysis carried out as described in Chapter 2. 
3.1.2.2.2  Luciferase Assays 
Quantification of CYP function was carried out using Promega P450 Glo assay system 
as per manufacturer’s directions. Briefly, in white opaque 96 well plates, 20µg of  
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microsomal protein was combined with 50mM of either Luciferin-ME or Luciferin-BE 
substrate in 100mM KPO4 buffer in a volume of 25µl. The plate was sealed and 
preincubated at 37°C for 10 minutes. 25µl of 200µM NADPH in KPO4 was added to 
initiate the reaction and the plate sealed and incubated for 30 minutes at 37°C. The plate 
was then developed following the method described in Chapter 2. 
 
3.1.2.3  Results 
3.1.2.3.1  Comparison Between HLM Isolated From Tissue or Hepatocytes 
CYP activity was compared in HLM from a single donor (PHH28) that had been 
prepared from either freshly resected tissue or freshly isolated PHH (Figure 3-10). 
 
For each assay measured, there were no significant differences observed between 
activities measured in HLM prepared from tissue or from hepatocytes although there 
was a lower (1.8 fold) CYP1A2 (Luciferin ME) activity when microsomes were 
prepared from PHH compared to tissue. 
 
Figure 3-10. CYP activities were compared for HLM from a single donor (PHH28) prepared from 
tissue (solid bars) or freshly isolated hepatocytes (hatched cells). Individual assays were compared 
by Student’s t test and differences were not found to be significant.  
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3.1.2.3.2  Comparing CYP Activity Between HLM and Freshly Isolated PHH From the 
Same Donor 
CYP activity was measured in HLM and freshly isolated PHH isolated from the same 
donor. For each assay type, the interindividual differences in activity between donors 
were maintained between HLM and PHH (Figure 3-11). 
 
 
Figure 3-11. Interindividual variation in CYP activity was maintained in (top) ECOD and (bottom) 
luciferase assays when activities were compared between (left) HLM and (right) freshly isolated 
PHH isolated from the same donor ( n=4+/-sd). Note that Su= measured in the presence of 10µM 
sulfaphenazole.  
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3.1.2.3.3  Variations in CYP Activity were Maintained Between HLM and Cultured 
PHH 
CYP activity was measured in HLM and hepatocytes isolated from the same donor and 
then maintained in culture for 72 hours, during which time CYP activity decreased as 
observed in section 3.1.1.2.3.  
 
As was observed for comparisons between HLM and freshly isolated PHH, for each 
assay type, the interindividual differences in activity between donors were maintained 
between HLM and PHH, although the differences between donors were less pronounced 
in cultured hepatocytes (Figure 3-12). 
 
 
Figure 3-12. Interindividual variation in CYP activity was maintained in (top) ECOD, (middle) 
Luciferin ME and (bottom) Luciferin BE assays when donor activities were  compared between 
(left) HLM and (right) PHH following 72 hours culture ( n=3+/-sd).  
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3.1.2.4  Discussion 
CYP activity was measured in HLM prepared from either liver tissue or freshly isolated 
PHH and overall CYP function was comparable between the two, although CYP1A2 
(Luciferin ME) activity was slightly decreased in HLM from PHH. This data implies 
that the hepatocyte isolation process does not have a significant effect on CYP activity; 
this could be further confirmed by expanding this comparison to incorporate multiple 
donors,  but  these  initial  findings  validate  the  use  of  freshly  isolated  PHH  as  an 
appropriate indicator of CYP function in adult liver to which BAL relevant cell lines 
can be compared.  
CYP activity was then compared using hepatocytes and HLM isolated from the same 
donor, and this confirmed that the significant variation in CYP activity in hepatocytes 
isolated from a range of donors was directly related to the individual rather than an 
artefact  of  hepatocyte  isolation  or  culture  conditions.  The  differences  were  more 
apparent in HLM prepared from tissue and freshly isolated PHH than in hepatocytes 
that had been cultured for a number of days, most likely due to loss of CYP activity 
during culture, however, the rank order of levels of CYP activity in both freshly isolated 
and cultured hepatocytes and HLM assays from individual donors was equivalent for 
each detection method considered. A similar comparison has previously been made in 
humans  between  CYP  activity  detected  in  vivo  and  CYP  mediated  metabolism  by 
primary hepatocytes 
224. The data presented in this report confirms that comparisons 
made between CYP activity in cultured hepatocytes and HLM are equally valid. This is 
in agreement with another published study which compared, in rats, CYP inhibition in 
hepatocytes and microsomes isolated from the same donor 
225. 
 
In terms of level of function, HLM assays are not representative of a complete cellular 
system. Concentrations of enzymes and cofactors used are non-physiological and the 
amount of available substrate at the enzyme active site differs in microsomal assay 
systems to hepatocytes. HLM were used here to measure interindividual variation and in 
this respect, provide invaluable data when considering the range of CYP function 
between individuals.  
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3.2  Cytochrome P450 Activity in Human Foetal Liver 
Foetal hepatocytes have been considered by other groups for use within a BAL 
122, 171 
and have been compared to HepG2 cells with regard to their biotransformation 
properties 
20 and so for these reasons CYP function in FHH was considered in this 
thesis. 
3.2.1  Methods 
Foetal liver was obtained from the UCL Institute of Child Health. Hepatocytes and non-
parenchymal cells were isolated from this tissue using a collagenase digestion protocol 
modified from Lázaro et al.
226. 
3.2.1.1  Isolation of Human Foetal Hepatocytes 
1x PBS 
Digestion buffer (HBSS containing calcium and magnesium supplemented with 20mM 
HEPES, 0.5% BSA, 50µg/ml ascorbic acid, 4mg/ml insulin, 3mg/ml Collagenase Type 
IV) 
Williams’ Medium E (WEM) 
Ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) 
 
Tissue was washed in PBS before being minced in collagenase digestion buffer. This 
tissue suspension was digested by gentle agitation at 37°C for 30 minutes. Cells were 
collected by centrifugation at 32g (400rpm) for 6 minutes at 4°C. The resultant pellet 
was resuspended in WEM containing 0.5mM EGTA and successively passed through 
23- and then 25-gauge needles to obtain a single cell suspension. Cells were washed, 
resuspended in WEM and counted. Viability was determined by trypan blue exclusion 
and ranged from 78-86%.    
 
3.2.1.2  Culture of Human Foetal Hepatocytes 
Post isolation, cells were resuspended in Foetal Hepatocyte Medium (FHM, Chapter 2) 
plus 5% FCS and seeded on 48-well collagen coated tissue culture plates (2.5x10
5 
cells/well in a volume of 300ml). Following an overnight incubation, cells were washed 
in WEM and medium changed to remove serum. At this point 20ng/ml of both HGF and 
EGF were added to cultures. Cultures were maintained in a 37°C, 5% CO2 incubator  
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and medium replenished every other day. Growth factors were removed from medium 
two days prior to the introduction of inducers. 
3.2.2  Results 
Luciferin BE metabolism was measured in FHH and data is shown in Figure 3-13. A 
significant donor dependent variation (P < 0.05) was observed in CYP3A activity in 
monolayer cultures of FHH isolated from 3 separate donors and cultured under basal 
conditions; all 3 preparations were within the range measured for freshly isolated PHH 
described in Table 3-2. 
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Figure 3-13. CYP3A (Luciferin BE) activity was measured in FHH isolated from 3 separate donors 
and expanded in culture until confluent (~14 days). For each donor n=3 +/- sd. 
 
Induction of CYP activity was explored in FHH prepared from a single donor (FHH3). 
Cells were cultured for 96 hours in presence of inducer and CYP3A function was 
measured by Luciferin BE and testosterone metabolism (Figure 3-14). Although 
changes in function were not statistically significant, common trends were indicated 
between the two assays. Following treatment with inducers, Luciferin BE metabolism 
was induced by dexamethasone (5.2 fold) and to a lesser extent by rifampicin (1.4 fold). 
Extent of testosterone depletion was also greater in cells treated with dexamethasone 
(2.2 fold above vehicle) than with rifampicin (0.82 fold). FHH produced detectable 
quantities of the 6β-OHTST metabolite, although dexamethasone induced cells 
produced a greater amount than rifampicin treated cells; for both inducers, levels were 
comparable with vehicle treated cells.  
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Figure 3-14. FHH (isolated from a single donor-FHH3) were expanded in culture for 10 days post 
isolation and then treated for 96 hours with 50µM inducers or 0.1% DMSO vehicle. CYP activity 
was then measured by (top) Luciferin BE assay, (middle) testosterone metabolism and                
(bottom) 6β-OHTST production. For each assay n=2 +/- range.  
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3.2.3  Discussion 
CYP3A activity was profiled in FHH isolated from 3 separate donors and, like adult 
PHH, a significant donor dependent variation in function was observed under basal 
conditions. However FHH differ from adult PHH with regard to their CYP induction. In 
agreement with other publications, data presented here demonstrated that CYP3A 
activity is better upregulated by dexamethasone than rifampicin in foetal hepatocytes 
138, 
164. In their study, Matsunaga et al. found a negligible expression of PXR in FHH and so 
also considered effects of dexamethasone on CYP3A induction in foetal hepatocytes in 
the presence of the glucocorticoid receptor (GR) antagonist RU486; it was found that 
this compound inhibited CYP induction which suggests that CYP3A induction in foetal 
hepatocytes is GR mediated.  
 
It was demonstrated above that in some circumstances, CYP3A (Luciferin BE) function 
in FHH matches that measured in some adult PHH. Although the specific isoform 
mediating this activity was not determined (CYP3A4/5/7) others have demonstrated 
expression and induction of both CYP3A4 and CYP3A7 in FHH 
138. Further to this, it 
was shown here that FHH metabolise TST and produce quantifiable amounts of 6β-
OHTST which is predominantly produced by CYP3A4. FHH are expandable and 
express relevant CYPs and so may be a considered as a source of Cytochrome P450 
function within a BAL. However, FHH differ from adult hepatocytes not only in their 
preferential expression of CYP3A7 to CYP3A4 but also in their negligible expression 
of pregnane X receptor (PXR) 
138, 164, which is a key mediator of CYP3A induction. 
Also, others have demonstrated that CYP functionality in passaged FHH is lower than 
in isolated adult primary human hepatocytes and although higher CYP activity can be 
achieved by clonal selection, extensive in vitro expansion of FHH may result in 
decreased hepatic functionality 
227. Consequently obtaining an adequate biomass 
comprised of foetal hepatocytes could be problematic. 
 
3.3  Conclusions 
Here  a  significant  variation  in  Cytochrome  P450  function  in  human  liver  was 
determined for a number of donors and it was established that interindividual changes in 
CYP function were consistent between PHH and HLM. This emphasises the need to 
select a number of donors when measuring CYP activity to compare with data obtained 
from immortalised cell lines.   
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Other published studies of CYP activity in PHH have used pools of cryopreserved cells 
from multiple donors (10 is recommended by one cohort 
114) to give a fair 
representation of CYP function in human liver. Effects of cryopreservation 
notwithstanding, here CYP activity in PHH from 8-10 individual donors was measured 
in order that the range of function could be determined rather than an average value 
alone. 
 
Determinants of CYP function were examined in adult PHH and FHH and differences 
in CYP induction between cells derived from adult and foetal cells were described. It 
was also determined that BAL relevant culture conditions including media composition 
and used of CYP inducers influenced CYP induction, however effects were also donor 
dependent. These conditions will therefore need to be defined for HepG2 cells and this 
will be reported in Chapter 4.  
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CHAPTER 4  Working with What’s Available: Adapting HepG2 
Culture Conditions to Improve Cytochrome P450 Function within a 
BAL 
 
Human liver-derived cell lines are widely used as surrogates for primary human 
hepatocytes as they confer many hepatocyte-specific characteristics. The 
hepatoblastoma-derived HepG2 cell line is currently being investigated as the potential 
cellular component of the Liver Group (LG) BAL, and, as discussed in Chapter 1, one 
system comprising C3A cells, a subclone of HepG2 cells, has been trialed clinically 
within another BAL device, albeit with limited success. HepG2 cells exhibit many 
hepatocyte-like functions which may be upregulated by 3D culture, but have lost some 
of their synthetic and detoxificatory capacity and have thus far been unable to provide 
the level of CYP function that is required of a BAL. 
 
As described in Chapter 3, CYP enzyme function is variable in primary cells and this is 
(partly) dependent upon their culture conditions. Moreover, it has been established by 
others that if culture medium does not support hepatocyte differentiation, a rapid drop 
of all hepatic-specific functions, including drug-metabolising capacity, occurs. This 
drop of drug metabolising capacity is (probably) due to the general shutdown of CYP 
gene expression 
115 and this subject has been addressed by several research groups with 
respect to HepG2 cells 
51, 137, 228.  
 
Adjustment of culture format can have positive effects on HepG2 function. In particular 
3D culture, resulting in spheroid formation, allows cells to mimic the natural 
configuration of liver cells in vivo; this improves many hepatocyte specific functions 
109, 
134, 229, 230. Practically, within a BAL, 3D culture allows a sufficient biomass to be 
generated in a feasible volume for use in an extracorporeal circuit, which would not be 
possible in conventional monolayer culture.  
 
LG complete culture medium has been optimised for HepG2 BAL culture to promote 
cell growth and hepatocellular differentiation; potentially this could have an effect on 
CYP induction in HepG2 cells. We have also demonstrated that culture medium 
containing 10% human fresh frozen plasma (FFP) in place of FCS results in enhanced 
cell proliferation and improved per bead performance in 3D culture. From a regulatory  
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perspective, use of FFP rather than FCS in culture medium is advantageous since use of 
animal derived products within a BAL would be undesirable. Furthermore, within a 
BAL, HepG2 cells are exposed to liver failure plasma (LFP) for periods of up to 8 
hours. Others have demonstrated effects of LFP on CYP function as discussed in 
Chapter 1. Exposure to FFP during HepG2 culture could influence CYP function and 
this will be explored here. 
 
The aim of Chapter 4, therefore, is to measure CYP induction in HepG2 cells in LG 
BAL culture conditions in monolayer cells and in encapsulated Hep G2 cells, cultured 
in static culture, or within a microgravity environment. The effect of exposure to human 
plasma on CYP activity in HepG2 cells was also considered in both monolayer and 3D 
culture systems.  
 
4.1  Chemical Induction of Cytochrome P450 in Monolayer HepG2 cells 
4.1.1  Methods 
HepG2 cells were seeded in 96 well plates at a density of 2.5x10
4 cells/well in a volume 
of 100 l complete culture medium (Chapter 2). Following overnight attachment, cells 
were treated with CYP inducers for 48 hours and then CYP activity was measured by 
ECOD activity, Luciferin BE metabolism or Luciferin ME metabolism (+ 10µM 
sulfaphenazole). Cell viability following exposure to inducers was measured by WST-1 
assay. Cell protein was determined by the BCA assay.  
4.1.2  Results 
Each monolayer culture experiment was repeated three times in triplicate and the data 
presented here are the mean values of the three experiments. 
 
4.1.2.1  Effect of Inducers on ECOD Activity  
ECOD activity was measured in HepG2 cells following exposure to inducers over a 
range of concentrations (Figure 4-1). Following treatment with DBA and indirubin, 
ECOD activity in HepG2 cells was comparable with lower levels measured in freshly 
isolated PHH. 
Significant induction was achieved in HepG2 cells following treatment with DBA 
(P<0.05), indirubin (P < 0.001) and rifampicin (P < 0.001). Effects of inducer were  
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concentration dependent; highest responses were observed with 10µM and 5µM of 
DBA, 20µM and 40µM indirubin and 50µM and 100µM rifampicin. Dexamethasone 
treatment did not cause induction of ECOD activity. 
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Figure 4-1. HepG2 cells were treated for 48 hours with decreasing concentrations of CYP inducers 
(1:2 dilution from top concentration indicated in brackets) and CYP function then measured by 
ECOD assay. Data is expressed as mean (n=3) +/- sd and was analysed by one-way ANOVA 
followed by Bonferroni post tests. *** P < 0.001, ** P < 0.01, * P < 0.05 when compared to 0.1% 
DMSO vehicle control (represented by orange bars). 
4.1.2.2  Effect of Inducers on CYP1A2 (Luciferin ME) Activity  
Luciferin ME metabolism was measured in the presence of 10µM sulfaphenazole and 
data is shown in Figure 4-2. Treatment with CYP1A inducers resulted in improved 
function. 
 
There was a significant increase in CYP1A2 activity following 10µM DBA treatment 
(70.8 fold above vehicle, P < 0.001); activity was also increased to a lesser extent 
following indirubin exposure (8.1 fold). CYP3A inducers dexamethasone, rifampicin 
and phenobarbital were without effect on CYP1A2 activity following 48 hour treatment. 
  
Even following DBA induction, function was markedly lower than measured in PHH 
for this assay. 
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Figure 4-2. CYP1A2 (Luciferin ME) activity was measured in the presence of 10µM sulfaphenazole 
in HepG2 cells following 48 hour treatment with (top) CYP1A and (bottom) CYP3A inducers. Data 
is expressed as mean (n=3) +/- sd and was analysed by one- way ANOVA and Bonferroni post test.  
*** P < 0.01 when compared to 0.1% DMSO vehicle control.   
 
4.1.2.3  Effect of Inducers on CYP3A (Luciferin BE) Activity  
Effects of inducers on CYP3A (Luciferin BE) activity are shown in Figure 4-3. There 
was a differential effect of CYP3A inducers on Luciferin BE metabolism. 
Dexamethasone and phenobarbital did not induce CYP3A function in HepG2 cells by a 
significant amount, whereas treatment with rifampicin resulted in a significant increase 
in CYP3A function (P < 0.01, 1.7 fold above vehicle). This activity was still lower 
(15%) than the lowest levels measured in PHH. CYP3A activity was also improved 
following treatment with indirubin (P< 0.05, 1.5 fold).  
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Figure 4-3. CYP3A (Luciferin BE) activity was measured in HepG2 cells following 48 hour 
treatment with (top) CYP3A and (bottom) CYP1A inducers.  Data is expressed as mean (n=3) +/- sd 
and was analysed by one- way ANOVA and Bonferroni post test. * P < 0.05, ** P < 0.01 when 
compared to 0.1% DMSO vehicle control.    
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4.1.2.3.1  Luciferase Assay Selectivity 
CYP3A induction was compared in HepG2 cells following measurement with either 
Luciferin BE or Luciferin PFBE substrate. Experimental conditions were the same for 
each substrate and were described in Chapter 2. As shown in Figure 4-4, fold induction 
above basal activity was comparable for each inducer for the two substrates.  
 
Figure 4-4. CYP3A induction in HepG2 cells was measured using Luciferin BE or Luciferin PFBE 
substrate following 48 hour exposure to a range of inducers. Fold induction above untreated cells 
was measured for each inducer and values (n=3+/- sd) are presented for each substrate.  
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4.1.2.4  Effect of Inducers on WST-1 Activity 
WST-1 activity was measured in HepG2 cells to determine the effect of 48 hour 
induction on cell viability and it was determined that, in HepG2 cells, exposure to any 
of the inducers measured did not affect WST-1 activity (Figure 4-5). 
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Figure 4-5. WST-1 activity was measured in monolayer HepG2 cells following 48 hour exposure to 
inducers (n=3 +/-sd). 
 
4.1.2.5  Effect of DBA on Cell Proliferation 
Although overall WST-1 activity was not affected by exposure to any inducer, it was 
evident by microscopy that DBA exposure had an effect on cell proliferation. This was 
roughly quantified by comparing total protein content in induced and vehicle treated 
cells.  
 
HepG2 cells were treated for 48 hours with either 0.1% DMSO vehicle or 10µM DBA. 
Cells were then washed twice with HBSS and culture medium without inducer added. 
Total protein content was determined by BCA assay 0-72 hours following removal of 
inducer.  
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Following two-way ANOVA, there was a significant interaction between time in culture 
and DBA exposure on cell proliferation (P < 0.001, F (3, 1281) = 45.76). Exposure of 
HepG2 cells to DBA resulted in inhibition of cell proliferation and this was not 
improved even 72 hours after inducer was removed from culture medium (Figure 4-6). 
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Figure 4-6. Total cell protein (measured by BCA assay) was compared up to 72 hours post 
induction for HepG2 cells treated for 48 hours with 10µM DBA or 0.1% DMSO vehicle. Following 
two-way ANOVA and Bonferroni post-test *** P < 0.001 when vehicle treated and induced cells are 
compared (n=3 +/- sd).  
 
4.1.3  Discussion 
The initial aim of Chapter 4 was to determine suitable concentrations of CYP inducers 
required to treat HepG2 cells in order to obtain induction of CYP function over a 48 
hour time period. This was firstly measured by ECOD activity over a range of 
concentrations and it was found that by treating HepG2 cells with indirubin (20µM) or 
DBA (10µM), activity approached lower levels measured in freshly isolated PHH. 
Based on ECOD response, a suitable concentration of each inducer was selected to 
measure induction by luciferase assays.  
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CYP3A (Luciferin BE) activity was lower in HepG2 cells than PHH although there was 
a positive effect of induction. Following rifampicin (50µM) induction, HepG2 cell 
CYP3A activity was improved above uninduced cells although this level was 15% 
lower than the lowest activity measured in PHH. Of the CYP3A inducers considered, 
rifampicin treatment resulted in the greatest improvement in CYP function. Others have 
also indicated that in humans rifampicin is a far greater inducer of CYP3A4 than 
dexamethasone or phenobarbital 
231.  
 
The greatest increase in CYP1A2 (Luciferin ME) activity was measured following DBA 
treatment (10µM). However even after this induction, the level of function achieved 
was substantially less (50%) than the lowest level measured in freshly isolated PHH.  
 
In addition to CYP1A2 activity, Luciferin ME assay also measures CYP2C function and 
so was therefore measured in the presence of 10µM sulfaphenazole, which has been 
shown, in Chapter 3 and by others 
136, to diminish CYP2C mediated Luciferin-ME 
metabolism. As discussed in Chapter 1, initially the Luciferin ME assay was marketed 
as a CYP1A2/2C8 specific assay. It was subsequently determined that this assay also 
detects other CYP isoforms most notably CYP4A11 which is expressed in the liver and 
is responsible for fatty acid and arachidonic acid metabolism. Potentially this isoforms 
could be active in PHH and not HepG2 cell which could account for the discrepancy in 
function between the two cell types.  
 
Different effects of the CYP1A inducers indirubin and DBA were also shown here 
between ECOD and Luciferin ME assays. DBA had a greater effect in the Luciferin ME 
assay, indirubin had a greater effect in the ECOD assay. Luciferin ME assay measures 
CYP1A2 but not CYP1A1. ECOD activity measures CYP1A1/1A2, in addition to 
CYP2 and CYP3 activity. Potentially DBA could have a greater effect on CYP1A2 
induction, whilst indirubin has a greater effect on CYP1A1 induction; both inducers 
have been reported by others to induce both CYP1A1 and CYP1A2 expression 
61, 136, 207. 
Additionally, indirubin could be having a greater effect on other subfamilies measured 
by the ECOD assay. This was confirmed when the effects of CYP1A inducers on 
CYP3A function were measured. 
 
As described in Chapter 1, CYP induction arises through nuclear receptor activation and 
agonists of different nuclear receptors activate various different CYP isoforms. At a  
  134 
simplistic level, treatment of cells with aryl hydrocarbon receptor (AhR) agonists results 
in CYP1A activation whereas Pregnane X Receptor (PXR), Constitutive Androstane 
Receptor (CAR) and Glucocorticoid Receptor (GR) agonists activate CYP2C and 
CYP3A expression. 
 
In monolayer HepG2 cultures, an effect of AhR agonists on CYP3A induction was 
observed: indirubin (20µM) increased Luciferin BE metabolism following a 48 hour 
exposure. There was also a moderate improvement in CYP1A2 function observed 
following treatment with dexamethasone (50µM) and rifampicin (50µM), although 
these changes were substantially lower than those measured with DBA and indirubin. In 
this thesis, the effect of nuclear receptor cross-talk on CYP induction will be addressed 
in greater detail in Chapter 6. 
 
Cytotoxic effects of each inducer were also measured by WST-1 assay. When 
normalised to account for total protein content, there was no effect of any of the 
inducers studied in this assay. It was, however, observed that DBA had a significant 
effect on cell proliferation, which was reduced following DBA exposure and did not 
show signs of recovery, even 72 hours after inducer was removed from culture medium.  
From a regulatory perspective, DBA would not be a preferable inducer for use within a 
BAL, since it is a polycyclic aromatic hydrocarbon (PAH) and many chemicals of this 
class are considered carcinogenic. It is also the least soluble of all the inducers selected 
in this thesis which could lead to difficulties finding a solvent vehicle which is BAL 
compatible. The effect of DBA on cell proliferation, demonstrated here, provides an 
additional reason why this chemical, although a powerful inducer of CYP1A enzymes, 
would not be fit for purpose.  
 
4.2  Cytochrome P450 Function in Encapsulated Hep G2 Cells 
Having demonstrated Cytochrome P450 induction in monolayer HepG2 cells, the 
effects of 3D culture on CYP function in HepG2 cells was then examined. 
 
It has been extensively demonstrated that alginate encapsulation and 3D culture of 
HepG2 cells can significantly enhance hepatocyte specific functions. Furthermore, 
bioreactor culture will improve proliferation rates of encapsulated cells; hence large  
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scale culture becomes feasible. This is, in part, achieved by greater mass transfer which 
arises through perfusion of cultures by mixing, stirring or rotation. 
 
When alginate encapsulated cells are cultured within a microgravity environment, the 
resultant decrease in sheer stress and increase in mass transfer that occurs leads to  
greater cell proliferation and improved viability; consequently the per bead performance 
is improved 
230. This may also impact on CYP function. 
 
The rotary cell culture system (RCCS) contains a culture module with a gas-permeable 
central core comprising of a silicone rubber membrane. The module, which is filled 
with beads and medium, constantly rotates at a slow speed (~8rpm) on a horizontal axis 
so that the beads are in constant free-fall but held in suspended animation by the 
rotational drag of the medium (Figure 4-7).  
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Fill port
Silicone membrane
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Figure 4-7. Setup of the RCCS. Beads and culture medium are added to the culture module (left) 
via a fill port which is then sealed. Up to 4 culture vessels can be screwed onto a base (middle) 
which is placed into a 37°C incubator and powered by a motor to rotate the vessels at 8rpm. The 
illustration of a cross section of an RCCS vessel (right) demonstrates how mass transfer occurs: 
each vessel is rotated on a horizontal axis (A) allowing culture medium to circulate and perfuse the 
beads which are maintained in suspension. Gas exchange (→) occurs through a central core which 
is gas permeable. 
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As described above, the RCCS is a sealed culture system which provides a perfused 
mass transfer system by rotating. In contrast, the fluidised bed bioreactor (FBB) consists 
of a perfusable culture chamber associated with a large medium reservoir. Fluidisation 
is achieved by pumping medium from the reservoir into the base of the culture chamber. 
Beads under fluidised conditions move in a loop from the bottom of the chamber to 
maximum fluidisation height due to the opposing forces of gravity acting on the beads, 
which are denser than the medium, and upward drag created by the flow of medium 
through the bioreactor (Figure 4-8). Temperature, pH and oxygen concentration are all 
controlled by a fermentor. 
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Figure 4-8. Setup of the FBB culture system. Beads are maintained within a culture module which 
is continually perfused with medium held in a separate reservoir.  Temperature, pH and 
oxygenation are tightly regulated by a fermentor. Media is pumped at a controlled rate through the 
culture module from the base to the top by a peristaltic pump. The flow of media causes the beads 
to rise and gravity then causes the beads to fall again meaning they move in a continual loop 
around the bioreactor. 
 
In the following section, Cytochrome P450 function was examined in encapsulated 
HepG2 cells maintained in static culture or within a microgravity/fluidised bed 
environment.   
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4.2.1  Methods 
4.2.1.1  CYP Function in Encapsulated HepG2 Cells Maintained in Static Culture 
HepG2 cells were encapsulated using the Inotech method described in Chapter 2 and 
beads resuspended in HG aMEM (Chapter 2) with 10% FCS at a ratio of 0.25ml of 
beads per 8ml of media. 8ml/well of this suspension was added to 6 well plates and 
beads maintained in static culture with media changes every 2 days. Inducers were 
added on day 6 for 48 hours. CYP function was measured on day 8 by ECOD, Luciferin 
BE or TST assay.  
 
4.2.1.2  CYP Function in HepG2 Cells Maintained in Microgravity Culture 
HepG2 cells were encapsulated using the Jetcutter method described in Chapter 2 and 
beads resuspended in HG aMEM with 10% FCS at a ratio of 0.25ml beads per 8ml 
media. Beads were added via a fill port to RCCS chambers (500mls of suspension 
(16ml beads)/vessel) which were screwed onto the RCCS base and then placed within a 
37°C humidified incubator (95% air, 5% CO2). Beads were maintained in culture for up 
to 10 days and 50% (250mls) of the culture medium was replenished every 2 days. 
Inducers were added on day 6 for 48 hours and CYP activity was then measured by 
ECOD or Luciferin BE assay. 
 
4.2.1.3  CYP Function in HLM Isolated From HepG2 Cells Following Bioreactor 
Culture 
As described, during FBB culture, conditions including pH and dissolved oxygen 
concentration are tightly regulated. The very high cell density achieved by this culture 
system means that assessing CYP function in these encapsulated cells under standard 
assay conditions would have impact on cell function and viability. Therefore, once 
HepG2 cells were removed from the FBB, human liver microsomes (HLM) were 
isolated and these were used for measurement of CYP activity. CYP function was 
compared in HLM prepared from freshly isolated primary human hepatocytes (HLM-
PHH) from 5 separate donors (PHH3, PHH8, PHH25, PHH28 and PHH31) or HepG2 
cells (HLM-HepG2). HepG2 cells were in their basal state (uninduced) and had either 
been grown in an RCCS for 8 days (section 4.2.1.2), or were obtained following 
propagation in a fluidised bed bioreactor (FBB).   
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4.2.1.3.1  FBB Culture of HepG2 Cells 
The overall aim of FBB experiments is to optimise large scale culture conditions for 
HepG2 cells in order to achieve maximum bead capacity without adversely affecting 
cell function. This work was performed by others who provided the alginate beads used 
here. 
 
HepG2 cells were encapsulated at an initial seeding density of 1.5x10
6 cells/ml using the 
Jetcutter method described in Chapter 2. A total volume of 200mls of alginate beads 
were encapsulated and these were resuspended in HG αMEM containing 10% FFP and 
then added to a 2.5L (15cm diameter) FBB associated with a 7.5L circuit. Medium was 
perfused through the circuit at 390ml/minute to achieve 1.5 times fluidisation height. 
Beads were maintained at 37°C; temperature, pH and oxygen supply were tightly 
regulated. 50% medium changes were carried out at d2, d5, d7, d9 and d11. A 25% 
medium change was performed at d12. Beads were harvested on d13 at which point cell 
viability was determined by FDA/PI staining to be 98%.  
4.2.1.3.2  HLM Isolation and Measurement of CYP Function 
HepG2 spheroids were released from alginate using the method described in Chapter 2. 
HLM were isolated from these or PHH and CYP function quantified (ECOD or 
Luciferin BE assay) using the methods described in Chapter 3 (section 3.1.2). 
 
4.2.2  Results 
Cytochrome P450 function was firstly measured in encapsulated HepG2 cells grown in 
static culture in 6 well plates. Subsequently, CYP function was compared in 
encapsulated HepG2 cells maintained in microgravity/FBB culture systems. 
 
4.2.2.1  3D Culture of HepG2 Cells Maintained in Static Culture 
Figure 4-9 shows the growth and viability of encapsulated cells maintained in static 
culture. FDA (live cell) staining demonstrates proliferation and spheroid formation 
throughout 8 days of culture. PI (dead cell) staining indicates that at day 8, when cell 
density in the beads was highest, there was a slight decline in viability.  
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Figure 4-9. Cell viability staining (x10 magnification) of encapsulated HepG2 cells maintained for 
up to 8 days in static culture. 
 
4.2.2.1.1  ECOD Activity in Encapsulated HepG2 cells Maintained in Static Culture 
ECOD activity was compared in monolayer and 3D cultures of HepG2 cells, following 
48 hour DBA induction, and improved function was observed after 3D culture.  
 
Data was analysed by two-way ANOVA and is shown in Figure 4-10. There was a 
significant effect of 3D culture on ECOD activity in HepG2 cells (P<0.05, F (1, 0.0025) 
=11.26) and a significant effect of DBA induction in these cultures (P<0.01, F (1, 
0.0047) =21.20) however there was no synergism between the two factors. 
d1 
d3 
d8 
d 
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  140 
 
ECOD activity was elevated in cells maintained in 3D culture following treatment with 
0.1% DMSO vehicle (2.6 fold above monolayer culture) and 10µM DBA (1.8 fold).  
 
In both culture formats, DBA resulted in induction of ECOD activity. Extent of 
induction was slightly higher in monolayer cultures (3.3 fold induction above basal) 
than in 3D cultures (2.3 fold) but this difference was not significant. 
 
 
 
Figure 4-10. Comparison of ECOD activity in HepG2 cells cultured in 3D format for 8 days or in 
monolayer and treated for 48 hours with either 0.1% DMSO vehicle or 10µM DBA (n=3 +/- sd). 
Data analysis was by two-way ANOVA with Bonferroni post test. * P <0.05 when compared to 
monolayer cultures.  
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4.2.2.1.2  CYP3A (Luciferin BE) Activity in Encapsulated HepG2 Cells Maintained in 
Static Culture 
Luciferin BE metabolism was compared in HepG2 cells maintained in monolayer or 3D 
culture and treated for 48 hours with 50µM rifampicin or 0.1% DMSO vehicle. 
Improved function was observed after 3D culture (Figure 4-11). 
 
There was a significant effect of 3D culture on CYP3A activity in HepG2 cells 
(P<0.001 F (1, 0.001) =53.54) and significant interaction between effects of rifampicin 
and effects of 3D culture (P < 0.01 F (1, 0.0001) =8.61). Under basal conditions, 3D 
culture resulted in an increase in CYP3A activity (2.8 fold). However, the effect of 
rifampicin induction in 3D cultured cells was lost; the difference in function between 
3D and monolayer cultures was therefore decreased (1.4 fold difference) following 
rifampicin treatment.  
 
 
Figure 4-11. CYP3A function was measured in HepG2 cells cultured in 3D format for 8 days or in 
monolayer and treated for 48 hours with either 0.1% DMSO vehicle or 50µM rifampicin (n=6 +/- 
sd). Data analysis was by two-way ANOVA with Bonferroni post test. * P <0.05, *** P < 0.001 when 
compared to monolayer cultures.  
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4.2.2.1.3  Testosterone Metabolism in Encapsulated HepG2 Cells  
Substrate metabolism was analysed in monolayer or encapsulated HepG2 cells that had 
been treated for 48 hours with 50µM rifampicin and incubated for up to 8 hours with 
200µM testosterone (TST). Included in the same analysis run was supernatant from 
freshly isolated PHH treated for 1 hour with 200µM TST. 
  
After 1 hour incubation with TST, encapsulated HepG2 cells did not produce any 
detectable metabolite of the substrate (Figure 4-12).  
 
a
b
a
b
a
b
 
Figure 4-12. HPLC was used to measure metabolism of testosterone in (a) encapsulated HepG2 
cells treated with 50µM rifampicin or (b) freshly isolated PHH incubated for 1 hour with 200µM 
TST.  TST spike is indicated by →. TST metabolites are indicated by →/→ and were measured in 
PHH only. One representative trace is shown of 4 independent measurements.  
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Following an 8 hour incubation with TST, HepG2 cells had produced a similar 
metabolite to that produced by PHH following 1 hour substrate incubation. Substrate 
metabolism was also compared with monolayer HepG2 cells and appeared greater in 3D 
culture (Figure 4-13). 
 
b
a
a
(3D)
(m)
b
a
a
(3D)
(m)
b
a
a
(3D)
(m)
 
Figure 4-13. HPLC was used to measure metabolism of testosterone in (a) HepG2 cells treated with 
50µM rifampicin in monolayer (m) or 3D culture and then incubated with 200µM TST for 8 hours, 
or (b) freshly isolated PHH incubated with 200µM TST for 1 hour.  TST spike is indicated by →. 
TST metabolites are indicated by →/→ and differed in PHH and HepG2 cells. One representative 
trace is shown of 4 independent measurements.  
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4.2.2.2  3D Culture of Encapsulated HepG2 Cells Maintained in Microgravity Culture 
Figure 4-14 shows the growth and viability of encapsulated cells maintained for 8 days 
within an RCCS microgravity environment. FDA staining demonstrates proliferation 
and spheroid following 8 days of culture. There was minimal PI staining which 
demonstrates that viability was improved with this culture system and was maintained 
even when bead density increased.  
 
 
Figure 4-14. Cell viability staining (x10 magnification) of encapsulated HepG2 cells following 8 days 
of RCCS microgravity culture. 
4.2.2.2.1  ECOD Activity in HepG2 Cells Following RCCS Culture 
ECOD activity was compared in monolayer cultures and in 3D cultures of HepG2 cells 
following either static or microgravity culture. Improved induction was observed 
following microgravity culture (Figure 4-15, note that, in this figure, activity is 
expressed relative to that seen in monolayer culture).  
 
Data was analysed by two-way ANOVA. There was a significant effect of culture 
format on ECOD activity in HepG2 cells (P<0.001, F (3, 0.143) =377) and a significant 
effect of DBA induction in these cultures (P<0.001, F (1, 0.106) =561). There was also 
a significant interaction between the two factors (P<0.001, F (2, 0.123) =322); DBA 
mediated induction was enhanced in cells maintained in RCCS environment.  
 
Under basal conditions, ECOD activity was increased by equivalent amounts following 
static (2.6 fold above monolayer) or RCCS (2.6 fold) culture. Following DBA exposure, 
a greater increase was seen in the RCCS (8.8 fold above monolayer) than in static 
culture (1.8 fold above monolayer). Therefore the extent of DBA mediated induction 
d8 
d10 
Phase x10  FDA  PI  
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was greater following RCCS culture (11.4 fold induction above basal), than in static 
(2.3 fold induction), or monolayer culture (3.3 fold induction). 
 
 
Figure 4-15. ECOD activity was measured in HepG2 cells cultured in 3D format maintained for 8 
days in either static or microgravity culture and treated for 48 hours with either 0.1% DMSO 
vehicle or 10µM DBA. For each culture system, change in activity relative to monolayer culture was 
calculated and is expressed here as mean (n=3) +/-sd. Data analysis was by two-way ANOVA and 
Bonferroni post test. * P <0.05, *** P<0.001 when compared to monolayer cultures.  
+++  P < 0.001 when static and RCCS cultures are compared. 
 
4.2.2.2.2  CYP3A (Luciferin BE) Activity in HepG2 Cells Following Microgravity 
Culture 
CYP3A (Luciferin BE) activity in monolayer cultures of HepG2 cells under basal 
conditions were compared with 3D cultures maintained in either static or microgravity 
culture. 3D culture resulted in improved CYP3A activity; the greatest improvement in 
function was observed when encapsulated cells were maintained in an RCCS 
environment (Figure 4-16).  
 
Data was analysed by one-way ANOVA.  There was a significant difference in 
Luciferin BE metabolism between culture systems (P<0.001). CYP3A activity was 
significantly increased in 3D culture when cells were maintained in static culture 
(P<0.01, 2.8 fold above monolayer). Function was further increased by RCCS culture of 
encapsulated cells (P<0.001, 3.8 fold above monolayer).  
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Figure 4-16. CYP3A (Luciferin BE) activity was measured in HepG2 cells cultured in 3D format 
maintained for 8 days in either static or microgravity culture. For each culture system, change in 
activity relative to monolayer culture was calculated and is expressed here as mean (n=3) +/-sd. 
Data analysis was by one-way ANOVA and Bonferroni post test. ** P < 0.01, *** P < 0.001 when 
compared to monolayer culture.  
++ P < 0.001 when static and RCCS cultures are compared. 
 
4.2.2.2.3  CYP Activity in HLM isolated from HepG2 Cells Following Bioreactor 
Culture 
CYP function was compared in HLM isolated from freshly isolated PHH and from 
HepG2 cells maintained in two different bioreactor systems (RCCS or FBB) in either 
10% FCS or 10% FFP respectively (Figure 4-17). PHH were isolated from 5 separate 
donors and activity in each HLM preparation was measured separately (as opposed to 
pooling donor samples). This was done so that both mean and range of activity for PHH 
from separate donors could be calculated.  
 
The level of ECOD activity in HLM-HepG2 was comparable between the two 
bioreactor systems. ECOD activity in HLM-HepG2 approached the lower levels of 
function measured in HLM-PHH but was substantially lower than the average value 
calculated for all 5 donors (5.0 - 6.6 fold less than HLM-PHH for FBB and RCCS 
HLM-HepG2). 
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CYP3A (Luciferin BE) activity in HLM-HepG2 from RCCS culture was only slightly 
lower (1.3 fold) than the average value measured in HLM-PHH but was considerably 
higher (4 fold) than HLM-HepG2 obtained following FBB culture. 
 
Figure 4-17. Cytochrome P450 function was measured by (top) ECOD assay and (bottom) Luciferin 
BE assay to compare activity in HLM isolated from freshly isolated PHH and 3D bioreactor 
cultures of HepG2 cells maintained in an RCCS in 10% FCS or an FBB in 10% FFP. Mean and 
range of activity is shown for PHH isolated from 5 separate donors (measured in triplicate/donor). 
HepG2 data is expressed as mean (n=2) +/-range. Note the logarithmic scale of the y axis.   
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4.2.3  Discussion 
HepG2 encapsulation and subsequent 3D culture resulted in a significant improvement 
in Cytochrome P450 function. ECOD activity was improved under basal conditions and 
following DBA induction, although extent of induction was slightly less in 3D cultures 
maintained in static culture. When static and microgravity cultures were compared, 
under basal conditions CYP function was comparable, however, DBA mediated 
induction was significantly improved following culture in an RCCS environment. This 
could be partly attributed to the increased viability of cells in microgravity culture since 
ECOD data was normalised to total protein rather than viable cell number. The observed 
effect in monolayer culture of DBA on cell proliferation could also have an effect. 
 
Under basal conditions, CYP3A activity was significantly improved by 3D culture; 
microgravity culture also resulted in further improvement in function relative to static 
culture. Once again this can probably be related to improved cell viability and cell 
density, and hence per bead performance, that is observed following microgravity 
culture. The effect of rifampicin mediated induction on CYP3A activity was also 
compared in monolayer and 3D (static) cultures and it was demonstrated that the effect 
of induction was reduced by 3D culture. This indicates that the extent of induction that 
can be achieved in HepG2 cells is limited. As described previously, CYP3A induction is 
governed by nuclear receptors including PXR and CAR and co-receptor RXRα. Others 
have reported diminished nuclear receptor expression in hepatoma cell lines 
157, 221, 232; 
potentially this could have a limiting effect on CYP3A induction in these cell lines in 
spite of the overall positive effect of 3D culture. 
 
Improved Luciferin BE metabolism in 3D culture indicates that CYP3A function was 
improved. Testosterone metabolism was also measured in encapsulated HepG2 cells. 
HepG2 cells were incubated with testosterone for up to 8 hours and after this time 
although they appeared to metabolise testosterone they did not produce the CYP3A4 
metabolite 6β-OHTST. Possibly alternative isoforms, including CYP3A7, were 
responsible for substrate metabolism and these were upregulated by 3D culture. This 
will be discussed further in Chapters 5 and 6.  
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HLM were prepared from HepG2 cells maintained in their basal state in two different 
bioreactor systems: RCCS and FBB. Cytochrome P450 activity was compared between 
the two systems and also in HLM prepared from freshly isolated PHH.  
 
ECOD activity was comparable between the two bioreactor systems (without induction) 
and was approaching lower levels measured in PHH. This is in contrast to monolayer 
culture whereby lower levels of PHH activity were only matched in HepG2 cells 
following DBA or indirubin induction.  
 
CYP3A (Luciferin BE) activity in HLM isolated from HepG2 cells following bioreactor 
culture matched levels measured in HLM from freshly isolated PHH, however, there 
was a difference in CYP3A function between the two bioreactor systems: CYP3A 
activity was decreased in HepG2 following FBB culture. Several differences in 
bioreactor setup could account for this variation. 
 
Whereas RCCS experiments were performed in an optimised culture system, the culture 
of beads in the FBB experiment was performed by others, with the aim optimising 
conditions for cell growth within a bioreactor, and experiment parameters were 
therefore different. Firstly, beads cultured in the RCCS were harvested following 8 days 
of culture, whereas beads in the FBB were maintained for 13 days, and it has been 
shown that many cell functions in HepG2 spheroids are optimal following 8 days of 
static culture 
109. Secondly, the RCCS is a sealed system in which pH and temperature 
are regulated by a 37°C 5% CO2 incubator, whereas the FBB is continually perfused 
with medium whose temperature, pH and oxygen content is tightly regulated by a 
fermentor; oxygen delivery in particular may have an effect on HepG2 CYP function. In 
hepatocytes, CYP enzymes are preferentially expressed in the perivenous zone, where 
oxygen concentration is lower and others have shown that CYP1A activity measured in 
HepG2 was decreased in hyperoxic conditions 
5. Most importantly, beads maintained in 
the FBB were cultured in 10% FFP rather than 10% FCS. Plasma, as well as the heparin 
which was used as an anticoagulant, may have had an effect on CYP function and this 
will be explored below.  
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4.3  Effects of Human Plasma Exposure on HepG2 cells 
A beneficial effect of FFP exposure on HepG2 proliferation has been observed when 
cells are cultured within the LG Fluidised Bed Bioreactor (FBB); potentially, CYP 
expression could be affected by plasma and so the influence of human FFP on CYP 
induction was investigated. Furthermore, it was observed that HLM prepared from 
HepG2 cells cultured in FFP (section 4.2.1.3.1) produced a greater quantity of fat during 
the isolation process. Possibly, exposure of HepG2 cells to FFP could render them 
steatotic and this could have an effect on CYP function 
64, 65. Fat loading was therefore 
investigated by labelling cells with Nile red, which is a lipophilic dye, which fluoresces 
strongly when partitioned into lipids, but not in aqueous solution 
233. 
4.3.1  Methods 
Human FFP obtained from multiple donors was prepared as described in Chapter 2. 
FCS containing 40 IU/ml heparin was also included in these experiments as a control. 
4.3.1.1  Monolayer Induction 
HepG2 Cells were seeded in 96 well plates at a density of 2.5x10
4 cells/well in a 
volume of 100 l of complete culture medium containing 10% of FCS +/- heparin or 
FFP. Following overnight attachment, cells were treated with CYP inducers for 48 
hours and then CYP activity measured by ECOD assay, Luciferin BE assay or Luciferin 
ME assay (+ 10µM sulfaphenazole). Cell protein was determined by the BCA assay.  
4.3.1.2  3D-Culture and P450 Induction of FFP Exposed Cells  
Cells were encapsulated using the Inotech method. Beads were resuspended in HG 
αMEM containing either 10% FCS + heparin or FFP. Medium was also supplemented 
with an additional amount of calcium chloride (200µM) to account for any further 
effects of calcium sequestration by FFP which would result in reversal of alginate 
polymerisation. Beads were maintained in static culture, as described for Chapter 2. 
Inducers were added for 48 hours on day 6 and, following induction, CYP activity was 
measured by ECOD assay. Spheroids were then released from alginate (Chapter 2) and 
protein determined by the BCA method. 
4.3.1.3  Nile Red Staining of HepG2 Cells 
Nile red is a phenoxazone dye which was used as a fluorescent hydrophobic probe to 
measure lipid accumulation in HepG2 cells 
234 following FFP exposure.  
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A 2mg/ml solution of Nile Red (Sigma N3013) was prepared in methanol. This was 
diluted to 5µg/ml in unsupplemented phenol red free DMEM. 
 
HepG2 cells were treated, as described above for monolayer culture, with CYP inducers 
or 0.1% DMSO (vehicle control) for 48 hours. Cells were then washed twice with PBS 
and 200µl of the diluted Nile red solution added. Cells were incubated at 37°C for 2 
hours with the dye and then washed twice again with PBS. Cells were incubated with 
phenol red-free DMEM for a further 30 minutes and visualised using a fluorescence 
microscope with a FITC filter (excitation 465-495 nm/ emission 515-555 nm). Nile red 
straining was quantified by reading plates using a cytofluor (excitation 485 nm emission 
530nm). 
4.3.2  Results 
CYP function was compared in HepG2 cells induced in αMEM complete containing 
either 10% FCS or 10% FFP and data was analysed by two-way ANOVA. 
4.3.2.1  Effect of FFP on ECOD Activity in Monolayer HepG2 Cultures  
Increased ECOD activity was observed following FFP exposure. This effect was 
inducer dependent and there was a slight influence of heparin in some instances. This 
data is shown in Figure 4-18. 
 
ECOD activity following induction was compared between cultures maintained in FCS 
+/- heparin and FFP. There was a significant effect of both FFP exposure (P<0.05, F (2, 
0.481) = 5.23) and chemical induction (P < 0.01, F (4, 0.216) = 11.77) on CYP function.  
 
Under basal conditions, ECOD activity in FCS cultures +/- heparin was comparable. 
FFP exposure led to a slight (1.3 fold above FCS function) increase in ECOD activity. 
This was further increased by rifampicin (1.7 fold) and DBA induction (P < 0.05, 1.8 
fold).  
 
Following exposure to heparin, CYP induction was increased, relative to cells cultured 
in 10% FCS alone, following treatment with indirubin (1.5 fold) and dexamethasone 
(1.4 fold). FFP had no further effect on cells treated with indirubin, however, 
dexamethasone induction was further increased (2.0 fold above FCS function) in cells 
cultured in 10% FFP. 
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Figure 4-18. Effect of CYP induction (48 hours) on ECOD activity was measured in HepG2 cells 
following monolayer culture in complete culture medium supplemented with 10% FCS +/- heparin 
or 10% FFP. For each inducer, change in function relative to standard culture conditions (αMEM 
complete 10% FCS) was calculated and is expressed as mean (n=3) +/-sd. Data analysis was by two-
way ANOVA and Bonferroni post test. * P < 0.05 when compared to FCS culture.  
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4.3.2.2  Effect of FFP on CYP1A2 (Luciferin ME) Activity in Monolayer HepG2 
Cultures 
Luciferin ME metabolism was measured in the presence of 10µM sulfaphenazole. In 
this assay there was no effect of heparin or FFP exposure on CYP function in either 
basal conditions or in the presence of inducer (Figure 4-19). 
 
Figure 4-19. Effect of CYP induction (48 hours) on CYP1A2 activity (Luciferin ME metabolism 
detected in the presence of 10µM sulfaphenazole) was measured in HepG2 cells following 
monolayer culture in complete culture medium supplemented with 10% FCS +/- heparin or 10% 
FFP. For each inducer, change in function relative to standard culture conditions (αMEM complete 
10% FCS) was calculated and is expressed as mean (n=3) +/-sd. 
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4.3.2.3  Effect of FFP on CYP3A (Luciferin BE) Activity in Monolayer HepG2 Cultures 
FFP exposure had a negative effect on CYP3A function; however this was lessened by 
rifampicin mediated induction. Data was analysed by two-way ANOVA and is 
presented in Figure 4-20. 
 
There was a significant effect of FFP exposure (P < 0.001 F (2, 0.924) = 35.22) and 
induction (P < 0.001, F (5, 1.325) = 18.79) on CYP3A activity in HepG2 cells,  
 
CYP induction was comparable in cells cultured in either 10% FCS or 10% FCS + 
heparin, however exposure to 10% FFP resulted in decreased CYP3A activity. 
Moreover, FFP mediated decreases in CYP3A function were further affected by 
induction. This was particularly apparent for cells treated with CYP1A inducers DBA 
(P<0.05 0.71 fold of FCS function) and indirubin (P < 0.05, 0.60 fold of FCS function); 
positive effects of these inducers on CYP3A function (described in section 4.1.2.2) were 
diminished following FFP exposure. 
 
The negative effect of FFP exposure on Luciferin BE metabolism was improved to a 
certain extent by rifampicin treatment; although still lower than measured in FCS 
cultures, CYP3A activity was increased (0.85 fold of FCS function) in cells cultured in 
10% FFP and treated with rifampicin, thus the effect of this inducer was maintained in 
the presence of FFP. 
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Figure 4-20. Effect of CYP induction (48 hours) on CYP3A activity (Luciferin BE metabolism) was 
measured in HepG2 cells following monolayer culture in complete culture medium supplemented 
with 10% FCS +/- heparin or 10% FFP. For each inducer, change in function relative to standard 
culture conditions (αMEM complete 10% FCS) was calculated and is expressed as mean (n=3) +/-
sd. Data analysis was by two-way ANOVA and Bonferroni post test. * P < 0.05, ** P<0.01 when 
compared to FCS culture.  
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4.3.2.4  Effect of 3D Culture on CYP Function Following FFP Exposure 
ECOD activity was measured in encapsulated cells induced for 48 hours in medium 
containing either 10% FCS or 10 % FFP (both treated with 40IU/ml heparin). For each 
condition function was compared to the corresponding monolayer culture.  
 
Under basal conditions, ECOD activity was increased (1.59 fold above monolayer) 
relative to monolayer culture in cultures exposed to 10% FCS + heparin, but was 
decreased (0.8 fold of monolayer activity) in cultures exposed to 10% FFP.  
The effect of 3D culture on ECOD activity differed for each inducer, however, these 
effects were comparable following exposure to either FCS or FFP; there were no 
statistically significant differences between the two media supplements. This data is 
shown in Figure 4-21 and is summarised below: 
 
10µM DBA (CYP1A inducer): as described in section 4.2.2.1.1, extent of DBA 
induction was slightly reduced in 3D culture. Following DBA exposure, ECOD activity 
was increased 1.29 fold above monolayer cultures in cells cultured in 10% FCS and was 
decreased (0.80 of monolayer culture) in cells cultured in 10% FFP. 
 
20µM Indirubin (CYP1A inducer): induction was increased in 3D culture. Following 
indirubin exposure, ECOD activity was increased 2.3/3.0 fold above monolayer cultures 
in cells cultured in 10% FCS/FFP. 
 
50µM Dexamethasone (CYP3A inducer): exposure resulted in decreased activity in 
3D culture. ECOD activity following treatment with dexamethasone was decreased in 
both FCS (0.17 fold of monolayer activity) and FFP (0.30 fold) cultures.   
 
50µM Rifampicin (CYP3A inducer): induction was increased in 3D culture. 
Following rifampicin exposure, ECOD activity was increased 2.6/1.6 fold above 
monolayer cultures in cells cultured in 10% FCS/FFP. 
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Figure 4-21. ECOD activity following treatment with CYP inducers was compared in monolayer 
and 3D cultures of HepG2 cells cultured in either 10 % FCS with heparin or 10% FFP. For each 
inducer fold difference between 3D and monolayer function was calculated and data is expressed as 
mean (n=3) +/- sd.  
 
4.3.2.5  Effect of FFP on Nile Red Staining 
The effect of FFP on Nile red staining in HepG2 cells is shown in Figure 4-22. There 
was a greater lipid accumulation in HepG2 cells cultured in human plasma (F=(1, 8.16) 
13.71, P<0.01). A significant effect of induction was also measured in both media types 
(F=(6, 103) 28.90, P<0.001) and there was a significant interaction between effects of 
plasma exposure and chemical induction (F=(6, 10.5) 2.94, P<0.05). Nile red staining 
was decreased in HepG2 cells exposed to DBA and indirubin in both media types. 
Rifampicin exposure also resulted in a decrease in Nile red staining in cells exposed to 
10% FFP. There was increased Nile Red binding following exposure to dexamethasone 
and this effect was significantly higher in cells exposed to FFP (P<0.05).  
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Figure 4-22. Nile red staining of HepG2 cells following culture in αMEM complete containing either 
10% FCS or 10%FFP was (top) visualised in uninduced HepG2 cells with a fluorescence 
microscope and (bottom) quantified in induced HepG2 cells by measuring fluorescence with a 
cytofluor. Data was analysed by two-way ANOVA with Bonferroni post test. * P< 0.05 when 
compared to FCS culture (n=3+/-sd). 
 
4.3.3  Discussion 
The use of heparin as an anticoagulant within a BAL could affect CYP function and this 
was investigated in HepG2 cells cultured in 10% FCS. Under basal conditions, heparin 
alone had no effect on CYP function. In the presence of some inducers, heparin resulted 
in an increase in ECOD activity but was without effect in other assays. Other authors 
have reported both positive 
235 and negative 
236 effects of heparin on CYP function 
although the former study was performed in rat liver and the latter in porcine 
hepatocytes. 
 
Once effects of heparin had been determined, the effect of FFP culture on CYP function 
was considered. ECOD and CYP1A2 activity were comparable following FFP 
exposure, however, CYP3A activity was decreased in cells cultured in 10% FFP. 
Beneficial effects of 3D culture were also diminished following FFP exposure.  
 
Isoform specific effects of human plasma exposure on CYP function have been reported 
in rat hepatocytes, although it should be noted that these cells were cultured in undiluted  
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plasma and furthermore, species differences should also be taken into consideration. 
Under basal conditions, plasma improved CYP1A/2B expression and pentoxy- and 
benzyloxy- resorufin o-dealkylation, but had no effect on ethoxy- or methoxy- resorufin 
metabolism 
237. The same authors also reported differing effects of FFP on 3MC 
(reduced induction) and phenobarbital (improved induction) mediated induction. 
 
In this study, effects of FFP on CYP induction were also variable. When ECOD activity 
was measured, there were inducer dependent effects of both heparin and FFP. Indirubin 
induction was improved by the presence of heparin in culture medium both in FCS and 
FFP cultures. Dexamethasone induction was improved by the presence of heparin and 
then further improved by FFP exposure. DBA and rifampicin mediated induction were 
both greater in cells cultured in 10% FFP.  
 
CYP1A2 (Luciferin ME) activities were comparable for all media types, however, 
CYP3A (Luciferin BE) activity was decreased in FFP culture even following induction. 
This was particularly apparent for AhR agonists indirubin and DBA which suggests that 
in contrast to the results obtained following FCS culture (section 4.1.2.3), these inducers 
do not improve CYP3A function in the presence of FFP. There was a slight 
improvement in CYP3A function in FFP cultures following rifampicin treatment, 
therefore the effect of this inducer on CYP3A function was maintained in the presence 
of FFP. 
 
It has previously been reported that, in rat hepatocytes, plasma exposure results in 
cytoplasmic accumulation of lipid droplets which may have an effect on hepatocyte-
specific functions, including urea synthesis 
238; although it was also shown that the 
negative effects of plasma exposure on function may be improved by media 
supplementation 
239, 240. Here it was confirmed that human plasma exposure resulted in 
increased lipid accumulation in HepG2 cells. This was firstly observed when FFP 
exposed cells were homogenised during the HLM isolation process and was then 
confirmed by Nile red staining. Effects of lipid accumulation on CYP function has been 
demonstrated in humans 
64, 65, 241; in PHH prepared from fatty liver (> 40% steatotic) 
and in cultured PHH that had been treated with free fatty acids to become fat 
overloaded. In both instances there was a general down-regulation in CYP expression 
and function (ECOD activity and testosterone metabolism) in steatotic samples. The 
effect of human plasma on lipid accumulation in HepG2 cells could be contributing to  
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the decreased CYP3A function that was measured, in this Chapter, following FFP 
culture, although other components of FFP cannot be discounted. For example, type 1 
and type 2 cytokines have both been shown to down-regulate expression of human 
CYPs and nuclear receptors relevant to drug metabolism 
67, 242-244. Also, many CYP 
inhibitors act at CYP3A4, and although plasma is pooled from multiple donors to 
prevent interindividual variation, potentially there could be a xenobiotic presence in 
plasma which, if not fully removed prior to functional assays, could inhibit enzyme 
function. 
 
Lipid accumulation following exposure to CYP inducers was also considered. The 
effect of steroid exposure on hepatic lipid accumulation has been measured by others 
using Nile red binding assays 
234 and was observed here for dexamethasone, particularly 
when HepG2 cells were cultured in 10% FFP. 
 
Dexamethasone induction has a surprising effect in 3D culture: in both media types, 
dexamethasone treatment resulted in a decrease in ECOD activity, relative to both 
vehicle treated cells and monolayer culture. The potential influence of media 
components on dexamethasone mediated induction will be discussed further in Chapter 
6. 
 
Non-specific binding effects of inducers to FFP components could also contribute to 
effects measured here: the potency of inducers could decrease since there would be less 
available to bind to nuclear receptors due to this phenomenon. Log P (partition 
coefficient) is a useful measure of hydrophobicity of compounds and values for the 
inducers used in this study are summarised below (Table 4-1).  
Table 4-1. Calculated Log P values for inducers used in this study. 
(http://www.syrres.com/esc/est_kowdemo.htm) 
Inducer  LogP 
DBA  6.7 
Indirubin  2.34 
Dexamethasone  1.72 
Rifampicin  4.24 
 
Lipophilic compounds (those with a higher Log P) have been shown to non-specifically 
bind to protein 
245-247. This does not appear to have had an effect on induction, since  
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DBA and rifampicin are both relatively lipophilic but their effect was maintained in FFP 
culture. Lipid accumulation could be affected by inducers: intracellular accumulation of 
lipophilic inducers could occur, which could affect induction, or lipophilic compounds 
could bind fatty plasma extracellularly, which could result in a build up of inducer-lipid 
complex in the culture media. Possibly lipid accumulation in FFP cultures was reduced 
in the presence of rifampicin. Alternatively, intracellular lipid accumulation could 
decrease if inducer binding occurs extracellularly and draws additional lipid from the 
cells – in both culture media DBA reduced intracellular lipid levels (evidenced by 
decreased Nile red staining following DBA exposure). 
 
4.4  Conclusion 
The results presented in this chapter have demonstrated that HepG2 cells cultured under 
LG BAL conditions demonstrate Cytochrome P450 function; moreover CYP activity 
approaching levels measured in primary human hepatocytes can be obtained by 
manipulating cell culture conditions for HepG2 cells. However, there were certain 
limitations.  
 
In monolayer culture, chemical induction can improve CYP function. Under basal 
conditions, ECOD and Luciferin BE metabolism were both markedly improved by 3D 
culture, however effects of inducers were reduced, which implies that mediators of CYP 
expression, in particular for CYP3A, are suppressed in HepG2 cells, therefore so is the 
extent to which CYP activity can be improved. 
 
Although Luciferin BE metabolism in HepG2 cells indicates that they have CYP3A 
activity, HepG2 cells, even in 3D culture, although able to metabolise testosterone, did 
not produce the CYP3A4 metabolite 6β-OHTST. This demonstrates that this isoform, 
which is predominant in PHH, is lacking in HepG2 cells  
 
The improved per bead performance that was achieved following microgravity culture 
also had a positive effect on HepG2 CYP function, but Luciferin BE metabolism was 
reduced in HepG2 cells following FBB culture. This can, in part, be attributed to the 
presence of human FFP in the culture medium. Overall, exposure to FFP had a positive 
effect on CYP1A induction but resulted in reduced CYP3A activity. 
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HepG2 cells can be manipulated to perform CYP functions and would readily provide 
CYP1A function within a BAL, however their CYP3A function is insufficient. HepG2 
cell testosterone metabolism is not CYP3A4 mediated and the limited CYP3A function 
these cells do have is reduced by plasma exposure. In the next Chapter, alternative cell 
lines will be explored which could be used to supplement CYP3A function within a 
BAL.  
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CHAPTER 5  Alternative Cell Lines to Provide Cytochrome P450 
Function Within a BAL 
 
As discussed in the previous chapter, the current cellular component of the LG BAL, 
HepG2 cells, are unable to provide ample CYP3A function; one option would be to 
introduce different cell types to enhance the function of HepG2 cells.  
In primary hepatocytes, it has been demonstrated that co-culture of other cell types, 
such as stellate cells or fibroblasts, will enhance existing CYP activity 
110, 184. However, 
since existing CYP function in HepG2 cells is marginal, this approach alone may be 
insufficient. An alternative would be to use HepG2 cells to provide the synthetic 
component of the BAL, and an additional cell line to provide CYP activity. In addition 
to exhibiting superior xenobiotic metabolism capacity (relative to HepG2 cells), in order 
to be considered fit for purpose, such cells would need to fulfil certain other criteria. 
Like HepG2 cells they must be: easily expandable, cryopreservable and readily 
available; maintain their phenotype over multiple passages; and fulfil regulatory 
requirements (for example come from a demonstrable source). Importantly for this 
project, any cell line considered must be adaptable to the culture conditions required of 
the BAL currently under development within the Liver Group. 
 
The aim of Chapter 5, therefore, is to consider alternative cell lines that could 
potentially be co-cultured with HepG2 cells to provide the detoxificatory pathways 
required of a BAL. Initially, CYP function in monolayer cells was measured. Further to 
this, cells were adapted to BAL specific media and finally encapsulation conditions and 
survival in alginate were profiled. 
 
Two approaches were considered: 
i)  adapting the human intestinal cell lines Caco2 and LS147T to a 3D culture 
system and profiling their CYP function under these conditions; and 
ii)  adapting the HC-04 human liver cell line for use within a BAL and profiling 
its CYP function under these conditions.  
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5.1  Cytochrome P450 Activity in Intestinal Cell Lines 
In the small intestine, epithelial cells provide the first site of metabolism of orally 
administered drugs. In humans, there is now a well-recognised role of the small 
intestine in CYP mediated metabolism and it is widely believed that the intestinal form 
of CYP3A4 is structurally and functionally identical to the hepatic form 
248. It was 
therefore hypothesised that human intestinal cell lines which expressed CYP3A4 could 
potentially provide xenobiotic metabolism in a BAL. 
 
The enterocyte-like cell line Caco2 is best known as a well established in vitro model 
system used to predict oral adsorption of xenobiotics. These cells express CYP3A4, 
3A5 and 3A7 mRNA, but under standard culture conditions do not express functional 
levels of CYP3A 
249, 250. Although it is widely reported that these cells have negligible 
expression of PXR and show minimal response to PXR ligands, myriad studies have 
demonstrated that CYP3A4 expression can be induced by 1α,25-dihydroxyvitamin 
D3(VD3) 
93, 186, 188, 251, which acts through the vitamin D receptor (VDR). Moreover, 
synergistic effects of Caco2 cells and HepG2 cells in CYP1A mediated EROD 
metabolism have been demonstrated in a double-layered co-culture system 
252 which 
indicates that these two cell lines would lend themselves favourably to a dual culture 
approach.  
 
As an alternative intestinal cell line, LS147T cells were also considered. These cells are 
a trypsinised variant of the LS180 cell line, are goblet-like in structure and as a result 
produce significant amounts of secretory mucin 
253. As models of drug metabolism both 
LS180 and LS147T express CYP3A4 and this enzyme can be induced with both PXR 
and VDR agonists 
254-256. 
 
The enterocytic characteristics of Caco2 cells results in a different morphology to the 
goblet-like secretory LS147T cells (Figure 5-1) and their growth characteristics are 
quite different.  
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Figure 5-1. Monolayer appearance (x10 magnification) of (left) Caco 2 cells and (right) LS147T 
cells. 
 
A summary of the two cell types is presented in Table 5-1, and although they differ in 
many ways, for this thesis, an important shared feature of these two cell lines is their 
CYP3A4 expression. 
 
Table 5-1. A comparison of intestinal cell lines Caco 2 and LS147T. 
Cell Line  Origin 
Growth/ 
Morphology 
CYP3A4 
Inducer/ Nuclear 
Receptor 
References 
Caco2  Colon 
adenocarcinoma 
72 year old 
Caucasian male 
Form confluent 
differentiated 
monolayers/ 
Enterocyte like 
VD3/ VDR 
 
188, 253 
LS147T  Colon 
adenocarcinoma  
58 year old 
Caucasian female 
Grow in islands 
Pile on top of one 
another/ 
Goblet like 
Rifampicin/ PXR 
VD3/ VDR 
 
253, 255 
 
In this section, monolayer Caco2 and LS147T cells, cultured in supplemented αMEM 
medium, were used to investigate CYP induction. To determine whether either cell line 
is suitable for use within a BAL, their growth, viability and CYP3A function was then 
measured following alginate encapsulation and 3D culture.  
  166 
 
5.1.1  Methods 
Initially, cells were maintained in DMEM as described in Chapter 2. After cells had 
been passaged at least once post thawing, and reached 50% confluency, growth medium 
was switched to complete culture medium as described for HepG2 culture (Chapter 2). 
Cells were maintained in this medium for at least 3 passages prior to any further studies. 
5.1.1.1  Gene Expression 
RNA samples were isolated from each cell type following monolayer culture in αMEM 
complete. Gene expression was performed by qRT-PCR as described in Chapter 2. 
5.1.1.2  Monolayer Induction of CYP Function 
CYP induction was carried out in Caco2 and LS147T cells in monolayer culture to 
measure CYP function in these intestinal cell lines. Cells were seeded in 96 well plates 
at a density of 1x10
4 cells/well in a volume of 100 l of complete culture medium. 
Following overnight attachment, cells were treated with CYP inducers for 48 hours and 
then CYP activity measured by ECOD assay, Luciferin BE assay or Luciferin ME assay 
(+10µM sulfaphenazole). Cell protein was determined by the BCA assay.  
5.1.1.3  Treatment of Caco2 Monolayers with VD3 
To assess longer term effects of VD3 exposure Caco2 cells were seeded in 12 well 
plates at a density of 1x10
4 cells/well and cultured for 7 days in varying concentrations 
of VD3 (0.1-2 µM) or 0.1% DMSO vehicle control. CYP activity was measured by 
Luciferin BE assay and cell protein determined by the BCA assay. 
 
5.1.1.4  Encapsulation of Intestinal Cell Lines 
Cells were encapsulated using the Inotech method described in Chapter 2. 
5.1.1.4.1  Determination of Encapsulation Conditions 
An initial experiment was carried out to determine optimum cell number for 
encapsulation using Caco2 cells. Cells were resuspended in a 1:1 ratio of HG complete 
culture medium and alginate at the following densities: 0.5 x10
6 cells/ml; 1 x10
6 
cells/ml; and 2 x10
6 cells/ml. 0.25ml/well of beads were added to 6 well plates in a 
medium volume of 8mls/well. Cells were maintained in static culture for 12 days with 
medium replenishment every 48 hours. When seeded at 0.5 x10
6 cells/ml, proliferation  
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was poor and very few spheroids formed within beads. When seeded at either 1 x10
6 
cells/ml or 2 x10
6 cells/ml, cells proliferated well and viability was maintained, 
however, at the higher seeding density a large number of cells broke free from the beads 
(determined by appearance of monolayer cell growth on the bottom of the culture 
plates). Therefore, 1x10
6 cells/ml was selected as the optimum cell number for further 
experiments. 
5.1.1.4.2  3D Culture of Intestinal Cell Lines 
Caco2 or LS147T cells were encapsulated at a density of 1x10
6 cells/ml. Beads were 
then resuspended in HG medium and added to 6 well plates as above. Cells were 
maintained in static culture for 8 days with medium changes every other day. 
5.1.1.5  CYP Induction in 3D Culture 
Following 6 days of 3D culture, cells were treated with 50µM rifampicin for 48 hours. 
Alternatively cells were treated for 7 days with 1µM VD3. CYP function was measured 
at day 8 post-encapsulation by Luciferin BE assay, or testosterone metabolism was 
measured over an 8 hour period. 
 
5.1.2  Results 
5.1.2.1  CYP Gene Expression in Caco2 and LS147T Cells 
Expression of CYP1A2, CYP3A4 and CYP3A7 were compared in Caco2 and LS147T 
cells (Figure 5-2). CYP3A4 and CYP1A2 expression were comparable between the two 
cell lines. CYP3A7 expression was higher (26 fold) in LS147T cells.  
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Figure 5-2. CYP expression was measured in mRNA isolated from Caco2 and LS147T cells 
following monolayer culture. CYP expression is normalised to ribosomal 18s expression and 
presented as n=2+/- range.  
 
5.1.2.2  Nuclear Receptor Gene Expression in Caco2 and LS147T Cells 
There was slightly higher expression of PXR and GR in LS147T cells and higher 
expression of CAR, RXR and GR in Caco2 cells (Figure 5-3). 
 
Figure 5-3. Nuclear receptor expression was measured in mRNA isolated from Caco2 and LS147T 
cells following monolayer culture. CYP expression is normalised to ribosomal 18s expression and 
presented as n=2+/- range.  
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5.1.2.3  ECOD Activity in Caco2 and LS147T Cells 
ECOD activities were comparable between the two cell lines but were not significantly 
enhanced by any inducer at the concentrations measured (Figure 5-4). 
 
Figure 5-4. ECOD activity was measured in monolayer Caco2 and LS147T cells following 48 hours 
treatment with (top) CYP1A and (bottom) CYP3A inducers (n=6+/-sd).  
  170 
 
5.1.2.4  CYP1A2 Induction in Monolayer Caco2 and LS147T Cells  
In monolayer culture, CYP1A2 function was equivalent in Caco2 and LS147T cells 
(Figure 5-5). In Caco2 cells, there was no significant difference in function following 48 
hour incubation with inducers, although 20µM indirubin treatment resulted in a small 
(1.6 fold) increase in Luciferin ME metabolism above basal. In LS147T cells there was 
an increase in Luciferin ME metabolism following 10µM DBA treatment (4.0 fold 
above vehicle); indirubin induction resulted in a significant induction in function in 
these cells (5.6 fold P < 0.05).   
 
Figure 5-5. Luciferin ME metabolism was measured in the presence of 10µM sulfaphenazole in 
monolayer Caco2  and LS147T cells following 48 hours induction with 10µM DBA or  20µM 
indirubin (n=6+/-sd). Data analysis was by one-way ANOVA * P < 0.05 when compared with 
vehicle treated cells. 
 
Dexamethasone, rifampicin, phenobarbital and VD3 did not affect CYP1A2 function in 
either cell line.  
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5.1.2.5  CYP3A Induction in Monolayer Caco2 and LS147T Cells 
In monolayer culture LS147T CYP3A (Luciferin BE) activity was not statistically 
different to the HepG2 CYP3A function that was described in Chapter 4.  
 
When intestinal cell lines were compared, Luciferin BE metabolism was  overall 
significantly higher in LS147T cells than in Caco2 cells independent of the effect of 
inducers (P< 0.0001, F (1, 0.003) = 92.36). 
 
In monolayer culture, for both cell lines, the effects of inducers on CYP3A (Luciferin 
BE) function were not statistically significant (Figure 5-6); although in LS147T cells 
increased CYP3A function was observed following treatment with dexamethasone (1.9 
fold above vehicle), rifampicin (2.8 fold), phenobarbital (2.4 fold) and VD3 (3.1 fold). 
Caco2 function did not increase with any of these inducers. 
 
 
Figure 5-6. Luciferin BE metabolism was measured in Caco2 and LS147T cells following 48 hour 
treatment with CYP3A inducers (n=6+/-sd). 
 
Since data was normalised during analysis to account for total protein content, the 
higher level of variability shown in LS147T data can probably be attributed to the 
manner in which these cells grow on top of each other in monolayer culture and the 
debris that they produce. 
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Increased CYP3A activity was also measured in LS147T cells (2.8 +/- 1.1 fold above 
vehicle) following 10µM DBA treatment and in both Caco2 (1.4 +/- 0.4 fold) and 
LS147T (3.4 +/- 1.6 fold) cells following 20µM indirubin treatment, although these 
were not statistically significant changes (Figure 5-7). 
 
 
 
Figure 5-7. CYP3A activity was also improved in Caco2 and LS147T cells following 48 hour 
treatment with CYP1A inducers (n=6+/-sd). 
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5.1.2.6  Effect of Prolonged Exposure to VD3 in Caco2 Cells 
Others have reported a dose dependent increase in CYP3A expression and function 
following long-term exposure to VD3 
250. Luciferin BE metabolism was therefore 
measured in Caco2 cells that had been exposed to VD3 or 0.1% DMSO vehicle for 7 
days (Figure 5-8). Activity in vehicle controls was comparable in Caco2 cells cultured 
for 7 days or 48 hours (0.0010+/-0.0006 and 0.0011 +/- 0.0005 pmoles d-luc/min/mg 
protein). Prolonged exposure (7 days) to higher concentrations of VD3 resulted in 
increased CYP3A activity above DMSO vehicle in Caco2 cells treated with 1µM or 
2µM; results were comparable for both concentrations of inducer. 
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Figure 5-8. An increase in CYP3A activity above 0.1% DMSO vehicle was measured for Caco2 
monolayers cultured in a range of VD3 concentrations for 7 days (n=2 +/- range).  
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5.1.2.7  Alginate Encapsulation of Caco2 Cells 
Caco2 cells were maintained for up to 12 days in alginate culture (Figure 5-9). During 
this time, proliferation remained steady and cell viability was high, as indicated by a 
minimal level of PI staining. 
 
Figure 5-9. Cell viability staining (x10 magnification) of Caco2 cells maintained in 3D static culture 
for up to 12 days. 
d1 
d3 
d6 
d8 
d12 
Phase x10  FDA  PI  
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5.1.2.8  Alginate Encapsulation of LS147T Cells  
LS147T cells were maintained for 8 days in 3D culture. As demonstrated by Figure 
5-10, they were able to proliferate. Spheroid formation occurred within 24 hours of 
encapsulation, however, following encapsulation viability was poor which is indicated 
by a high level of PI staining and, although there was some recovery in viability during 
subsequent culture, PI staining remained high throughout. 
 
 
Figure 5-10. Cell viability staining (x10 magnification) of LS147T cells maintained in 3D static 
culture for up to 8 days. 
 
 
d1 
d3 
d6 
d8 
Phase x10  FDA  PI  
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5.1.2.9  CYP3A Function in 3D Cultures of Caco2 and LS147T Cells 
For each cell line, overall there were significant effects of both 3D culture and induction 
on CYP3A (Luciferin BE) activity. These were cell line dependent and are summarised 
in Table 5-2.  
 
Table 5-2. Independent and synergistic effects of induction and 3D culture on CYP3A function 
were examined in Caco2 and LS147T cells. Data was analysed by two-way ANOVA, and 
significance values P and F (degrees freedom, sum squares) are stated for each variable. 
  Caco2  LS147T 
Induction  P>0.05 
F (2, 2.5
-5) = 2.31 
P<0.01 
F (2, 0.02) = 6.39 
Culture Type  P<0.001 
F (1, 1.5
-4) = 27.31 
P<0.05 
F (1, 0.01) = 5.43 
Interaction Between 
Variables 
P<0.05 
F (2, 4.3
-5) = 4.01 
P<0.05 
F (2, 0.02) = 4.71 
 
For Caco2 cells, 3D culture alone resulted in a significant increase in Luciferin BE 
metabolism. Inducer alone has no significant influence on activity, however, there was 
an interaction between the effects of induction and 3D culture, which resulted in 
significant improvement in CYP3A activity.  
 
For LS147T cells, significant effects of both 3D culture and induction were observed, 
moreover, there was also an interaction between the two factors. 
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5.1.2.9.1  Effects of Induction on CYP3A (Luciferin BE) Activity in 3D Culture 
Effects of induction on CYP3A activity in intestinal cell lines are shown in Figure 5-11. 
 
Following rifampicin induction, CYP3A activity was significantly improved in 3D 
cultures compared to monolayer cultures for Caco2 cells (18 fold P < 0.001), although 
this level of function was 2.1 fold lower than in rifampicin induced 3D cultures of 
LS147T cells. 
 
Following VD3 induction, CYP3A activity was significantly increased (7 fold, P<0.01) 
in 3D cultures compared to monolayer cultures for LS147T cells. 
 
Figure 5-11. CYP3A activity was compared in monolayer and 3D cultures following induction in 
(top) Caco2 cells and (bottom) LS147T cells (n=6 +/- SD). Note that the scales are different for the 
top and bottom graphs. Data analysis was by two-way ANOVA with Bonferroni post test.             
**P < 0.01, *** P <0.001 in 3D cultures compared to monolayer.  
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5.1.2.9.2  Metabolism of Testosterone by Encapsulated Intestinal Cell Lines 
Encapsulated Caco2 or LS147T cells that had been treated, as described above, with 
either 0.1% DMSO vehicle, 50µM rifampicin or 1µM VD3, were incubated for up to 8 
hours with 200µM testosterone. Included in the same analysis run was supernatant from 
freshly isolated primary human hepatocytes (PHH) incubated for 1 hour with 200µM 
testosterone. 
 
Caco2 cells did not produce any detectable metabolites of testosterone even after an 8 
hour incubation period with the substrate (Figure 5-12). 
 
a
b
c
d
a
b
c
d
 
Figure 5-12. HPLC was used to measure metabolism of testosterone in encapsulated Caco2 cells 
induced with (a) 0.1% DMSO vehicle, (b) 50µM rifampicin or (c) 1µM VD3 and then incubated 
with 200µM testosterone for 8 hours, or (d) freshly isolated PHH incubated with 200µM TST for 1 
hour. TST spike is indicated by →. TST metabolites are indicated by → / → and were measured in 
PHH only. One representative trace is shown of 5 independent measurements. 
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After 1 hour incubation with TST, LS147T cells did not produce any detectable 
metabolite of the substrate. After an 8 hour TST exposure, all LS147T cells had 
produced a metabolite with the same retention characteristics as one produced by PHH 
following 1 hour TST exposure. This is indicated in Figure 5-13. Additionally, after 8 
hours, LS147T cells treated with 1µM VD3 had also produced a very small amount of 
6β-OHTST. However, this peak size lay below the limits of the standard curve that had 
been defined for the assay and so could not be quantified.    
 
Figure 5-13. HPLC was used to measure metabolism of testosterone in encapsulated LS147T cells 
induced with (a) 0.1% DMSO vehicle, (b) 50µM rifampicin or (c) 1µM VD3 and then incubated 
with 200µM Testosterone for 8 hours, or (d) freshly isolated PHH incubated with 200µM 
testosterone for 1 hour. Testosterone spike is indicated by →. 6β-OHTST metabolite is indicated by 
→ and was measured only in PHH and VD3 cells after 8 hour TST incubation. A further metabolite 
is indicated by → and was detected in PHH and all LS147T cells only after an  8 hour TST 
incubation. One representative trace is shown of 5 independent measurements.  
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5.1.2.10 A Comparison of PHH, HepG2 and Intestinal Cell Lines 
CYP3A activity in LS147T and Caco2 cells was compared with activity measured in 
freshly isolated PHH (results from Chapter 3) and with HepG2 cells treated with 
rifampicin (results from Chapter 4). LS147T CYP3A function was highest in 3D culture 
following treatment with 1µM VD3 and was higher than measured in HepG2 cells and 
the average value measured in PHH. CYP3A activity in Caco2 cells was highest in 3D 
culture following treatment with 50µM rifampicin but was lower than in HepG2 cells 
and freshly isolated PHH (Table 5-3). 
 
Table 5-3. CYP3A (Luciferin-BE) activity was higher in freshly isolated primary human 
hepatocytes than in Caco2 cells but not LS147T cells following 3D culture. Data was compared 
from PHH isolated from 9 separate donors assayed in quadruplicate and monolayer and 3D 
cultures of HepG2 (48 hours 50µM rifampicin), Caco2 cells (48 hours 50µM rifampicin) or LS147T 
cells (48 hours 1µM VD3). Data is expressed as pmoles d-luc/min/mg protein (mean+/-SD for cell 
lines, mean, median and range for PHH). 
 
Cell Type
PHH            
  Average (9 donors)
PHH            
Median (9 donors)
PHH                
  Range (9 donors)
Monolayer 3D
 HepG2 
+ Rifampcin
0.019
+/-0.002
0.028
+/-0.007
Caco2
+ Rifampicin
0.0004                              
+/-0.0002
0.0078 
0.0044
LS147T
+ VD3
0.017                             
+/-0.010
0.117
+/- 0.092
CYP3A Activity 
(pmoles d-luc/min/mg protein)
0.071
0.051
0.022 - 0.167
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5.1.3  Discussion 
In this Chapter, expression and function of CYP1A2 and CYP3A were demonstrated in 
both Caco2 and LS147T cells. In both cell lines, mRNA expression data demonstrates 
that CYP3A4 expression predominates over CYP3A7 although there was a greater 
expression of CYP3A7 in LS147T cells than in Caco2 cells. Expression profiles of 
nuclear receptors (NR) were also examined and there were slight differences between 
the cell lines: VDR and PXR expression were slightly higher in LS147T cells and CAR, 
GR and RXR expression were higher in Caco2 cells. Others have reported that LS147T 
cells are lacking in CAR and Caco2 cells are lacking in PXR expression 
251, 255. These 
discrepancies could be ascribed to both cell source and the culture media used in these 
studies, which may affect both CYP and NR expression in intestinal cell lines 
55. 
 
In monolayer culture, ECOD activity was comparable for both cell lines but was not 
improved by induction. CYP1A2 function was also equivalent in uninduced cells, 
however, a greater induction was observed in LS147T cells following indirubin, and to 
a lesser extent DBA, exposure. CYP3A function was also superior in monolayer 
LS147T cells to Caco2 cells; Caco2 CYP3A function was only improved following 
prolonged (7 day) exposure to VD3. For both Caco2 and LS147T cells, a slight effect of 
CYP1A2 inducers on Luciferin BE function was also observed. This implies either that 
these inducers are able to act as ligands at NR which mediate CYP3A function such as 
PXR or CAR, or NR cross-talk between mediators of CYP1A2 and CYP3A. This will 
be investigated further for HepG2 cells in Chapter 6.  
 
Variations in Caco2 function that are dependent on differentiation state and passage 
number have been presented by a number of researchers 
248, 250, 257, 258. Here, it is shown 
that Caco2 cells responded well to alginate encapsulation and that 3D culture resulted in 
significant improvement in CYP3A function of this cell line. Importantly, it was 
demonstrated in 3D culture that CYP3A function was better upregulated by 48 hour 
induction with 50µM rifampicin than by long-term treatment with 1µM VD3. This 
contradicts not only research reported by other groups, but also the monolayer results 
described above.  
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It has previously been reported that CYP3A4 induction in Caco2 cells can be induced 
by VD3 and not by rifampicin 
188, 258. It is also proposed that in Caco2 cells, CYP3A4 
function is dependent upon ECM, serum and long-term VD3 exposure 
250. One role 
these authors suggest for VD3 is that it acts as a precursor of cellular differentiation; it 
may be that other components of LG complete αMEM were also able to perform this 
role. This, combined with the effects of 3D culture on cellular architecture (resulting in 
improved cell-cell communication and ECM deposition 
259), could be sufficient to 
promote rifampicin mediated induction in Caco2 cells.  
 
Culture media dependent CYP3A function of Caco2 cells has previously been reported 
by Schmiedlin Ren et al 
250, although changes in function reported by these authors 
were moderately low. Caco2 cells profiled in this thesis were initially cultured in 
DMEM but were adapted to αMEM containing supplements, which may have had an 
effect on cellular differentiation and CYP expression, including hydrocortisone, insulin, 
TRH and sodium selenite.  
 
Raeissi 
249 demonstrated by RT-PCR that CYP3A5 is the predominant form of CYP in 
uninduced Caco2 cells maintained in DMEM. One other possibility is that other 
isoforms of CYP3A (CYP3A5/CYP3A7) are the predominant isoforms induced in 3D 
culture following rifampicin induction, and that CYP3A4 is not the predominant 
functional isoform in Caco2 cells under these culture conditions. Although it has been 
demonstrated that rifampicin has a minimal effect on CYP3A5 (and CYP3A4) 
expression in Caco2 cells 
55, it is plausible that 3D culture has an influence on CYP3A7 
expression in Caco2 cells. This could account for the decreased effect of VD3 induction 
in 3D culture relative to rifampicin, since it has been reported that VD3 has a minimal 
effect on CYP3A7 (and CYP3A5) induction and is a greater inducer of CYP3A4 
93, 188. 
It could also account for why Caco2 cells are unable to produce 6β-OHTST even 
following 3D culture, CYP induction and prolonged (8 hour) TST exposure. 
 
The hypothesis that rifampicin was inducing CYP3A7 in 3D cultures of Caco2 cells is 
further strengthened by other reports which suggest that expression of PXR in Caco2 
cells is negligible 
251, or that PXR ligands do not improve CYP3A4 function in these 
cells. NR expression data presented in section 5.1.2.2 demonstrated that PXR is 
expressed in the Caco2 cells used in this study; possibly, rifampicin caused induction of  
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CYP3A7 by acting at PXR 
138. Alternatively, rifampicin could have acted at GR or 
CAR both of which could cause induction of CYP3A7. 
 
Effects of 3D culture on LS147T CYP3A function were different to those observed in 
Caco2 cells. The influence of rifampicin in 3D culture was negligible, whereas 
encapsulated LS147T exposed to VD3 demonstrated significantly increased Luciferin 
BE metabolism, and also appeared to produce the CYP3A4 metabolite 6β-OHTST. This 
both confirms the selectivity of the Luciferin BE substrate for CYP3A and suggests a 
dominant role of CYP3A4 metabolism in this cell type. A greater effect of VD3 relative 
to rifampicin on CYP expression has been reported by others in LS180 cells 
258, which 
are a variant of LS147T cells, and it is postulated that CYP3A4 induction in response to 
VD3 is a characteristic that is typical to intestinal cell lines. Both of these factors are 
supported by the evidence that VD3 induction is mediated by VDR, which is expressed 
in higher amounts in the intestine than the liver 
251. 
 
Unlike Caco2 cells, viability of LS147T cells appeared poor in 3D culture. This is likely 
to be a replication of their properties in monolayer culture where they shed a lot of 
debris. In monolayer culture, this debris can be mechanically cleared from cultures by 
frequent media changes however, in 3D culture, cell debris appears to be held within the 
alginate beads for prolonged periods of time. One effect of this was decreased per bead 
performance. Function of LS147T cells was significantly improved in 3D culture, 
however data was reported per mg protein. If this value were corrected to account for 
viable cell number only, functional activity, and hence per bead performance, would be 
higher than the values reported here. Potentially 3D culture of LS147T cells could be 
optimised through microgravity culture; improved media flow would increase the 
nutrient availability and removal of toxic waste products. However, the amount of 
debris produced by LS147T cells would remain problematic when considering these 
cells for BAL use. 
 
As described above, differences in CYP function were observed for both cell lines, and 
many factors could account for this, not least their original site of isolation. Both cell 
lines are adenocarcinoma derived and secrete carcinoembryonic antigen, which is 
detected in humans as a marker of tumour formation. As described for HepG2 cells, 
normal cellular functions may not be conserved by these cell lines. Furthermore, it has 
been demonstrated that intestinal CYP3A4 function is affected by disease; although  
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CYP3A expression was not directly affected by presence of tumour in the large intestine 
260, testosterone metabolism was decreased in duodenal biopsy samples taken from a 
paediatric coeliac population, and was then recovered following treatment 
261, and this 
may account for some of the discrepancies measured between the two cell lines since 
neither should be considered as a model of healthy human intestine 
249, 262. Additionally, 
cell source and culture media could equally account for some of the properties of these 
cells.  
 
In this chapter, it has been demonstrated that 3D culture has a beneficial effect on 
function of intestinal cell lines. Others have reported that when Caco2 cells are cultured 
on ECM and stimulated to produce differentiated monolayers, under certain conditions, 
these cells have a tendency to form complex structures rather than maintain a monolayer 
growth pattern 
250. LS147T cells, even in monolayer culture, grow on top of each other 
forming their own structures. Both of these factors indicate that these cell lines would 
favour a 3D culture environment for optimum function.  
 
Caco2 cells arguably adapted better to 3D culture than LS147T cells in terms of 
maintained viability, however, their function was not comparable to PHH even after 
induction. Intestinal CYP expression, in vivo, is far lower than in the liver and this was 
reflected in Caco2 cell function. The advantages of marked upregulation of CYP3A4 
function in LS147T cells following 3D culture and VD3 exposure were offset by the 
large amount of cell debris produced by this cell line. Additionally, intestinal cell lines 
can only offer CYP function to a BAL rather than the range of hepatic functions that 
could potentially be offered by a cell line of hepatic, origin and so for these reasons a 
liver derived cell line remains the most appealing option.  
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5.2  Cytochrome P450 Activity in the HC-04 Liver Cell Line 
Hep G2 cells are of tumor origin and, as is often the case with cancer cells, do not retain 
normal hepatocellular metabolising capacities, most likely as a result of 
dedifferentiation. Immortalised human hepatocytes from normal liver could offer a 
solution as, unlike primary cells, they are easily expandable and may maintain a fuller 
range of hepatocyte functions. The spontaneously immortalised human hepatocyte cell 
line HC-04 functionally expresses the major CYPs, in addition to nuclear receptors, 
enzymes involved in Phase II metabolism and hepatic transcription factors 
160. These 
cells were derived from normal liver following resection of hepatoma. Unlike many 
immortalised hepatocyte cell lines, HC-04 cells were generated without the use of 
simian virus 40 large tumor antigen (SV40) transfection or co-culture with liver 
epithelial cells, both of which are methods that could be problematic for BAL relevant 
cell lines. 
 
Morphologically, these cells are not dissimilar to HepG2 cells (Figure 5-14).  
CYP3A4 protein expression can be increased in HC-04 cells by the PXR agonist 
rifampicin, and these cells are able to metabolise the CYP3A4 substrate midazolam, 
although their reported drug metabolising capacities were equivalent only to PHH from 
donors with low levels of CYP3A4 function 
160.  
 
 
 
Figure 5-14. Monolayer appearance (x10 magnification) of (left) HC-04 cells compared to (right) 
HepG2 cells. 
 
The suitability of HC-04 cells for use in a BAL has not so far been evaluated. The 
conditions under which they were developed would be unsuitable for large scale 3D 
culture. This cell line was developed on an extracellular matrix (ECM) consisting of  
  186 
collagen and fibronectin, and the culture medium that they were developed in (HCM, 
Chapter 2), in addition to being costly, contains supplements, including dexamethasone 
and growth factors, which may alter CYP activity as discussed in previous chapters. 
With respect to HC-04 cells therefore, there were several questions to address. 
 
i)  Will HC-04 cells attach to tissue culture plastic and proliferate in LG BAL 
developed αMEM? 
ii)  Are CYP activities comparable in HC-04 cells cultured +/- ECM in αMEM 
or HCM? 
iii)  Is CYP function maintained over multiple passages in BAL relevant culture 
conditions? 
iv)  Can HC-04 cells be encapsulated in alginate and maintained in 3D culture?  
 
With regard to points (i) and (ii), it subsequently transpired that the HC-04 cells used to 
carry out this work were supplied from the original source heavily contaminated with 
mycoplasma and this affected cell function, with a resultant loss in CYP function. This 
data is therefore not included in this Chapter but is presented in Appendix A. The 
following work was carried out on HC-04 cells cultured on tissue culture plastic, 
adapted to αMEM complete and treated with BM-Cyclin which successfully eliminated 
mycoplasma contamination. To ensure that no contamination remained, cells were 
tested weekly for mycoplasma by PCR whilst the following experiments were carried 
out. 
 
5.2.1  Methods 
5.2.1.1  CYP Induction in Monolayer Culture 
HC-04 cells (2.5x10
4 cells/well in a volume of 100 l) were added to 96 well plates. 
Following overnight attachment, cells were treated with CYP inducers for 48 hours and 
then CYP activity measured by either ECOD assay, Luciferin BE assay or Luciferin ME 
assay (measured in the presence of 10µM sulfaphenazole). Protein content was 
determined by the BCA method.  
This experiment was performed weekly over a period of one month to determine 
whether activity was maintained during time in culture in adapted culture conditions.   
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5.2.1.2  Metabolism of Testosterone 
HC-04 cells were plated out at a density of 2.5x10
4 cells/well, allowed to attach 
overnight and then incubated with either 0.1% DMSO vehicle or 50µM rifampicin for 
48 hours. Cells were subsequently incubated at 37ºC with 200µM testosterone for 8 
hours; supernatant was removed for analysis after 1 hour and 8 hours. Protein content 
was determined by the BCA method.  
5.2.1.3  Encapsulation of HC-04 Cells 
HC-04 cells were revived from liquid nitrogen and cultured in T175 culture flask 
without collagen matrix in αMEM complete. Once confluent, cells were encapsulated 
by Inotech encapsulation as described in Chapter 2. Initially cells were encapsulated at 
0.5x10
6 cells /ml, however, at this density cell proliferation and spheroid formation was 
poor and therefore 1x10
6cells/ml was selected as the seeding density for further 
experiments. Beads were resuspended at a ratio of 0.25ml beads: 8ml HG medium and 
maintained in static culture for 8 or 15 days. Medium was replenished every other day 
and viability and cell growth assessed by FDA/PI staining.  
 
5.2.1.4  CYP Induction in 3D Culture 
At day 6 or day 13 post encapsulation, cells were treated with 0.1% DMSO vehicle or 
50 M rifampicin in HG medium. Following a 48 hour induction period, CYP function 
was measured by Luciferin BE assay.  
 
5.2.1.5  Gene Expression in HC-04 Cells 
RNA was isolated from HC-04 cells that had either been maintained in monolayer 
culture or grown in 3D culture for 8 days and in both instances treated for 48 hours with 
either 0.1% DMSO vehicle or 50µM rifampicin. Following DNase I treatment and 
cDNA preparation (Chapter 2), gene expression was determined by qRT-PCR.  
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5.2.2  Results 
Over the month-long period in which their function was measured, HC-04 cells 
maintained their activity. The following data is therefore presented as the average 
function from the four weekly experiments, performed in quadruplicate, +/-SD.  
5.2.2.1  ECOD Activity in HC-04 Cells 
ECOD activity in monolayer HC-04 cells was significantly increased (41 fold P< 0.001) 
following indirubin mediated induction. ECOD activity was also increased following 
DBA induction (5.2 fold) however this change was not significantly different to vehicle 
treated cells (Figure 5-15).  
 
 
Figure 5-15. ECOD activity was measured in monolayer HC-04 cells following 48 hours induction 
with 10µM DBA or 20µM indirubin. Data analysis was by one-way ANOVA. *** P < 0.001 when 
compared to vehicle treated cells. 
 
CYP3A inducers dexamethasone, rifampicin and phenobarbital did not affect ECOD 
activity in HC-04 cells.   
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5.2.2.2  CYP1A2 induction in Monolayer Culture 
Luciferin ME metabolism in monolayer HC-04 cells was significantly increased (5.2 
fold, P< 0.001) following indirubin mediated induction. There was a slight but 
insignificant increase in CYP1A2 activity following DBA mediated induction (1.5 
fold), but this change was not significantly different to the vehicle treated cells (Figure 
5-16).  
 
 
Figure 5-16. Luciferin ME metabolism was measured in the presence of 10µM sulfaphenazole in 
monolayer HC-04 cells following 48 hours induction with 10µM DBA or  20µM indirubin. Data 
analysis was by one-way ANOVA. *** P < 0.001 when compared with vehicle treated cells. 
 
CYP3A inducers dexamethasone, rifampicin and phenobarbital did not affect CYP1A2 
function in HC-04 cells.   
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5.2.2.3  CYP3A Function in Monolayer Culture 
Effects of CYP3A inducers on CYP3A (Luciferin BE) activity are shown in Figure 
5-17. Dexamethasone did not alter CYP3A function in HC-04 cells. Moderate induction 
was observed following treatment with phenobarbital (1.3 fold above vehicle) and 
rifampicin (1.4 fold above vehicle), however, neither of these results were statistically 
significant. 
 
Figure 5-17. CYP3A (Luciferin BE) activity was measured in monolayer HC-04 cells following 48 
hour treatment with CYP3A inducers.  
 
CYP1A inducers DBA and indirubin had no effect on CYP3A (Luciferin BE) activity in 
HC-04 cells.  
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5.2.2.4  Metabolism of Testosterone 
HC-04 cells treated for 48 hours with 0.1% DMSO vehicle or 50µM rifampicin were 
incubated for up to 8 hours with 200µM testosterone. Included in the same analysis run 
was supernatant from freshly isolated PHH, incubated for 1 hour with 200µM 
testosterone. Unlike data obtained with PHH, HPLC analysis of testosterone 
metabolism by HC-04 cells did not indicate metabolism of TST or detectable amounts 
of 6β-OHTST after a 1 hour exposure. Following 8 hours of TST exposure, HC-04 cells 
that had been treated with rifampicin produced a detectable amount of a TST metabolite 
that was also produced by PHH (Figure 5-18). 
 
   
 
Figure 5-18. Measurement of testosterone metabolism in (top) rifampicin treated HC-04 cells 
incubated for 8 hours with 200µM testosterone and (bottom) freshly isolated PHH incubated for 1 
hour with µM testosterone. Testosterone peaks are indicated by →. Production of 6β-OHTST 
metabolite is indicated by → and was observed only in PHH. A further metabolite → was detected 
in PHH and in HC-04 cells only after rifampicin treatment and 8 hour incubation with 200µM TST. 
One representative trace is shown of 4 independent measurements. 
 
5.2.2.5  3D Culture of HC-04 Cells 
Figure 5-19 shows the growth and viability of HC-04 cells when cultured in 3D format 
for up to 15 days. Proliferation and spheroid formation appeared slower than in HepG2 
cells over 8 days of culture but viability was maintained throughout this culture period. 
Although improved spheroid formation was observed following prolonged (15 days) 
culture, cell viability was markedly decreased.  
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Figure 5-19. Cell viability staining (x10 magnification) of encapsulated HC-04 cells maintained in 
3D static culture for up to 15 days. 
5.2.2.6  CYP3A Function in HC-04 Cells is Improved in 3D-Culture 
Significant effects of both culture format (F (2, 0.017) = 40.96, P< 0.0001) and 
chemical induction (F (1, 0.0016) =7.76, P< 0.01) on CYP3A function (Luciferin BE 
metabolism) were found in HC-04 cells, and there was significant interaction between 
culture type and induction (F (2, 0.0014) = 3.37, P< 0.05).  
d1 
d3 
d6 
d8 
d15 
Phase x10  FDA  PI  
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Following 8 days of static culture, CYP3A function was significantly improved in 
alginate encapsulated HC-04 cells above monolayer culture in both vehicle (4.5 fold 
P<0.001) and rifampicin (5.1 fold, P<0.001) treated encapsulated cells. Following 15 
days of static culture, CYP3A function remained increased relative to monolayer 
cultures in both vehicle (P < 0.05) and rifampicin (P < 0.05) treated cells but was 
significantly lower than in day 8 3D cultures following rifampicin induction (2.5 fold, 
P< 0.001) (Figure 5-20).   
 
Figure 5-20. CYP3A function was measured in HC-04 cells cultured in 3D format for 8 or 15 days 
and treated for 48 hours with either 0.1% DMSO vehicle or 50µM rifampicin (n=6 +/- SD).  Data 
analysis was by two-way ANOVA. ** P <0.01, *** P < 0.001 when compared to monolayer cultures,     
+++ P < 0.001 when d8 and d15 cultures are compared. 
 
5.2.2.7  Influences on mRNA Expression in HC-04 Cells 
Gene expression was compared in RNA isolated from HC-04 cells, maintained in either 
monolayer or 3D culture (8 days), and treated for 48 hours with either 0.1% DMSO 
vehicle or 50µM rifampicin.  
5.2.2.7.1  Effect of Rifampicin Induction and 3D Culture on HC-04 CYP Induction 
For each CYP isoform, significant effects of both rifampicin induction and 3D culture 
on CYP mRNA expression levels were observed, and there was significant interaction 
between the two variables. A summary of this is presented in Table 5-4.  
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Table 5-4. Independent and synergistic effects of rifampicin mediated induction and 3D culture on 
CYP expression were examined in HC-04 cells. Following two-way ANOVA, significance values P 
and F (degrees freedom, sum squares) are stated for each variable. 
  CYP3A4  CYP3A7  CYP1A2 
Induction  P<0.05 
F (1, 4.7
-10) = 9.876 
P<0.01 
F (1, 238) = 22.10 
P<0.01 
F (1, 4.1
-10) = 28.73 
Culture Type  P<0.01 
F (1, 1.4
-9) = 28.77 
P<0.001 
F (1, 406) = 37.75 
P<0.001 
F (1, 1.0
-9) = 70.38 
Interaction Between 
Variables 
P<0.05 
F (1, 5.1
-10) = 10.59 
P<0.01 
F (1, 234) = 21.76 
P<0.01 
F (1, 4.1
-10) = 28.32 
 
Bonferroni post tests demonstrated a significant increase in expression of each CYP 
gene in 3D culture, compared to monolayer, following rifampicin mediated induction 
(Figure 5-21). The greatest increase was measured in CYP3A7 mRNA expression (249 
fold P< 0.001). Lesser increases were measured for CYP3A4 expression (27.7 fold P< 
0.001) and CYP1A2 expression (16.7 fold P< 0.001).  
 
 
Figure 5-21. CYP mRNA expression was measured in HC-04 cells cultured in monolayer or 3D 
format and treated for 48 hours with 50µM rifampicin. CYP expression is normalised to ribosomal 
18s expression and presented as n=3+/- SD. Following two-way ANOVA, *** P < 0.001 when 
monolayer and 3D cultures are compared. 
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5.2.2.7.2  Effect of 3D Culture on Nuclear Receptor Expression 
Effects of rifampicin induction and 3D culture on gene expression were both nuclear 
receptor dependent, and are summarised in Table 5-5 and Figure 5-22.  
 
PXR and RXRα expression were not significantly improved by either rifampicin 
induction or 3D culture. CAR expression was not influenced by rifampicin but was 
significantly upregulated in 3D culture (P < 0.01). Significant effects of both rifampicin 
(P < 0.001) and 3D culture (P<0.001) were observed for GR expression and there was a 
significant interaction between the two variables (P<0.01).   
 
Table 5-5. Effects of 50µM rifampicin exposure and 3D culture on nuclear receptor expression were 
analysed by two-way ANOVA. Significance values P and F (degrees freedom, sum squares) are 
stated for each variable.  
   
CAR  PXR  RXRα  GR 
Induction 
 
P>0.05 
F (1, 1.8
-27) 
= 0.007 
P>0.05 
F (1, 1.8
-7) 
= 0.97 
P>0.05 
F (1, 7.6
-20) 
=1.88 
P<0.001 
F (1, 5.7
-15) 
=29.62 
Culture Type 
 
P<0.01 
F (1, 3.3
-24) 
= 12.43 
P>0.05 
F (1, 5.4
-7) 
= 2.89 
P>0.05 
F (1, 1.3
-20) 
=0.32 
P<0.001 
F (1, 1.4
-14) 
=74.66 
Interaction 
Between 
Variables 
P>0.05 
F (1, 2.5
-25) 
= 0.96 
P>0.05 
F (1, 1.9
-7) 
= 1.03 
P>0.05 
F (1, 1.1
-20) 
=0.28 
P<0.01 
F (1, 5.5
-15) 
=28.53 
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Bonferroni post tests demonstrated significant increases in both CAR (21.5 fold P<0.05) 
and GR (104.7 fold P<0.001) expression in 3D culture compared to monolayer culture, 
following rifampicin exposure (Figure 5-22). There were slight increases in both PXR 
(2.2 fold) and RXR (2.2 fold) expression in rifampicin treated 3D cultures compared to 
monolayer, however, these changes were not significant. 
 
Figure 5-22. NR mRNA expression was measured in HC-04 cells cultured in monolayer or 3D 
format and treated for 48 hours with 50µM rifampicin. NR expression is normalised to ribosomal 
18s expression and presented as n=3+/- SD. Following two-way ANOVA, * P < 0.05, *** P < 0.001 
when monolayer and 3D cultures are compared. 
 
5.2.2.8  A Comparison of PHH, HepG2 and HC-04 Cells 
CYP3A activity in HC-04 cells treated with rifampicin was compared with activity 
measured in freshly isolated PHH (results from Chapter 3) and with HepG2 cells treated 
with rifampicin (results from Chapter 4). In monolayer culture, CYP3A function was 
comparable in HepG2 cells and HC-04 cells treated with 50µM rifampicin, but for both 
cell lines activity was lower than that measured in freshly isolated PHH. Following 3D 
culture and rifampicin treatment, CYP3A activity was higher in HC-04 cells than in 
HepG2 cells, and matched the average value measured in freshly isolated PHH (Table 
5-6).  
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Table 5-6. CYP3A (Luciferin-BE) activity was higher in freshly isolated primary human 
hepatocytes than HC-04 cells but the difference was abrogated by 3D culture. Data was compared 
from PHH isolated from 9 separate donors assayed in quadruplicate and monolayer and day 8 3D 
cultures of HepG2 and HC-04 cells treated for 48 hours with 50µM rifampicin. Data is expressed as 
pmoles d-luc/min/mg protein (mean+/-SD for cell lines, mean, median and range for PHH). 
 
Cell Type
PHH            
  Average (9 donors)
PHH            
Median (9 donors)
PHH                
  Range (9 donors)
Monolayer 3D (Day 8)
 HepG2 
+ Rifampcin
0.019
+/-0.002
0.028
+/-0.007
HC-04
+ Rifampicin
0.015                             
+/-0.009
0.079
+/- 0.036
CYP3A Activity 
(pmoles d-luc/min/mg protein)
0.071
0.051
0.022 - 0.167
 
 
5.2.3  Discussion 
CYP1A2 and CYP 3A induction were both demonstrated here in monolayer HC-04 
cells. Significant effects of indirubin induction on CYP1A2 function were 
demonstrated, and improvement was shown in CYP3A function following 
dexamethasone and rifampicin exposure. When cultured in the same monolayer 
conditions, CYP3A function was comparable in HepG2 and HC-04 cells. 
 
The beneficial effects of 3D culture on hepatocyte function are well documented and 
were demonstrated here for HC-04 cells with respect to their CYP function. Expression 
of CYP1A2, 3A4 and 3A7, as well as nuclear receptors that govern their expression, 
were all upregulated following alginate encapsulation. Importantly CYP3A function 
was significantly improved in 3D culture; following rifampicin induction CYP3A 
activity in d8 HC-04 spheroids matched the mean value measured in freshly isolated 
PHH (0.076 vs 0.071 pmoles/min/mg protein). In HC-04 cells, mRNA expression data 
indicates that CYP3A7 is a greater contributor to CYP3A function than CYP3A4 which  
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could (partly) explain (as described above for Caco2 cells) why these cells do not 
produce detectable quantities of the CYP3A4 testosterone metabolite 6β-OHTST 
51, 215.  
 
Interestingly, an influence of rifampicin on GR expression was also demonstrated in 
HC-04 cells. Induction of various NR by dexamethasone has been demonstrated in PHH 
and HepG2 cells 
55, 96. Furthermore, expression of GR may also influence PXR and 
CAR 
263. The implication of these findings would be improved CYP3A induction, 
which was successfully demonstrated in 3D culture, not only in HC-04 cells but also 
Caco2 cells.  
 
There were drawbacks associated with alginate encapsulation of HC-04 cells. The 
slower proliferation of encapsulated HC-04 cells relative to both monolayer cultures and 
HepG2 cells would result in difficulties in obtaining an adequate biomass. Moreover, 
following prolonged 3D culture (which would be required for an adequate cell number), 
cell viability was not maintained and cell function was decreased. This phenomenon has 
been observed in HepG2 cells cultured in static culture and can in part be attributed to 
decreased oxygenation and nutrient availability and a build up of toxic waste products. 
This could be addressed by culturing HC-04 cells in a microgravity environment such as 
that provided by an RCCS or fluidised bed bioreactor (FBB). Although there are 
conflicting reports regarding improvement of CYP function in rotary bioreactor systems 
181, 230, positive effects of RCCS function on CYP3A function were shown in Chapter 4 
for HepG2 cells and at the very least, these culture methods would improve cell 
viability and proliferation and so, in the respect of per bead performance, would be 
beneficial. 
 
Others have demonstrated that, in monolayer culture, HC-04 cells retain features that 
can be related to hepatocyte differentiation 
160. Albumin secretion occurs at a level 
comparable to PHH, additionally, low levels of ornithine transcarbamoylase and 
glucose-6-phosphatase are present. Arguably, slower HC-04 proliferation could be 
attributed to improved differentiation, which occurs in 3D culture through superior 
polarity and cell-cell interaction, however, this could only be proved by attempting to 
enhance HC-04 growth in 3D format and then re-examining CYP3A function.  
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5.3  Conclusions 
In this Chapter, alternative cell sources that could provide a source of CYP3A mediated 
drug metabolism within a BAL were investigated.  
 
Inducible CY3A function was demonstrated in Caco2 cells and this function was 
significantly enhanced in 3D culture following rifampicin induction, however, this 
function was still 3 fold less than the lowest level measured in PHH. Additionally, 
Caco2 cells were unable to metabolise testosterone in an equivalent manner to PHH. 
 
Inducible CYP3A function was demonstrated in LS147T cells, and it was higher overall 
in these cells than in Caco2 cells. CYP3A activity was also significantly improved in 
LS147T cells by 3D culture; following prolonged exposure to VD3, LS147T cells 
produced the CYP3A4 testosterone metabolite 6β-OHTST and Luciferin BE activity 
was within the upper quartile limits of activity measured in PHH. Unfortunately there 
were several practical reasons why LS147T cells would not be suitable for BAL use. 
Firstly, CYP3A function comparable to PHH was only achieved after prolonged VD3 
exposure. VD3 is a relatively expensive compound, and this would be a prohibitive 
factor for large scale BAL culture. Secondly, LS147T cells in monolayer culture 
produce a large amount of debris; this was not improved in 3D culture and would 
present practical difficulties when fulfilling regulatory requirements for a BAL, which 
include complete removal of DNA contamination from the biomass before plasma is 
returned to the patient. 
 
HC-04 cells, as an alternative hepatic cell line for a BAL, could provide inducible 
CYP3A function. This function remains stable over multiple passages, but not at 
sufficient levels in monolayer culture. It was demonstrated here that alginate 
encapsulated HC-04 cells can be successfully cultured over a prolonged period of time 
(up to 15 days) and although further work would be required to optimise the growth and 
performance of these cells within a 3D culture system, the functional data obtained thus 
far is promising: following rifampicin induction Luciferin BE activity in d8 HC-04 
spheroids matched the mean value measured in freshly isolated PHH. Additionally, 
functional data obtained in monolayer culture together with mRNA expression data 
indicate that HC-04 cells would be able to provide CYP1A2 metabolism at sufficient 
levels also. Limitations of HC-04 cells with respect to their use in a BAL include their 
poor testosterone metabolism relative to PHH and their rate of proliferation in 3D  
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culture, which was decreased relative to HepG2 cells even when cells were 
encapsulated at double the seeding density. Also, as mentioned previously, these cells 
were initially contaminated with mycoplamsa, which could result in difficulties 
fulfilling regulatory requirements surrounding the original source of a cell line suitable 
for use in a device to be used to treat humans. 
 
Although HepG2 cells have diminished CYP function and limited CYP3A induction, 
many other factors, including the achievable biomass size and synthetic capacity of 
these cells, mean that they remain an attractive option for a BAL. A genetic 
manipulation approach has been used successfully to restore urea cycle function to 
HepG2 cells 
13, and this may be an option for achieving drug metabolism capacity. 
 
It has been demonstrated that CYP mRNAs including CYP3A are expressed in HepG2 
cells, albeit at a lower level than in PHH; methods that improve existing CYP 
expression could result in increased CYP3A function within these cells. Other groups 
have demonstrated the potential for CYP3A function in HepG2 cells, often by 
transfection of single CYP isoforms 
142-144. Methods by which the function of multiple 
CYP isoforms can be improved in HepG2 cells by genetic manipulation will be 
investigated in Chapter 6.  
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CHAPTER 6  Modifying CYP3A Function in HepG2 Cells 
 
As described in Chapter 4, HepG2 cells can be manipulated to perform CYP mediated 
functions and would provide CYP1A function within a BAL; however, even though 
significantly improved by 3D culture (relative to monolayer), only limited CYP3A 
function can be achieved. CYP1A activity alone is insufficient for a BAL since in 
humans it accounts for only 10% of xenobiotic metabolism and may result in 
procarcinogen production 
42, 264. 
 
Alternative cell lines to provide CYP3A activity were described in Chapter 5. Intestinal 
cell lines had inducible CYP3A4 function that was upregulated by 3D culture and 
induction, however, in the case of Caco2 cells, CYP3A activity was insufficient. 
LS147T cells had relatively greater CYP3A4 function but were unsuitable for BAL 
culture. Also, intestinal cell lines within a BAL could only be used to provide 
detoxificatory capacity and would not perform other hepatocyte specific functions.  
HC-04 cells were therefore assessed as an alternative liver-derived cell line. They 
demonstrated CYP3A activity which was significantly enhanced by 3D function, 
however their growth in 3D culture was relatively slow which could present a problem 
obtaining an adequate biomass. There were also regulatory difficulties associated with 
this cell line. 
 
In spite of their limited detoxificatory capacity, HepG2 cells remain an attractive 
candidate for BAL use. These cells have been well characterised within the Liver Group 
(LG) BAL 
135 and perform many hepatocyte specific functions; furthermore a subclone 
of these cells have been used in clinical trials which sets a precedent for regulatory 
approval 
131. 
 
The aim of Chapter 6 is to improve, by genetic manipulation, CYP3A function in 
HepG2 cells. Further to this, an alternative source of HepG2 cells will be considered, as 
will the effects of adaptation of these cells to LG αMEM complete medium. 
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6.1  Improving Inducible CYP3A Function in HepG2 Cells 
Decreased mRNA expression of CYPs provides one explanation for the low functional 
activities of these enzymes in hepatoma cells 
45. CYP3A4 transcripts are present in 
HepG2 cells although mRNA levels are far lower (100-1000 fold) than in adult primary 
human hepatocytes 
136. It is therefore a reasonable hypothesis that improving expression 
of CYP mRNA could improve enzyme function. Other laboratories have previously 
engineered HepG2 cell lines which stably express single CYP isoforms 
143, 144 but 
sustained function of multiple CYP isoforms, at a high level, through this approach is 
difficult to achieve. 
 
As described in Chapter 1, CYP induction occurs by ligand activated nuclear receptors 
(NR) forming heterodimers with a co-receptor leading to increased CYP gene 
transcription. CYP3A induction is governed by a heterodimer of Pregnane X Receptor 
(PXR) or Constitutive Androstane Receptor (CAR) with Retinoid X Receptor alpha 
(RXRa) 
30, 77, 265, 266. These heterodimers bind to response elements (RE) in the CYP3A 
gene increasing CYP3A transcription resulting in enhanced enzyme production. Others 
have established that altering HepG2 NR expression can improve CYP3A transcription 
147, 150. 
 
Inducers may act directly at nuclear receptors (rifampicin at PXR), indirectly 
(phenobarbital causes translocation of CAR from cytoplasm to nucleus following 
receptor dephosphorylation) 
267, and synergistically (dexamethasone not only directly 
activates PXR, but can mediate the expression of RXRα, PXR and CAR via 
glucocorticoid receptor activation) 
96.  
CAR expression is diminished in HepG2 cells relative to primary human hepatocytes 
157, 221, and expression levels vary throughout the cell cycle 
268, which may contribute to 
lower expression of CYP3A in these cells. RXRα mRNA expression is decreased in 
HepG2 cells relative to other human hepatoma cell lines 
232; additionally, in certain 
circumstances, ligands binding to RXRα may reduce the availability of this receptor for 
CAR, repressing CYP gene expression 
269, 270. It is therefore hypothesised that transient 
transfection of the nuclear receptor CAR and/or co-receptor RXRα in conjunction with 
chemical induction could improve CYP function in HepG2 cells to provide function 
comparable to that in primary human hepatocytes.  
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Each CYP gene contains multiple response elements which may be activated by more 
than one nuclear receptor. Multiple CYP enzymes may be induced by a single inducing 
agent or alternatively, a single CYP gene may be activated by more than one inducing 
agent. CAR is primarily reported to be an inducer of CYP2B6, but activation of CAR 
also results in increased CYP3A transcription and it has been implicated in the 
induction of other isoforms including CYP1A 
231, 271-273. Due to this receptor cross-
talk/non-selectivity of nuclear receptor induction pathways, a single transfectant might 
result in improved function of multiple CYP isoforms resulting in the creation of a BAL 
relevant cell line that can provide xenobiotic metabolism. A sub-hypothesis is that co-
transfecting combinations of nuclear receptors or associated co-receptors will result in 
increased inducible CYP3A function.  
 
The data here characterises CYP1A2 and CYP3A function in HepG2 cells following 
RXRα and/or CAR transfection. Proof of concept was achieved in HepG2 cells in a 
transient system by measuring CYP functional activity with and without inducers.  
This work consisted of the following. 
 
i.)  Creating Constructs Expressing CAR and RXRα 
a.)  Designing cloning primers for nuclear receptor sequences 
b.)  Amplifying nuclear receptor sequences from human liver cDNA 
c.)  Inserting amplified sequences into pTracer EF/BSD 
 
ii.)  CYP Induction in HepG2 Cells Transiently Expressing DNA Constructs 
a.)  Transiently transfecting HepG2 cells with nuclear receptor constructs 
b.)  Treating transfectants with CYP inducers  
c.)  Measuring CYP function 
 
iii.)  CYP Function of CAR Transfectants in 3D Culture 
a.)  Creation of stable single transfectant 
b.)  Measurement of function in monolayer culture 
c.)  Measurement of function in 3D culture  
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6.1.1  Creation of Constructs 
6.1.1.1  Methods 
6.1.1.1.1  Designing Primers for Cloning 
Oligocalc (http://www.basic.northwestern.edu/biotools/oligocalc.html) software was 
used to design primers which were BLAST screened for specificity.   
 
For CAR (NM_001077482) and RXRα (NM_002957), a nested PCR approach was 
selected. Full Genbank sequences were obtained for each nuclear receptor. Forward and 
reverse outer primers were designed ~ 200bp upstream and downstream of the full 
cDNA sequence to obtain a PCR product that contained the full sequence for these 
nuclear receptors.   
 
Cloning primers were designed to amplify the full cDNA sequence of each nuclear 
receptor. A Kozak initiation sequence was added to the forward primers; KPN I (RXRα) 
or EcoRV (CAR) restriction sites were added to the beginning of the forward primers 
and an XbaI restriction site added to the ends of the reverse primers (Table 6-1).  
 
Table 6-1. Nested PCR primers for amplification of RXRα and CAR listed in 5’-3’ orientation. 
Restriction sites and a Kozak sequence were incorporated into Cloning Primers. 
RXRα
Forward GGCATGAGTTAGTCGCAG  
Reverse GCCACAGACAAGTAGTAAC 
Forward GAGGTACCCGCCACCATGGACACCAAACATTTC
Reverse GGGCCTCTAGACCTAAGTCATTTGGTG 
CAR
Forward CAGCCACCCCAACACGTGAC
Reverse GGTGAGCTGGGGAAGGAAGT
Forward CACGATATCACGTGCCACCATGGCCAGTAGGGAAGATG
Reverse GGAACGATCTAGAATGGCCTCAGCTGCAGATCTCCTGGA 
Outer Primers
Cloning Primers
Outer Primers
Cloning Primers
 
 
6.1.1.1.2  Amplifying Nuclear Receptors from Human Liver 
High-fidelity DNA polymerase was used to amplify sequences from human liver cDNA 
which was synthesised from RNA isolated from human liver using the methods 
described in Chapter 2.  
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Materials 
Human Liver cDNA 
Phusion High-Fidelity DNA Polymerase, HF buffer and accompanying reagents (NEB 
F5305)  
10 M Outer Primers (OP) 
10 M Cloning Primers (CP) 
Sterile Water 
Montage DNA extraction Columns  
 
Methods 
For each set of outer primers, PCR reactions were set up in triplicate as follows:  
 
 
 
 
 
 
 
 
 
 
 
PCR conditions were: 98°C for 30s for initial denaturation, followed by 30 cycles of 10s 
at 98°C denaturation, 30s at 60°C annealing and 60s at 72°C extension, with a final 
extension step of 10 minutes at 72°C. Product was then run on a 1% agarose gel, and 
DNA extracted (using Montage DNA Gel Extraction Columns), purified and 
concentrated by ethanol precipitation as described in Chapter 2. Purified PCR product 
or a diluted sample (1:20 or 1:200) of the original PCR product was loaded into a 
subsequent reaction with cloning primers to add restriction sites. Product was run on a 
1% agarose gel, and extracted, concentrated and purified for subsequent steps as 
described above. 
 
 
 
Reagent  µl/20µl Reaction 
H20  11.4 
5x HF Buffer  4 
10mM dNTP  0.4 
Forward Primer  1.2 
Reverse Primer  1.2 
DMSO  0.6 
Template  1 
Phusion  0.2  
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6.1.1.1.3  Inserting Sequences into pTracer EF/BSD Vector 
pTracer™-EF/Bsd A contains a cycle 3-GFP (green fluorescent protein) tag fused to a 
blasticidin resistance gene. The GFP in this vector has been optimised for expression in 
mammalian cells and gives a greater fluorescent yield than the wild type. This allows 
transfection efficiency and subsequent gene expression to be easily monitored by 
fluorescence microscopy and the fused blasticidin resistance gene allows selection in 
mammalian cell lines which can be directly correlated with GFP expression. Gene 
expression in this vector is driven by human elongation factor 1α-subunit (hEF-1α) 
promoter (Figure 6-1).  
 
Figure 6-1. Configuration of pTracer EF/BSD A (Invitrogen V889-20 Version C May 2003 ) 
6.1.1.1.4  Restriction Digests of Vector and Insert 
Restriction Enzymes (NEB: Eco RV, Kpn I, Xba I) 
NEB Buffer 2 (10x concentration) 
10mg/ml BSA (NEB 10x concentration) 
pTracer™-EF/Bsd A (Invitrogen V889-20) 
DNA purified from Phusion PCR (CAR, RXRα) 
Sterile water  
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Kpn I and XbaI were used to digest RXRα DNA; CAR DNA was digested using 
EcoRV and XbaI; and the vector was digested with both sets of restriction enzymes.  
For each restriction digest, the following reaction was prepared in a 0.2ml PCR tube: 
 
1µg DNA (typically 5-10µl) 
1.5µl Buffer 2 
1.5µl BSA 
0.5µl EcoRV or Kpn I 
0.5µl XbaI 
Sterile water to a final volume of 15µl 
 
Tubes were incubated at 37°C for 2 hours. Digestion was confirmed by running 2µl of 
product on a 1% agarose gel. The remainder of each reaction was then concentrated by 
ethanol precipitation as described above. 
 
6.1.1.1.5  Ligation of Vectors and DNA 
NEB Quick Ligase was used to ligate vector and insert. For each reaction a control 
ligation containing vector without insert was also performed. 
 
Materials 
Digested vector and insert 
NEB Quick Ligase Kit (M2200) 
Sterile water 
0.2ml PCR tubes 
 
A 3:1 ratio (ng/ng) of digested insert and corresponding vector were combined in a 
volume of 4µl in 0.2ml PCR tubes. To this mix, 5µl of 2x Quick Ligase buffer was 
added followed by 1µl Quick Ligase. The reaction was mixed by pipetting and then 
incubated at 25°C for 1 hour.  
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6.1.1.1.6  Transforming Competent Cells (E. coli) with Constructs 
XL10-Gold Ultracompetent Cells (Stratagene 200315) 
β-Mercaptoethanol 
Ligation Mix 
SOC Broth  pH 7.0 (for1L: 0.5g NaCl, 5g yeast extract, 20g tryptone, sterile distilled H2O to 950ml, 
add 10ml 250mM KCl, autoclave autoclave 121°C, 20 minutes, add 20ml filter sterilized 1M glucose and 
5ml autoclaved 2M MgCl2) 
LB Agar containing 100 g/ml carbenicillin (for 1L: 5g NaCl, 2.5g yeast extract, 5g 
tryptone, 10g agar, pH7.0  with 5M NaOH autoclave 121°C, 20 minutes and then add the antibiotic when 
cooled sufficiently) 
42°C Water bath 
37°C Shaker 
37°C Incubator 
 
LB Agar plates were poured and dried upside down in a 37°C incubator. For the 
transformation, the manufacturer’s protocol was followed. XL10-Gold Ultracompetent 
cells were thawed on ice, 4 l of β-mercaptoethanol added and mixed every 2 minutes, 
by gentle swirling, for 10 minutes. After this time, 40 l aliquots of the cells were 
transferred into sterile microfuge tubes, 4 l of ligation mix added and the mixture 
incubated on ice for 30 minutes. Tubes were heat pulsed in a 42°C water bath for 30 
seconds, returned to ice for 2 minutes and then 400 l of warmed SOC broth added. 
Samples were incubated at 37°C for 1 hour with shaking at 225rpm. 200 l of 
transformation mix was then spread onto the prepared agar plates and incubated 
overnight at 37°C.   
6.1.1.1.7  Identifying Positive Colonies 
Positive transformation was confirmed by the growth of discreet white colonies on the 
agar plates. The control ligation was used to indicate transformation efficiency of the 
empty vector. Primers which spanned the multiple cloning site (MCS) of the vector 
were then used to screen selected colonies.   
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A PCR was set up using HotstarTaq, as described in Chapter 2. 
Primers (5’-3’orientation): 
Forward (EF-1α priming site): TCA AGC CTC AGA CAG TGG TTC  
Reverse (BGH priming site): TAG AAG GCA CAG TCG AGG 
Cycling conditions: 
95°C 10 minutes
95°C 30s
55°C 30s
72°C 90s
72°C 10 minutes
30x cycles
95°C 10 minutes
95°C 30s
55°C 30s
72°C 90s
72°C 10 minutes
30x cycles
 
PCR mix (20µl) was aliquoted into 0.2 l PCR tubes. A selection of colonies, usually 
10-20 depending on transformation efficiency were picked individually and streaked 
onto fresh LB agar plates using a 20 l pipette tip. The used tip was then inserted into 
the PCR mix. The PCR was performed as indicated above and product run on a 1% 
agarose gel. 
6.1.1.1.8  Miniprep of E.coli Containing Constructs 
LB broth containing 100 g/ml carbenicillin (for 1L LB 5g NaCl, 2.5g yeast extract, 5g 
tryptone, pH7.0 with 5M NaOH autoclave 121°C 20 minutes) 
37°C shaker 
50ml tubes 
Miniprep plasmid extraction kit (Qiagen 27106) 
Sterile Glycerol 
1.5ml and 2ml microfuge tubes 
Micro centrifuge 
NanoDrop 
 
Positive colonies, as shown by the MCS PCR were picked off the streaked plates. Each 
colony was used to inoculate 5ml of LB broth which was incubated overnight (but less 
than 17 hours) at 37°C in a shaker. The following day, 2ml of each culture, in duplicate, 
was centrifuged at 16000g for 1 minute. From the remaining culture a 15% (v/v) 
glycerol stock was prepared which was stored at -80°C until required. The construct 
was isolated from the pelleted culture mix according to the miniprep plasmid extraction 
kit protocol. The amount of DNA obtained was quantified using the NanoDrop.  
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Restriction digests were performed for each construct as described in section 6.1.1.1.4. 
to confirm that both vector and insert were of the desired product size. 300ng of each 
construct was sent to the UCL Facility for Sequencing and Genotyping to be sequenced. 
6.1.1.2  Results 
6.1.1.2.1  Cloning of CAR and RXRα from Human Liver cDNA 
The amplification of CAR from human liver and analysis of colonies obtained when 
DNA was inserted into pTracer vector are shown in Figure 6-2. The coding region of 
CAR is 1074bp and primers that spanned the MCS gave a PCR product of 1362bp. 
1000bp
n n
1000bp
d e
1000bp
n n
1000bp
1000bp 1000bp 1000bp
n n
1000bp
n n n n
1000bp
d e
 
Figure 6-2. Cloning of CAR from human liver DNA.  
The top gels show nested PCR amplification of CAR from human liver cDNA. Arrows indicate 
1000 bp markers.  
(top left) Product was first amplified with outer primers and the circled band excised from gel and 
purified. (top middle) Using cloning primers to add restriction sites, a second PCR was prepared to 
amplify CAR from PCR product from the first reaction that had (d) been diluted 1:200 or  (e) 
extracted from the gel on the left. No template controls are marked n. Circled bands were then 
excised from the gel and purified by ethanol precipitation to give a product of 1074bp (top right).  
The bottom gel shows MCS PCR of transformed colonies for which the desired product size was 
1362 bp. The circled product was used for subsequent transfections following sequencing.  
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The amplification of RXRα from human liver and analysis of colonies obtained when 
DNA was inserted into pTracer vector are shown in Figure 6-3. The coding region of 
RXRα is 1389bp and primers that spanned the MCS gave a PCR product of 1635bp. 
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ntc
1500bp
1500bp
a b c d
ntc
1500bp
a b c d
ntc
a b c d
ntc ntc
1500bp
1500bp 1500bp
 
Figure 6-3. Cloning of RXRα from human liver DNA.  
The top gels show nested PCR amplification of RXRα from human liver cDNA. 
(top left) Product was first amplified with outer primers and the circled band excised from gel and 
purified. (top middle) Using cloning primers to add restriction sites, a second PCR was prepared to 
amplify RXRα from PCR product from the first reaction that had been diluted (a) 1:20, (b) 1: 200 
or (c) been extracted from the gel on the left. No template control is indicated (d). Bands from (c) 
were then excised from the gel and purified by ethanol precipitation to give a product of 1389bp. 
The bottom gel shows MCS PCR of transformed colonies following miniprep for which the desired 
product size was 1635 bp. This product was used for subsequent transfections following sequencing. 
 
6.1.2  Transient Transfection of Nuclear Receptors and CYP Induction 
6.1.2.1  Methods 
6.1.2.1.1  Transient Transfection and CYP Induction in HepG2 Cells 
A reverse transfection method was used to transfect cells using Lipofectamine
™ 2000 
reagent (Invitrogen UK) according to manufacturer’s instructions. HepG2 cells (1x10
5) 
were added to each well of a 96 well plate along with transfection mix containing 0.2 g 
of DNA construct and 0.5 l of lipofectamine, or lipofectamine alone as a mock  
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transfection control. Following an overnight incubation, serum free medium without 
antibiotics was replaced with normal growth medium (αMEM Complete 10%FCS) 
containing CYP inducers. Prior to measurement of CYP function, cells were incubated 
for 48 hours in the presence of inducers, and medium replenished daily. CYP function 
was measured by Luciferase and Vivid® BOMFC assays. Cell viability was measured 
by WST-1 assay. Protein content was determined by the BCA assay. Each experiment 
was repeated three times in triplicate and data are presented as mean of 9 values +/- 
SEM. 
6.1.2.1.2  Gene Expression in Transfected HepG2 Cells 
Gene expression studies (mRNA) were carried out at 72 hours post transfection. RNA 
was isolated from transfected HepG2 cells and gene expression was performed by qRT-
PCR as described in Chapter 2. 
 
6.1.2.2  Results  
6.1.2.2.1  Transfection Efficiency in HepG2 Cells 
Transfection efficiency was monitored by GFP expression in the NR transfected cells 
(Figure 6-4). 
 
Figure 6-4. Transfection efficiency was monitored by comparing GFP expression in (top) 
untransfected HepG2 cells and (bottom) HepG2 cells 96 hours post transfection. Images are x20 
magnification.   
Phase x20  GFP  
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Increased transgene expression was confirmed 72 hours post transfection by qRT-PCR. 
Gene expression was compared in HepG2 cells and human liver pooled from 4 different 
donors and although gene expression of both RXRα and CAR were diminished in 
HepG2 cells, it was restored to levels similar to those measured in human hepatocytes 
by transient transfection (Figure 6-5). 
 
Figure 6-5. HepG2 cell CAR and RXRα expression was determined by RT-qPCR in mRNA isolated 
72 hours post transfection from control transfected cells and cells transfected with CAR, RXRα and 
CAR/RXRα. mRNA was included from freshly isolated PHH cells pooled from 4 separate donors as 
a comparator. Data was normalised to 18s expression and is expressed as mean (n=2) +/- range 
(repeated twice). 
 
6.1.2.2.2  Effect of Transfection on CYP3A (Luciferin BE) Activity 
Data was analysed by two-way ANOVA and significant effects of both gene 
transfection (F (3, 196) =16.03, P< 0.0001) and chemical induction (F (6, 196) =7.60, 
P< 0.0001) were measured on CYP3A function in HepG2 cells, however no interaction 
was observed between the two variables. In their uninduced state, Luciferin BE 
metabolism was somewhat higher in cells transfected with CAR/RXRα (1.5-fold) and to 
a lesser extent with CAR (1.2-fold), than in untransfected HepG2 cells but the changes 
were not significant. 
 
As shown in Figure 6-6, for each inducer, the fold induction above basal achieved was 
equivalent for each transfectant (although a trend towards increased induction is 
indicated for the CAR transfectant).  
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Figure 6-6. CYP3A induction in HepG2 cells following 48 hour treatment with CYP3A inducers 
was measured by Luciferin BE activity in HepG2 cells following transfection with either mock 
control, CAR, RXRα or CAR/RXRα. For each transfectant, basal (uninduced) activity was set at 1 
and induction was measured above this level. 
 
Transfected HepG2 cells had a higher basal activity. Since this study was concerned 
with achieving a cell line with high inducible activity, the fold increase in activity above 
untransfected uninduced HepG2 cells was then examined for each transfectant to 
measure which inducer/transfectant combination resulted in the most significant 
increase in CYP3A function above this level. 
 
6.1.2.2.3  Effect of Transfection on CYP3A (Luciferin BE) Activity Following 
Treatment with CYP3A Inducers (Figure 6-7) 
 
In untransfected HepG2 cells, there was slight induction of CYP3A function above 
uninduced cells using rifampicin (1.6-fold), dexamethasone (1.3-fold) and 
Phenobarbital (1.4-fold) but these changes were not statistically significant.  
After CAR transfection, rifampicin induced CYP3A activity was enhanced (2.1-fold, 
P<0.05). This was further improved by RXRα co-transfection (2.3-fold, P<0.001).  
 
After  CAR  transfection,  phenobarbital  induced  CYP3A  activity  was  increased  (1.9-
fold); this was not improved by RXRα co-transfection. 
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Dexamethasone mediated induction was not enhanced by RXRα or CAR transfection 
alone, however, co-transfection of these genes led to a 1.9-fold induction in CYP3A 
activity compared to uninduced untransfected HepG2 cells.  
 
 
Figure 6-7. CYP3A activity was measured in HepG2 cells following transfection with CAR, RXRα, 
CAR/RXRα or mock control and 48 hour treatment with CYP3A inducers. CYP3A activity in 
untransfected uninduced cells was set as 1 and data is expressed as fold increase in activity 
compared to this. Following one way ANOVA, * P<0.05, *** P< 0.001 when compared to 
untransfected uninduced HepG2 cells. 
 
6.1.2.2.4  Effect of Transfection on CYP3A (Luciferin BE) Activity Following 
Treatment with CYP1A Inducers 
Effect of AhR agonists (CYP1A inducers) on CYP3A activity is shown in Figure 6-8.  
In untransfected cells, CYP3A function was increased above basal in cells treated with 
both DBA (1.5-fold) and indirubin (1.8 fold). 
 
The increased basal activity, after CAR and CAR/RXRα transfection, improved activity 
relative to untransfected cells following treatment with either inducer. This resulted in a 
significant increase in CYP3A activity above untransfected uninduced cells following 
indirubin treatment of CAR/RXRα transfected cells (2.3 -fold, P<0.001). 
 
Transfection of RXRα alone had a limiting effect on Luciferin BE metabolism 
following treatment with both DBA and indirubin. When measured against 
untransfected uninduced cells, the extent of indirubin mediated CYP3A induction was  
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significantly reduced in RXRα transfected cells (1.2-fold) compared to CAR/RXRα 
transfected cells (P<0.05).   
 
 
Figure 6-8. Effect of AhR agonists on CYP3A activity was measured in HepG2 cells transfected 
with mock control, CAR, RXRα or CAR/RXRα and treated for 48 hours with inducers to assess 
receptor cross-talk. CYP3A activity in untransfected uninduced cells was set as 1 and data is 
expressed as fold increase in activity compared to this. Following one way ANOVA, *** P< 0.001 
when compared to untransfected uninduced cells.  + P<0.05 when RXRα transfectant was 
compared with CAR/RXRα co-transfectant.  
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6.1.2.2.5  Effect of Transfection and Induction on CYP1A2 (Luciferin ME) Activity 
Luciferin ME assay was performed in the presence of 10µM sulfaphenazole. Significant 
effects of both gene transfection (F (3, 188) =13.86, P< 0.0001) and chemical induction 
(F (6, 188) =53.87, P< 0.0001) on CYP1A2 function were found in HepG2 cells, with a 
significant interaction between transfection and induction (F (18, (188) = 18.31, P< 
0.0001).  
Although not statistically significant changes, CAR transfection resulted in a slight (1.2-
fold) increase in Luciferin ME metabolism in basal cells which was also reflected in the 
co-transfected cells (1.4-fold increase). 
 
Effects of CYP1A2 inducers on Luciferin ME metabolism are shown in Figure 6-9. 
In untransfected cells, DBA and indirubin each resulted in increased CYP1A2 function 
(93-fold and 9-fold induction above basal cells respectively). 
 
Transfection of HepG2 cells resulted in a significant reduction of DBA-mediated 
Luciferin ME metabolism compared to untransfected cells. DBA induction was lower in 
each of CAR, RXRα (P< 0.001) and CAR/RXRα (P< 0.05) transfectants. 
 
Significant effects of gene expression on DBA mediated CYP1A2 activity were also 
observed when transfectants were compared. DBA induction was significantly lower in 
CAR (24-fold above untransfectected uninduced, P<0.001) and CAR/RXRα (27-fold, 
P<0.001) transfected cells than RXRα transfectants (40-fold). 
Furthermore, co-transfection of CAR/RXRα resulted in a significant increase in 
Luciferin ME metabolism above cells transfected with CAR only, (P<0.05) following 
DBA mediated induction. 
 
When transfectants were compared, effects of indirubin mediated induction on CYP1A2 
function were also observed. Following CAR transfection, indirubin resulted in a 13-
fold increase in CYP1A2 activity above untransfected uninduced cells. This was 
significantly higher than the induction measured in RXRα transfected cells (7-fold, 
P<0.01).  
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Figure 6-9. Effect of CYP1A2 inducers on Luciferin ME metabolism was measured to assess effect 
of transfection on CYP1A2 function. CYP1A2 activity was set at 1 for untransfected uninduced 
cells and compared for mock control and HepG2 cells transfected with CAR, RXRα or CAR/RXRα 
and treated for 48 hours with inducers. Data is plotted on a logarithmic scale and was analysed by 
two way ANOVA followed by Bonferroni post hoc analysis.  
*P<0.05, *** P< 0.01 when transfectants were compared to untransfected uninduced HepG2 cells. 
++P<0.01, +++ P<0.001 when CAR and CAR/RXRα transfectants were compared to RXRα 
transfected cells. 
# P<0.05 when CAR transfectants were compared to CAR/RXRα transfectants.  
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As shown in Figure 6-10, CYP3A inducers did not significantly affect CYP1A2 
activity. 
 
Figure 6-10. CYP1A2 activity was measured in HepG2 cells following transfection with mock 
control, CAR, RXRα, or CAR/RXRα and 48 hour treatment with CYP3A inducers. CYP1A2 
activity in untransfected uninduced cells was set as 1 and data is expressed as fold increase in 
activity compared to this.  
 
6.1.2.2.6  Effect of Transient Transfection and Induction on Vivid® BOMFC CYP2B6 
Activity 
As described in Chapter 3, BOMFC assay was developed in primary human hepatocytes 
(PHH) to test CYP2B6 metabolism by measuring substrate metabolism in the presence 
of 100µM clarithromycin. The same method was used to measure CYP function in 
transfected induced HepG2 cells but was too insensitive in these cells. Although a good 
standard curve could be generated, and positive readings were obtained with PHH 
samples (shown in Chapter 3), fluorescence generated with HepG2 samples was no 
higher than background level.  
6.1.2.2.7  Metabolic Viability of Transfected Cells in the Presence of CYP Inducers 
WST-1 activity was not significantly different between transfected cells and 
untransfected cells both with and without addition of inducers (Figure 6-11).  
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Figure 6-11. WST-1 assay demonstrates that cell viability was unaffected by both inducer treatment 
and transfection of CAR, RXRα, CAR/RXRα or mock control. 
 
6.1.2.2.8  A Comparison of PHH and HepG2 Transfectants in Monolayer Culture 
CYP3A activity in transfected HepG2 cells treated with 50µM rifampicin was compared 
with activity measured in freshly isolated PHH (presented in Chapter 3). CYP3A 
activity in untransfected HepG2 cells was lower than each of the PHH preparations. 
Rifampicin treatment of CAR and CAR/RXRα HepG2 cells increased CYP3A activity 
to approach lower levels of activity measured in PHH (Table 6-2).  
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Table 6-2. CYP3A (Luciferin-BE) activity was higher in freshly isolated primary human 
hepatocytes than HepG2 cells but the difference was diminished in transfected HepG2 cells treated 
with rifampicin. Data was compared from PHH isolated from 9 separate donors assayed in 
quadruplicate, untreated HepG2 cells and HepG2 cells transfected with CAR or CAR/RXRα and 
treated for 48 hours with inducer. Data is expressed as pmoles d-luc/min/mg protein (mean+/-SD 
for HepG2 cells, mean, median and range for PHH). 
Cell Type
CYP3A Activity 
(pmoles d-luc/min/mg protein)
PHH            
  Average (9 donors)
0.071
PHH            
  Median (9 donors)
0.051
PHH                
  Range (9 donors)
0.022 - 0.167
Untransfected HepG2
 + Rifampicin 
0.019
+/-0.002
CAR HepG2 
+ Rifampicin
0.024
+/-0.002
CAR/RXRα HepG2
 + Rifampicin
0.026
+/-0.007  
 
6.1.2.3  Discussion 
In this section, Cytochrome P450 induction was improved in HepG2 cells by nuclear 
receptor transfection and a range of inducers and NR combinations were measured. This 
was firstly to determine which experimental condition resulted in the highest CYP3A 
function in order to provide proof of concept for BAL purposes. Secondly NR cross talk 
was examined by measuring effects of NR transfection on CYP1A2 and CYP3A 
induction in the presence of a number of inducers of each isoform. 
 
CYP3A Function was Improved Following Nuclear Receptor Transfection 
Following transfection of both CAR and CAR with RXRa, CYP3A activity was 
increased in the absence of inducing agent. This could be due to medium components 
having an effect either on PXR or CAR expression or CYP3A induction, or CAR 
exhibiting transcriptional activity in the absence of inducer 
274. For this to be plausible 
CAR would have to locate to the nuclei of HepG2 cells following transfection, a 
possibility that is supported by Kowamoto 
267 who found that GFP-fused CAR 
spontaneously localised to the nuclei of transfected HepG2 cells where it could  
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constitutively activate response elements, resulting in CYP induction. HepG2 cells have 
been shown to lack expression of the co-chaperone, cytosolic CAR 
retention protein 
275 which, under physiological conditions, retains CAR within the 
cytoplasm. Lack of this co-chaperone or an increase in HepG2 CAR DNA by transient 
transfection without concomitant increase in the co-chaperone would result in nuclear 
accumulation of CAR and so CYP3A induction could occur in the absence of inducing 
agent. 
 
In the co-transfection experiments, the amount of each DNA used was half the amount 
added for the single transfectants, which was reflected in the gene expression levels for 
both CAR and RXRα following co-transfection. Increasing the total amount of DNA 
added to increase expression to the level measured in single transfectants could result in 
improved CYP3A induction; however this would be limited by the maximum amount of 
DNA that can be taken up by the cells. 
 
Other Nuclear Receptors to Regulate CYP Expression 
It was demonstrated here that the greatest increase in CYP3A activity following HepG2 
CAR and CAR/RXRα transfection was measured following rifampicin induction. 
Rifampicin mediated CYP3A induction also occurs through binding of PXR to RXRα. 
Crosstalk between CAR and PXR has been well illustrated in vivo through the use of 
PXR/CAR null mice and in vitro evidence confirms that CAR/RXRα heterodimers are 
able  to  bind  PXR/RXRα  response  elements  in  the  CYP3A  gene 
37.  Although  PXR 
expression has been shown to be higher than CAR expression in HepG2 cells 
221, it has 
been extensively demonstrated in a reporter gene system 
150, 276 that transfection of PXR 
into  HepG2  cells  improves  CYP3A  induction.  Moreover  others  have  shown  that 
transfection  of  PXR  has  a  stronger  effect  on  CYP3A  function  than  CAR 
277.  Co-
transfecting  PXR  with  RXRα  would  equally  improve  CYP3A  activity.  However,  in 
previous  studies,  treatment  of  human  hepatocytes  with  PXR  siRNA  was  without 
significant effect on CAR or RXRα and additionally, the expression of CYP1A2 and 
CYP2D6 mRNA were not affected by the introduction of hPXR-siRNA, which implies 
that PXR plays no direct functional role in the expression of either of these genes 
221. 
 
Manipulation of glucocorticoid receptor (GR) expression in HepG2 cells presents an 
opportunity to increase expression of PXR, CAR and RXRα 
96. Transfection of GR 
improves  CYP3A  function  in  HepG2  cells  and  this  is  further  improved  by  co- 
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transfection of PXR 
278. Other transcription factors could also act synergistically with 
CAR and PXR including HNF4α 
279. 
 
Effects of Dexamethasone 
Lesser effects of dexamethasone in this study may be partly due to the corticosteroid in 
our culture media raising baseline CYP3A levels making effects of induction difficult to 
monitor, although it may also be due to an inducer dependent variation in CAR 
mediated transactivation of CYP which can occur 
267. Dexamethasone mediated CYP3A 
induction was improved only by co-transfection of CAR and RXRα which suggests that 
increased expression of both these genes is necessary for CYP3A function to be 
improved in HepG2 cells by this inducer. Effects of dexamethasone on HepG2 CYP3A 
function will be explored further in section 6.2. 
 
Transient Nuclear Receptor Transfection Altered AhR Agonist Effects in HepG2 Cells  
The effects of CAR and RXRα expression on CYP1A2 function were examined. AhR 
agonists had differential effects on CYP1A2 activity: Indirubin mediated CYP1A2 
function was increased in CAR transfected HepG2 cells and suppressed in RXRα 
transfected cells. DBA mediated CYP1A2 induction was suppressed by CAR 
transfection and to a lesser extent by RXRα transfection.   
 
With  respect  to  CYP3A  function,  indirubin  also  resulted  in  an  increase  in  CYP3A 
activity  which  was  improved  following  transfection  of  CAR/RXRα  but  not  in  the 
presence of RXRα alone. DBA resulted in slight (although not statistically significant) 
induction of CYP3A in all instances. 
 
When these effects are considered together, there are a number of possible implications: 
 
i)  AhR ligands such as indirubin (and DBA) can activate CAR resulting 
CYP3A induction (agonist cross-talk). 
 
ii)  AhR ligands bind to CAR and activate CYP1A2 induction (nuclear 
receptor response element cross-talk).  
 
Both of these possibilities imply cross-talk in mediators of CYP3A and CYP1A2 
induction. The slight increase in CYP1A2 function following CAR transfection, both  
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with and without RXRα, implies that CAR/RXRα is capable of binding CYP1A2 
response elements, or controls the regulation of CYP1A by modulating AhR expression. 
Ueda 
280 found a regulatory element in the CYP1A1 gene that simultaneously controlled 
the induction of both CYP1A1 and CYP1A2 supporting the finding that gene regulation 
may be controlled by neighbouring genes. In primary human hepatocytes, the PXR 
agonist rifampicin was shown to increase CYP1A1/1A2 expression 
74. Also it has been 
demonstrated that treating HepG2 cells with CYP1A2 inducers indigo, indirubin and 3-
MC significantly increased CYP3A4 gene expression, whilst the CAR/PXR activator 
phenobarbital led to an increase in CYP1A1/1A2 expression 
136. Other authors have 
implied a role for CAR in CYP1A2 induction 
271. Pyrene treatment led to CYP1A2 
induction in transgenic AhR
-/
- mice with a concomitant increase in CAR expression 
and, in the instance of pyrene treatment, CYP1A2 induction was attributed to CAR 
activation. 
 
From this, it is tempting to conclude that NR cross-talk is responsible for improved 
CYP induction following NR transfection; it is plausible, even, that improved CYP3A 
induction following DBA treatment and CAR transfection is a consequence of increased 
CAR binding and decreased AhR binding/CYP1A induction by this inducer. Neither of 
these possibilities, however, fully rationalise the effects of indirubin mediated induction 
following transfection which leads to a third possibility: 
 
iii)  the actions of indirubin as a kinase inhibitor result in improved 
HepG2 differentiation which in turn results in improved CYP 
function. 
 
It was shown in Chapter 4 that improved HepG2 differentiation, which arises as a 
consequence of 3D culture, results in improved CYP function. Indirubin treatment has 
also been implied in stem cell biology for this purpose 
281 and has been shown, in other 
cell types, to improve differentiation.  
 
Indirubin incubation was shown in HL-60 promyelocytic leukemia cells to act 
synergistically with VD3 or all-trans retinoic acid (ATRA) to improve differentiation 
following a 72 hour incubation 
282. Neuronal differentiation was also improved after 
incubation with indirubin and this occurred by inhibition of glycogen synthase kinase 3 
β (GSK 3β) and subsequent β-catenin stabilisation 
283.   
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GSK 3β and β-catenin are both involved in the Wnt signalling pathway which controls 
the expression of cells with predefined fates. GSK 3β regulates levels of the free form 
of β-catenin. Activation of the Wnt pathway inhibits GSK 3β resulting in cellular 
accumulation and nuclear translocation of β-catenin whereby it plays a role in gene 
transcription (Figure 6-12). 
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Figure 6-12. β -Catenin is an intracellular signalling molecule whose levels are regulated by 
proteolytic degradation mediated by GSK-3β, APC-axin complex (left). 
In the canonical Wnt pathway (right), Wnt binding of Frizzled receptor results in phosphorylation 
of cytoplasmic mediator Dishevelled and inhibition of GSK-3. This results in accumulation of β-
Catenin which enters the nucleus and interacts with TCF/LEF transcription factors causing gene 
activation and/or cell proliferation (APC: adenomatous polyposis coli, GSK-3β glycogen synthase 
kinase 3β, LEF: lymphoid enhancer factor, TCF: T cell factor). 
 
Possible consequences of indirubin exposure or RXRα transfection on β-catenin 
signalling are shown in Figure 6-13. Indirubin is a GSK-3β inhibitor and as described 
for the Wnt pathway, indirubin mediated GSK-3β inhibition prevents degradation of β-
catenin which is then able to translocate to the cell nucleus and control gene regulation. 
Crosstalk between RXR and the Wnt/β-catenin pathway has been reported by several 
authors 
284, 285. RXRα activation has been implied in β-catenin degradation. This effect 
is not associated with RXRα mediated gene activation, is independent of GSk-3β 
activity and is thus is not inhibited by GSK-3 inhibitors such as indirubin 
286.    
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Figure 6-13. Proposed effects of (left) indirubin and (right) RXRα on β-catenin signalling. 
Indirubin inhibits GSK-3β resulting in cellular accumulation of β-catenin and positive effects on 
differentiation. RXR-α activation leads to GSK-3β independent β-catenin degradation preventing 
subsequent nuclear translocation and gene regulation. 
 
Potentially indirubin has an effect on CYP activity which is mediated by increased 
differentiation. The effect of indirubin mediated GSK-3β inhibition on β-catenin 
degradation is then lost following RXRα transfection. 
 
In HepG2 cells, nuclear accumulation of mutated β-catenin has been detected which is 
insensitive to GSK-3β degradation and potentially involved in tumorigenesis 
287. 
Indirubin exposure results in an accumulation of wild type β-catenin which is involved 
in cellular differentiation. 
 
Hepatic carcinomas and associated tumour cell lines such as HepG2 have a high nuclear 
accumulation of phosphorylated RXRα which is insensitive to degradation but lacking 
in transactivating activity 
288. Accumulation of phosphorylated RXRα has been 
attributed to MAP-kinase action. Indirubin is also a MAP kinase inhibitor and so could 
prevent RXRα phosphorylation. 
 
The Wnt signalling pathway, although well characterised is complex and the 
conclusions described above are based on a number of assumptions which would have 
to be confirmed experimentally, however the proposed consequences and implications 
of what is described are summarised below. 
  
  227 
a.) Indirubin improves HepG2 differentiation leading to improved CYP activity. 
 
b.) When RXRα is transfected alone it could activate β-catenin degradation pathway, in 
this instance less is available to act as a co-receptor for CYP induction. 
 
c.) When CAR alone or CAR and RXRα are transfected, CAR binds RXRα resulting in 
increased CYP transcription; RXRα is then not able to degrade β-catenin. 
 
CYP2B6 Function in HepG2 Cells Following CAR Transfection 
Heterodimer formation of CAR with RXRα can result in CYP3A gene induction 
through activation of XREM and the proximal ER-6 response element, or activation of 
CYP2B through activation of the phenobarbital-responsive enhancer module (PBREM) 
289. In the experiments performed above (section 6.1.2.2.6), measurement of HepG2 
CYP2B6 function using BOMFC metabolism was below the level of quantification 
even following induction. CITCO is a potent inducer of CYP2B6 which induces HepG2 
CYP2B6 mRNA at nanomolar concentrations 
74; a further experiment would be to 
measure CITCO induction in HepG2 cells. Alternative substrates for CYP2B6 such as 
buproprion metabolism could also be considered.  
 
CYP3A Function in Transfected HepG2 Cells is Comparable to PHH 
When CYP3A function in transfected HepG2 cells was compared with freshly isolated 
PHH it was found that CYP3A activity in rifampicin induced HepG2 cells transfected 
with CAR or CAR/RXRα matched CYP3A activity in those PHH with lower levels of 
activity. Therefore, in a transient system, it was demonstrated that increasing HepG2 
cell expression of RXRα or CAR results in an increase in CYP3A function, whereby 
inducible CYP function is significantly improved relative to untreated cells to levels 
similar to those measured in hepatocytes from donors with lower CYP metabolising 
capacity. In a stable expression system this method could be used to provide CYP3A 
function within a BAL. In order to confirm this, CYP3A function was explored in cells 
stably transfected with CAR and maintained in 3D culture. 
 
6.1.3  Creation of a Stable Cell Line for Encapsulation 
HepG2 cells were transfected with pTracer CAR construct using Lipofectamine
™ 2000 
reagent as described above. To create stable transfectants the cells were placed under  
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selective pressure using blasticidin S-HCL. Cells under selective pressure were 
expanded in culture and then encapsulated and maintained in 3D culture to measure 
CYP function in cells cultured in this format. 
6.1.3.1  Methods 
6.1.3.1.1  Establishing a Blasticidin Sensitivity in HepG2 Cells 
A 10mg/ml solution of blasticidin S-HCL (Invitrogen 461120) was prepared in sterile 
water. This solution was filter sterilised and dispensed into single-use aliquots which 
were stored at -20°C until required. Medium containing blasticidin (Bsd) was stored at 
+4°C for no longer than one week. To determine Bsd sensitivity in HepG2 cells, 
2.5x10
5 cells were added to 6 well plates in αMEM complete and allowed to attach 
overnight. Cells were incubated with 0, 2, 4, 6, 8 or 10 µg/ml Bsd for up to 2 weeks. 
Selection medium was replenished every 48 hours to remove dead cells that had 
accumulated in the medium and cells were passaged as required. From this experiment 
it was determined that 4-6µg/ml was a sufficient concentration of Bsd to prevent cell 
growth after 2 weeks of culture. 
6.1.3.1.2  Stable Transfection of HepG2 Cells 
HepG2 cells were transfected in 12 well plates with 1.6µg of CAR using a reverse 
transfection method, as described in section 6.1.2.1. The following day, transfection 
medium was replaced with αMEM complete containing 10% FCS. Cells were then 
detached from the plate using a cell scraper, syringed 3x with a 21g needle and 
transferred to a new well of a 12-well plate. The following day, culture medium was 
replaced with antibiotic selection medium comprising αMEM complete (10% FCS) with 
6µg/ml Bsd. Medium changes were performed every 48 hours.  
 
After 2 weeks those cells that had not been killed by the antibiotic had begun to 
proliferate. These cells were passaged by trypsinisation into a 6 well plate and were 
cultured in this format for one week after which time they were transferred into a T25 
flask. Cells were passaged once and then, in order to remove those cells with lower gene 
expression, Bsd concentration was increased to 10µg/ml. Once cell proliferation 
recovered, cells were maintained at this level of selection and were expanded in culture 
until a confluent T175 was attained (a portion of cells was frozen at each passage using 
the protocol described in Chapter 2); this was achieved in 6 passages for CAR and at 
this point cells were used for encapsulation. On the same day as encapsulation, cells  
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were plated for monolayer assays to confirm gene expression and CYP3A function in 
CAR transfectants independent of 3D culture.  
6.1.3.1.3  CYP3A Induction in Stable Transfectants: Monolayer Culture 
CAR transfectant or control HepG2 cells (untransfected) were added to 96 well plates 
(2.5x10
6 cells/well) in 100µM αMEM complete 10% FCS (+/- 10µg/ml Bsd) and 
allowed to attach overnight. Cells were then treated for 48 hours with 50µM rifampicin 
at which point CYP3A activity was measured by Luciferin BE assay. Total protein 
content was assessed by the BCA assay. For the CAR transfectant, Luciferin BE activity 
was also measured in the presence of 1-100µM clarithromycin or vehicle (0.1% MeOH) 
control.  
6.1.3.1.4  Gene Expression in Stable Transfectants: Monolayer Culture 
RNA samples were isolated from control (untransfected) HepG2 cells or CAR 
transfectants maintained in monolayer culture and treated for 48 hours with 50µM 
rifampicin. Gene expression was performed by qRT-PCR as described in Chapter 2. 
6.1.3.1.5  CYP3A Induction in Encapsulated Transfectants 
HepG2 CAR transfectant cells were encapsulated using the Inotech method described in 
Chapter 2. Beads were resuspended at a ratio of 0.25ml beads: 8ml HG medium and 
maintained in static culture, in the presence of 10µg/ml Bsd, for 8 days. Medium was 
replenished every other day and viability and cell growth assessed by phase contrast 
microscopy and FDA/PI staining.  
 
At day 6 post encapsulation, 0.1% DMSO vehicle or 50 M rifampicin were added to 
the growth medium. Following a 48 hour induction period, CYP function was measured 
by Luciferase assay or testosterone metabolism. Total protein content was assessed by 
the BCA assay.  
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6.1.3.2  Results 
6.1.3.2.1  HepG2 CAR Expression Following Blasticidin Selection 
Selection of Bsd resistant (CAR expressing) HepG2 cells was detected by monitoring 
GFP expression using fluorescence microscopy (Figure 6-14). 
 
 
Figure 6-14. (left) Phase contrast and (right) GFP expression in HepG2 cells which have been 
transfected with pTracer construct and undergone blasticidin selection. The top images show 
HepG2 transfectants after 3 weeks selection in 6µg/ml Bsd. Selection was subsequently increased to 
eliminate cells with lower gene expression. Bottom images were recorded following 3 passages in 
10µg/ml Bsd. Images are x10 magnification.  
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6.1.3.2.2  Gene Expression in Monolayer CAR Transfectant 
Gene expression was compared in mRNA isolated from CAR transfectant (following 
Bsd selection) and control (untransfected) HepG2 cells, following 48 hour treatment 
with 50µM rifampicin in monolayer culture. Increased expression of CAR was 
confirmed in the transfected cells that had undergone Bsd selection. There was also 
increased CYP expression in the CAR transfectant. The greatest increase observed was 
in CYP3A4 mRNA (1240 fold), followed by CYP3A7 (150 fold); there was less of a 
difference in CYP1A2 expression (7 fold) between the two cell types (Figure 6-15). 
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Figure 6-15. Gene expression was compared in control (untransfected) HepG2 cells and Bsd 
selected CAR transfectant treated in monolayer culture for 48 hours with 50µM rifampicin. For 
each gene, expression was normalised to ribosomal 18s expression and change in expression then 
calculated relative to untransfected HepG2 cells. This was repeated twice and data is presented as 
n=2 +/- range. 
 
6.1.3.2.3  CYP3A (Luciferin BE) Function in Monolayer CAR Transfectant 
CYP3A (Luciferin BE) activity was compared in CAR transfectant (following Bsd 
selection) and control (untransfected) HepG2 cells, following 48 hour treatment with 
50µM rifampicin in monolayer culture. There was slight (but not significant) increase in 
Luciferin BE activity in the CAR transfectant (1.2 fold relative to untransfected cells) 
(Figure 6-16, top). Luciferin BE activity was significantly diminished (F (4, 0.0004)  
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=11.92, P< 0.01), in a dose-dependent manner, when measured in the CAR transfectant 
in presence of the CYP3A inhibitor clarithromycin (Figure 6-16, bottom).  
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Figure 6-16. CYP3A (Luciferin BE) activity was measured in CAR transfectants that had 
undergone blasticidin selection prior to encapsulation. CYP3A activity was higher in CAR 
transfected HepG2 cells than in untransfected control following 48 hour treatment with 50µM 
rifampicin (top) and was inhibited when measured in the presence of clarithromycin in HepG2 
CAR transfectant (bottom). Data is presented as mean (n=3)+/-sd and is expressed as (top) pmoles 
d-luc/min/mg of protein or (bottom) % inhibition of CYP3A activity relative to cells without 
inhibitor.  
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6.1.3.2.4  3D Culture of Transfectants Maintained in Static Culture 
Figure 6-17 shows the growth and viability of encapsulated transfectants maintained in 
static culture. FDA (live cell) staining demonstrates proliferation and spheroid 
formation throughout 8 days of culture. PI (dead cell) staining indicates that at day 8, 
when functional assays were performed, viability was high. 
 
 
Figure 6-17. Cell viability staining (x10 magnification) of encapsulated HepG2 cell CAR 
transfectant following 8 days of static culture. 
 
6.1.3.2.5  CYP3A Function (Luciferase Activity) in Encapsulated CAR Transfectant 
CYP3A (Luciferin BE) activity was compared in CAR transfectant following Bsd 
selection or control (untransfected) HepG2 cells that had been cultured in 3D format for 
8 days and treated for 48 hours (from day 6) with 50µM rifampicin or 0.1% DMSO 
vehicle. Improved induction was observed in the CAR transfectant. 
 
Under basal conditions Luciferin BE metabolism was slightly higher in the CAR 
transfectant (1.2 fold above control cells), and was further increased (2.6 fold) following 
rifampicin mediated induction, although neither of these changes were statistically 
significant (Figure 6-18, top). 
 
CYP3A activity was also measured using the alternative (and more selective) CYP3A 
substrate Luciferin PFBE and in this assay there was a greater effect of CAR expression 
on CYP3A induction (Figure 6-18, bottom). Data was analysed by two-way ANOVA. 
There was a significant effect of CAR expression on Luciferin PFBE activity (F (1, 
0.008)=94.99, P < 0.001) and a significant effect of rifampicin induction in these 
cultures (F (1, 0.005)=54.87, P < 0.001). There was also a significant interaction 
Phase x10  FDA  PI  
  234 
between the two factors (F (1, 0.004)=52.88, P <0.001); rifampicin mediated induction 
was increased in the CAR transfectant. Under basal conditions, Luciferin PFBE was 
higher in the CAR transfectant (2.8 fold above control cells) and was further increased 
following rifampicin exposure (21 fold above control cells). In both assays, extent of 
rifampicin mediated CYP3A induction was therefore greater in the CAR transfectant. 
 
Figure 6-18. CYP3A induction was compared in control (untransfected) HepG2 cells and Bsd 
selected CAR transfectant maintained for 8 days 3D format and treated for  48 hours (on day 6) 
with 50µM rifampicin or 0.1% DMSO Vehicle. CYP3A activity was measured using (top) Luciferin 
BE or (bottom) Luciferin PFBE substrates. For each assay fold change in CYP activity of the CAR 
transfectant was calculated and is expressed here as mean (n=4)+/- sd. Data analysis was by two-
way ANOVA and Bonferroni post test. ***P < 0.001 when compared to untransfected HepG2 cells. 
 
6.1.3.2.6   Testosterone Metabolism in Encapsulated CAR Transfectant 
Substrate metabolism was analysed in Bsd selected CAR transfectants that had been 
treated for 48 hours with 50µM rifampicin and incubated for up to 8 hours with 200µM 
testosterone (TST). Included in the same analysis run was supernatant from control  
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(untransfected) HepG2 cells treated in the same manner, and freshly isolated PHH 
treated for 1 hour with 200µM TST. 
 
Both CAR transfectant and control (untransfected) HepG2 cells were able to metabolise 
TST; the retention characteristics of metabolites produced by CAR transfectants and 
freshly isolated PHH were broadly similar and differed from untransfected HepG2 cells 
(Figure 6-19). 
 
 
Figure 6-19. HPLC was used to measure metabolism of testosterone in (a) CAR transfectants 
treated for 48 hours with 50µM rifampicin in 3D culture and then incubated with 200µM TST for 
1, 3 or 8 hours, (b) control (untransfected) HepG2 cells treated in with 50µM rifampicin in 3D 
culture and then incubated with 200µM TST for 8 hours or (c) freshly isolated PHH incubated with 
TST for 1 hour. TST spike is indicated by →. TST metabolites are indicated by →/→. One 
representative trace is shown of 4 independent measurements. 
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6.1.3.3  Discussion 
In 3D culture, HepG2 cells need to be proliferated for extended periods (around 8 days) 
to maximise the benefits of spheroid formation. This presents a limitation when 
attempting to measure effects mediated by gene expression in a transient system; 
furthermore large numbers of cells are required for encapsulation which makes a 
transient transfection approach impractical. HepG2 cells stably transfected with CAR 
were thus proliferated under Bsd selection to allow encapsulation. 
 
Prior to encapsulation, increased CAR expression was confirmed in cells under Bsd 
selection in monolayer culture. CAR transfectants also has increased CYP3A expression 
following rifampicin exposure and CYP3A function was improved in these cells: this 
function was diminished by the CYP3A inhibitor clarithromycin.  
 
CYP1A2 expression was also higher in the CAR transfectant following rifampicin 
induction. Others have also demonstrated a CYP1A2 induction following rifampicin 
induction both in PHH and HC-04 cells 
74, 160 which adds further credence to the 
hypothesis that multiple isoforms of CYP can be induced by the presence of a single 
transfectant.  
 
In 3D culture, basal activity was improved in the CAR transfected cells relative to 
untransfected cells. Moreover the increase in CYP3A function detected in the CAR 
transfectant was greater following rifampicin treatment. This implies that upregulation 
in CYP3A induction following 3D culture, which (as demonstrated in Chapter 4) is 
limited in HepG2 cells, can be achieved when CAR expression is increased. 
 
CYP3A induction of CAR transfected and control (untransfected) HepG2 cells in 3D 
culture was compared using Luciferin BE and Luciferin PFBE assays and there were 
differences between the two substrates. As described in Chapter 1, Luciferin BE is also 
metabolised by CYP4F12 and the CYP3A affinities of each substrate are different: 
Luciferin BE is metabolised by CYP3A7 > CYP3A4 > CYP3A5, Luciferin PFBE is 
metabolised by CYP3A5>CYP3A7>CYP3A4; the difference in affinities between 
individual isoforms is less for Luciferin PFBE. In Chapter 4, it was demonstrated that 
CYP3A induction achieved with either substrate in untransfected HepG2 cells was 
equivalent in monolayer culture. Following 3D culture of the CAR transfectant, greater 
upregulation of function was measured using the Luciferin PFBE substrate.   
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Gene expression data derived from monolayer cells, together with the TST metabolism 
profile of the encapsulated CAR transfectant, implies that improving CAR expression 
results in upregulation of CYP3A4 function; CYP3A4 expression was increased to a 
greater extent than CYP3A7 expression in the CAR transfectant following rifampicin 
treatment. Others have demonstrated that CAR binds the CYP3A4 promoter with 
greater affinity than the CYP3A7 promoter 
46, 84. Potentially this was reflected in the 
results obtained here and demonstrated at a functional level in 3D culture following 
rifampicin induction. 
 
Creation of a single transfectant potentially could create an imbalance between HepG2 
expression of CAR and of its obligate co-receptor RXRα, hence limiting CYP induction 
67, 94. Here this was demonstrated in a transient system (section 6.1.2); co-transfection of 
CAR and RXRα increased the extent of CYP3A function that could be induced in 
HepG2 cells. Using the approach described in this Chapter, stable expression of more 
than one gene would have required the use of more than one selection antibiotic. This 
would have placed additional stress on the transfected cells, with a resultant impact on 
proliferation and viability and so would need to be addressed in order for a dual gene 
transfer method to be applicable within a BAL. 
6.2  Cytochrome P450 Function in HepG2 Cells from an Alternative Source 
(BALG2 Cells) 
In was hypothesised that previous adaptation to the supplemented αMEM used within 
the Liver Group is responsible for some regulation of the CYP function described 
throughout this thesis. Further to this, others have noted differences in HepG2 cell 
function depending upon their original source 
51. In order to confirm this, a new HepG2 
stock was obtained from the HPACC. For clarity these cells will be referred to as 
BALG2. These cells were either maintained in a simple culture medium (DMEM) or 
adapted to αMEM complete. CYP induction was then compared in these cells and in LG 
HepG2 cells. 
6.2.1  Methods 
6.2.1.1  Adaptation to Culture Media 
BALG2 cells were maintained in DMEM (as per delivery medium) as described in 
Chapter 2 for intestinal cell culture. After cells had been passaged at least once post 
thawing and reached 50% confluency, growth medium was switched to complete  
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culture medium as described for HepG2 culture (Chapter 2). Cells were maintained in 
this medium for at least 3 passages prior to any further studies. 
 
HepG2 cells were maintained in αMEM as described in Chapter 2. After cells had been 
passaged at least once post thawing and reached 50% confluency, growth medium was 
switched to DMEM as described for intestinal cell culture (Chapter 2). Cells were 
maintained in this medium for at least 3 passages prior to any further studies. 
 
6.2.1.2  Cytochrome P450 Induction in BALG2 Cells 
HepG2 cells were induced as in Chapter 4 and CYP function measured by testosterone 
or Luciferase assay. Luciferin ME assay was performed in the presence of 10µM 
sulfaphenazole. 
 
6.2.1.3  Gene Expression in BALG2 Cells 
HepG2 or BALG2 cells were plated in 12 well plates (2.5x10
5 cells/well) in 1ml of 
either DMEM or αMEM complete and allowed to attach overnight. The following day, 
50µM dexamethasone was added. Cells were incubated with inducer for 48 hours. RNA 
was then isolated and gene expression determined by qRT-PCR using the methods 
described in Chapter 2. 
 
6.2.2  Results 
Cytochrome P450 activity was compared in HepG2 or BALG2 cells adapted to either 
DMEM or αMEM and then treated for 48 hours in monolayer culture with inducers. 
Data was analysed by two-way ANOVA and Bonferroni post test.  
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6.2.2.1  A Comparison of CYP1A2 (Luciferin ME) Activity in HepG2 and BALG2 Cells 
There was a significant effect of both cell type (F (3, 1.4x10
-7) =3.96, P< 0.01) and 
inducer (F (6, 1.4x10
-6) =19.03, P< 0.0001) on CYP1A2 activity, however there was no 
significant interaction between the two effects. 
 
The following results are shown in Figure 6-20. 
 
Under basal conditions, CYP1A2 activity was slightly higher in BALG2 αMEM cells 
(1.3 fold). Basal activities of HepG2 and BALG2 DMEM cultures were comparable.  
 
The effects of DBA (10µM) and rifampicin (50µM) on CYP1A2 activity were 
unaffected by cell type or media composition.  
Indirubin had a greater effect on substrate metabolism in cells cultured in DMEM; 
CYP1A2 activity was higher than HepG2 αMEM for both HepG2 DMEM (1.5 fold, 
P<0.05) and BALG2 DMEM (1.5 fold).  
 
There were no additional increases observed in CYP1A2 function following 
dexamethasone (50µm) and phenobarbital (500µM) exposure in HepG2 DMEM and 
BALG2αMEM. However following treatment with both these inducers, CYP1A2 
activity was improved in BALG2 DMEM to levels matching BALG2 αMEM. 
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Figure 6-20. CYP1A2 (Luciferin ME) activity was measured in HepG2 cells or BALG2 cells 
cultured in αMEM or DMEM and treated for 48 hours with (top) CYP1A inducers and (bottom) 
CYP3A inducers.  Data is expressed as fold change in activity compared to corresponding induction 
in HepG2 cells cultured in αMEM. Data analysis was by two-way ANOVA and Bonferroni post test 
(n=6 +/-sd). * P<0.05 when compared to HepG2 cells in αMEM.  
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6.2.2.2  A Comparison of CYP3A (Luciferin BE) Activity in HepG2 and BALG2 Cells 
There was a significant effect of both cell type (F (3, 0.003)=48.61, P< 0.0001) and 
inducer (F (6, 0.001) =10.34, P< 0.0001) on CYP3A function, however no significant 
interaction between the two variables. 
 
The following results are shown in Figure 6-21. 
 
 Under basal conditions, CYP3A activity was higher in BAL G2 cells cultured in both 
αMEM (1.6 fold higher than HepG2 αMEM) and DMEM (1.4 fold). 
 
The effects of rifampicin (50µM) and phenobarbital (500µM) on CYP3A activity were 
unaffected by cell type or media composition. Activity was significantly higher than 
observed in HepG2 cells in BALG2 αMEM and BALG2 DMEM treated with 
rifampicin (1.5 fold P<0.001 and 1.5 fold P<0.001) and phenobarbital (1.5 fold P<0.01 
and 1.6 fold  P<0.001), however the increase in activity observed following treatment 
with inducers was comparable between the cell types. 
 
Dexamethasone mediated CYP3A induction was affected by both cell type and media 
composition. Substrate metabolism following dexamethasone exposure (50µM) was 
higher in BALG2 αMEM (2.0 fold above HepG2αMEM, P<0.001) and further 
improved in BALG2 DMEM (2.7 fold above HepG2 αMEM, 2.5 fold above HepG2 
DMEM, P<0.001). 
 
The effects of DBA (10µM) and indirubin (20µM) on CYP3A activity were unaffected 
by cell type or media composition.  
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Figure 6-21. CYP3A (Luciferin BE) activity was measured in HepG2 cells or BALG2 cells cultured 
in αMEM or DMEM and treated for 48 hours with (top) CYP1A inducers and (bottom) CYP3A 
inducers.  Data is expressed as fold change in activity compared to corresponding induction in 
HepG2 cells cultured in αMEM. Data analysis was by two-way ANOVA and Bonferroni post test 
(n=6 +/-sd). **  P<0.01, P<0.001 when compared to HepG2 cells in αMEM. +++ P<0.001 when 
compared to HepG2 cells in DMEM. 
 
6.2.2.3  A Comparison of CYP mRNA Expression in BALG2 and HepG2 Cells 
CYP expression was measured in HepG2 or BAL G2 adapted to either αMEM or 
DMEM and treated for 48 hours with 50µM dexamethasone and was dependent on both 
cell type and media composition (Figure 6-22). 
 
CYP3A4 expression was higher in BALG2 cells. For both HepG2 and BALG2, 
CYP3A4 expression was comparable in cells cultured in either αMEM or DMEM. 
 
CYP3A7 expression was higher in BALG2 cells. For both HepG2 and BALG2, 
CYP3A7 expression was increased in cells cultured in αMEM.  
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CYP1A2 expression was higher in BALG2 cells although the difference was less 
apparent than for CYP3A isoforms. For BALG2, CYP1A2 expression was higher in 
cells cultured in αMEM. 
 
 
Figure 6-22. CYP expression in HepG2 cultured in DMEM and BALG2 cultured in αMEM or 
DMEM was compared to expression in HepG2 cells cultured in αMEM (normal LG conditions). In 
each instance CYP expression was normalised to ribosomal 18s expression and change in 
expression then calculated relative to normal LG conditions. Data is presented as n=2 +/- range.  
 
6.2.2.4  A Comparison of Nuclear Receptor mRNA Expression in BALG2 and HepG2 
Cells 
NR Expression was compared in HepG2 and BALG2 cells adapted to either αMEM or 
DMEM and then treated for 48 hours with 50µM dexamethasone, and was dependent on 
both cell type and media composition (Figure 6-23). 
 
CAR expression was lower in BALG2 cells. For both HepG2 and BALG2, CAR 
expression was improved in cells cultured in αMEM. 
 
PXR expression was comparable between the two cell types. For HepG2 cells, 
expression of PXR was slightly higher in cells adapted to DMEM. 
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RXRα expression was doubled in BALG2 cells cultured in αMEM compared to HepG2 
cells under the same conditions. For both cell lines RXRα expression was higher in cells 
cultured in DMEM. 
 
GR expression on HepG2 cells was comparable between media types. GR expression 
was lower in BALG2 cells cultured in αMEM but was increased to levels matching 
HepG2 cells in BALG2 cells cultured in DMEM.   
 
 
Figure 6-23. NR expression in HepG2 cultured in DMEM and BALG2 cultured in αMEM or 
DMEM was compared to expression in HepG2 cells cultured in αMEM (normal LG conditions). In 
each instance, cells were treated for 48 hours with 50µM dexamethasone. NR expression was 
normalised to ribosomal 18s expression and change in expression then calculated relative to normal 
LG conditions. Data is presented as n=2 +/- range.   
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6.2.2.5  Testosterone Metabolism in BALG2 Cells 
Monolayer HepG2 or BALG2 cells were cultured in αMEM complete in the presence of 
50µM rifampicin for 48 hours. Cells were then exposed to 200µM testosterone for 8 
hours. Included in the same analysis run was supernatant from freshly isolated PHH 
incubated for 1 hour with 200µM testosterone. Testosterone metabolism profiles were 
comparable for HepG2 and BAL G2 cells however neither cells produced 6β-OHTST 
as a product of testosterone metabolism (Figure 6-24). 
 
 
Figure 6-24. HPLC was used to measure metabolism of testosterone in (middle) HepG2 cells and 
(bottom) BALG2 cells treated with 50µM rifampicin in monolayer culture and then incubated with 
200µM TST for 8 hours, or (top) freshly isolated PHH incubated with 200µM TST for 1 hour. TST 
spike is indicated by →. TST metabolites are indicated by →/→. One representative trace is shown 
of 4 independent measurements. 
 
6.2.2.6  A Comparison of PHH and BALG2 in Monolayer Culture 
CYP3A activity in HepG2 or BALG2 cells treated with 50µM rifampicin or 
dexamethasone was compared with activity measured in freshly isolated PHH 
(presented in Chapter 3). CYP3A activity in HepG2 cells was lower than each of the  
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PHH preparations. Rifampicin or dexamethasone treatment of BALG2 cells increased 
CYP3A activity to approach lower levels of activity measured in PHH (Table 6-3).  
 
Table 6-3. CYP3A (Luciferin-BE) activity was higher in freshly isolated primary human 
hepatocytes than HepG2 cells but not BALG2 cells. Data was compared from PHH isolated from 9 
separate donors assayed in quadruplicate and monolayer HepG2 (cultured in αMEM) or BALG2 
(cultured in αMEM or DMEM) cells treated for 48 hours with 50µM dexamethasone or rifampicin. 
Data is expressed as pmoles d-luc/min/mg protein (mean+/-SD for HepG2 cells, mean, median and 
range for PHH). 
 
Cell Type
PHH            
  Average (9 donors)
PHH            
Median (9 donors)
PHH                
  Range (9 donors)
+ DEX + RIF
 HepG2 
αMEM
0.014
+/-0.001
0.019
+/-0.002
BALG2 
αMEM
0.029                              
+/-0.004
0.029 
0.004
BALG2
DMEM
0.039                             
+/-0.014
0.028
+/- 0.008
CYP3A Activity 
(pmoles d-luc/min/mg protein)
0.071
0.022 - 0.167
0.051
 
 
6.2.3  Discussion 
Hewitt and Hewitt 
51 emphasise the need for independent confirmation of CYP 
expression in HepG2 cells and propose that the belief these cells are lacking in drug 
metabolising capacity is not entirely accurate. An evaluation of two sources of HepG2 
cells carried out by these authors demonstrated that both Phase I and II enzyme 
metabolising capacities depend on source and culture conditions. Doostdar et al. 
137 
suggest that reported absence of CYP activity in HepG2 cells is (partly) due to the use 
of inappropriate culture media and other authors have established that media 
components and supplements including serum and growth factors and dexamethasone, 
in addition to oxygenation of cultures can all affect HepG2 cell CYP function 
5, 55, 228.  
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Overall CYP1A2 activity was better in BALG2 cells cultured in αMEM. CYP3A 
function and mRNA expression in BAL G2 cells was substantially higher than in 
HepG2 cells in both media types; both cell types were able to metabolise testosterone 
but neither produced 6β-OHTST. The higher CYP capacity of BALG2 cells could be 
due to a strain difference between the HepG2 cells as well as a consequence of the 
multiple passages and media types that the HepG2 cells had previously been subject to 
51, 55, 139. 
 
Glucocorticoid agonists, such as dexamethasone, prednisolone, or hydrocortisone, 
increase human CAR expression and upregulate PXR and CYP3A4 expression in 
HepG2 cells 
55, and induce RXRα at nanomolar concentrations in primary human 
hepatocytes 
95. Here, the effect of induction particularly for dexamethasone was greater 
in cells cultured in DMEM.  
 
The effect of glucocorticoids in culture medium was also examined by measuring NR 
expression in cells cultured in DMEM or αMEM complete following treatment with 
dexamethasone. Both cell types cells cultured in DMEM had higher expression of 
RXRα and GR following dexamethasone treatment. Potentially components of the 
αMEM such as hydrocortisone or insulin maintain a more physiological environment 
for the cells which has a regulatory effect on NR expression 
203, 205. 
 
Activity in BALG2 cells, described above, was measured in monolayer culture and 
following induction fell within the range of levels measured for PHH. As described in 
Chapter 4, it was found that 3D culture resulted in a 3-fold increase in CYP3A activity 
in HepG2 cells. If the same could be achieved in BALG2 cells then their CYP3A 
activity would achieve the average level measured in PHH. Since the cells used in this 
study had been maintained in culture for a maximum of 8 passages, monitoring the 
impact of longer term adaption to αMEM on CYP function in BALG2 cells would be 
critical.   
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6.3  Conclusions 
In a transient system, increased CAR expression improves CYP3A function in HepG2 
cells. Using an appropriate stable expression system, genetic manipulation of nuclear 
receptor expression could improve CYP function within a HepG2 BAL .However, as 
described above, this approach is limited. In hepatocytes, multiple NR and transcription 
factors are involved in the induction of CYP enzymes. Whilst increasing NR by genetic 
manipulation improves CYP3A function it does not account for the full range of NR 
and transcription factors that can be achieved in a well differentiated cell line. 
 
With regard to HepG2 cells, CYP function varied markedly between cell sources and it 
was demonstrated here, in agreement with others, that HepG2 function is media 
dependant and strain dependent; BALG2 cells appear to provide better function and in 
some instances were able to match PHH levels of function. This emphasises the need to 
maintain a well characterised cell bank to provide a BAL cell source.  
  249 
CHAPTER 7  General Discussion 
A Summary of Findings and Future Work 
 
The overall aim of this thesis was to identify a cell source that could provide xenobiotic 
metabolism within the LG BAL. Specifically, CYP1A2 and CYP3A function were 
considered. 
7.1  Characterising and Improving CYP Function in the LG BAL 
The first aspect of this thesis was to define how much Cytochrome P450 function a 
BAL would need to provide by measuring activity in adult human liver. Secondly, the 
limitations of the existing LG BAL, comprising alginate-encapsulated HepG2 cells, 
with regard to Cytochrome P450 function were investigated. Lastly, methods to 
improve CYP3A function within the LG BAL were explored. 
7.1.1  How Much Function is Sufficient for a BAL? 
Primary human hepatocytes (PHH) are the closest in vitro model to human liver and 
although Cytochrome P450 function is affected by culture conditions, PHH produce the 
metabolic profile of a drug most similar to that found in vivo. Freshly isolated PHH 
were therefore used to define the level of CYP activity required of a BAL. For both 
CYP1A2 and CYP3A there was a large donor dependent variation in CYP activity, 
confirmed by measuring function in human liver microsomes (HLM) isolated from the 
same donor; this range of function was used to define the limits within which CYP 
function in other cell lines should fall. 
 
One caveat to these limits is that although PHH were isolated from normal liver tissue, 
these samples were not obtained from healthy individuals; all samples were obtained 
following tumour resection as a result of secondary colon cancer, and so are not 
representative of an entirely normal population 
290. Although cells in a BAL will 
supplement the patient’s residual function, due to the diverse aetiology of acute liver 
failure (ALF), and the wide range of factors that affect CYP function in vivo, a target 
population is complicated by definition. Others have shown that PHH isolated from 
tissue derived from therapeutic hepatectomy have a lower metabolic competency 
compared to samples obtained from elective biopsy (up to 50% decrease in the case of 
CYP3A4 function, although this data was derived 24 hours post isolation) 
291. This  
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suggests that aiming to achieve a level of function within the lower range measured here 
in PHH may be insufficient; a value at least twice the lowest level of function in PHH 
would be a more realistic aim.  
 
7.1.2  What Were the Limitations of HepG2 Cells? 
CYP activity could be induced in HepG2 cells, moreover, 3D culture resulted in 
significant upregulation of CYP1A and CYP3A function, which was further improved 
by microgravity culture. However, although HepG2 cells were able to metabolise 
testosterone, they did not perform the CYP3A4 mediated 6β-hydroxylation reaction. 
CYP3A7 capacity could provide substrate metabolism in most cases and although 
following RCCS culture CYP3A function fell within the limits measured in PHH, it was 
still limited in HepG2 cells.  
 
Within the LG BAL, FFP will be used in place of FCS to avoid the use of animal 
derived products. HepG2 cell proliferation is improved in the presence of FFP and 
synthetic capacity is retained (unpublished data). In Chapter 3, it was shown that ECOD 
activity decreased less in PHH maintained in 10% FFP than those maintained in 10% 
FCS, which also infers a role for FFP in maintaining differentiation. 
 
In Chapter 4, the impact of FFP exposure on CYP function in HepG2 cells was 
considered. It was demonstrated that exposure to FPP improved ECOD activity and 
CYP1A2 function, but there was a limiting effect of FFP exposure on CYP3A function, 
which reduced the restricted level of function that could be achieved in HepG2 cells. 
This effect will have to be accounted for in any BAL relevant cell line. Exposure to FFP 
did not however diminish rifampicin mediated CYP3A induction therefore the activity 
lost as a result of FFP exposure could be partially restored. Moreover the improvement 
in viable cell density within a bead cultured with FFP would offset the decreases in 
CYP activity. 
 
Unfortunately, when HepG2 cells were maintained in 3D culture, although CYP3A 
function was improved, the effect of rifampicin induction was lost. This suggested that 
the extent of CYP3A function that could be obtained in HepG2 cells was limited in 
some way, and also, that mechanisms that governing CYP expression were not  
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improved in 3D culture. Additional methods to provide BAL CYP3A function were 
therefore explored. 
7.1.3  Why Are Intestinal Cells Unsuitable? 
In Chapter 5, intestinal cells were evaluated for their BAL potential. Promisingly, both 
Caco2 cells and LS147T cells adapted well to 3D culture, with a differentiating effect of 
this culture format on CYP3A function, which was upregulated in both cell lines. 
However, of the two cell lines considered, neither could be used in the LG BAL. Caco2 
cells were unable to provide sufficient CYP3A function even in 3D culture. LS147T 
cells had far higher CYP3A function, which matched freshly isolated PHH, and 
following induction were able to perform 6β-hydroxylation of testosterone in 3D 
culture. However, viability of LS147T cells was low in the encapsulated cells and, since 
this can probably be attributed to their debris shedding properties, it is unlikely that this 
could be fully resolved through optimisation of culture conditions. Within a BAL, a 
DNA binding membrane is included to prevent transfer to the patient, but these 
membranes have a limited capacity, therefore any BAL component that adds to their 
burden should be carefully justified. Given that that LS147T cells are of intestinal 
origin, their role within a BAL would be limited, hence, in spite of the CYP3A function 
that can be achieved in encapsulated LS147T cells, their use within a BAL would be too 
great a compromise. 
7.1.4  Do HC-04 Cells Have LG BAL Potential? 
In Chapter 5, CYP3A function under BAL conditions of the immortalised human liver 
cell line HC-04 was also evaluated. In monolayer culture under equivalent conditions, 
HC-04 and HepG2 CYP3A functions were similar. Luciferin BE activity was lower 
than PHH and was comparable for both cells lines.  
 
Alginate encapsulated HC-04 cells were successfully cultured over a prolonged period 
of time. Expression of CYP1A2, 3A4 and 3A7, as well as nuclear receptors that govern 
their expression, were all upregulated following alginate encapsulation. Unlike HepG2 
cells, CYP3A induction was improved in 3D culture. Following rifampicin induction, 
Luciferin BE activity in d8 HC-04 spheroids matched the mean value measured in 
freshly isolated PHH, although, similarly to HepG2 cells, HC-04 cells did not produce 
detectable quantities of the CYP3A4 testosterone metabolite 6β-OHTST, and mRNA 
expression data indicates that CYP3A7 is a greater contributor to HC-04 CYP3A 
function than CYP3A4.  
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The rate of HC-04 cell proliferation in 3D culture was decreased relative to HepG2 
cells, even when cells were encapsulated at double the seeding density and prolonged 
culture resulted in a decrease in viable cell number. This can partly be attributed to 
decreased oxygenation and nutrient availability and a build up of cytotoxic waste 
products, and could therefore be improved using RCCS culture 
230.  
 
In future work, proliferation of HC-04 cells could be optimised by culture in the 
presence of FFP. Possibly, (based upon HepG2 data) this would be at the cost of some 
CYP3A function. Reduced CYP3A function following FFP exposure could be partially 
restored by rifampicin induction, and so would be balanced against the benefits of 
improved proliferation, viability and therefore per bead performance that could be 
achieved by culturing HC-04 cells, in the presence of FFP, in microgravity culture.  
 
Due to regulatory concerns associated with HC-04 cells, including traceability and cell 
line contamination (both by ECM of bovine origin and adventitious microbial 
elements), it was decided that these use of these cells within the LG BAL would be 
inappropriate. In the future, an alternative cell line could be developed in a similar 
manner to HC-04 cells for BAL use. 
7.1.5  Can CYP Function be Improved in HepG2 Cells? 
In Chapter 6, methods to improve HepG2 CYP3A function were considered. It was 
demonstrated in a transient system that increasing CAR and RXRα expression resulted 
in improved CYP3A function. In 3D culture, CYP3A induction was improved using a 
CAR transfectant and these cells had an improved testosterone metabolism profile. 
 
In 3D culture, the effect of CAR transfection only was examined. The balance of 
nuclear receptor (NR) expression that can be achieved through this approach should be 
considered, since the amount of genes that can be altered by genetic manipulation in one 
system is a limiting factor, and altering one gene alone may be insufficient. This is 
apparent for HNF4α, which is implicated in CYP expression, yet the comparatively high 
levels of HNF4α (relative to PHH) that have been found in HepG2 cells are alone 
insufficient to promote CYP expression; this suggests further elements such as PXR and 
CAR are required 
45, 279, 292.  
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Nuclear receptors share ligands, dimerisation partners, response elements and target 
genes 
82, and within this thesis, as summarised in Figure 7.1, inducers were selected that 
would reflect this.  
 
 
Figure 7-1. Pathways of CYP induction by chemical inducers and instances of receptor cross-talk 
discussed in this thesis: (1) Rifampicin binds PXR leading to the induction of multiple CYP 
isoforms. (2) Phenobarbital has an indirect influence on the CAR receptor leading to induction of 
multiple CYP isoforms. (3) Physiological concentrations of glucocorticoids (GC) bind at GR to 
increase PXR, CAR and GR levels; high concentrations of GC directly activate PXR/CAR causing 
induction of multiple CYP isoforms; GR activation also directly influences CYP expression.          
(4) DBA binds AhR resulting in CYP1A2 induction. (5) In chapters 4 and 6 it was proposed that in 
addition to acting as an AhR agonist, indirubin acts at other nuclear receptors (probably PXR) 
resulting in induction of multiple CYP isoforms. (6) In Chapter 6, CAR transfection led to an 
increase in CYP1A2 activity.  
 
Transfection of PXR or CAR both increase CYP3A function in HepG2 cells. Co-
transfection of PXR and CAR would probably be of limited benefit since they share the 
same response elements and would compete for their shared co-receptor RXRα. It was 
demonstrated in Chapter 6 that transfection of RXRα alone has a limiting effect on CYP 
induction, and RXRα ligands have been shown to decrease CYP3A4 activity in human 
cell lines 
188; however, co-expression of CAR or PXR with RXRα in a stable cell line 
could lead to increased expression of multiple CYP isoforms.  
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Within HepG2 cells, sustained expression of multiple genes could be achieved by using 
a multicistronic vector with liver specific promoters to reduce promoter down-
regulation by the host cells. Potentially, more than one cell type would have to be 
developed to account for the interaction of transcription factors involved in CYP 
regulation. CYP2D6 in particular should be considered since it metabolises a relatively 
large but distinct set of substrates (up to 25% of hepatic xenobiotic metabolism) but is 
not chemically induced. Others have shown that re-expression of CYP2D6 can occur 
following functional expression of C/EBPα in HepG2 cells 
148. Transcription factors, 
including C/EBP, may not be upregulated by HepG2 cells in 3D culture, but act 
synergistically with PXR and CAR to regulate CYP expression 
229. 
 
A multiple gene transfer approach could also be used to directly express multiple CYP 
isoforms and a similar approach has recently been described in HepG2 cells using 
adenovirus vectors to express multiple CYPs 
293. Equally, there would be considerable 
limitations to the number of CYP isoforms that can be expressed at a functional level. 
Furthermore, transfection of CYP enzymes alone limits the opportunity for their 
expression to be manipulated in culture. 
 
7.2  Further Considerations  
7.2.1  Indirubin Improves Cytochrome P450 Function by Multiple Mechanisms 
Indirubin is an AhR agonist and is established as a CYP1A inducer. In this thesis it was 
shown that indirubin exposure also resulted in increased CYP3A function in HepG2 and 
LS147T cells but not HC-04 cells. In Chapter 6, a potential mechanism was proposed 
whereby rather than directly inducing CYP, indirubin acts as a mediator of 
differentiation leading to improved CYP activity.  
 
A similar role was proposed for VD3 in intestinal cell lines in Chapter 5 (and by others), 
moreover, a combined effect of VD3 treatment and 3D culture on CYP3A function in 
LS147T cells was observed. Additionally, cellular differentiation and VD3 mediated 
CYP3A induction can be augmented by the retinoic acid receptor ligand ATRA 
188, 282. 
Synergistic effects of RXRα signaling and indirubin in the mediation of cellular 
differentiation through regulation of the Wnt/β-catenin pathway were also described in 
Chapter 6.  
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Indirubin could therefore have a role in HepG2 cells as both an inducer of CYP function 
and also a promoter of hepatocyte differentiation, and both processes could be altered 
by mediators of CYP induction such as RXRα. This could be explored further by 
measuring the effects of indirubin on other hepatocyte specific functions/markers of 
differentiation, including albumin and alpha-1 antitrypsin synthesis. Indirubin could 
also improve PXR signalling through repression of protein kinase C 
294. 
 
The cell line specific effects of indirubin on CYP3A function infers not only that the 
effect is greatest in less differentiated cells such as carcinoma derived cell lines, but also 
that HC-04 cells are better differentiated in monolayer culture and hence, that 
differentiating effects of indirubin were abrogated. Additionally, the effects of indirubin 
on CYP3A function were diminished in HepG2 cells in the presence of FFP. This could 
limit the role of indirubin in the better differentiated 3D culture environment that is 
provided by the LG BAL. 
 
7.2.2  What is Preventing CYP Expression/Protein Translation and is this 
Recovered Following Improved Differentiation? 
DNA methylation is a mechanism by which hepatoma cells regulate expression of genes 
deemed unnecessary to promote survival/proliferation, and has been implicated as a 
restricting factor in expression of xenobiotic metabolising enzymes in HepG2 cells 
295, 
296. Gene expression can be regained by exposing cells to a demethylating agent such as 
5-aza-2'-deoxycytidine. However, for the long term culture of cells on a large scale, and 
for cells to be used in a BAL, this is not a suitable approach. There is a risk of patient 
exposure to 5-aza-2'-deoxycytidine, which is toxic and would also be detrimental to the 
cells over a prolonged exposure period. It is also probable that the genes will be re-
silenced when the demethylating agent is removed. 
 
Dannenberg et al. 
295 also found that exposure of HepG2 cells to a demethylating agent 
resulted in the down-regulation of C/EBPβ, which is responsible for the transcription of 
CYP enzymes as well as additional hepatocyte specific genes. The C/EBPβ gene can 
form two isoforms from a single mRNA: liver activation protein (LAP) which is the 
full-length isoform; and liver inhibitory protein (LIP), which is a truncated isoform that 
lacks most of the transactivation domain and serves as a dominant negative regulator of 
LAP transcriptional activity 
295-297.  
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C/EBPβ LAP/LIP ratio has a strong influence on CYP3A4 expression/induction and 
also modulates flavin-containing monooxygenase 3 (FMO3) expression. A low 
LAP/LIP ratio is associated with foetal phenotype and is also found in HepG2 cells 
maintained in monolayer culture 
45, 295-297. In HepG2 cells, transfection of recombinant 
LAP or LIP causes corresponding increase or decrease in rifampicin mediated CYP3A4 
activation. Although the expression of C/EBPβ has been measured in 3D cultures of 
HepG2 cells 
229, the LAP/LIP ratio needs to be defined and, if deficient, could be 
manipulated in HepG2 cell to improve CYP3A function. 
 
7.2.3  Maintaining CYP Expression Following Induction (Post Translational 
Stabilisation) 
As discussed in Chapter 1, CYP activity in vivo takes time to return to basal levels 
following induction. The same would have to be true of HepG2 cells if chemical 
induction were to be applicable to provide BAL CYP activity. In addition to the data 
presented in previous chapters, ECOD activity was also measured in DBA treated 
HepG2 cells up to 48 hours post induction and was maintained above basal levels in the 
absence of inducer (this data is presented in Appendix B). 
 
Post translational stabilisation of CYP enzymes could also be improved by the presence 
of catalase, which provides antioxidant activity and protects CYP enzymes from drug 
induced degradation (including acetaminophen) 
298 and proteasome inhibitors, which 
would decrease enzyme turnover as well as NR degradation 
82, 299. When considering 
the development of a system that can be cryopreserved, both of these methods could 
potentially stabilise CYP expression in the period between bioreactor thawing and 
patient exposure; addition of catalase is part of our cryopreservation protocol.  
7.2.4  Considering Flavin-Containing Monooxygenases  
Non-CYP mediated oxidative reactions can also play a major role in xenobiotic 
metabolism, and FMOs catalyse NADPH-dependent monoxygenation of a number of 
xenobiotics. FMO3 is the predominant form of the FMO family expressed in human 
liver that is involved in this process, and could therefore provide an alternative drug 
metabolism pathway. Although it is generally accepted that CYP enzymes have the 
more significant role in xenobiotic metabolism, there is a degree of substrate overlap  
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between CYPs and FMO3- examples include clozapine, ketoconazole, cimetidine, 
tamoxifen and agrichemicals 
15, 16. 
 
FMO3 has not been reported at functional levels in HepG2 cells 
296. Possibly, it is 
upregulated by 3D culture or could be replaced by genetic manipulation. 
Supplementation of transcription factors that control CYP metabolism, including 
HNF4α , but not C/EBPβ or HNF3β, could also augment FMO3 expression in HepG2 
cells 
296, alternatively FMO3 could be directly transfected (into HepG2 cells). This 
approach should be simpler than attempting to restore the complex CYP enzyme system 
and has the additional advantage that relatively few compounds inhibit FMO3 compared 
to CYP enzymes. By decreasing the dependence on CYP mediated catalysis and 
distributing drug metabolism across multiple enzyme systems, FMO3 could thus 
provide oxidative drug metabolism function that is additive to both the patient’s own 
liver and the CYP function provided by HepG2 cells. In practice, this may not be so 
straightforward since FMO3 metabolites may inhibit the CYP system 
15. In order to 
measure the success of this approach, it would be necessary to distinguish between 
FMO3 and CYP mediated catalysis in HepG2 cells. In vitro the two systems differ; 
FMO catalysis typically occurs faster, and experimental conditions in a microsomal 
system (such as increased pH and presence of detergents) could be manipulated to 
favour FMO activity. FMO enzymes are, however, more thermally labile than CYPs; 
this is especially evident in HLM systems and so a suitable assay to monitor gene 
expression would also be required. 
 
7.3  What the Current System Can Achieve 
When considering an established, well characterised, cell line that is readily available, 
HepG2 cells remain an appealing candidate for the LG BAL. HepG2 cells have 
substantial synthetic capacity, can proliferate to form a sufficient biomass and although 
in monolayer culture their CYP function can be low, this can be improved, in particular 
by 3D culture. 
 
Within this thesis, Cytochrome P450 function was considered with respect to CYP1A2 
and CYP3A enzymes. To obtain a broader representation of drug metabolism, further 
work would include measuring the metabolism profiles of a number of drug substrates  
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that are metabolised by additional CYP isoforms; Phase II metabolism should also be 
confirmed. 
 
Strain dependent differences in function, that were profiled in Chapter 6, further 
demonstrate that HepG2 cell function can be highly variable, dependent on a number of 
factors. BALG2 cells had a greater basal level of CYP function and higher CYP3A 
expression, yet the extent of CYP induction that was achieved in BALG2 cells in 
monolayer culture was, in most cases, no greater than in the LG HepG2 cells. Although 
this demonstrates that CYP3A induction may still be limited, by a combination of 
chemical induction and genetic manipulation, BALG2 cells have the potential to 
provide a range of Cytochrome P450 functions that in 3D culture are equivalent to that 
measured in human liver.   
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Appendix A 
Adaption of HC-04 Cells to LG Culture 
Initially, HC-04 cells were maintained in HCM media, supplemented as described in 
Chapter 2, on a matrix of collagen and fibronectin. It was therefore necessary to 
determine both their ability to proliferate and their CYP function when cultured with or 
without culture matrix in either HCM or αMEM complete. 
Methods 
Preparation of Collagen Coated Plasticware 
1mg/ml Fibronectin 
1mg/ml Collagen Solution from Calf Skin Type I 
10% Bovine Serum Albumin (BSA) 
HBM (Lonza) 
T25 Primaria Flasks (BD) 
96 Well Plates 
A solution containing 0.01mg/ml fibronectin, 0.03mg/ml collagen solution and 
0.01mg/ml BSA was prepared in HBM. 1.5ml or 100 l of this solution was added to 
T25 flasks or 96 well plates respectively which were incubated for 2 hours at 37°C. 
Excess liquid was then removed prior to addition of cells. 
 
Adapting Culture Conditions of HC-04 Cells 
Cells were maintained in HCM media on collagen/fibronectin matrix in T25 flasks. At ~ 
60% confluency, HCM media was replaced with αMEM complete. Cells were 
maintained for one passage in αMEM complete, and at the subsequent trypsinisation 
were then plated in T25 flasks without matrix.  
CYP Induction in Monolayer Culture 
CYP induction was measured in both HC-04 cells that had been adapted to their culture 
conditions and cells that had been cultured in HCM on matrix prior to CYP induction as 
described in Chapter 5. HepG2 cells were cultured in the same conditions as a 
comparator. This experiment was performed weekly over a period of 1 month to 
determine whether activity was maintained during time in culture and effect of 
prolonged adaption to alternative culture conditions.   
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Results  
CYP3A Activity Comparison: Original versus Adapted Conditions  
CYP3A activity following rifampicin induction was measured in HC-04 cells cultured 
in HCM on collagen matrix or in αMEM on tissue culture plastic (Figure A-1). CYP3A 
activity was higher in the αMEM adapted cells, however, under these conditions the 
effect of rifampicin induction was lost. Activity was comparable but not better than 
HepG2 activity and was less than the lowest level measured in freshly isolated PHH. 
 
Figure A-1. CYP3A activity was compared in HC-04 cells cultured in HCM culture medium on 
collagen matrix or adapted to αMEM and cultured on tissue culture plastic. Activity was measured 
following 48 hour treatment with either 50µM rifampicin or 0.1% DMSO vehicle. Activity levels of 
freshly isolated PHH and HepG2 cells are indicated by arrows on the y axis. Indicated PHH activity 
was the lowest level of activity measured (n=4 +/- sd). 
CYP3A Activity Decreased Following a Month in Culture  
CYP3A activity was measured in unadpated or adapted HC-04 cells each week for a 
month. During this time a decrease in CYP3A activity was measured in all culture 
conditions (Figure A-2).  
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Figure A-2. CYP3A activity was measured over 4 weeks in HC-04 cells cultured in HCM or αMEM 
+/- collagen matrix. (n=4+/-sd).   
 
HC-04 Cells Performed Poorly in 3D Culture 
Even when encapsulated at higher seeding densities, HC-04 cells did not proliferate 
well in 3D culture. Spheroid formation was poor and CYP3A activity was negligible 
under these conditions (Figure A-3, encapsulation experiment was repeated twice, 
functional data not shown). 
 
Figure A-3. Phase contrast (x10 magnification) and FDA/PI (live/dead) viability staining of alginate 
encapsulated HC-04 cells following 8 days of culture.  
 
Phase x10  FDA  PI  
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Subsequent Finding 
HC-04 Cells were Infected with Mycoplasma Which Affected Cell Function 
 
Following the initially poor results obtained with HC-04 cells, it was subsequently 
determined that these cells were heavily detected with mycoplasma. Furthermore it was 
ascertained that mycoplasma was present in a sample of the supernatant that the cells 
were received in originally (Figure A-4). 
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Figure A-4. Mycoplasma PCR carried out February 2009. Mycoplasma band appears at 280bp and 
was shown in all HC-04 cells and HepG2 cells encapsulated after contaminated HC-04 cells. 
 
Mycoplasma contamination was not removed by ciproxin treatment, but was eliminated 
following 4 cycles of BM-Cyclin treatment (Roche 10 799 050 001). Cells were tested 
each week and remained mycoplasma free for the remaining time (Figure A-5). 
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Figure A-5. (left) Mycoplasma PCR carried out on HC-04 cells following BM-Cyclin treatment and 
on a number of other LG cell lines. (right) Mycoplasma PCR carried out on HC-04 cells 3 months 
after BM cyclin treatment and on HepG2 cells obtained from 3 separate lab researchers. 
Mycoplasma band appears at 280bp and was shown in positive control samples only. The PCR 
shown in this figure was carried out by a colleague. 
 
Due to a number of constraints, including the cost of reagents, only HC-04 cells that 
were adapted to LG culture conditions were treated with BM-Cyclin. Therefore it was 
not possible to repeat experiments 1 and 2. The subsequent functional assays of HC-04 
cells demonstrated that the presence of mycoplasma had a significant effect on CYP3A 
function in HC-04 cells; any results obtained with the contaminated cells were 
discounted.  
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Appendix B 
The Duration of Cytochrome P450 Induction in HepG2 Cells 
Following Removal of Inducer 
 
The duration of CYP induction in vitro following removal of inducer was measured in 
HepG2 cells following exposure to the CYP1A inducer DBA. 
Methods 
Hep G2 cells were cultured in the presence of 10mM DBA for either 24 or 48 hours. 
After this time, culture media containing inducer was removed, cells were washed 3 
times with HBSS and complete culture medium without inducer added. ECOD activity 
was measured either 0, 24 or 48 hours following removal of inducer. Data was 
normalised to total protein content, measured by the BCA assay. 
Results 
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Figure B-1. DBA exposure (10µM) resulted in increased ECOD activity in HepG2 cells following a 
24 hour induction. ECOD activity was then maintained in the absence of inducer and decreased 
gradually 0-48 hours after DBA removal. 
  
  265 
0.000
0.025
0.050
0.075
0.100
0h 24h 48h
Recovery Period Following Removal of Inducer
0.1% DMSO Vehicle
10µM DBA
p
m
o
l
e
s
7
-
H
C
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
0.000
0.025
0.050
0.075
0.100
0h 24h 48h
Recovery Period Following Removal of Inducer
0.1% DMSO Vehicle
10µM DBA
p
m
o
l
e
s
7
-
H
C
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
 
Figure B-2. There was a greater initial induction of ECOD activity following 48 hours DBA 
exposure, however, there was a greater decline in activity during the first 24 hours following 
removal of inducer. 
 
Figure B-3. Increased ECOD activity following exposure to 10µM DBA was maintained in HepG2 
cells following removal of inducer. Although a 48 hour DBA incubation resulted in greater 
induction (seen in Figure B2), the greater decline in ECOD activity during the first 24 hours 
reduced ECOD activity to the level measured following a shorter initial incubation (24 hours).  
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